n n u l r e p r march shareholders alex gorsky chairman chief executive officer iiii hhhhaaaavvvveeee tttthhhheeee pppprrrriiiivvvviiiilllleeeeggggeeee ooooffff bbbbeeeeiiiinnnngggg tttthhhheeee cccceeeeoooo ooooffff aaaannnndddd mmmmaaaarrrrkkkkeeeetttt sssshhhhaaaarrrreeee nnnnuuuummmmbbbbeeeerrrrssss tttthhhhiiiissss pppphhhhiiiilllloooossssoooopppphhhhyyyy jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn dddduuuurrrriiiinnnngggg aaaa rrrreeeemmmmaaaarrrrkkkkaaaabbbblllleeee ttttiiiimmmmeeee aaaalllllllloooowwwwssss uuuussss ttttoooo lllleeeeaaaadddd wwwwiiiitttthhhh cccceeeerrrrttttaaaaiiiinnnnttttyyyy eeeevvvveeeennnn iiiinnnn tttthhhheeee iiiinnnn hhhhiiiissssttttoooorrrryyyy tttthhhhrrrroooouuuugggghhhhoooouuuutttt mmmmyyyy sssseeeevvvveeeennnn yyyyeeeeaaaarrrrssss iiiinnnn tttthhhhiiiissss mmmmoooosssstttt cccchhhhaaaalllllllleeeennnnggggiiiinnnngggg ttttiiiimmmmeeeessss ttttoooo ddddrrrriiiivvvveeee ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee rrrroooolllleeee tttthhhheeeerrrreeee hhhhaaaavvvveeee bbbbeeeeeeeennnn mmmmaaaannnnyyyy ddddrrrraaaammmmaaaattttiiiicccc cccchhhhaaaannnnggggeeeessss aaaannnndddd ppppuuuurrrrppppoooosssseeee wwwwiiiitttthhhh eeeeqqqquuuuaaaallll ccccoooommmmmmmmiiiittttmmmmeeeennnntttt aaaannnndddd iiiinnnn gggglllloooobbbbaaaallll ppppoooolllliiiittttiiiiccccssss tttthhhheeee wwwwoooorrrrlllldddd eeeeccccoooonnnnoooommmmyyyy sssscccciiiieeeennnncccceeee eeeennnnaaaabbbblllleeeessss uuuussss ttttoooo mmmmaaaaiiiinnnnttttaaaaiiiinnnn aaaa lllleeeeaaaaddddiiiinnnngggg rrrroooolllleeee iiiinnnn tttteeeecccchhhhnnnnoooollllooooggggyyyy aaaannnndddd ccccuuuullllttttuuuurrrreeee aaaatttt tttthhhheeee ssssaaaammmmeeee ttttiiiimmmmeeee tttthhhheeeerrrreeee ddddeeeefifififinnnniiiinnnngggg tttthhhheeee ffffuuuuttttuuuurrrreeee ooooffff hhhheeeeaaaalllltttthhhhccccaaaarrrreeee wwwwoooorrrrllllddddwwwwiiiiddddeeee hhhhaaaassss aaaallllssssoooo bbbbeeeeeeeennnn aaaannnn aaaacccccccceeeelllleeeerrrraaaatttteeeedddd ppppaaaacccceeee ooooffff pppprrrrooooggggrrrreeeessssssss iiiinnnn hhhhuuuummmmaaaannnn hhhheeeeaaaalllltttthhhh uuuunnnnlllloooocccckkkkiiiinnnngggg tttthhhheeee ppppoooossssssssiiiibbbbiiiilllliiiittttiiiieeeessss ooooffff tttthhhheeee hhhhuuuummmmaaaannnn ggggeeeennnnoooommmmeeee eeeevvvvoooollllvvvviiiinnnngggg aaaannnndddd eeeexxxxppppaaaannnnddddiiiinnnngggg tttthhhheeee honor lead innovationdriven uuuusssseeee ooooffff rrrroooobbbboooottttiiiiccccssss aaaannnndddd mmmmiiiiccccrrrroooo ssssuuuurrrrggggeeeerrrryyyy eeeexxxxtttteeeennnnddddiiiinnnngggg culture continue demonstrate tttthhhheeee lllliiiiffffeeee eeeexxxxppppeeeeccccttttaaaannnnccccyyyy ffffoooorrrr ppppeeeeoooopppplllleeee wwwwiiiitttthhhh hhhhiiiivvvv aaaannnndddd energy drive passion startup ccccoooonnnnttttiiiinnnnuuuuiiiinnnngggg ttttoooo wwwwaaaaggggeeee aaaannnndddd wwwwiiiinnnn tttthhhheeee fifififigggghhhhtttt aaaaggggaaaaiiiinnnnsssstttt ccccaaaannnncccceeeerrrr aaaannnndddd ooootttthhhheeeerrrr ddddeeeebbbbiiiilllliiiittttaaaattttiiiinnnngggg ddddiiiisssseeeeaaaasssseeeessss tttthhhhaaaatttt iiiinnnn tttthhhhiiiissss lllleeeetttttttteeeerrrr iiii sssshhhhaaaarrrreeee tttthhhheeee hhhhiiiigggghhhhlllliiiigggghhhhttttssss ooooffff oooouuuurrrr hhhhaaaavvvveeee rrrreeeessssiiiisssstttteeeedddd ttttrrrreeeeaaaattttmmmmeeeennnntttt ffffoooorrrr ggggeeeennnneeeerrrraaaattttiiiioooonnnnssss ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee oooouuuurrrr nnnnoooottttaaaabbbblllleeee aaaacccchhhhiiiieeeevvvveeeemmmmeeeennnnttttssss aaaannnndddd oooouuuurrrr aaaassssppppiiiirrrraaaattttiiiioooonnnnssss ffffoooorrrr tttthhhheeee yyyyeeeeaaaarrrrssss ttttoooo ccccoooommmmeeee mmmmyyyy ggggooooaaaallll iiiissss ttttoooo wwwwhhhhaaaattttssss mmmmoooosssstttt eeeexxxxcccciiiittttiiiinnnngggg aaaabbbboooouuuutttt tttthhhhiiiissss pppprrrrooooggggrrrreeeessssssss pppprrrroooovvvviiiiddddeeee aaaannnn aaaaeeeerrrriiiiaaaallll vvvviiiieeeewwww ooooffff jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn iiiissss tttthhhhaaaatttt jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn hhhhaaaassss bbbbeeeeeeeennnn aaaatttt tttthhhheeee ttttooooddddaaaayyyyaaaa ccccoooommmmppppaaaannnnyyyy tttthhhhaaaatttt ssssppppaaaannnnssss ssssiiiixxxx ccccoooonnnnttttiiiinnnneeeennnnttttssss vvvveeeerrrryyyy ffffoooorrrreeeeffffrrrroooonnnntttt ooooffff mmmmaaaannnnyyyy ooooffff tttthhhheeeesssseeee rrrreeeevvvvoooolllluuuuttttiiiioooonnnnaaaarrrryyyy aaaannnndddd ccccoooouuuunnnnttttrrrriiiieeeessss ddddeeeevvvveeeellllooooppppssss nnnnuuuummmmeeeerrrroooouuuussss iiiinnnnnnnnoooovvvvaaaattttiiiivvvveeee cccchhhhaaaannnnggggeeeessss aaaannnndddd eeeexxxxppppaaaannnnddddiiiinnnngggg hhhhoooorrrriiiizzzzoooonnnnssssttttiiiimmmmeeee pppprrrroooodddduuuuccccttttssss aaaannnndddd sssseeeerrrrvvvviiiicccceeeessss aaaannnndddd ttttoooouuuucccchhhheeeessss tttthhhheeee lllliiiivvvveeeessss aaaannnndddd ttttiiiimmmmeeee aaaaggggaaaaiiiinnnn ddddeeeelllliiiivvvveeeerrrriiiinnnngggg lllliiiiffffeeee ssssaaaavvvviiiinnnngggg ooooffff ppppeeeeoooopppplllleeee aaaallllllll aaaarrrroooouuuunnnndddd tttthhhheeee wwwwoooorrrrlllldddd eeeevvvveeeerrrryyyy ddddaaaayyyy mmmmeeeeddddiiiicccciiiinnnneeeessss aaaannnndddd lllliiiiffffeeeecccchhhhaaaannnnggggiiiinnnngggg ssssoooolllluuuuttttiiiioooonnnnssss mmmmoooosssstttt iiiimmmmppppoooorrrrttttaaaannnnttttllllyyyy iiii wwwwaaaannnntttt ttttoooo eeeemmmmpppphhhhaaaassssiiiizzzzeeee mmmmyyyy iiiitttt iiiissss aaaannnn hhhhoooonnnnoooorrrr ttttoooo lllleeeeaaaadddd aaaannnn iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnnddddrrrriiiivvvveeeennnn ccccuuuullllttttuuuurrrreeee ccccoooonnnnfifififiddddeeeennnncccceeee iiiinnnn oooouuuurrrr eeeexxxxppppaaaannnnssssiiiivvvveeee ccccaaaappppaaaabbbbiiiilllliiiittttiiiieeeessss eeeexxxxpppprrrreeeessssssss tttthhhhaaaatttt ccccoooonnnnttttiiiinnnnuuuueeeessss ttttoooo ddddeeeemmmmoooonnnnssssttttrrrraaaatttteeee tttthhhheeee eeeennnneeeerrrrggggyyyy ddddrrrriiiivvvveeee mmmmyyyy rrrreeeeaaaalllliiiissssttttiiiicccc ooooppppttttiiiimmmmiiiissssmmmm aaaabbbboooouuuutttt oooouuuurrrr ooooppppppppoooorrrrttttuuuunnnniiiittttiiiieeeessss aaaannnndddd aaaannnndddd ppppaaaassssssssiiiioooonnnn ooooffff aaaa ssssttttaaaarrrrttttuuuupppp hhhhoooowwwweeeevvvveeeerrrr wwwweeee aaaallllssssoooo cccchhhhaaaalllllllleeeennnnggggeeeessss aaaannnndddd ooooffffffffeeeerrrr mmmmyyyy iiiinnnnssssiiiigggghhhhttttssss oooonnnn hhhhoooowwww wwwweeee wwwwiiiillllllll hhhhaaaavvvveeee tttthhhheeee ddddiiiissssttttiiiinnnncccctttt aaaaddddvvvvaaaannnnttttaaaaggggeeee ooooffff oooouuuurrrr ttttiiiimmmmeeeelllleeeessssssss ccccoooonnnnttttiiiinnnnuuuueeee ttttoooo sssshhhhaaaappppeeee tttthhhheeee ffffuuuuttttuuuurrrreeee ooooffff hhhheeeeaaaalllltttthhhhccccaaaarrrreeee ttttooooddddaaaayyyy vvvvaaaalllluuuueeeessss ssssuuuucccchhhh aaaassss tttthhhheeee ssssttttrrrroooonnnngggg iiiinnnnflflflfluuuueeeennnncccceeee ooooffff oooouuuurrrr lllloooonnnnggggtttteeeerrrrmmmm ssssttttrrrraaaatttteeeeggggiiiicccc vvvviiiieeeewwww tttthhhheeee uuuunnnnwwwwaaaavvvveeeerrrriiiinnnngggg cccceeeelllleeeebbbbrrrraaaattttiiiinnnngggg oooouuuurrrr ccccrrrreeeeddddoooo gggguuuuiiiiddddaaaannnncccceeee ooooffff oooouuuurrrr ccccrrrreeeeddddoooo aaaannnndddd tttthhhheeee pppprrrrooooffffoooouuuunnnndddd wwwwaaaayyyy iiiinnnn wwwweeee cccceeeelllleeeebbbbrrrraaaatttteeeedddd tttthhhheeee tttthhhh aaaannnnnnnniiiivvvveeeerrrrssssaaaarrrryyyy iiiinnnn wwwwhhhhiiiicccchhhh wwwweeee mmmmeeeeaaaassssuuuurrrreeee pppprrrrooooggggrrrreeeessssssss aaaannnndddd ssssuuuucccccccceeeessssssss ooooffff oooouuuurrrr ccccrrrreeeeddddoooo wwwwrrrriiiitttttttteeeennnn aaaannnndddd iiiinnnnttttrrrroooodddduuuucccceeeedddd iiiinnnn oooouuuurrrr ccccrrrreeeeddddoooo cccchhhhaaaalllllllleeeennnnggggeeeessss uuuussss ttttoooo ffffooooccccuuuussss oooonnnn iiiimmmmpppprrrroooovvvviiiinnnngggg bbbbyyyy ggggeeeennnneeeerrrraaaallll rrrroooobbbbeeeerrrrtttt wwwwoooooooodddd jjjjoooohhhhnnnnssssoooonnnn oooouuuurrrr ccccrrrreeeeddddoooo oooouuuuttttccccoooommmmeeeessss ffffoooorrrr ppppaaaattttiiiieeeennnnttttssss aaaannnndddd ccccoooonnnnssssuuuummmmeeeerrrrssss gggglllloooobbbbaaaallllllllyyyy hhhhaaaassss bbbbeeeeeeeennnn tttthhhheeee bbbblllluuuueeeepppprrrriiiinnnntttt ffffoooorrrr sssshhhhaaaappppiiiinnnngggg tttthhhheeee rrrroooolllleeee wwwwhhhhiiiilllleeee wwwweeee aaaallllssssoooo ffffooooccccuuuussss oooonnnn iiiimmmmpppprrrroooovvvviiiinnnngggg rrrreeeevvvveeeennnnuuuueeee tttthhhhaaaatttt jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn ppppllllaaaayyyyssss iiiinnnn ssssoooocccciiiieeeettttyyyy cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidaaaalllltttthhhhoooouuuugggghhhh oooouuuurrrr ccccrrrreeeeddddoooo iiiissss lllliiiitttteeeerrrraaaallllllllyyyy eeeettttcccchhhheeeedddd iiiinnnn ccccaaaappppaaaabbbbiiiilllliiiittttiiiieeeessss eeeexxxxppppeeeerrrriiiieeeennnncccceeeessss ooooppppiiiinnnniiiioooonnnnssss aaaannnndddd ssssttttoooonnnneeee iiiitttt iiiissss aaaa lllliiiivvvviiiinnnngggg ddddooooccccuuuummmmeeeennnntttt tttthhhhaaaatttt oooonnnn aaaa vvvveeeerrrryyyy aaaapppppppprrrrooooaaaacccchhhheeeessss eeeennnnrrrriiiicccchhhheeeessss oooouuuurrrr ccccoooollllllllaaaabbbboooorrrraaaattttiiiivvvveeee ffffeeeewwww sssseeeelllleeeecccctttt ooooccccccccaaaassssiiiioooonnnnssss wwwweeee hhhhaaaavvvveeee eeeevvvvoooollllvvvveeeedddd ttttoooo iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn pppprrrroooocccceeeessssssss aaaannnndddd tttthhhhiiiissss ccccoooollllllllaaaabbbboooorrrraaaattttiiiioooonnnn kkkkeeeeeeeepppp ppppaaaacccceeee wwwwiiiitttthhhh tttthhhheeee wwwwoooorrrrlllldddd iiiinnnn wwwwhhhhiiiicccchhhh wwwweeee lllliiiivvvveeee rrrreeeeaaaacccchhhheeeessss ffffaaaarrrr bbbbeeeeyyyyoooonnnndddd tttthhhheeee wwwwaaaallllllllssss ooooffff jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn ffffoooorrrr iiiinnnnssssttttaaaannnncccceeee wwwweeee aaaarrrreeee ppppaaaarrrrttttnnnneeeerrrriiiinnnngggg wwwwiiiitttthhhh iiiinnnn ffffaaaacccctttt llllaaaatttteeee llllaaaasssstttt yyyyeeeeaaaarrrr wwwweeee ddddiiiidddd eeeexxxxaaaaccccttttllllyyyy tttthhhhiiiissss bbbbyyyy ssssoooommmmeeee ooooffff tttthhhheeee wwwwoooorrrrllllddddssss mmmmoooosssstttt rrrreeeessssppppeeeecccctttteeeedddd uuuunnnniiiivvvveeeerrrrssssiiiittttiiiieeeessss iiiinnnnttttrrrroooodddduuuucccciiiinnnngggg ssssoooommmmeeee eeeennnnhhhhaaaannnncccceeeemmmmeeeennnnttttssss ttttoooo oooouuuurrrr rrrreeeesssseeeeaaaarrrrcccchhhh iiiinnnnssssttttiiiittttuuuuttttiiiioooonnnnssss tttteeeecccchhhhnnnnoooollllooooggggyyyy ggggiiiiaaaannnnttttssss aaaannnndddd ccccrrrreeeeddddoooo rrrreeeessssppppoooonnnnssssiiiibbbbiiiilllliiiittttiiiieeeessss tttthhhhaaaatttt wwwweeeerrrreeee iiiinnnnssssppppiiiirrrreeeedddd bbbbyyyy ttttrrrraaaaddddiiiittttiiiioooonnnnaaaallll ssssttttaaaarrrrttttuuuuppppssss aaaassss wwwweeee ssssuuuuppppppppoooorrrrtttt tttthhhhoooosssseeee wwwwhhhhoooo ffffeeeeeeeeddddbbbbaaaacccckkkk ffffrrrroooommmm mmmmoooorrrreeee tttthhhhaaaannnn ooooffff oooouuuurrrr ddddiiiivvvveeeerrrrsssseeee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn eeeemmmmppppllllooooyyyyeeeeeeeessss rrrreeeepppprrrreeeesssseeeennnnttttiiiinnnngggg jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn iiiinnnnccccuuuubbbbaaaattttoooorrrrssss aaaallllllll rrrreeeeggggiiiioooonnnnssss sssseeeeggggmmmmeeeennnnttttssss aaaannnndddd ffffuuuunnnnccccttttiiiioooonnnnssss aaaa kkkkeeeeyyyy eeeexxxxaaaammmmpppplllleeee iiiissss hhhhoooowwww wwwweeee aaaarrrreeee hhhhaaaarrrrnnnneeeessssssssiiiinnnngggg tttthhhheeee tttthhhheeeesssseeee eeeennnnhhhhaaaannnncccceeeemmmmeeeennnnttttssss ssssttttrrrreeeennnnggggtttthhhh ooooffff aaaallllllll tttthhhhrrrreeeeeeee ooooffff oooouuuurrrr bbbbuuuussssiiiinnnneeeessssssss sssseeeeggggmmmmeeeennnnttttssss cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaatttt tttthhhheeee cccceeeennnntttteeeerrrr ooooffff oooouuuurrrr ffffooooccccuuuussss sssscccciiiieeeennnnttttiiiissssttttssss ttttoooo iiiiddddeeeennnnttttiiiiffffyyyy wwwwaaaayyyyssss ttttoooo bbbbeeeetttttttteeeerrrr ddddeeeetttteeeecccctttt aaaannnndddd ttttrrrreeeeaaaatttt tttthhhheeee eeeennnnttttiiiirrrreeee ccccyyyycccclllleeee ooooffff lllluuuunnnngggg ccccaaaannnncccceeeerrrr tttthhhhiiiissss cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaannnndddd aaaa nnnneeeewwww ggggeeeennnneeeerrrraaaattttiiiioooonnnn ooooffff eeeemmmmppppllllooooyyyyeeeeeeeessss ddddiiiisssseeeeaaaasssseeee iiiissss tttthhhheeee lllleeeeaaaaddddiiiinnnngggg ccccaaaauuuusssseeee ooooffff ccccaaaannnncccceeeerrrr mmmmoooorrrrttttaaaalllliiiittttyyyy aaaarrrroooouuuunnnndddd tttthhhheeee gggglllloooobbbbeeeewwwweeee rrrreeeeccccooooggggnnnniiiizzzzeeee tttthhhheeee nnnneeeeeeeedddd cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaannnndddd uuuurrrrggggeeeennnnccccyyyy aaaannnndddd wwwweeee aaaarrrreeee rrrreeeessssppppoooonnnnddddiiiinnnngggg ttttoooo tttthhhhiiiissss ddddiiiivvvveeeerrrrssssiiiittttyyyy aaaannnndddd iiiinnnncccclllluuuussssiiiioooonnnn aaaannnndddd ccccaaaallllllll ttttoooo aaaaccccttttiiiioooonnnn wwwwiiiitttthhhh tttthhhhiiiissss eeeexxxxcccciiiittttiiiinnnngggg ppppaaaarrrrttttnnnneeeerrrrsssshhhhiiiipppp cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid tttthhhheeee hhhheeeeaaaalllltttthhhh ooooffff hhhhuuuummmmaaaannnniiiittttyyyy ppppoooowwwweeeerrrrffffuuuullll iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn hhhhaaaassss aaaallllssssoooo bbbbeeeeeeeennnn mmmmaaaaddddeeee ppppoooossssssssiiiibbbblllleeee bbbbyyyy tttthhhheeee fifififinnnnaaaannnncccciiiiaaaallll ssssttttrrrreeeennnnggggtttthhhh wwwweeeevvvveeee bbbbuuuuiiiilllltttt oooovvvveeeerrrr tttthhhheeee oooouuuurrrr ccccrrrreeeeddddoooo rrrreeeemmmmaaaaiiiinnnnssss aaaassss rrrreeeelllleeeevvvvaaaannnntttt ttttooooddddaaaayyyy aaaassss wwwwhhhheeeennnn cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid iiiitttt wwwwaaaassss fifififirrrrsssstttt iiiinnnnttttrrrroooodddduuuucccceeeedddd yyyyeeeeaaaarrrrssss aaaaggggoooo aaaannnndddd iiiimmmm iiiissss cccceeeennnnttttrrrraaaallll ttttoooo oooouuuurrrr aaaabbbbiiiilllliiiittttyyyy ttttoooo ccccrrrreeeeaaaatttteeee mmmmeeeeaaaannnniiiinnnnggggffffuuuullll ccccoooonnnnfifififiddddeeeennnntttt tttthhhhaaaatttt iiiitttt wwwwiiiillllllll pppprrrrooooppppeeeellll jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn cccchhhhaaaannnnggggeeee aaaannnndddd ccccoooommmmppppeeeettttiiiittttiiiivvvveeee ddddiiiiffffffffeeeerrrreeeennnnttttiiiiaaaattttiiiioooonnnn iiiinnnn ffffoooorrrrwwwwaaaarrrrdddd ffffoooorrrr tttthhhheeee nnnneeeexxxxtttt yyyyeeeeaaaarrrrssss aaaannnndddd bbbbeeeeyyyyoooonnnndddd wwwweeee aaaacccchhhhiiiieeeevvvveeeedddd aaaa rrrreeeeccccoooorrrrddddlllleeeevvvveeeellll ooooffff rrrreeeesssseeeeaaaarrrrcccchhhh aaaannnndddd iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn iiiissss oooouuuurrrr ccccaaaalllllllliiiinnnngggg ccccaaaarrrrdddd ddddeeeevvvveeeellllooooppppmmmmeeeennnntttt rrrrdddd iiiinnnnvvvveeeessssttttmmmmeeeennnntttt ooooffff aaaapppppppprrrrooooxxxxiiiimmmmaaaatttteeeellllyyyy wwwwhhhheeeennnn wwwweeee hhhheeeeaaaarrrr tttthhhheeee tttteeeerrrrmmmm ssssttttaaaarrrrttttuuuupppp wwwweeee tttthhhhiiiinnnnkkkk ooooffff aaaannnn bbbbiiiilllllllliiiioooonnnn iiiinnnn ffffaaaacccctttt aaaaccccrrrroooossssssss aaaallllllll iiiinnnndddduuuussssttttrrrriiiieeeessss wwwweeee oooorrrrggggaaaannnniiiizzzzaaaattttiiiioooonnnn wwwwiiiitttthhhh hhhhiiiigggghhhh eeeennnneeeerrrrggggyyyy aaaannnndddd ccccrrrreeeeaaaattttiiiivvvviiiittttyyyy oooonnnneeee aaaarrrreeee oooonnnneeee ooooffff tttthhhheeee ttttoooopppp ccccoooommmmppppaaaannnniiiieeeessss tttthhhhaaaatttt iiiinnnnvvvveeeesssstttteeeedddd tttthhhhaaaatttt vvvvaaaalllluuuueeeessss aaaaggggiiiilllliiiittttyyyy aaaannnndddd hhhhaaaassss aaaa bbbboooolllldddd vvvviiiissssiiiioooonnnn ttttoooo cccchhhhaaaannnnggggeeee aaaatttt tttthhhheeee hhhhiiiigggghhhheeeesssstttt lllleeeevvvveeeellllssss iiiinnnn iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn aaaannnndddd rrrrdddd tttthhhheeee wwwwoooorrrrlllldddd aaaassss iiii llllooooooookkkk aaaatttt tttthhhheeee tttteeeecccchhhhnnnnoooollllooooggggiiiieeeessss wwwweeee aaaarrrreeee llllaaaasssstttt yyyyeeeeaaaarrrr tttthhhheeee jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn ffffaaaammmmiiiillllyyyy ooooffff iiiinnnnvvvveeeessssttttiiiinnnngggg iiiinnnn tttthhhheeee ccccoooommmmppppaaaannnniiiieeeessss wwwweeee aaaarrrreeee ppppaaaarrrrttttnnnneeeerrrriiiinnnngggg wwwwiiiitttthhhh ccccoooommmmppppaaaannnniiiieeeessss iiiinnnnvvvveeeesssstttteeeedddd iiiinnnn aaaa nnnnuuuummmmbbbbeeeerrrr ooooffff vvvvaaaalllluuuueeeeccccrrrreeeeaaaattttiiiinnnngggg aaaannnndddd tttthhhheeee ppppeeeeoooopppplllleeee wwwwhhhhoooo ccccoooommmmeeee ttttoooo wwwwoooorrrrkkkk ffffoooorrrr uuuussss eeeevvvveeeerrrryyyy aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnnssss aaaannnndddd ccccoooollllllllaaaabbbboooorrrraaaattttiiiioooonnnnssss wwwwhhhhiiiicccchhhh iiiinnnncccclllluuuuddddeeeedddd ddddaaaayyyy iiii bbbbeeeelllliiiieeeevvvveeee tttthhhhoooosssseeee ssssttttaaaarrrrttttuuuupppp aaaattttttttrrrriiiibbbbuuuutttteeeessss ddddeeeefifififinnnneeee oooouuuurrrr zzzzaaaarrrrbbbbeeeeeeeessss iiiinnnncccc aaaa lllleeeeaaaaddddeeeerrrr iiiinnnn nnnnaaaattttuuuurrrraaaallllllllyyyy bbbbaaaasssseeeedddd oooovvvveeeerrrrtttthhhheeee ccccoooommmmppppaaaannnnyyyy ttttooooooooddddrrrriiiivvvviiiinnnngggg aaaa vvvviiiissssiiiioooonnnn ooooffff cccchhhhaaaannnnggggeeee tttthhhhaaaatttt wwwwiiiillllllll ccccoooouuuunnnntttteeeerrrr oooottttcccc rrrreeeemmmmeeeeddddiiiieeeessss oooorrrrtttthhhhoooottttaaaaxxxxyyyy aaaa ddddeeeevvvveeeellllooooppppeeeerrrr hhhhaaaavvvveeee lllloooonnnnggggllllaaaassssttttiiiinnnngggg iiiimmmmppppaaaacccctttt ffffoooorrrr ppppeeeeoooopppplllleeee eeeevvvveeeerrrryyyywwwwhhhheeeerrrreeee ooooffff ssssooooffffttttwwwwaaaarrrreeeeeeeennnnaaaabbbblllleeeedddd oooorrrrtttthhhhooooppppaaaaeeeeddddiiiicccc ssssuuuurrrrggggeeeerrrryyyy tttteeeecccchhhhnnnnoooollllooooggggiiiieeeessss aaaannnndddd aaaarrrrrrrroooowwwwhhhheeeeaaaadddd pppphhhhaaaarrrrmmmmaaaacccceeeeuuuuttttiiiiccccaaaallllssss iiiinnnncccc wwwwhhhheeeerrrreeee wwwweeee aaaarrrreeee wwwwoooorrrrkkkkiiiinnnngggg ttttoooo bbbbrrrriiiinnnngggg aaaa ffffuuuunnnnccccttttiiiioooonnnnaaaallll sustain investment innovation ccccuuuurrrreeee ttttoooo ppppaaaattttiiiieeeennnnttttssss wwwwiiiitttthhhh cccchhhhrrrroooonnnniiiicccc hhhheeeeppppaaaattttiiiittttiiiissss bbbb iiiinnnn central ability create meaningful ttttoooottttaaaallll wwwweeee eeeexxxxeeeeccccuuuutttteeeedddd aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnnssss aaaannnndddd lllliiiicccceeeennnnsssseeeessss change competitive differentiation ooooffff vvvvaaaarrrriiiioooouuuussss ssssiiiizzzzeeeessss iiiinnnncccclllluuuuddddiiiinnnngggg oooouuuurrrr aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnn ooooffff tttthhhheeee ccccoooommmmppppaaaannnnyyyy tttthhhhaaaatttt mmmmaaaarrrrkkkkeeeettttssss tttthhhheeee ddddrrrr cccciiii llllaaaabbbboooo lllliiiinnnneeee ooooffff hhhhoooowwwweeeevvvveeeerrrr tttthhhheeee ttttiiiimmmmeeeelllleeeessssssss vvvvaaaalllluuuueeeessss tttthhhhaaaatttt ssssuuuuppppppppoooorrrrtttt sssskkkkiiiinnnnccccaaaarrrreeee pppprrrroooodddduuuuccccttttssss wwwwhhhhiiiicccchhhh ooooffiffiffifficccciiiiaaaallllllllyyyy cccclllloooosssseeeedddd iiiinnnn tttthhhheeeesssseeee ssssttttrrrraaaatttteeeeggggiiiieeeessss aaaallllssssoooo mmmmaaaakkkkeeee uuuussss ddddiiiiffffffffeeeerrrreeeennnntttt aaaaddddddddiiiittttiiiioooonnnnaaaallllllllyyyy wwwweeee ssssiiiiggggnnnneeeedddd iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn ddddeeeeaaaallllssss aaaassss wwwweeeellllllll ffffrrrroooommmm tttthhhheeee ttttyyyyppppiiiiccccaaaallll ssssttttaaaarrrrttttuuuupppp oooouuuurrrr yyyyeeeeaaaarrrrssss ooooffff aaaassss nnnneeeewwww ddddeeeevvvveeeellllooooppppmmmmeeeennnntttt ddddeeeeaaaallllssss aaaannnndddd wwwweeee ccccoooonnnnttttiiiinnnnuuuueeee ssssuuuucccccccceeeessssssss aaaannnndddd aaaacccchhhhiiiieeeevvvveeeemmmmeeeennnntttt mmmmoooottttiiiivvvvaaaatttteeee uuuussss eeeevvvveeeennnn ttttoooo mmmmaaaakkkkeeee iiiinnnnvvvveeeessssttttmmmmeeeennnnttttssss aaaaccccrrrroooossssssss aaaallllllll iiiinnnndddduuuussssttttrrrriiiieeeessss tttthhhhrrrroooouuuugggghhhh mmmmoooorrrreeee ttttoooo bbbbrrrriiiinnnngggg nnnneeeewwww iiiiddddeeeeaaaassss aaaannnndddd aaaapppppppprrrrooooaaaacccchhhheeeessss ttttoooo jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnnjjjjjjjjddddcccc iiiinnnncccc jjjjjjjjddddcccc mmmmaaaarrrrkkkkeeeetttt ttttooooddddaaaayyyy aaaannnndddd wwwweeeellllllll iiiinnnnttttoooo tttthhhheeee ffffuuuuttttuuuurrrreeee aaaassss iiii jjjjuuuusssstttt mmmmeeeennnnttttiiiioooonnnneeeedddd wwwweeee ccccoooonnnnttttiiiinnnnuuuueeee ttttoooo iiiinnnnnnnnoooovvvvaaaatttteeee tttthhhheeee ddddiiiivvvveeeerrrrssssiiiittttyyyy ooooffff oooouuuurrrr oooorrrrggggaaaannnniiiizzzzaaaattttiiiioooonnnn wwwwhhhhiiiicccchhhh iiiinnnn ssssuuuurrrrggggeeeerrrryyyy oooovvvveeeerrrr yyyyeeeeaaaarrrrssss aaaaggggoooo wwwweeee wwwweeeerrrreeee tttthhhheeee ccccoooommmmpppprrrriiiisssseeeessss aaaa wwwwiiiiddddeeee aaaarrrrrrrraaaayyyy ooooffff bbbbaaaacccckkkkggggrrrroooouuuunnnnddddssss ppppiiiioooonnnneeeeeeeerrrrssss ooooffff sssstttteeeerrrriiiilllleeee ssssuuuurrrrggggeeeerrrryyyy eeeessssttttaaaabbbblllliiiisssshhhhiiiinnnngggg aaaannnn cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidiiiinnnnccccrrrreeeeddddiiiibbbblllleeee hhhheeeerrrriiiittttaaaaggggeeee tttthhhhaaaatttt ttttooooddddaaaayyyy iiiinnnncccclllluuuuddddeeeessss oooouuuurrrr ddddrrrriiiivvvviiiinnnngggg lllloooonnnnggggtttteeeerrrrmmmm sssshhhhaaaarrrreeeehhhhoooollllddddeeeerrrr vvvvaaaalllluuuueeee lllleeeeaaaaddddeeeerrrrsssshhhhiiiipppp iiiinnnn mmmmiiiinnnniiiimmmmaaaallllllllyyyy iiiinnnnvvvvaaaassssiiiivvvveeee ssssuuuurrrrggggeeeerrrryyyy aaaannnndddd oooouuuurrrr ffffrrrreeeeeeee ccccaaaasssshhhh flflflfloooowwww ffffoooorrrr iiiimmmmpppprrrroooovvvveeeedddd ttttoooo iiiinnnnnnnnoooovvvvaaaattttiiiivvvveeeellllyyyy ccccoooonnnnttttrrrroooolllllllliiiinnnngggg ssssuuuurrrrggggiiiiccccaaaallll bbbblllleeeeeeeeddddiiiinnnngggg aaaannnndddd bbbbiiiilllllllliiiioooonnnn aaaannnndddd eeeemmmmppppllllooooyyyyiiiinnnngggg oooouuuurrrr pppprrrroooovvvveeeennnn ccccaaaappppiiiittttaaaallll iiiinnnnffffeeeeccccttttiiiioooonnnn gggglllloooobbbbaaaallllllllyyyy oooouuuurrrr ggggooooaaaallll aaaannnndddd ccccoooommmmmmmmiiiittttmmmmeeeennnntttt iiiissss aaaallllllllooooccccaaaattttiiiioooonnnn ssssttttrrrraaaatttteeeeggggyyyy wwwweeee aaaarrrreeee aaaabbbblllleeee ttttoooo eeeeffffffffeeeeccccttttiiiivvvveeeellllyyyy ttttoooo nnnnoooowwww ccccrrrreeeeaaaatttteeee tttthhhheeee nnnneeeexxxxtttt ffffrrrroooonnnnttttiiiieeeerrrr ooooffff ssssuuuurrrrggggeeeerrrryyyy tttthhhhaaaattttssss iiiinnnnvvvveeeesssstttt iiiinnnn oooouuuurrrr bbbbuuuussssiiiinnnneeeessssssss aaaannnndddd iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn ttttoooo ddddrrrriiiivvvveeee wwwwhhhhyyyy iiiimmmm eeeexxxxcccciiiitttteeeedddd tttthhhhaaaatttt wwwweeee eeeennnntttteeeerrrreeeedddd iiiinnnnttttoooo aaaa ddddeeeefifififinnnniiiittttiiiivvvveeee ggggrrrroooowwwwtttthhhh ffffoooorrrr lllloooonnnnggggtttteeeerrrrmmmm vvvvaaaalllluuuueeee wwwwhhhhiiiilllleeee aaaallllssssoooo rrrreeeettttuuuurrrrnnnniiiinnnngggg aaaaggggrrrreeeeeeeemmmmeeeennnntttt ttttoooo aaaaccccqqqquuuuiiiirrrreeee aaaauuuurrrriiiissss hhhheeeeaaaalllltttthhhh iiiinnnncccc aaaauuuurrrriiiissss vvvvaaaalllluuuueeee ttttoooo sssshhhhaaaarrrreeeehhhhoooollllddddeeeerrrrssss oooouuuurrrr ccccaaaappppiiiittttaaaallll aaaallllllllooooccccaaaattttiiiioooonnnn hhhheeeeaaaalllltttthhhh iiiissss aaaa ddddeeeevvvveeeellllooooppppeeeerrrr ooooffff rrrroooobbbboooottttiiiicccc tttteeeecccchhhhnnnnoooollllooooggggiiiieeeessss ssssttttrrrraaaatttteeeeggggyyyy iiiinnnncccclllluuuuddddeeeessss ffffoooouuuurrrr kkkkeeeeyyyy pppprrrriiiioooorrrriiiittttiiiieeeessss tttthhhhaaaatttt ccccuuuurrrrrrrreeeennnnttttllllyyyy ffffooooccccuuuusssseeeessss oooonnnn lllluuuunnnngggg ccccaaaannnncccceeeerrrr tttthhhhiiiissss cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnn wwwwiiiillllllll aaaacccccccceeeelllleeeerrrraaaatttteeee oooouuuurrrr eeeennnnttttrrrryyyy iiiinnnnttttoooo ddddiiiiggggiiiittttaaaallllllllyyyy cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid eeeennnnaaaabbbblllleeeedddd rrrroooobbbboooottttiiiiccccssss pppprrrroooocccceeeedddduuuurrrreeeessss wwwwiiiitttthhhh tttthhhheeee ppppooootttteeeennnnttttiiiiaaaallll mmmmaaaarrrrkkkkeeeettttiiiinnnngggg aaaannnndddd aaaaddddmmmmiiiinnnniiiissssttttrrrraaaattttiiiivvvveeee iiiinnnniiiittttiiiiaaaattttiiiivvvveeeessss ffffoooorrrr ggggrrrroooowwwwtttthhhh aaaannnndddd eeeexxxxppppaaaannnnssssiiiioooonnnn iiiinnnnttttoooo ooootttthhhheeeerrrr iiiinnnntttteeeerrrrvvvveeeennnnttttiiiioooonnnnaaaallll aaaapppppppplllliiiiccccaaaattttiiiioooonnnnssss iiiinnnn tttthhhhiiiissss nnnneeeewwww eeeerrrraaaa ooooffff hhhheeeeaaaalllltttthhhhccccaaaarrrreeee wwwweeee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaarrrreeee aaaaiiiimmmmiiiinnnngggg ttttoooo ssssiiiimmmmpppplllliiiiffffyyyy ssssuuuurrrrggggeeeerrrryyyy ddddrrrriiiivvvveeee eeeeffiffiffifficccciiiieeeennnnccccyyyy ddddiiiivvvviiiiddddeeeennnndddd ttttoooo oooouuuurrrr sssshhhhaaaarrrreeeehhhhoooollllddddeeeerrrrssss aaaannnndddd iiiinnnn rrrreeeedddduuuucccceeee ccccoooommmmpppplllliiiiccccaaaattttiiiioooonnnnssss iiiimmmmpppprrrroooovvvveeee oooouuuuttttccccoooommmmeeeessss ffffoooorrrr wwwweeee ppppaaaaiiiidddd bbbbiiiilllllllliiiioooonnnn iiiinnnn ddddiiiivvvviiiiddddeeeennnnddddssss wwwweeee aaaarrrreeee ppppaaaattttiiiieeeennnnttttssss aaaannnndddd mmmmaaaakkkkeeee ssssuuuurrrrggggeeeerrrryyyy eeeevvvveeeennnn ssssaaaaffffeeeerrrr tttthhhhiiiissss vvvveeeerrrryyyy pppprrrroooouuuudddd tttthhhhaaaatttt oooouuuurrrr ddddiiiivvvviiiiddddeeeennnndddd hhhhaaaassss iiiinnnnccccrrrreeeeaaaasssseeeedddd ccccoooonnnnttttiiiinnnnuuuueeeessss oooouuuurrrr ssssuuuurrrrggggiiiiccccaaaallll lllleeeeaaaaddddeeeerrrrsssshhhhiiiipppp tttthhhhaaaatttt hhhhaaaassss bbbbeeeeeeeennnn ffffoooorrrr tttthhhheeee llllaaaasssstttt ccccoooonnnnsssseeeeccccuuuuttttiiiivvvveeee yyyyeeeeaaaarrrrssss iiiinnnn mmmmoooottttiiiioooonnnn ssssiiiinnnncccceeee tttthhhheeee bbbbeeeeggggiiiinnnnnnnniiiinnnngggg ooooffff oooouuuurrrr ccccoooommmmppppaaaannnnyyyy cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ttttaaaarrrrggggeeeetttt mmmmeeeerrrrggggeeeerrrrssss aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnnssss aaaannnndddd lllliiiicccceeeennnnssssiiiinnnngggg llllooooooookkkkiiiinnnngggg aaaahhhheeeeaaaadddd iiii aaaammmm aaaallllssssoooo vvvveeeerrrryyyy eeeexxxxcccciiiitttteeeedddd aaaabbbboooouuuutttt oooouuuurrrr aaaaggggrrrreeeeeeeemmmmeeeennnnttttssss tttthhhhaaaatttt wwwweeee bbbbeeeelllliiiieeeevvvveeee wwwwiiiillllllll aaaadddddddd ccccoooollllllllaaaabbbboooorrrraaaattttiiiioooonnnn wwwwiiiitttthhhh aaaapppppppplllleeee iiiinnnncccc tttthhhhaaaatttt wwwweeee aaaannnnnnnnoooouuuunnnncccceeeedddd ssssiiiiggggnnnniiiifififificcccaaaannnntttt lllloooonnnnggggtttteeeerrrrmmmm vvvvaaaalllluuuueeee ccccrrrreeeeaaaattttiiiioooonnnn ffffoooorrrr oooouuuurrrr eeeeaaaarrrrllllyyyy iiiinnnn ttttooooggggeeeetttthhhheeeerrrr wwwweeee wwwwiiiillllllll bbbbeeee ccccoooonnnndddduuuuccccttttiiiinnnngggg aaaa sssshhhhaaaarrrreeeehhhhoooollllddddeeeerrrrssss aaaannnndddd aaaallllllll ooootttthhhheeeerrrr ssssttttaaaakkkkeeeehhhhoooollllddddeeeerrrrssss rrrreeeesssseeeeaaaarrrrcccchhhh ssssttttuuuuddddyyyy tttthhhhaaaatttt aaaannnnaaaallllyyyyzzzzeeeessss wwwwhhhheeeetttthhhheeeerrrr aaaa nnnneeeewwww hhhheeeeaaaarrrrtttt hhhheeeeaaaalllltttthhhh pppprrrrooooggggrrrraaaammmm uuuussssiiiinnnngggg aaaannnn aaaapppppppp ffffrrrroooommmm tttthhhheeee jjjjoooohhhhnnnnssssoooonnnn cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid jjjjoooohhhhnnnnssssoooonnnn ffffaaaammmmiiiillllyyyy ooooffff ccccoooommmmppppaaaannnniiiieeeessss iiiinnnn ccccoooommmmbbbbiiiinnnnaaaattttiiiioooonnnn ttttoooo rrrreeeettttuuuurrrrnnnn vvvvaaaalllluuuueeee ttttoooo sssshhhhaaaarrrreeeehhhhoooollllddddeeeerrrrssss ssssuuuucccchhhh aaaassss sssshhhhaaaarrrreeee wwwiiiittthhhh aaapppppplllleee wwwaaatttccchhhhsss iiiirrrrrreeeggguuullllaaarrr rrrhhhhyyyttthhhhmmm nnnoootttiiiifififificccaaatttiiiiooonnnsss rrrreeeeppppuuuurrrrcccchhhhaaaasssseeee pppprrrrooooggggrrrraaaammmmssss aaaannnndddd wwwweeee aaaarrrreeee ccccuuuurrrrrrrreeeennnnttttllllyyyy aaaannnndddd eeeelllleeeeccccttttrrrroooo ccccaaaarrrrddddiiiiooooggggrrrraaaammmm eeeeccccgggg aaaapppppppp ccccaaaannnn eeeexxxxeeeeccccuuuuttttiiiinnnngggg aaaaggggaaaaiiiinnnnsssstttt aaaa bbbbiiiilllllllliiiioooonnnn sssshhhhaaaarrrreeee rrrreeeeppppuuuurrrrcccchhhhaaaasssseeee aaaacccccccceeeelllleeeerrrraaaatttteeee aaaattttrrrriiiiaaaallll fifififibbbbrrrriiiillllllllaaaattttiiiioooonnnn aaaaffffiiiibbbb ddddiiiiaaaaggggnnnnoooossssiiiissss aaaannnndddd tttthhhhaaaatttt wwwweeee aaaannnnnnnnoooouuuunnnncccceeeedddd llllaaaasssstttt ddddeeeecccceeeemmmmbbbbeeeerrrr iiiimmmmpppprrrroooovvvveeee hhhheeeeaaaalllltttthhhh oooouuuuttttccccoooommmmeeeessss iiiinnnncccclllluuuuddddiiiinnnngggg tttthhhheeee pppprrrreeeevvvveeeennnnttttiiiioooonnnn ggggiiiivvvveeeennnn oooouuuurrrr fifififinnnnaaaannnncccciiiiaaaallll ssssttttrrrreeeennnnggggtttthhhh wwwweeee ccccaaaannnn ppppuuuurrrrssssuuuueeee aaaallllllll ooooffff ssssttttrrrrooookkkkeeee ffffoooorrrr tttthhhheeee mmmmiiiilllllllliiiioooonnnn ppppeeeeoooopppplllleeee wwwwoooorrrrllllddddwwwwiiiiddddeeee ooooffff tttthhhheeeesssseeee pppprrrriiiioooorrrriiiittttiiiieeeessss ssssiiiimmmmuuuullllttttaaaannnneeeeoooouuuussssllllyyyy aaaassss wwwweeee ddddiiiidddd iiiinnnn lllliiiivvvviiiinnnngggg wwwwiiiitttthhhh aaaaffffiiiibbbb tttthhhhiiiissss iiiissss aaaa ccccoooonnnnddddiiiittttiiiioooonnnn tttthhhhaaaatttt ccccaaaannnn tttthhhhrrrroooouuuugggghhhhoooouuuutttt jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnnssss hhhhiiiissssttttoooorrrryyyy lllleeeeaaaadddd ttttoooo ssssttttrrrrooookkkkeeee aaaannnndddd ooootttthhhheeeerrrr ppppooootttteeeennnnttttiiiiaaaallllllllyyyy ddddeeeevvvvaaaassssttttaaaattttiiiinnnngggg wwwweeee hhhhaaaavvvveeee mmmmaaaaiiiinnnnttttaaaaiiiinnnneeeedddd aaaa ssssttttrrrroooonnnngggg ccccoooonnnnssssiiiisssstttteeeennnntttt aaaannnndddd cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ssssuuuussssttttaaaaiiiinnnnaaaabbbblllleeee bbbbuuuussssiiiinnnneeeessssssss tttthhhhiiiissss iiiissss iiiilllllllluuuussssttttrrrraaaatttteeeedddd bbbbyyyy rrrreeeessssppppoooonnnnssssiiiibbbblllleeee ffffoooorrrr aaaapppppppprrrrooooxxxxiiiimmmmaaaatttteeeellllyyyy ddddeeeeaaaatttthhhhssss aaaannnndddd hhhhoooossssppppiiiittttaaaalllliiiizzzzaaaattttiiiioooonnnnssss eeeevvvveeeerrrryyyy yyyyeeeeaaaarrrr cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ooooppppeeeerrrraaaattttiiiioooonnnnaaaallll eeeeaaaarrrrnnnniiiinnnnggggssss ggggrrrroooowwwwtttthhhh wwwweeee aaaarrrreeee vvvveeeerrrryyyy ooooppppttttiiiimmmmiiiissssttttiiiicccc aaaabbbboooouuuutttt tttthhhheeee ppppooootttteeeennnnttttiiiiaaaallll ooooffff tttthhhhiiiissss wwwweeeeaaaarrrraaaabbbblllleeee tttteeeecccchhhhnnnnoooollllooooggggyyyy aaaannnndddd bbbbaaaasssseeeedddd oooonnnn cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid tttthhhheeee iiiinnnnssssiiiigggghhhhttttssss ggggeeeennnneeeerrrraaaatttteeeedddd tttthhhhrrrroooouuuugggghhhh tttthhhhiiiissss rrrreeeesssseeeeaaaarrrrcccchhhh hhhhoooolllldddd aaaa ttttrrrriiiipppplllleeee aaaa ccccrrrreeeeddddiiiitttt rrrraaaattttiiiinnnngggg aaaannnndddd pppprrrrooooggggrrrraaaammmm iiiinnnn tttthhhheeee ffffuuuuttttuuuurrrreeee wwwweeee mmmmaaaayyyy aaaallllssssoooo bbbbeeee aaaabbbblllleeee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ttttoooo ddddeeeevvvveeeelllloooopppp nnnneeeewwww wwwwaaaayyyyssss ttttoooo ddddeeeetttteeeecccctttt ooootttthhhheeeerrrr hhhheeeeaaaalllltttthhhh ttttoooopppp mmmmaaaarrrrkkkkeeeetttt ccccaaaapppp ccccoooommmmppppaaaannnniiiieeeessss ccccoooonnnnddddiiiittttiiiioooonnnnssss ssssoooooooonnnneeeerrrr eeeeaaaarrrrllllyyyy ddddiiiiaaaaggggnnnnoooossssiiiissss nnnnooootttt oooonnnnllllyyyy tttthhhheeee ssssttttrrrraaaatttteeeeggggiiiiccccaaaaddddvvvvaaaannnnttttaaaaggggeeee ooooffff oooouuuurrrr bbbbrrrrooooaaaadddd bbbbaaaasssseeee hhhhaaaassss tttthhhheeee ppppooootttteeeennnnttttiiiiaaaallll ttttoooo ssssaaaavvvveeee lllliiiivvvveeeessss bbbbuuuutttt iiiitttt mmmmaaaayyyy aaaallllssssoooo ppppoooossssiiiittttiiiioooonnnneeeedddd aaaaccccrrrroooossssssss tttthhhhrrrreeeeeeee vvvviiiittttaaaallll aaaassssppppeeeeccccttttssss ooooffff lllloooowwwweeeerrrr ccccoooossssttttssss aaaaccccrrrroooossssssss tttthhhheeee hhhheeeeaaaalllltttthhhhccccaaaarrrreeee ssssyyyysssstttteeeemmmm hhhheeeeaaaalllltttthhhhccccaaaarrrreeeepppphhhhaaaarrrrmmmmaaaacccceeeeuuuuttttiiiiccccaaaallll ccccoooonnnnssssuuuummmmeeeerrrr aaaannnndddd iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn iiiissss oooouuuurrrr ccccaaaalllllllliiiinnnngggg ccccaaaarrrrdddd ttttoooo tttthhhheeee wwwwoooorrrrlllldddd ooooffff mmmmeeeeddddiiiiccccaaaallll ddddeeeevvvviiiicccceeeesssswwwweeee hhhhaaaavvvveeee uuuunnnniiiiqqqquuuueeee iiiinnnnssssiiiigggghhhhtttt iiiinnnnttttoooo sssscccciiiieeeennnncccceeee aaaannnndddd tttteeeecccchhhhnnnnoooollllooooggggyyyy wwwweeee rrrreeeemmmmaaaaiiiinnnn ooooppppeeeennnn ttttoooo tttthhhheeee cccchhhhaaaalllllllleeeennnnggggeeeessss aaaannnndddd ooooppppppppoooorrrrttttuuuunnnniiiittttiiiieeeessss wwwwhhhheeeennnneeeevvvveeeerrrr aaaannnndddd bbbbeeeesssstttt iiiiddddeeeeaaaassss nnnnoooo mmmmaaaatttttttteeeerrrr wwwwhhhheeeerrrreeee tttthhhheeeeyyyy ccccoooommmmeeee ffffrrrroooommmm wwwwhhhheeeerrrreeeevvvveeeerrrr tttthhhheeeeyyyy eeeemmmmeeeerrrrggggeeee wwwweeee aaaarrrreeee ssssttttrrrruuuuccccttttuuuurrrreeeedddd ttttoooo aaaassss wwwweeee rrrreeeelllleeeennnnttttlllleeeessssssssllllyyyy ppppuuuurrrrssssuuuueeee ttttrrrraaaannnnssssffffoooorrrrmmmmaaaattttiiiioooonnnnaaaallll mmmmeeeeeeeetttt tttthhhheeee ccccuuuurrrrrrrreeeennnntttt aaaannnndddd ffffuuuuttttuuuurrrreeee nnnneeeeeeeeddddssss ooooffff ppppaaaattttiiiieeeennnnttttssss iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn ttttoooo bbbbeeeennnneeeefifififitttt hhhhuuuummmmaaaannnn hhhheeeeaaaalllltttthhhh iiiinnnntttteeeerrrrnnnnaaaallllllllyyyy aaaannnndddd ccccoooonnnnssssuuuummmmeeeerrrrssss gggglllloooobbbbaaaallllllllyyyy aaaannnndddd ttttoooo aaaaddddddddrrrreeeessssssss tttthhhheeee aaaannnndddd tttthhhhrrrroooouuuugggghhhhoooouuuutttt oooouuuurrrr iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn eeeeccccoooossssyyyysssstttteeeemmmm cccchhhhaaaalllllllleeeennnnggggeeeessss aaaannnndddd ooooppppppppoooorrrrttttuuuunnnniiiittttiiiieeeessss tttthhhhaaaatttt tttthhhheeee wwwwoooorrrrlllldddd aaaaccccrrrroooossssssss oooouuuurrrr iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn cccceeeennnntttteeeerrrrssss jjjjllllaaaabbbbssss ooooffff hhhheeeeaaaalllltttthhhhccccaaaarrrreeee pppprrrreeeesssseeeennnnttttssss wwwweeee rrrreeeemmmmaaaaiiiinnnn ffffooooccccuuuusssseeeedddd oooonnnn jjjjjjjjddddcccc aaaannnndddd mmmmaaaannnnyyyy ssssttttrrrraaaatttteeeeggggiiiicccc ppppaaaarrrrttttnnnneeeerrrrsssshhhhiiiippppssss lllleeeevvvveeeerrrraaaaggggiiiinnnngggg oooouuuurrrr bbbbrrrrooooaaaaddddbbbbaaaasssseeeedddd ccccaaaappppaaaabbbbiiiilllliiiittttiiiieeeessss ttttoooo cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidccccoooonnnnttttiiiinnnnuuuueeee ttttoooo ddddrrrriiiivvvveeee tttthhhheeee nnnneeeexxxxtttt ggggeeeennnneeeerrrraaaattttiiiioooonnnn ooooffff ggggrrrroooowwwwtttthhhh bbbbuuuussssiiiinnnneeeessssssss ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee aaaannnndddd oooouuuuttttllllooooooookkkk aaaaccccrrrroooossssssss oooouuuurrrr eeeennnnttttiiiirrrreeee ppppoooorrrrttttffffoooolllliiiioooo bbbbooootttthhhh iiiinnnn mmmmaaaarrrrkkkkeeeettttssss pppphhhhaaaarrrrmmmmaaaacccceeeeuuuuttttiiiiccccaaaallll wwwwhhhheeeerrrreeee wwwweeee hhhhaaaavvvveeee ggggrrrreeeeaaaatttteeeerrrr ooooppppppppoooorrrrttttuuuunnnniiiittttyyyy ttttoooo ccccoooommmmppppeeeetttteeee wwwiiiittthhhh aaannn iiiinnndddduuussstttrrryyylllleeeaaaddddiiiinnnggg pppiiiipppeeelllliiiinnneee aaannndddd eeessstttaaabbbblllliiiissshhhheeedddd aaaassss wwwweeeellllllll aaaassss iiiinnnn tttthhhheeee mmmmaaaarrrrkkkkeeeettttssss wwwwhhhheeeerrrreeee wwwweeee lllleeeeaaaadddd wwwwhhhhiiiicccchhhh ccccoooommmmmmmmeeeerrrrcccciiiiaaaallll eeeexxxxcccceeeelllllllleeeennnncccceeee oooouuuurrrr pppphhhhaaaarrrrmmmmaaaacccceeeeuuuuttttiiiiccccaaaallll iiiinnnncccclllluuuuddddeeee oooouuuurrrr ppppllllaaaattttffffoooorrrrmmmmssss tttthhhhaaaatttt eeeeaaaacccchhhh ddddeeeelllliiiivvvveeeerrrreeeedddd bbbbuuusssiiiinnneeessssss hhhhaaasss ddddeeelllliiiivvveeerrreeedddd ooouuutttssstttaaannnddddiiiinnnggg pppeeerrrffffooorrrmmmaaannnccceee aaaa bbbbiiiilllllllliiiioooonnnn ddddoooollllllllaaaarrrrssss oooorrrr mmmmoooorrrreeee iiiinnnn ssssaaaalllleeeessss llllaaaasssstttt yyyyeeeeaaaarrrr cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid oooouuuurrrr bbbbrrrrooooaaaadddd bbbbaaaasssseeee iiiissss nnnnooootttt jjjjuuuusssstttt oooouuuurrrr hhhheeeerrrriiiittttaaaaggggeeee iiiitttt llllaaaauuuunnnncccchhhheeeessss aaaannnndddd ssssttttrrrroooonnnngggg ggggrrrroooowwwwtttthhhh iiiinnnn sssseeeevvvveeeerrrraaaallll ooooffff iiiissss aaaa ssssttttrrrraaaatttteeeeggggiiiicccc cccchhhhooooiiiicccceeee ggggrrrroooouuuunnnnddddeeeedddd aaaannnndddd pppprrrroooovvvveeeennnn oooouuuurrrr bbbblllloooocccckkkkbbbbuuuusssstttteeeerrrr mmmmeeeeddddiiiicccciiiinnnneeeessss ccccrrrreeeeaaaatttteeeedddd iiiinnnn lllloooonnnnggggtttteeeerrrrmmmm ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee aaaannnndddd oooouuuurrrr bbbbrrrrooooaaaadddd ooopppeeerrraaatttiiiiooonnnaaallll gggrrrooowwwttthhhh aaannndddd ooouuurrr ppphhhhaaarrrmmmaaaccceeeuuutttiiiicccaaallll aaaannnndddd ddddeeeeeeeepppp uuuunnnnddddeeeerrrrssssttttaaaannnnddddiiiinnnngggg ooooffff tttthhhheeee iiiinnnndddduuuussssttttrrrryyyyssss bbbbuuuussssiiiinnnneeeessssssss ccccoooonnnnttttiiiinnnnuuuueeeessss ttttoooo bbbbeeee aaaannnn iiiinnnndddduuuussssttttrrrryyyy lllleeeeaaaaddddeeeerrrr iiiinnnn pppprrrreeeesssseeeennnntttt aaaannnndddd ffffuuuuttttuuuurrrreeee wwwweeee cccclllleeeeaaaarrrrllllyyyy rrrreeeeccccooooggggnnnniiiizzzzeeee tttthhhheeee aaaallllllll ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee mmmmeeeeaaaassssuuuurrrreeeessss iiiinnnncccclllluuuuddddiiiinnnngggg rrrrdddd iiiimmmmppppoooorrrrttttaaaannnntttt rrrroooolllleeee wwwweeee ppppllllaaaayyyy iiiinnnn lllleeeeaaaaddddiiiinnnngggg rrrreeeessssppppoooonnnnssssiiiibbbbllllyyyy aaaannnndddd rrrreeeepppprrrreeeesssseeeennnnttttiiiinnnngggg oooouuuurrrr iiiinnnndddduuuussssttttrrrryyyy wwwwiiiitttthhhh iiiinnnntttteeeeggggrrrriiiittttyyyy aaaassss wwwweeee llllooooooookkkk ttttoooowwwwaaaarrrrdddd aaaannnndddd bbbbeeeeyyyyoooonnnndddd wwwweeee rrrreeeemmmmaaaaiiiinnnn fffooocccuuussseeeddd ooonnn bbbrrriiinnnggggiiinnngggg iiinnnnnnooovvvaaatttiiivvveee sssooollluuutttiiiooonnnsss tttooo oooouuuurrrr hhhheeeeaaaalllltttthhhh ffffoooorrrr hhhhuuuummmmaaaannnniiiittttyyyy rrrreeeeppppoooorrrrtttt uuuunnnnddddeeeerrrrssssccccoooorrrreeeessss ppppaaaattttiiiieeeennnnttttssss aaaannnndddd hhhheeeeaaaalllltttthhhhccccaaaarrrreeee pppprrrroooovvvviiiiddddeeeerrrrssss gggglllloooobbbbaaaallllllllyyyy oooouuuurrrr ccccoooommmmmmmmiiiittttmmmmeeeennnntttt ttttoooo hhhheeeellllpppp eeeennnnssssuuuurrrreeee tttthhhhaaaatttt eeeeaaaacccchhhh nnnneeeewwww wwwwhhhhiiiilllleeee ddddrrrriiiivvvviiiinnnngggg ssssttttrrrroooonnnngggg ggggrrrroooowwwwtttthhhh aaaannnndddd ccccoooonnnnttttiiiinnnnuuuuiiiinnnngggg ggggeeeennnneeeerrrraaaattttiiiioooonnnn iiiissss hhhheeeeaaaalllltttthhhhiiiieeeerrrr tttthhhhaaaannnn tttthhhheeee llllaaaasssstttt wwwweeee bbbbeeeelllliiiieeeevvvveeee ttttoooo aaaaddddvvvvaaaannnncccceeee oooouuuurrrr ppppiiiippppeeeelllliiiinnnneeee ppppaaaatttteeeennnntttt pppprrrreeeessssssssuuuurrrreeee iiiissss aaaa oooouuuurrrr bbbbrrrrooooaaaadddd bbbbaaaasssseeee hhhheeeellllppppssss uuuussss bbbbeeeetttttttteeeerrrr uuuunnnnddddeeeerrrrssssttttaaaannnndddd aaaannnndddd fffeeeaaatttuuurrreee ooofff tttooodddaaayyyysss pppphhhaaarrrmmmaaaccceeeuuutttiiicccaaalll iiinnnddduuussstttrrryyyy aaannnddd ppppoooossssiiiittttiiiivvvveeeellllyyyy iiiimmmmppppaaaacccctttt hhhhuuuummmmaaaannnn hhhheeeeaaaalllltttthhhh aaaatttt eeeevvvveeeerrrryyyy aaaaggggeeee aaaannnndddd wwweee hhhhaaavvveee ddddeeelllliiiibbbbeeerrraaattteeellllyyy aaannndddd aaaccctttiiiivvveeellllyyy mmmaaannnaaagggeeedddd ooouuurrr aaaatttt eeeevvvveeeerrrryyyy ssssttttaaaaggggeeee iiiinnnn wwwweeee wwwweeeerrrreeee rrrreeeeccccooooggggnnnniiiizzzzeeeedddd aaaassss oooonnnneeee ppppoooorrrrttttffffoooolllliiiioooo oooovvvveeeerrrr tttthhhheeee llllaaaasssstttt ffffeeeewwww yyyyeeeeaaaarrrrssss ttttoooo eeeennnnaaaabbbblllleeee uuuussss ooooffff tttthhhheeee ttttoooopppp tttteeeennnn ccccoooorrrrppppoooorrrraaaattttiiiioooonnnnssss ffffoooorrrr oooouuuurrrr eeeennnnvvvviiiirrrroooonnnnmmmmeeeennnnttttaaaallll tttooo mmmaaakkkeee ttthhheee iiinnnvvveeessstttmmmeeennntttsss nnneeeccceeessssssaaarrryyyy tttooo nnnooottt ooonnnlllyyyy ssssoooocccciiiiaaaallll aaaannnndddd ggggoooovvvveeeerrrrnnnnaaaannnncccceeee ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee bbbbyyyy wwwiiiittthhhhssstttaaannndddd ttthhhhiiiisss iiiimmmpppaaacccttt bbbbuuuttt tttooo gggrrrooowww aaattt cccooommmpppeeetttiiiitttiiiivvveee ccccoooorrrrppppoooorrrraaaatttteeee rrrreeeessssppppoooonnnnssssiiiibbbbiiiilllliiiittttyyyy mmmmaaaaggggaaaazzzziiiinnnneeee rrraaattteeesss iiiinnn wwweee rrreeemmmaaaiiiinnn ffffooocccuuussseeedddd ooonnn ddddeeevvveeellllooopppiiiinnnggg mmmmeeeeddddiiiicccciiiinnnneeeessss aaaannnndddd ssssoooolllluuuuttttiiiioooonnnnssss tttthhhhaaaatttt ddddeeeelllliiiivvvveeeerrrr ggggrrrreeeeaaaatttt vvvvaaaalllluuuueeee tttooo ttthhheee ppppaaatttiiieeennntttsss aaannnddd cccooonnnsssuuummmeeerrrsss wwwhhhooo dddeeeppppeeennnddd broad base heritage oooonnnn oooouuuurrrr pppprrrroooodddduuuuccccttttssss ttttoooo mmmmaaaakkkkeeee tttthhhheeeeiiiirrrr lllliiiivvvveeeessss bbbbeeeetttttttteeeerrrr oooouuuurrrr strategic choice ground ggggooooaaaallll aaaannnndddd eeeexxxxppppeeeeccccttttaaaattttiiiioooonnnn ffffoooorrrr aaaannnndddd bbbbeeeeyyyyoooonnnndddd iiiissss prove longterm performance ssssuuuussssttttaaaaiiiinnnneeeedddd lllloooonnnnggggtttteeeerrrrmmmm aaaabbbboooovvvveeeemmmmaaaarrrrkkkkeeeetttt ggggrrrroooowwwwtttthhhh broad deep understanding wwweee kkkknnnooowww ttthhhhaaattt iiiinnnnnnooovvvaaatttiiiiooonnn ddddrrriiiivvveeesss ooouuurrr industry present future ppphhhaaarrrmmmaaaccceeeuuutttiiicccaaalll bbbuuusssiiinnneeesssssssss sssuuucccccceeessssss aaannnddd wwweee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ccccoooollllllllaaaabbbboooorrrraaaattttiiiioooonnnn iiiissss ffffuuuunnnnddddaaaammmmeeeennnnttttaaaallll ttttoooo tttthhhheeee wwwwoooorrrrkkkk wwwweeee ddddoooo cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid eeeevvvveeeerrrryyyy ddddaaaayyyy aaaannnndddd oooouuuurrrr pppprrrreeeesssseeeennnncccceeee iiiinnnn jjjjuuuusssstttt aaaabbbboooouuuutttt eeeevvvveeeerrrryyyy cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaarrrreeeeaaaa ooooffff hhhheeeeaaaalllltttthhhhccccaaaarrrreeee tttthhhhiiiissss lllleeeevvvveeeellll ooooffff eeeennnnggggaaaaggggeeeemmmmeeeennnntttt ttttrrrreeeeaaaattttmmmmeeeennnntttt rrrreeeessssiiiissssttttaaaannnntttt ddddeeeepppprrrreeeessssssssiiiioooonnnn ttttrrrrdddd wwwwhhhhoooo aaaalllllllloooowwwwssss uuuussss ttttoooo mmmmaaaaiiiinnnnttttaaaaiiiinnnn aaaa ccccoooonnnnttttiiiinnnnuuuuoooouuuussss ddddiiiiaaaalllloooogggguuuueeee hhhhaaaavvvveeee ccccyyyycccclllleeeedddd tttthhhhrrrroooouuuugggghhhh mmmmuuuullllttttiiiipppplllleeee ttttrrrreeeeaaaattttmmmmeeeennnnttttssss wwwwiiiitttthhhh hhhheeeeaaaalllltttthhhhccccaaaarrrreeee pppprrrrooooffffeeeessssssssiiiioooonnnnaaaallllssss bbbbuuuussssiiiinnnneeeessssssss lllleeeeaaaaddddeeeerrrrssss wwwwiiiitttthhhhoooouuuutttt rrrreeeelllliiiieeeeffff ttttrrrrdddd iiiissss aaaa ddddeeeebbbbiiiilllliiiittttaaaattttiiiinnnngggg ddddiiiisssseeeeaaaasssseeee tttthhhhaaaatttt aaaaccccaaaaddddeeeemmmmiiiiccccssss ggggoooovvvveeeerrrrnnnnmmmmeeeennnntttt ooooffiffiffifficccciiiiaaaallllssss sssscccciiiieeeennnnttttiiiissssttttssss iiiissss aaaassssssssoooocccciiiiaaaatttteeeedddd wwwwiiiitttthhhh cccchhhhrrrroooonnnniiiicccc hhhheeeeaaaalllltttthhhh pppprrrroooobbbblllleeeemmmmssss aaaannnndddd pppprrrroooovvvviiiiddddeeeerrrr ssssyyyysssstttteeeemmmmssss ccccuuuussssttttoooommmmeeeerrrrssss ppppaaaattttiiiieeeennnnttttssss aaaannnndddd qqqquuuuiiiitttteeee ttttrrrraaaaggggiiiiccccaaaallllllllyyyy ccccaaaannnn lllleeeeaaaadddd ttttoooo ssssuuuuiiiicccciiiiddddeeee iiiiffff nnnnooootttt ttttrrrreeeeaaaatttteeeedddd ccccoooonnnnssssuuuummmmeeeerrrrssss wwwweeee rrrreeeemmmmaaaaiiiinnnn ccccoooommmmmmmmiiiitttttttteeeedddd ttttoooo bbbbeeeeiiiinnnngggg aaaa cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid lllleeeeaaaaddddeeeerrrr iiiinnnn tttthhhheeee gggglllloooobbbbaaaallll hhhheeeeaaaalllltttthhhhccccaaaarrrreeee ssssppppaaaacccceeee ttttoooo hhhheeeellllpppp ddddrrrriiiivvvveeee bbbbrrrreeeeaaaakkkktttthhhhrrrroooouuuugggghhhh mmmmeeeeddddiiiicccciiiinnnneeee iiiinnnn oooouuuurrrr pppprrrroooodddduuuucccctttt ppppoooorrrrttttffffoooolllliiiioooo tttthhhheeee cccchhhhaaaannnnggggeeee tttthhhhaaaatttt ppppeeeeoooopppplllleeee aaaarrrroooouuuunnnndddd tttthhhheeee wwwwoooorrrrlllldddd wwwwaaaannnntttt bbbbuuuutttt aaaallllssssoooo aaaa nnnneeeewwww hhhhooooppppeeee ffffoooorrrr aaaadddduuuullllttttssss wwwwhhhhoooo ssssuuuuffffffffeeeerrrr ffffrrrroooommmm aaaannnndddd nnnneeeeeeeedddd ttttoooo sssseeeeeeee ttttrrrrdddd iiiitttt aaaallllssssoooo ooooffffffffeeeerrrrssss tttthhhheeee fifififirrrrsssstttt nnnneeeewwww mmmmeeeecccchhhhaaaannnniiiissssmmmm wwwweeee sssseeeeeeee aaaa vvvviiiittttaaaallll aaaannnndddd vvvviiiibbbbrrrraaaannnntttt ffffuuuuttttuuuurrrreeee ffffoooorrrr hhhheeeeaaaalllltttthhhhccccaaaarrrreeee ooooffff aaaaccccttttiiiioooonnnn ttttoooo aaaaddddddddrrrreeeessssssss ttttrrrrdddd aaaannnndddd iiiimmmmppppoooorrrrttttaaaannnnttttllllyyyy iiiinnnn aaaarrrroooouuuunnnndddd tttthhhheeee wwwwoooorrrrlllldddd tttthhhhaaaatttt iiiissss bbbbeeeeiiiinnnngggg ddddrrrriiiivvvveeeennnn bbbbyyyy tttthhhheeee aaaaccccccccoooorrrrddddaaaannnncccceeee wwwwiiiitttthhhh rrrriiiisssskkkk mmmmiiiittttiiiiggggaaaattttiiiioooonnnn gggguuuuiiiiddddaaaannnncccceeee ffffrrrroooommmm ccccoooonnnnttttiiiinnnnuuuuiiiinnnngggg eeeexxxxppppaaaannnnssssiiiioooonnnn ooooffff tttthhhheeee gggglllloooobbbbaaaallll mmmmiiiiddddddddlllleeee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ccccllllaaaassssssss iiiitttt iiiissss tttthhhheeee mmmmiiiiddddddddlllleeee ccccllllaaaassssssss tttthhhhaaaatttt ddddrrrriiiivvvveeeessss gggglllloooobbbbaaaallll bbbbyyyy cccceeeerrrrttttiiiififififieeeedddd ttttrrrreeeeaaaattttmmmmeeeennnntttt cccceeeennnntttteeeerrrrssss aaaannnndddd wwwwiiiillllllll nnnnooootttt bbbbeeee eeeeccccoooonnnnoooommmmiiiicccc ggggrrrroooowwwwtttthhhh aaaannnndddd wwwwiiiitttthhhh iiiitttt tttthhhheeee ddddeeeemmmmaaaannnndddd ffffoooorrrr ddddiiiissssppppeeeennnnsssseeeedddd ddddiiiirrrreeeeccccttttllllyyyy ttttoooo ppppaaaattttiiiieeeennnnttttssss ttttoooo ttttaaaakkkkeeee aaaatttt hhhhoooommmmeeee ggggrrrreeeeaaaatttteeeerrrr aaaacccccccceeeessssssss ttttoooo qqqquuuuaaaalllliiiittttyyyy hhhheeeeaaaalllltttthhhhccccaaaarrrreeee iiii bbbbeeeelllliiiieeeevvvveeee tttthhhhaaaatttt nnnnoooo ccccoooommmmppppaaaannnnyyyy oooonnnn eeeeaaaarrrrtttthhhh iiiissss bbbbeeeetttttttteeeerrrr ppppoooossssiiiittttiiiioooonnnneeeedddd wwwweeee hhhhaaaavvvveeee lllliiiisssstttteeeennnneeeedddd wwwwiiiitttthhhh ggggrrrreeeeaaaatttt iiiinnnntttteeeennnntttt ttttoooo tttthhhheeee ccccoooonnnncccceeeerrrrnnnnssss tttthhhhaaaannnn jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn ttttoooo ccccaaaappppttttuuuurrrreeee tttthhhhiiiissss vvvvooooiiiicccceeeedddd bbbbyyyy mmmmaaaannnnyyyy ssssttttaaaakkkkeeeehhhhoooollllddddeeeerrrrssss oooovvvveeeerrrr tttthhhheeee pppprrrriiiicccciiiinnnngggg aaaannnndddd ooooppppppppoooorrrrttttuuuunnnniiiittttyyyy aaaannnndddd lllleeeeaaaadddd tttthhhheeee hhhheeeeaaaalllltttthhhhccccaaaarrrreeee iiiinnnndddduuuussssttttrrrryyyy ttttrrrraaaannnnssssppppaaaarrrreeeennnnccccyyyy ooooffff pppprrrroooodddduuuuccccttttssss aaaannnndddd oooouuuurrrr hhhheeeeaaaalllltttthhhhccccaaaarrrreeee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ffffrrrraaaaggggrrrraaaannnncccceeee iiiinnnnggggrrrreeeeddddiiiieeeennnnttttssss aaaabbbboooovvvveeee ppppaaaarrrrttttssss ppppeeeerrrr mmmmiiiilllllllliiiioooonnnn wwwwoooorrrrlllldddd wwwweeee aaaarrrreeee ccccoooommmmmmmmiiiitttttttteeeedddd ttttoooo ttttaaaakkkkiiiinnnngggg tttthhhheeee lllleeeeaaaadddd ppppppppmmmm iiiinnnn oooouuuurrrr sssshhhhaaaammmmppppoooooooossss wwwwaaaasssshhhheeeessss aaaannnndddd lllloooottttiiiioooonnnnssss bbbbeeeeiiiinnnngggg rrrreeeessssppppoooonnnnssssiiiibbbblllleeee ppppaaaarrrrttttnnnneeeerrrrssss aaaannnndddd ddddooooiiiinnnngggg oooouuuurrrr ppppaaaarrrrtttt ttttoooo aaaannnndddd wwwweeeevvvveeee bbbbeeeeeeeennnn rrrreeeeccccooooggggnnnniiiizzzzeeeedddd ffffoooorrrr tttthhhhiiiissss ggggrrrreeeeaaaatttteeeerrrr nnnnooootttt oooonnnnllllyyyy ttttrrrreeeeaaaatttt ppppaaaattttiiiieeeennnnttttssss bbbbuuuutttt aaaallllssssoooo eeeennnnssssuuuurrrreeee tttthhhheeeeyyyy ccccaaaannnn ttttrrrraaaannnnssssppppaaaarrrreeeennnnccccyyyy bbbbyyyy tttthhhheeee eeeennnnvvvviiiirrrroooonnnnmmmmeeeennnnttttaaaallll wwwwoooorrrrkkkkiiiinnnngggg ggggeeeetttt aaaacccccccceeeessssssss iiiinnnn aaaannnn ooooppppeeeennnn aaaannnndddd aaaaffffffffoooorrrrddddaaaabbbblllleeee mmmmaaaannnnnnnneeeerrrr ggggrrrroooouuuupppp oooouuuurrrr rrrreeeellllaaaauuuunnnncccchhhh aaaallllssssoooo iiiinnnncccclllluuuuddddeeeessss nnnneeeewwww ppppaaaacccckkkkaaaaggggiiiinnnngggg aaaannnndddd iiiinnnnffffoooorrrrmmmmaaaattttiiiioooonnnnaaaallll ssssoooocccciiiiaaaallll mmmmeeeeddddiiiiaaaa ccccoooommmmmmmmuuuunnnniiiiccccaaaattttiiiioooonnnnssss aaaassss aaaa rrrreeeessssuuuulllltttt ooooffff ddddiiiirrrreeeecccctttt iiiinnnntttteeeerrrraaaaccccttttiiiioooonnnn wwwwiiiitttthhhh ppppaaaattttiiiieeeennnnttttssss ttttaaaaiiiilllloooorrrreeeedddd ttttoooo tttthhhheeee nnnneeeeeeeeddddssss aaaannnndddd wwwwaaaannnnttttssss ooooffff mmmmiiiilllllllleeeennnnnnnniiiiaaaallll tttthhhheeeeiiiirrrr ffffaaaammmmiiiilllliiiieeeessss aaaannnndddd hhhheeeeaaaalllltttthhhhccccaaaarrrreeee pppprrrrooooffffeeeessssssssiiiioooonnnnaaaallllssss cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid rrrreeeellllaaaauuuunnnncccchhhh iiiissss ooooffffffff ttttoooo aaaa ssssoooolllliiiidddd ssssttttaaaarrrrtttt aaaannnndddd wwwweeee wwwwiiiillllllll ccccoooonnnnttttiiiinnnnuuuueeee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ttttoooo llllaaaauuuunnnncccchhhh aaaaccccrrrroooossssssss gggglllloooobbbbaaaallll mmmmaaaarrrrkkkkeeeettttssss tttthhhhrrrroooouuuugggghhhhoooouuuutttt cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaannnn iiiimmmmppppoooorrrrttttaaaannnntttt mmmmeeeeaaaassssuuuurrrreeee ttttoooo hhhheeeellllpppp ccccoooonnnnssssuuuummmmeeeerrrrssss ggggaaaaiiiinnnn aaaa aaaaddddddddiiiittttiiiioooonnnnaaaallllllllyyyy iiiinnnn rrrreeeessssppppoooonnnnsssseeee ttttoooo oooouuuurrrr ccccoooonnnnssssuuuummmmeeeerrrrssss aaaasssskkkkiiiinnnngggg bbbbeeeetttttttteeeerrrr ppppiiiiccccttttuuuurrrreeee ooooffff wwwwhhhhaaaatttt tttthhhheeeeyyyy sssshhhhoooouuuulllldddd eeeexxxxppppeeeecccctttt ttttoooo ppppaaaayyyy ffffoooorrrr ppppeeeerrrrssssoooonnnnaaaalllliiiizzzzeeeedddd sssskkkkiiiinnnnccccaaaarrrreeee ssssoooolllluuuuttttiiiioooonnnnssss tttthhhhaaaatttt aaaaddddddddrrrreeeessssssss ffffoooorrrr tttthhhheeeeiiiirrrr mmmmeeeeddddiiiicccciiiinnnneeeessss wwwweeee hhhhaaaavvvveeee pppprrrrooooppppoooosssseeeedddd iiiinnnncccclllluuuuddddiiiinnnngggg tttthhhheeeeiiiirrrr sssskkkkiiiinnnnssss uuuunnnniiiiqqqquuuueeee nnnneeeeeeeeddddssss wwwweeee aaaarrrreeee ddddeeeevvvveeeellllooooppppiiiinnnngggg lllliiiissssttttpppprrrriiiicccceeee iiiinnnnffffoooorrrrmmmmaaaattttiiiioooonnnn iiiinnnn ddddiiiirrrreeeeccccttttttttooooccccoooonnnnssssuuuummmmeeeerrrr ttttvvvv oooouuuurrrr mmmmoooosssstttt ppppeeeerrrrssssoooonnnnaaaalllliiiizzzzeeeedddd sssskkkkiiiinnnnccccaaaarrrreeee pppprrrroooodddduuuucccctttt ttttoooo aaaaddddssss ssssttttaaaarrrrttttiiiinnnngggg wwwwiiiitttthhhh oooouuuurrrr mmmmoooossssttttpppprrrreeeessssccccrrrriiiibbbbeeeedddd mmmmeeeeddddiiiicccciiiinnnneeee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid xxxxaaaarrrreeeellllttttoooo rrrriiiivvvvaaaarrrrooooxxxxaaaabbbbaaaannnn aaaannnn oooorrrraaaallll aaaannnnttttiiiiccccooooaaaagggguuuullllaaaannnntttt ddddpppprrrriiiinnnntttteeeedddd sssshhhheeeeeeeetttt mmmmaaaasssskkkk iiiissss iiiinnnnssssppppiiiirrrreeeedddd bbbbyyyy uuuusssseeeerrrr ddddaaaattttaaaa ttttoooo eeeennnnssssuuuurrrreeee ppppaaaattttiiiieeeennnnttttssss hhhhaaaavvvveeee ccccllllaaaarrrriiiittttyyyy wwwweeee ppppllllaaaannnn ttttoooo aaaannnndddd wwwwiiiillllllll ddddeeeelllliiiivvvveeeerrrr tttthhhheeee cccclllliiiinnnniiiiccccaaaallll eeeeffiffiffifficcccaaaaccccyyyy eeeexxxxppppeeeecccctttteeeedddd iiiinnnncccclllluuuuddddeeee bbbbooootttthhhh tttthhhheeee lllliiiisssstttt pppprrrriiiicccceeee aaaannnndddd ppppooootttteeeennnnttttiiiiaaaallll ppppaaaattttiiiieeeennnntttt ffffrrrroooommmm tttthhhheeee ddddeeeerrrrmmmmaaaattttoooollllooooggggiiiissssttttrrrreeeeccccoooommmmmmmmeeeennnnddddeeeedddd oooouuuuttttooooffffppppoooocccckkkkeeeetttt ccccoooossssttttssss wwwweeee bbbbeeeelllliiiieeeevvvveeee ttttrrrraaaannnnssssppppaaaarrrreeeennnnccccyyyy iiiissss cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaa ffffuuuunnnnddddaaaammmmeeeennnnttttaaaallll rrrreeeessssppppoooonnnnssssiiiibbbbiiiilllliiiittttyyyy ooooffff tttthhhhiiiissss ccccoooommmmppppaaaannnnyyyy iiiissss aaaallllrrrreeeeaaaaddddyyyy gggglllloooobbbbaaaallllllllyyyy rrrreeeeccccooooggggnnnniiiizzzzeeeedddd ffffoooorrrr ddddeeeelllliiiivvvveeeerrrriiiinnnngggg iiiittttssss aaaallllssssoooo aaaannnnooootttthhhheeeerrrr ssssttttrrrroooonnnngggg ddddeeeemmmmoooonnnnssssttttrrrraaaattttiiiioooonnnn tttthhhhaaaatttt ttttooooppppiiiiccccaaaallll sssskkkkiiiinnnnccccaaaarrrreeee ssssoooolllluuuuttttiiiioooonnnnssss aaaatttt tttthhhheeee iiiinnnntttteeeerrrrsssseeeeccccttttiiiioooonnnn oooouuuurrrr ppppuuuurrrrppppoooosssseeee ffffooooccccuuuusssseeeedddd oooonnnn hhhheeeellllppppiiiinnnngggg ppppaaaattttiiiieeeennnnttttssss iiiissss ooooffff sssscccciiiieeeennnncccceeee aaaannnndddd tttteeeecccchhhhnnnnoooollllooooggggyyyy tttthhhhiiiissss nnnneeeewwww pppprrrroooodddduuuucccctttt ddddrrrriiiivvvviiiinnnngggg oooouuuurrrr bbbbuuuussssiiiinnnneeeessssssss jjjjuuuusssstttt aaaassss iiiitttt sssshhhhoooouuuulllldddd bbbbeeee wwwwiiiillllllll rrrreeeepppprrrreeeesssseeeennnntttt oooonnnneeee ffffuuuurrrrtttthhhheeeerrrr sssstttteeeepppp ttttoooowwwwaaaarrrrdddd aaaa nnnneeeewwww mmmmooooddddeeeellll ooooffff pppprrrroooodddduuuucccctttt ddddeeeevvvveeeellllooooppppmmmmeeeennnntttt wwwwhhhheeeerrrreeee wwwweeee fifififinnnndddd oooouuuurrrr pppphhhhaaaarrrrmmmmaaaacccceeeeuuuuttttiiiiccccaaaallll bbbbuuuussssiiiinnnneeeessssssss hhhhaaaassss ttttaaaakkkkeeeennnn aaaa ssssttttrrrroooonnnngggg ccccrrrreeeeaaaattttiiiivvvveeee uuuusssseeeessss ffffoooorrrr tttthhhheeee llllaaaatttteeeesssstttt tttteeeecccchhhhnnnnoooollllooooggggyyyy ssssuuuucccchhhh aaaassss lllleeeeaaaaddddeeeerrrrsssshhhhiiiipppp ssssttttaaaannnncccceeee oooonnnn iiiinnnnccccrrrreeeeaaaassssiiiinnnngggg ttttrrrraaaannnnssssppppaaaarrrreeeennnnccccyyyy ddddiiiiggggiiiittttaaaallll iiiimmmmaaaaggggiiiinnnngggg sssskkkkiiiinnnn aaaannnnaaaallllyyyyssssiiiissss aaaannnndddd dddd pppprrrriiiinnnnttttiiiinnnngggg iiiinnnn tttthhhheeee iiiinnnndddduuuussssttttrrrryyyy iiii aaaammmm pppplllleeeeaaaasssseeeedddd ttttoooo sssshhhhaaaarrrreeee wwwweeee ttttoooo ggggiiiivvvveeee ccccoooonnnnssssuuuummmmeeeerrrrssss nnnneeeewwww wwwwaaaayyyyssss ttttoooo aaaacccchhhhiiiieeeevvvveeee tttthhhheeeeiiiirrrr cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid bbbbeeeesssstttt sssskkkkiiiinnnnccccaaaarrrreeee ppppoooossssssssiiiibbbblllleeee iiiitttt iiiissss aaaallllssssoooo aaaa ggggrrrreeeeaaaatttt eeeexxxxaaaammmmpppplllleeee ttttrrrraaaannnnssssppppaaaarrrreeeennnnccccyyyy rrrreeeeppppoooorrrrtttt iiiinnnn llllaaaatttteeee mmmmaaaarrrrcccchhhh tttthhhhiiiissss rrrreeeeppppoooorrrrtttt ooooffff hhhhoooowwww wwwweeee aaaarrrreeee lllleeeevvvveeeerrrraaaaggggiiiinnnngggg iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn aaaaccccrrrroooossssssss rrrreeeeflflflfleeeeccccttttiiiivvvveeee ooooffff oooouuuurrrr aaaaccccttttiiiioooonnnnssss iiiinnnn sssshhhhoooowwwwssss tttthhhhaaaatttt oooouuuurrrr oooouuuurrrr bbbbuuuussssiiiinnnneeeessssssss sssseeeeggggmmmmeeeennnnttttssss aaaassss oooouuuurrrr dddd pppprrrriiiinnnnttttiiiinnnngggg nnnneeeetttt pppprrrriiiicccceeeessss hhhhaaaavvvveeee ddddeeeeccccrrrreeeeaaaasssseeeedddd aaaaggggaaaaiiiinnnn bbbbyyyy ccccaaaappppaaaabbbbiiiilllliiiittttyyyy oooorrrriiiiggggiiiinnnnaaaatttteeeedddd wwwwiiiitttthhhhiiiinnnn mmmmeeeeddddiiiiccccaaaallll ddddeeeevvvviiiicccceeeessss ccccoooonnnnssssuuuummmmeeeerrrr mmmmeeeeddddiiiiccccaaaallll ddddeeeevvvviiiicccceeeessss iiiinnnn ffffuuuueeeelllleeeedddd bbbbyyyy oooouuuurrrr iiiiccccoooonnnniiiicccc bbbbrrrraaaannnnddddssss aaaannnndddd ddddeeeeeeeepppp oooouuuurrrr mmmmeeeeddddiiiiccccaaaallll ddddeeeevvvviiiicccceeeessss bbbbuuuussssiiiinnnneeeesssssssseeeessss aaaarrrreeee aaaammmmoooonnnngggg tttthhhheeee ccccoooonnnnssssuuuummmmeeeerrrr iiiinnnnssssiiiigggghhhhttttssss oooouuuurrrr ccccoooonnnnssssuuuummmmeeeerrrr bbbbuuuussssiiiinnnneeeessssssss mmmmoooosssstttt ddddiiiivvvveeeerrrrsssseeee aaaannnndddd ssssuuuucccccccceeeessssssssffffuuuullll iiiinnnn tttthhhheeee hhhheeeeaaaalllltttthhhhccccaaaarrrreeee aaaacccchhhhiiiieeeevvvveeeedddd aaaabbbboooovvvveeeemmmmaaaarrrrkkkkeeeetttt ggggrrrroooowwwwtttthhhh aaaassss wwwweeee llllooooooookkkk iiiinnnndddduuuussssttttrrrryyyy aaaatttt tttthhhheeee ssssaaaammmmeeee ttttiiiimmmmeeee wwwweeee ffffuuuullllllllyyyy rrrreeeeccccooooggggnnnniiiizzzzeeee aaaahhhheeeeaaaadddd wwwweeee wwwwiiiillllllll wwwwoooorrrrkkkk ttttoooo eeeennnnhhhhaaaannnncccceeee oooouuuurrrr lllleeeeaaaaddddeeeerrrrsssshhhhiiiipppp tttthhhhaaaatttt oooouuuurrrr pppprrrrooooggggrrrreeeessssssss hhhhaaaassss nnnnooootttt bbbbeeeeeeeennnn uuuunnnniiiiffffoooorrrrmmmm aaaaccccrrrroooossssssss iiiinnnn pppprrrriiiioooorrrriiiittttyyyy ccccaaaatttteeeeggggoooorrrriiiieeeessss bbbbyyyy ffffooooccccuuuussssiiiinnnngggg oooonnnn ccccrrrriiiittttiiiiccccaaaallll tttthhhheeee mmmmeeeeddddiiiiccccaaaallll ddddeeeevvvviiiicccceeeessss ppppoooorrrrttttffffoooolllliiiioooo wwwweeee hhhhaaaavvvveeee mmmmaaaannnnyyyy ggggeeeeooooggggrrrraaaapppphhhhiiiieeeessss aaaannnndddd oooouuuurrrr mmmmeeeeggggaaaabbbbrrrraaaannnnddddssss wwwwhhhhiiiilllleeee aaaallllssssoooo aaaarrrreeeeaaaassss ooooffff ppppaaaarrrrttttiiiiccccuuuullllaaaarrrrllllyyyy ssssttttrrrroooonnnngggg ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee ssssuuuucccchhhh ccccoooonnnnttttiiiinnnnuuuuiiiinnnngggg ttttoooo eeeexxxxppppaaaannnndddd iiiinnnnttttoooo tttthhhheeee ffffaaaassssttttggggrrrroooowwwwiiiinnnngggg aaaassss eeeelllleeeeccccttttrrrroooopppphhhhyyyyssssiiiioooollllooooggggyyyy vvvviiiissssiiiioooonnnn ccccaaaarrrreeee wwwwoooouuuunnnndddd nnnnaaaattttuuuurrrraaaallllssss ccccaaaatttteeeeggggoooorrrryyyy oooouuuurrrr aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnn ooooffff zzzzaaaarrrrbbbbeeeeeeeessss iiiinnnncccc cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid iiiinnnn oooottttcccc iiiissss aaaa kkkkeeeeyyyy eeeexxxxaaaammmmpppplllleeee ooooffff tttthhhhiiiissss eeeexxxxppppaaaannnnddddiiiinnnngggg ffffooooccccuuuussss aaaallllssssoooo aaaarrrreeeeaaaassss wwwwhhhheeeerrrreeee wwwweeee mmmmuuuusssstttt iiiimmmmpppprrrroooovvvveeee ssssppppeeeecccciiiifififificcccaaaallllllllyyyy wwwwiiiitttthhhhiiiinnnn oooorrrrtttthhhhooooppppaaaaeeeeddddiiiiccccssss wwwweeee ddddeeeemmmmoooonnnnssssttttrrrraaaatttteeeedddd pppprrrrooooggggrrrreeeessssssss wwwweeee hhhhaaaavvvveeee tttthhhheeee ssssttttrrrraaaatttteeeeggggiiiieeeessss iiiinnnn ppppllllaaaacccceeee ttttoooo mmmmoooovvvveeee wwwwiiiitttthhhh tttthhhheeee tttthhhhrrrroooouuuugggghhhhoooouuuutttt wwwwiiiitttthhhh tttthhhheeee ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee ooooffff oooouuuurrrr aaaaggggiiiilllliiiittttyyyy rrrreeeeqqqquuuuiiiirrrreeeedddd ttttoooo aaaaddddddddrrrreeeessssssss eeeevvvvoooollllvvvviiiinnnngggg mmmmaaaarrrrkkkkeeeetttt nnnneeeeeeeeddddssss kkkknnnneeeeeeee aaaannnndddd ssssppppiiiinnnneeee bbbbuuuussssiiiinnnneeeesssssssseeeessss aaaannnndddd wwwweeee bbbbeeeelllliiiieeeevvvveeee wwwweeee hhhhaaaavvvveeee aaaaddddoooopppptttteeeedddd aaaa mmmmuuuullllttttiiiicccchhhhaaaannnnnnnneeeellll aaaapppppppprrrrooooaaaacccchhhh tttthhhhiiiissss ppppoooossssiiiittttiiiioooonnnnssss uuuussss wwwweeeellllllll ffffoooorrrr aaaannnndddd bbbbeeeeyyyyoooonnnndddd ffffrrrroooommmm tttthhhheeee bbbbiiiiggggbbbbooooxxxx rrrreeeettttaaaaiiiilllleeeerrrrssss ttttoooo eeeeccccoooommmmmmmmeeeerrrrcccceeee cccchhhhaaaannnnnnnneeeellllssss ttttoooo bbbbeeeetttttttteeeerrrr sssseeeerrrrvvvveeee oooouuuurrrr ccccoooonnnnssssuuuummmmeeeerrrrssss iiiinnnn wwwweeee iiiimmmmpppprrrroooovvvveeeedddd ooooppppeeeerrrraaaattttiiiioooonnnnaaaallll ggggrrrroooowwwwtttthhhh tttthhhheeee rrrreeeessssuuuullllttttssss ooooffff oooouuuurrrr ccccoooonnnnttttiiiinnnnuuuuaaaallll ccccoooonnnnnnnneeeeccccttttiiiioooonnnn wwwwiiiitttthhhh eeeexxxxcccclllluuuuddddiiiinnnngggg aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnnssss aaaannnndddd ddddiiiivvvveeeessssttttiiiittttuuuurrrreeeessss bbbbyyyy ccccoooonnnnssssuuuummmmeeeerrrrssss ccccaaaannnn bbbbeeee sssseeeeeeeennnn iiiinnnn tttthhhheeee gggglllloooobbbbaaaallll rrrreeeellllaaaauuuunnnncccchhhh ooooffff aaaassss ccccoooommmmppppaaaarrrreeeedddd ttttoooo aaaaddddddddiiiittttiiiioooonnnnaaaallllllllyyyy cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid wwwweeee iiiimmmmpppprrrroooovvvveeeedddd oooouuuurrrr ccccaaaaddddeeeennnncccceeee ooooffff iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn bbbbyyyy wwwweeee aaaarrrreeee ccccoooommmmmmmmiiiitttttttteeeedddd ttttoooo ddddiiiisssscccclllloooossssiiiinnnngggg ooooffff oooouuuurrrr ddddeeeelllliiiivvvveeeerrrriiiinnnngggg mmmmaaaajjjjoooorrrr pppprrrroooodddduuuucccctttt llllaaaauuuunnnncccchhhheeeessss iiiinnnn cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidoooonnnneeee eeeexxxxaaaammmmpppplllleeee iiiissss tttthhhheeee llllaaaauuuunnnncccchhhh ooooffff tttthhhheeee eeeemmmmbbbboooottttrrrraaaapppp nnnnaaaammmmeeee jjjjuuuusssstttt aaaa ffffeeeewwww aaaannnndddd lllliiiittttiiiiggggaaaattttiiiioooonnnn uuuunnnnffffoooorrrrttttuuuunnnnaaaatttteeeellllyyyy iiiissss iiiiiiii rrrreeeevvvvaaaassssccccuuuullllaaaarrrriiiizzzzaaaattttiiiioooonnnn ddddeeeevvvviiiicccceeee aaaa nnnneeeexxxxttttggggeeeennnneeeerrrraaaattttiiiioooonnnn pppprrrreeeevvvvaaaalllleeeennnntttt tttthhhhrrrroooouuuugggghhhhoooouuuutttt tttthhhheeee hhhheeeeaaaalllltttthhhhccccaaaarrrreeee iiiinnnndddduuuussssttttrrrryyyy sssstttteeeennnntttt rrrreeeettttrrrriiiieeeevvvveeeerrrr uuuusssseeeedddd ttttoooo ccccaaaappppttttuuuurrrreeee aaaannnndddd rrrreeeemmmmoooovvvveeee tttthhhheeeesssseeee kkkkiiiinnnnddddssss ooooffff eeeexxxxtttteeeerrrrnnnnaaaallll ffffaaaaccccttttoooorrrrssss ccccaaaannnn iiiimmmmppppaaaacccctttt aaaannnnyyyy lllliiiiffffeeeetttthhhhrrrreeeeaaaatttteeeennnniiiinnnngggg bbbblllloooooooodddd cccclllloooottttssss ffffrrrroooommmm tttthhhheeee bbbbrrrraaaaiiiinnnn bbbbuuuussssiiiinnnneeeessssssss bbbbrrrraaaannnndddd rrrreeeeppppuuuuttttaaaattttiiiioooonnnn aaaannnndddd bbbbuuuussssiiiinnnneeeessssssss mmmmooooddddeeeellll ffffoooolllllllloooowwwwiiiinnnngggg aaaannnn iiiisssscccchhhheeeemmmmiiiicccc ssssttttrrrrooookkkkeeee wwwweeee rrrreeeecccceeeeiiiivvvveeeedddd ssssoooo iiiinnnn ppppaaaarrrrttttnnnneeeerrrrsssshhhhiiiipppp wwwwiiiitttthhhh oooouuuurrrr bbbbooooaaaarrrrdddd ooooffff ddddiiiirrrreeeeccccttttoooorrrrssss ffffddddaaaa cccclllleeeeaaaarrrraaaannnncccceeee ttttoooo mmmmaaaarrrrkkkkeeeetttt tttthhhheeee mmmmeeeecccchhhhaaaannnniiiiccccaaaallll ccccllllooootttt eeeexxxxeeeeccccuuuuttttiiiivvvveeee ccccoooommmmmmmmiiiitttttttteeeeeeee aaaannnndddd lllleeeeaaaaddddeeeerrrrsssshhhhiiiipppp tttteeeeaaaammmmssss rrrreeeemmmmoooovvvvaaaallll oooorrrr tttthhhhrrrroooommmmbbbbeeeeccccttttoooommmmyyyy ddddeeeevvvviiiicccceeee llllaaaasssstttt mmmmaaaayyyy aaaaccccrrrroooossssssss tttthhhheeee ccccoooommmmppppaaaannnnyyyy wwwweeee llllooooooookkkk ttttoooo mmmmiiiittttiiiiggggaaaatttteeee tttthhhheeeesssseeee iiiinnnn wwwweeee ppppllllaaaannnn ttttoooo llllaaaauuuunnnncccchhhh ttttoooo mmmmaaaajjjjoooorrrr kkkkiiiinnnnddddssss ooooffff eeeexxxxtttteeeerrrrnnnnaaaallll rrrriiiisssskkkk ffffaaaaccccttttoooorrrrssss wwwwhhhheeeerrrreeeevvvveeeerrrr ppppoooossssssssiiiibbbblllleeee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaaddddddddiiiittttiiiioooonnnnaaaallllllllyyyy iiii wwwwaaaannnntttt ttttoooo eeeemmmmpppphhhhaaaassssiiiizzzzeeee tttthhhhaaaatttt pppprrrroooodddduuuucccctttt aaaa fifififirrrrssssttttooooffffiiiittttsssskkkkiiiinnnndddd ccccoooonnnnttttaaaacccctttt lllleeeennnnssss tttthhhhaaaatttt wwwwaaaassss nnnnaaaammmmeeeedddd qqqquuuuaaaalllliiiittttyyyy aaaannnndddd ssssaaaaffffeeeettttyyyy aaaarrrreeee nnnnooootttt oooonnnnllllyyyy ttttoooopppp bbbbuuuussssiiiinnnneeeessssssss oooonnnneeee ooooffff ttttiiiimmmmeeee mmmmaaaaggggaaaazzzziiiinnnneeeessss bbbbeeeesssstttt iiiinnnnvvvveeeennnnttttiiiioooonnnnssss ooooffff pppprrrriiiioooorrrriiiittttiiiieeeessss ffffoooorrrr jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn tttthhhheeeeyyyy aaaarrrreeee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaallllssssoooo ccccoooorrrreeee oooobbbblllliiiiggggaaaattttiiiioooonnnnssss eeeemmmmbbbbooooddddiiiieeeedddd iiiinnnn oooouuuurrrr ccccrrrreeeeddddoooo cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaaccccrrrroooossssssss eeeevvvveeeerrrryyyy jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn bbbbuuuussssiiiinnnneeeessssssss wwwweeee ttttoooo rrrreeeedddduuuucccceeee ccccoooommmmpppplllliiiiccccaaaattttiiiioooonnnnssss iiiinnnn ccccoooolllloooorrrreeeeccccttttaaaallll ggggaaaassssttttrrrriiiicccc aaaappppppppllllyyyy aaaa sssscccciiiieeeennnnttttiiiifififificccc eeeevvvviiiiddddeeeennnncccceeeebbbbaaaasssseeeedddd aaaapppppppprrrrooooaaaacccchhhh iiiinnnn aaaannnndddd tttthhhhoooorrrraaaacccciiiicccc ccccaaaannnncccceeeerrrr ssssuuuurrrrggggeeeerrrriiiieeeessss cccclllleeeeaaaarrrrllllyyyy ddddeeeecccciiiissssiiiioooonnnnssss aaaabbbboooouuuutttt tttthhhheeee rrrreeeesssseeeeaaaarrrrcccchhhh mmmmaaaarrrrkkkkeeeettttiiiinnnngggg aaaannnndddd aaaaddddvvvvaaaannnncccciiiinnnngggg oooouuuurrrr ssssttttrrrraaaatttteeeeggggyyyy iiiinnnn ddddiiiiggggiiiittttaaaallll ssssuuuurrrrggggeeeerrrryyyy iiiissss aaaa uuuusssseeee ooooffff oooouuuurrrr pppprrrroooodddduuuuccccttttssss mmmmaaaannnnyyyy ooooffff oooouuuurrrr bbbbrrrraaaannnnddddssss aaaannnndddd mmmmaaaajjjjoooorrrr iiiinnnnvvvveeeessssttttmmmmeeeennnntttt ffffoooorrrr oooouuuurrrr ffffuuuuttttuuuurrrreeee oooouuuurrrr ddddiiiiggggiiiittttaaaallll pppprrrroooodddduuuuccccttttssss hhhhaaaavvvveeee bbbbeeeeeeeennnn ttttrrrruuuusssstttteeeedddd bbbbyyyy ccccoooonnnnssssuuuummmmeeeerrrrssss ffffoooorrrr ssssuuuurrrrggggeeeerrrryyyy ppppllllaaaattttffffoooorrrrmmmm iiiissss bbbbeeeeiiiinnnngggg ddddeeeessssiiiiggggnnnneeeedddd ttttoooo ccccoooommmmbbbbiiiinnnneeee ddddeeeeccccaaaaddddeeeessss aaaannnndddd wwwwhhhheeeennnn tttthhhheeee ssssaaaaffffeeeettttyyyy ooooffff oooouuuurrrr pppprrrroooodddduuuuccccttttssss rrrroooobbbboooottttiiiiccccssss aaaaddddvvvvaaaannnncccceeeedddd iiiinnnnssssttttrrrruuuummmmeeeennnnttttaaaattttiiiioooonnnn aaaannnndddd ddddaaaattttaaaa iiiissss cccchhhhaaaalllllllleeeennnnggggeeeedddd wwwweeee wwwwiiiillllllll ccccoooonnnnttttiiiinnnnuuuueeee ttttoooo ddddeeeeffffeeeennnndddd tttthhhheeeemmmm aaaannnnaaaallllyyyyttttiiiiccccssss ttttoooo eeeennnnaaaabbbblllleeee bbbbeeeetttttttteeeerrrr ppppaaaattttiiiieeeennnntttt oooouuuuttttccccoooommmmeeeessss bbbbyyyy wwwweeee hhhhaaaavvvveeee aaaa lllleeeeggggaaaaccccyyyy ooooffff wwwwoooorrrrkkkkiiiinnnngggg hhhhaaaarrrrdddd ttttoooo eeeeaaaarrrrnnnn oooouuuurrrr iiiimmmmpppprrrroooovvvviiiinnnngggg aaaacccccccceeeessssssss ttttoooo mmmmiiiinnnniiiimmmmaaaallllllllyyyy iiiinnnnvvvvaaaassssiiiivvvveeee ssssuuuurrrrggggeeeerrrryyyy ccccuuuussssttttoooommmmeeeerrrrssss ttttrrrruuuusssstttt aaaannnndddd wwwwoooorrrrkkkkiiiinnnngggg eeeeqqqquuuuaaaallllllllyyyy hhhhaaaarrrrdddd ttttoooo kkkkeeeeeeeepppp aaaannnndddd hhhheeeellllppppiiiinnnngggg ttttoooo rrrreeeedddduuuucccceeee tttthhhheeee ccccoooosssstttt ooooffff ccccaaaarrrreeee iiiitttttttthhhhiiiissss ccccoooommmmmmmmiiiittttmmmmeeeennnntttt wwwwiiiillllllll aaaallllwwwwaaaayyyyssss rrrreeeemmmmaaaaiiiinnnn iiiinnnnttttaaaacccctttt aaaassss wwwweeee ccccaaaappppiiiittttaaaalllliiiizzzzeeee oooonnnn oooouuuurrrr ccccoooommmmpppprrrreeeehhhheeeennnnssssiiiivvvveeee wwwweeee aaaarrrreeee ccccoooonnnnfifififiddddeeeennnntttt iiiinnnn oooouuuurrrr aaaabbbbiiiilllliiiittttyyyy ttttoooo lllleeeeaaaadddd wwwwiiiitttthhhh ppppoooorrrrttttffffoooolllliiiioooo aaaannnndddd aaaannnn aaaacccccccceeeelllleeeerrrraaaatttteeeedddd ggggrrrroooowwwwtttthhhh ssssttttrrrraaaatttteeeeggggyyyy cccceeeerrrrttttaaaaiiiinnnnttttyyyy aaaannnndddd ttttoooo rrrreeeessssppppoooonnnnssssiiiibbbbllllyyyy nnnnaaaavvvviiiiggggaaaatttteeee oooouuuurrrr wwwwaaaayyyy wwwweeee aaaarrrreeee ccccoooommmmmmmmiiiitttttttteeeedddd ttttoooo iiiimmmmpppprrrroooovvvviiiinnnngggg ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee tttthhhhrrrroooouuuugggghhhh tttthhhheeeesssseeee ppppooootttteeeennnnttttiiiiaaaallll cccchhhhaaaalllllllleeeennnnggggeeeessss aaaannnndddd bbbbeeeeccccaaaauuuusssseeee aaaaccccrrrroooossssssss oooouuuurrrr mmmmeeeeddddiiiiccccaaaallll ddddeeeevvvviiiicccceeeessss bbbbuuuussssiiiinnnneeeessssssss wwwweeee aaaarrrreeee ccccoooommmmmmmmiiiitttttttteeeedddd ttttoooo tttthhhhrrrriiiivvvviiiinnnngggg iiiinnnn tttthhhhiiiissss cccchhhhaaaannnnggggeeee eeeennnnvvvviiiirrrroooonnnnmmmmeeeennnntttt oooouuuurrrr ggggooooaaaallll iiiissss nnnnooootttt mmmmeeeerrrreeeellllyyyy ttttoooo aaaaddddaaaapppptttt wwwwhhhhiiiilllleeee wwwweeee aaaarrrreeee pppplllleeeeaaaasssseeeedddd wwwwiiiitttthhhh oooouuuurrrr ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee ttttoooo cccchhhhaaaannnnggggeeee bbbbuuuutttt ttttoooo bbbbeeee tttthhhheeee ccccaaaattttaaaallllyyyysssstttt ffffoooorrrr nnnneeeeeeeeddddeeeedddd wwwweeee aaaarrrreeee nnnneeeevvvveeeerrrr ssssaaaattttiiiissssfifififieeeedddd llllooooooookkkkiiiinnnngggg aaaahhhheeeeaaaadddd wwwweeee aaaarrrreeee cccchhhhaaaannnnggggeeee wwwweeee aaaallllssssoooo lllleeeeaaaadddd wwwwiiiitttthhhh cccceeeerrrrttttaaaaiiiinnnnttttyyyy bbbbeeeeccccaaaauuuusssseeee ccccoooommmmmmmmiiiitttttttteeeedddd ttttoooo aaaaddddvvvvaaaannnncccciiiinnnngggg tttthhhheeee iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn ppppiiiippppeeeelllliiiinnnneeee wwwweeee aaaarrrreeee iiiinnnn tttthhhheeee bbbbuuuussssiiiinnnneeeessssssss ooooffff ccccaaaarrrriiiinnnngggg ffffoooorrrr tttthhhheeee wwwwoooorrrrlllldddd aaaallllllll iiiinnnn oooouuuurrrr pppphhhhaaaarrrrmmmmaaaacccceeeeuuuuttttiiiiccccaaaallll bbbbuuuussssiiiinnnneeeessssssss bbbbrrrrooooaaaaddddeeeennnniiiinnnngggg tttthhhheeee ddddaaaayyyy eeeevvvveeeerrrryyyy ddddaaaayyyy gggguuuuiiiiddddeeeedddd bbbbyyyy oooouuuurrrr ccccrrrreeeeddddoooo wwwweeee hhhhaaaavvvveeee rrrreeeeaaaacccchhhh ooooffff oooouuuurrrr ccccoooonnnnssssuuuummmmeeeerrrr bbbbuuuussssiiiinnnneeeessssssss aaaannnndddd mmmmeeeeeeeettttiiiinnnngggg tttthhhheeee aaaa ssssoooolllliiiidddd fifififinnnnaaaannnncccciiiiaaaallll ffffoooouuuunnnnddddaaaattttiiiioooonnnn aaaa ssssttttrrrroooonnnngggg ssssttttrrrraaaatttteeeeggggiiiicccc ffffuuuullllllll ppppooootttteeeennnnttttiiiiaaaallll ooooffff oooouuuurrrr mmmmeeeeddddiiiiccccaaaallll ddddeeeevvvviiiicccceeeessss bbbbuuuussssiiiinnnneeeessssssss ffffrrrraaaammmmeeeewwwwoooorrrrkkkk aaaannnn iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn mmmmiiiinnnnddddsssseeeetttt aaaa ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee ddddrrrriiiivvvveeeennnn ccccuuuullllttttuuuurrrreeee aaaannnndddd aaaa vvvveeeerrrryyyy bbbbrrrriiiigggghhhhtttt ffffuuuuttttuuuurrrreeee ffffooooccccuuuusssseeeedddd oooonnnn aaaaddddvvvvaaaannnncccciiiinnnngggg tttthhhheeee hhhheeeeaaaalllltttthhhh aaaannnndddd wwwweeeellllllllbbbbeeeeiiiinnnngggg ooooffff aaaallllllll oooouuuurrrr want emphasize product quality ssssttttaaaakkkkeeeehhhhoooollllddddeeeerrrrssssttttooooddddaaaayyyy aaaannnndddd ffffoooorrrr ggggeeeennnneeeerrrraaaattttiiiioooonnnnssss ttttoooo ccccoooommmmeeee safety business priority oooouuuurrrr ppppeeeeoooopppplllleeee ppppaaaassssssssiiiioooonnnn aaaannnndddd ppppuuuurrrrppppoooosssseeee johnson johnson core iiiivvvveeee oooofffftttteeeennnn nnnnooootttteeeedddd hhhheeeeaaaalllltttthhhhccccaaaarrrreeee iiiissss aaaannnn iiiinnnndddduuuussssttttrrrryyyy tttthhhhaaaatttt obligation embody credo aaaattttttttrrrraaaaccccttttssss vvvveeeerrrryyyy ssssppppeeeecccciiiiaaaallll ppppeeeeoooopppplllleeee wwwwhhhhiiiilllleeee tttthhhheeeeyyyy wwwwaaaannnntttt tttthhhheeee ooooppppppppoooorrrrttttuuuunnnniiiittttyyyy ttttoooo bbbbuuuuiiiilllldddd aaaa mmmmeeeeaaaannnniiiinnnnggggffffuuuullll ccccaaaarrrreeeeeeeerrrr lllleeeeaaaaddddiiiinnnngggg wwwwiiiitttthhhh cccceeeerrrrttttaaaaiiiinnnnttttyyyy tttthhhheeeeyyyy aaaallllssssoooo wwwwaaaannnntttt ttttoooo bbbbeeee aaaa ppppaaaarrrrtttt ooooffff ssssoooommmmeeeetttthhhhiiiinnnngggg ttttrrrruuuullllyyyy tttthhhheeee vvvvoooolllluuuummmmeeee aaaannnndddd ssssppppeeeeeeeedddd ooooffff cccchhhhaaaannnnggggeeee aaaarrrroooouuuunnnndddd tttthhhheeee ssssiiiiggggnnnniiiifififificcccaaaannnntttt tttthhhhaaaatttt mmmmaaaakkkkeeeessss aaaannnn iiiimmmmppppoooorrrrttttaaaannnntttt ddddiiiiffffffffeeeerrrreeeennnncccceeee iiiinnnn wwwwoooorrrrlllldddd aaaannnndddd aaaaccccrrrroooossssssss aaaallllllll bbbbuuuussssiiiinnnneeeessssssss iiiinnnndddduuuussssttttrrrriiiieeeessss iiiissss ppppeeeeoooopppplllleeeessss lllliiiivvvveeeessss ffffoooorrrrttttuuuunnnnaaaatttteeeellllyyyy wwwweeee hhhhaaaavvvveeee tttthhhheeee vvvveeeerrrryyyy bbbbeeeesssstttt tttthhhheeee nnnneeeewwww nnnnoooorrrrmmmmaaaallll tttthhhheeee vvvveeeelllloooocccciiiittttyyyy ooooffff tttthhhhiiiissss cccchhhhaaaannnnggggeeee ooooffff tttthhhheeeesssseeee ssssppppeeeecccciiiiaaaallll ppppeeeeoooopppplllleeee aaaatttt tttthhhheeee jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn iiiissss aaaappppppppaaaarrrreeeennnntttt wwwwiiiitttthhhh cccciiiirrrrccccuuuummmmssssttttaaaannnncccceeeessss lllliiiikkkkeeee tttthhhheeee ffffaaaammmmiiiillllyyyy ooooffff ccccoooommmmppppaaaannnniiiieeeessss aaaannnndddd iiii bbbbeeeelllliiiieeeevvvveeee oooouuuurrrr ccccuuuullllttttuuuurrrreeee eeeevvvvoooollllvvvviiiinnnngggg ggggeeeeooooppppoooolllliiiittttiiiiccccaaaallll llllaaaannnnddddssssccccaaaappppeeee oooonnnnggggooooiiiinnnngggg ooooffff ddddiiiivvvveeeerrrrssssiiiittttyyyy aaaannnndddd iiiinnnncccclllluuuussssiiiioooonnnn bbbbrrrriiiinnnnggggssss oooouuuutttt tttthhhheeee bbbbeeeesssstttt tttthhhhaaaatttt mmmmaaaarrrrkkkkeeeetttt vvvvoooollllaaaattttiiiilllliiiittttyyyy rrrriiiissssiiiinnnngggg pppprrrreeeessssssssuuuurrrreeee ttttoooo rrrreeeedddduuuucccceeee oooouuuurrrr jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn ccccoooolllllllleeeeaaaagggguuuueeeessss hhhhaaaavvvveeee ttttoooo ooooffffffffeeeerrrr pppprrrriiiicccciiiinnnngggg rrrraaaappppiiiidddd eeeennnnttttrrrryyyy ooooffff ddddiiiissssrrrruuuuppppttttiiiivvvveeee tttteeeecccchhhhnnnnoooollllooooggggiiiieeeessss aaaa ccccrrrroooowwwwddddeeeedddd ccccoooommmmppppeeeettttiiiittttiiiivvvveeee mmmmaaaarrrrkkkkeeeettttppppllllaaaacccceeee aaaannnndddd aaaannnn ttttooooddddaaaayyyy wwwweeee hhhhaaaavvvveeee aaaapppppppprrrrooooxxxxiiiimmmmaaaatttteeeellllyyyy gggglllloooobbbbaaaallll eeeexxxxppppaaaannnnddddiiiinnnngggg rrrraaaannnnggggeeee ooooffff ccccuuuussssttttoooommmmeeeerrrr pppprrrreeeeffffeeeerrrreeeennnncccceeeesss ttttoooo eeeemmmmppppllllooooyyyyeeeeeeeessss uuuunnnniiiitttteeeedddd bbbbyyyy aaaa sssshhhhaaaarrrreeeedddd ccccoooommmmmmmmiiiittttmmmmeeeennnntttt cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidaaaannnndddd aaaa ccccoooommmmmmmmoooonnnn ppppuuuurrrrppppoooosssseeee tttthhhhaaaatttt aaaassssppppiiiirrrreeeessss ttttoooo ccccrrrreeeeaaaatttteeee gggguuuuiiiiddddiiiinnnngggg ssssuuuuppppppppoooorrrrtttt ooooffff oooouuuurrrr hhhhiiiigggghhhhllllyyyy aaaaccccccccoooommmmpppplllliiiisssshhhheeeedddd aaaa wwwwoooorrrrlllldddd wwwwiiiitttthhhhoooouuuutttt ddddiiiisssseeeeaaaasssseeee aaaannnndddd wwwwiiiitttthhhh ggggrrrreeeeaaaatttteeeerrrr bbbbooooaaaarrrrdddd ooooffff ddddiiiirrrreeeeccccttttoooorrrrssss aaaannnndddd ccccoooonnnnttttiiiinnnnuuuueeee ttttoooo bbbbeeee pppprrrroooouuuudddd aaaannnndddd aaaacccccccceeeessssssss ttttoooo qqqquuuuaaaalllliiiittttyyyy hhhheeeeaaaalllltttthhhhccccaaaarrrreeeelllliiiiffffeeeessssaaaavvvviiiinnnngggg hhhhuuuummmmbbbblllleeeedddd aaaassss iiii wwwwoooorrrrkkkk ssssiiiiddddeeee bbbbyyyy ssssiiiiddddeeee wwwwiiiitttthhhh tttthhhhiiiissss tttteeeeaaaammmm ooooffff mmmmeeeeddddiiiicccciiiinnnneeeessss lllliiiiffffeeeecccchhhhaaaannnnggggiiiinnnngggg mmmmeeeeddddiiiiccccaaaallll ssssoooolllluuuuttttiiiioooonnnnssss aaaannnndddd iiiimmmmpppprrrreeeessssssssiiiivvvveeee eeeexxxxeeeeccccuuuuttttiiiivvvveeee lllleeeeaaaaddddeeeerrrrssss wwwwhhhhoooosssseeee ppppaaaarrrrttttnnnneeeerrrrsssshhhhiiiipppp lllliiiiffffeeeeeeeennnnhhhhaaaannnncccciiiinnnngggg ccccoooonnnnssssuuuummmmeeeerrrr pppprrrroooodddduuuuccccttttssss aaaallllllll ooooffff uuuussss aaaannnndddd eeeexxxxppppeeeerrrrttttiiiisssseeee mmmmoooottttiiiivvvvaaaatttteeee mmmmeeee aaaannnndddd aaaallllllll oooouuuurrrr jjjjoooohhhhnnnnssssoooonnnn mmmmaaaaiiiinnnnttttaaaaiiiinnnn aaaa ppppeeeerrrrssssiiiisssstttteeeennnntttt ffffooooccccuuuussss oooonnnn ddddeeeevvvveeeellllooooppppiiiinnnngggg aaaannnndddd jjjjoooohhhhnnnnssssoooonnnn ccccoooolllllllleeeeaaaagggguuuueeeessss eeeevvvveeeerrrryyyy ddddaaaayyyy iiiinnnn oooouuuurrrr sssshhhhaaaarrrreeeedddd ddddeeeelllliiiivvvveeeerrrriiiinnnngggg qqqquuuuaaaalllliiiittttyyyy aaaannnndddd ssssaaaaffffeeee pppprrrroooodddduuuuccccttttssss aaaannnndddd sssseeeerrrrvvvviiiicccceeeessss ccccoooommmmmmmmiiiittttmmmmeeeennnntttt ttttoooo aaaaddddvvvvaaaannnncccceeee hhhheeeeaaaalllltttthhhh ffffoooorrrr hhhhuuuummmmaaaannnniiiittttyyyy ddddeeeelllliiiivvvveeeerrrriiiinnnngggg oooonnnn tttthhhheeee pppprrrroooommmmiiiisssseeeessss ooooffff oooouuuurrrr bbbbrrrraaaannnnddddssss iiiissss bbbbooootttthhhh aaaa ppppeeeerrrrssssoooonnnnaaaallll aaaannnndddd pppprrrrooooffffeeeessssssssiiiioooonnnnaaaallll ccccoooommmmmmmmiiiittttmmmmeeeennnntttt approximately global tttthhhhiiiissss iiiissss ddddeeeemmmmoooonnnnssssttttrrrraaaatttteeeedddd iiiinnnn tttthhhheeee ttttiiiirrrreeeelllleeeessssssss eeeeffffffffoooorrrrttttssss employee unite share commitment aaaannnndddd rrrreeeelllleeeennnnttttlllleeeessssssss ppppaaaassssssssiiiioooonnnn tttthhhhaaaatttt ddddrrrriiiivvvveeee oooouuuurrrr aaaammmmbbbbiiiittttiiiioooonnnn common purpose aspire ttttoooo rrrreeeeaaaacccchhhh tttthhhheeee nnnneeeexxxxtttt ffffrrrroooonnnnttttiiiieeeerrrr ooooffff ccccaaaannnncccceeeerrrr ccccaaaarrrreeee ccccoooonnnnttttiiiinnnnuuuueeee ttttoooo ccccoooommmmbbbbaaaatttt eeeebbbboooollllaaaa aaaannnndddd hhhhiiiivvvv bbbbrrrriiiinnnngggg hhhheeeeaaaalllltttthhhhyyyy create world disease vvvviiiissssiiiioooonnnn ttttoooo ppppeeeeoooopppplllleeee eeeevvvveeeerrrryyyywwwwhhhheeeerrrreeee ccccrrrreeeeaaaatttteeee aaaa wwwwoooorrrrlllldddd great access quality healthcare ffffrrrreeeeeeee ffffrrrroooommmm ttttuuuubbbbeeeerrrrccccuuuulllloooossssiiiissss rrrreeeedddduuuucccceeee oooouuuurrrr ccccaaaarrrrbbbboooonnnn ffffoooooooottttpppprrrriiiinnnntttt iiiimmmmpppprrrroooovvvveeee oooouuuurrrr pppprrrroooodddduuuucccctttt ssssuuuussssttttaaaaiiiinnnnaaaabbbbiiiilllliiiittttyyyy mmmmyyyy ooooppppttttiiiimmmmiiiissssmmmm ffffoooorrrr tttthhhheeee ffffuuuuttttuuuurrrreeee iiiissss iiiinnnnssssppppiiiirrrreeeedddd bbbbyyyy tttthhhheeee aaaannnndddd rrrreeeeiiiimmmmaaaaggggiiiinnnneeee tttthhhheeee wwwwaaaayyyy tttthhhhaaaatttt ccccaaaarrrreeee iiiissss ddddeeeelllliiiivvvveeeerrrreeeedddd rrrraaaappppiiiidddd aaaannnndddd ccccoooonnnnttttiiiinnnnuuuuoooouuuussss iiiimmmmpppprrrroooovvvveeeemmmmeeeennnnttttssss iiiinnnn tttthhhheeee wwwwhhhhiiiilllleeee aaaallllssssoooo eeeexxxxppppaaaannnnddddiiiinnnngggg aaaacccccccceeeessssssss ffffoooorrrr tttthhhheeee wwwwoooorrrrllllddddssss mmmmoooosssstttt ccccoooonnnnddddiiiittttiiiioooonnnn ooooffff hhhhuuuummmmaaaannnn hhhheeeeaaaalllltttthhhh aaaannnndddd tttthhhheeee iiiinnnnccccrrrreeeeaaaassssiiiinnnngggg vvvvuuuullllnnnneeeerrrraaaabbbblllleeee ppppooooppppuuuullllaaaattttiiiioooonnnnssss jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn ppppoooossssssssiiiibbbbiiiilllliiiittttiiiieeeessss ffffoooorrrr hhhheeeeaaaalllltttthhhhccccaaaarrrreeee iiiinnnn tttthhhheeee wwwwoooorrrrlllldddd mmmmoooosssstttt mmmmaaaaddddeeee ffffoooorrrrttttuuuunnnneeeessss cccchhhhaaaannnnggggeeee tttthhhheeee wwwwoooorrrrlllldddd lllliiiisssstttt aaaaggggaaaaiiiinnnn iiiimmmmppppoooorrrrttttaaaannnnttttllllyyyy wwwweeee hhhhaaaavvvveeee tttthhhheeee aaaammmmaaaazzzziiiinnnngggg pppprrrriiiivvvviiiilllleeeeggggeeee iiiinnnn iiiinnnn rrrreeeeccccooooggggnnnniiiittttiiiioooonnnn ooooffff oooouuuurrrr eeeeffffffffoooorrrrttttssss ttttoooo hhhheeeellllpppp ttttrrrraaaaiiiinnnn ooooffff ttttoooouuuucccchhhhiiiinnnngggg lllliiiivvvveeeessss aaaarrrroooouuuunnnndddd tttthhhheeee wwwwoooorrrrlllldddd eeeevvvveeeerrrryyyy ssssuuuurrrrggggeeeeoooonnnnssss ppppaaaarrrraaaammmmeeeeddddiiiiccccssss aaaannnndddd ooootttthhhheeeerrrr hhhheeeeaaaalllltttthhhhccccaaaarrrreeee ddddaaaayyyyffffrrrroooommmm bbbbaaaabbbbiiiieeeessss ttttaaaakkkkiiiinnnngggg tttthhhheeeeiiiirrrr fifififirrrrsssstttt bbbbrrrreeeeaaaatttthhhh ttttoooo pppprrrroooovvvviiiiddddeeeerrrrssss gggglllloooobbbbaaaallllllllyyyy tttthhhhrrrroooouuuugggghhhh oooouuuurrrr jjjjoooohhhhnnnnssssoooonnnn bbbbaaaabbbbyyyy bbbboooooooommmmeeeerrrrssss ttttaaaakkkkiiiinnnngggg aaaa bbbbrrrreeeeaaaatttthhhh aaaafffftttteeeerrrr ddddooooiiiinnnngggg tttthhhheeee jjjjoooohhhhnnnnssssoooonnnn iiiinnnnssssttttiiiittttuuuutttteeee aaaannnndddd ooootttthhhheeeerrrr ccccaaaarrrreeee pppprrrrooooggggrrrraaaammmmssss jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn ooooffiffiffifficccciiiiaaaallll mmmmiiiinnnnuuuutttteeee wwwwoooorrrrkkkkoooouuuutttt oooouuuurrrr ggggooooaaaallll iiiissss ttttoooo lllleeeeaaaadddd bbbbyyyy eeeexxxxaaaammmmpppplllleeee bbbbyyyy ccccuuuullllttttiiiivvvvaaaattttiiiinnnngggg wwwweeee aaaallllssssoooo hhhhaaaavvvveeee tttthhhheeee pppplllleeeeaaaassssuuuurrrreeee ooooffff sssseeeerrrrvvvviiiinnnngggg ppppaaaattttiiiieeeennnnttttssss tttthhhheeee wwwwoooorrrrllllddddssss hhhheeeeaaaalllltttthhhhiiiieeeesssstttt mmmmoooosssstttt pppprrrroooodddduuuuccccttttiiiivvvveeee aaaannnndddd mmmmoooosssstttt aaaannnndddd ccccoooonnnnssssuuuummmmeeeerrrrssss eeeevvvveeeerrrryyyywwwwhhhheeeerrrreeee oooonnnn eeeeaaaarrrrtttthhhhppppeeeeoooopppplllleeee eeeennnnggggaaaaggggeeeedddd wwwwoooorrrrkkkkffffoooorrrrcccceeee iiii bbbbeeeelllliiiieeeevvvveeee tttthhhhiiiissss iiiissss ccccrrrriiiittttiiiiccccaaaallll ffffoooorrrr wwwwhhhhoooo ppppuuuutttt tttthhhheeeeiiiirrrr ttttrrrruuuusssstttt iiiinnnn oooouuuurrrr jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn ooooppppeeeerrrraaaattttiiiinnnngggg aaaa hhhheeeeaaaalllltttthhhhyyyy aaaannnndddd ssssuuuucccccccceeeessssssssffffuuuullll bbbbuuuussssiiiinnnneeeessssssss aaaannnndddd bbbbrrrraaaannnnddddssss wwwweeee nnnneeeevvvveeeerrrr ffffoooorrrrggggeeeetttt tttthhhheeee rrrreeeessssppppoooonnnnssssiiiibbbbiiiilllliiiittttyyyy tttthhhhaaaatttt tttthhhhiiiissss iiiissss hhhhoooowwww wwwweeee wwwwiiiillllllll ddddeeeelllliiiivvvveeeerrrr aaaannnndddd eeeennnnssssuuuurrrreeee tttthhhhaaaatttt aaaannnnooootttthhhheeeerrrr ccccoooommmmeeeessss wwwwiiiitttthhhh tttthhhhiiiissss ttttrrrruuuusssstttt aaaannnndddd wwwweeee nnnneeeevvvveeeerrrr ffffoooorrrrggggeeeetttt oooouuuurrrr yyyyeeeeaaaarrrrssss ooooffff qqqquuuuaaaalllliiiittttyyyy hhhheeeeaaaalllltttthhhhccccaaaarrrreeee iiiissss wwwwiiiitttthhhhiiiinnnn rrrreeeeaaaacccchhhh ooooffff eeeesssssssseeeennnnttttiiiiaaaallll ppppaaaarrrrttttnnnneeeerrrrsssshhhhiiiipppp wwwwiiiitttthhhh oooouuuurrrr sssshhhhaaaarrrreeeehhhhoooollllddddeeeerrrrssss eeeevvvveeeerrrryyyyoooonnnneeee eeeevvvveeeerrrryyyywwwwhhhheeeerrrreeee wwwwhhhhoooo ssssuuuuppppppppoooorrrrtttt oooouuuurrrr mmmmiiiissssssssiiiioooonnnn aaaannnndddd hhhheeeellllpppp uuuussss ppppuuuurrrrssssuuuueeee aaaa nnnnoooobbbblllleeee ppppuuuurrrrppppoooosssseeee wwwwhhhhiiiilllleeee tttthhhheeee cccchhhhaaaalllllllleeeennnnggggeeeessss aaaarrrreeee aaaannnn eeeedddduuuuccccaaaattttiiiioooonnnn iiiinnnnhhhhuuuummmmaaaannnn hhhheeeeaaaalllltttthhhh ggggrrrreeeeaaaatttt tttthhhheeee rrrreeeewwwwaaaarrrrddddssss aaaarrrreeee eeeevvvveeeennnn ggggrrrreeeeaaaatttteeeerrrr iiii ccccaaaannnntttt iiii aaaammmm aaaassss eeeexxxxcccciiiitttteeeedddd aaaannnndddd eeeennnnccccoooouuuurrrraaaaggggeeeedddd ttttooooddddaaaayyyy aaaassss iiii wwwwaaaassss iiiimmmmaaaaggggiiiinnnneeee aaaa bbbbeeeetttttttteeeerrrr oooorrrr mmmmoooorrrreeee ffffuuuullllfifififilllllllliiiinnnngggg ccccaaaalllllllliiiinnnngggg oooonnnn tttthhhheeee ddddaaaayyyy iiii ssssttttaaaarrrrtttteeeedddd aaaassss cccceeeeoooo ooooffff tttthhhhiiiissss ccccoooommmmppppaaaannnnyyyy aaaannnndddd aaaacccccccceeeepppptttteeeedddd tttthhhheeee rrrreeeessssppppoooonnnnssssiiiibbbbiiiilllliiiittttiiiieeeessss tttthhhhaaaatttt ccccoooommmmeeee wwwwiiiitttthhhh iiiitttt iiii ooooffffffffeeeerrrr mmmmyyyy ssssiiiinnnncccceeeerrrreeee tttthhhhaaaannnnkkkkssss ttttoooo aaaallllllll ooooffff yyyyoooouuuu ffffoooorrrr tttthhhhiiiissss ggggrrrreeeeaaaatttt pppprrrriiiivvvviiiilllleeeeggggeeee ooooppppppppoooorrrrttttuuuunnnniiiittttyyyy aaaannnndddd eeeexxxxppppeeeerrrriiiieeeennnncccceeee tttthhhhrrrroooouuuugggghhhhoooouuuutttt mmmmyyyy ccccaaaarrrreeeeeeeerrrr aaaatttt jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn iiii hhhhaaaavvvveeee bbbbeeeeeeeennnn vvvveeeerrrryyyy ffffoooorrrrttttuuuunnnnaaaatttteeee ttttoooo lllleeeeaaaarrrrnnnn tttthhhhiiiissss bbbbuuuussssiiiinnnneeeessssssss cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ffffrrrroooommmm tttthhhheeee ppppeeeerrrrssssppppeeeeccccttttiiiivvvveeee ooooffff aaaa ccccoooommmmppppaaaannnnyyyy tttthhhhaaaatttt iiiissss bbbbuuuuiiiilllltttt oooonnnn tttthhhheeee bbbbeeeelllliiiieeeeffff iiiinnnn tttthhhheeee ttttrrrraaaannnnssssffffoooorrrrmmmmaaaattttiiiivvvveeee ppppoooossssssssiiiibbbbiiiilllliiiittttiiiieeeessss ooooffff hhhhuuuummmmaaaannnn iiiinnnnggggeeeennnnuuuuiiiittttyyyy aaaannnndddd ppppeeeerrrrssssoooonnnnaaaallll ccccaaaarrrriiiinnnngggg tttthhhheeee wwwwoooorrrrlllldddd hhhhaaaassss bbbbeeeeeeeennnn tttthhhheeee ccccaaaammmmppppuuuussss ffffoooorrrr mmmmyyyy eeeedddduuuuccccaaaattttiiiioooonnnn iiiinnnn aaaalllleeeexxxx ggggoooorrrrsssskkkkyyyy hhhhuuuummmmaaaannnn hhhheeeeaaaalllltttthhhh aaaassss iiiitttt hhhhaaaassss bbbbeeeeeeeennnn ffffoooorrrr mmmmyyyy jjjjoooohhhhnnnnssssoooonnnn cccchhhhaaaaiiiirrrrmmmmaaaannnn aaaannnndddd cccchhhhiiiieeeeffff eeeexxxxeeeeccccuuuuttttiiiivvvveeee ooooffiffiffifficccceeeerrrr jjjjoooohhhhnnnnssssoooonnnn ccccoooolllllllleeeeaaaagggguuuueeeessss iiii ddddeeeeeeeeppppllllyyyy aaaapppppppprrrreeeecccciiiiaaaatttteeee tttthhhheeee jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn nongaap measure free cash flow define operate cash flow capital spending adjust operational earning growth exclude special item intangible cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid tion free cash flow operational sale growth exclude acquisition divestiture medical device segment annual report cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid letter contain forwardlooke statement relate thing future operate financial performance product development market position business strategy reader caution rely statement base current expectation future event important information statement include risk uncertainty factor cause actual result vary materially assumption expectation projection express forwardlooke statement reader review enclose annual report fiscal year end december cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid update forwardlooke statement result new information future event developmentsunite states securities exchange commission washington dc annual report pursuant section security exchange act forthefiscalyearendeddecember commissionfilenumber johnson johnson exactnameofregistrantasspecifiedinitscharter newjersey stateofincorporation irsemployeridentificationno onejohnsonjohnsonplaza newbrunswicknewjersey addressofprincipalexecutiveoffice zipcode registrantstelephonenumberincludingareacode securitiesregisteredpursuanttosectionboftheact titleofeachclass nameofeachexchangeonwhichregistered commonstockparvalue newyorkstockexchange notesduenovember newyorkstockexchange notesduejanuary newyorkstockexchange notesduemay newyorkstockexchange notesduenovember newyorkstockexchange notesduenovember newyorkstockexchange notesduemay newyorkstockexchange indicatebycheckmarkiftheregistrantisawellknownseasonedissuerasdefinedinruleofthesecurities act yes indicatebycheckmarkiftheregistrantisnotrequiredtofilereportspursuanttosectionorsectiondoftheexchange act yes indicatebycheckmarkwhethertheregistranthasfiledallreportsrequiredtobefiledbysectionordofthe exchangeactduringtheprecedingmonthsorforsuchshorterperiodthattheregistrantwasrequiredtofilesuch reportsandhasbeensubjecttosuchfilingrequirementsforthepastday yes indicatebycheckmarkwhethertheregistranthassubmittedelectronicallyeveryinteractivedatafilerequiredtobesubmitte pursuanttoruleofregulationstduringtheprecedingmonthsorforsuchshorterperiodthattheregistrantwas requiredtosubmitsuchfile yes indicatebycheckmarkifdisclosureofdelinquentfilerspursuanttoitemofregulationskisnotcontainedhereinand willnotbecontainedtothebestofregistrantsknowledgeindefinitiveproxyorinformationstatementsincorporatedby referenceinpartiiiofthisformkoranyamendmenttothisformk indicatebycheckmarkwhethertheregistrantisalargeacceleratedfileranacceleratedfileranonacceleratedfilerasmaller reportingcompanyoremerginggrowthcompanyseethedefinitionsoflargeacceleratedfileracceleratedfilersmaller reportingcompanyandemerginggrowthcompanyinruleboftheexchangeact largeacceleratedfiler acceleratedfiler nonacceleratedfiler smallerreportingcompany emerginggrowthcompany ifanemerginggrowthcompanyindicatebycheckmarkiftheregistranthaselectednottousetheextendedtransitionperiod forcomplyingwithanyneworrevisedfinancialaccountingstandardsprovidedpursuanttosectionaoftheexchange act indicatebycheckmarkwhethertheregistrantisashellcompanyasdefinedinruleboftheexchange act yes theaggregatemarketvalueofthecommonstockheldbynonaffiliatescomputedbyreferencetothepriceatwhichthe commonstockwaslastsoldasofthelastbusinessdayoftheregistrantsmostrecentlycompletedsecondfiscalquarter wasapproximatelybillion onfebruarythereweresharesofcommonstockoutstanding documentsincorporatedbyreference partsiandiii portionsofregistrantsproxystatementforitsannualmeetingofshareholdersfiledwithin daysafterthecloseoftheregistrantsfiscalyeartheproxystatementareincorporatedby referencetothisreportonformkthisreportitem parti business general segmentsofbusiness geographicareas rawmaterial patent trademark seasonality competition environment regulation availableinformation riskfactor b unresolvedstaffcomment property legalproceeding minesafetydisclosure executiveofficersoftheregistrant partii marketforregistrantscommonequityrelatedstockholdermattersandissuerpurchasesof equitysecuritie selectedfinancialdata managementsdiscussionandanalysisofresultsofoperationsandfinancialcondition quantitativeandqualitativedisclosuresaboutmarketrisk financialstatementsandsupplementarydata changesinanddisagreementswithaccountantsonaccountingandfinancialdisclosure controlsandprocedures b otherinformation partiii directorsexecutiveofficersandcorporategovernance executivecompensation securityownershipofcertainbeneficialownersandmanagementandrelatedstockholder matter certainrelationshipsandrelatedtransactionsanddirectorindependence principalaccountantfeesandservice partiv exhibitsandfinancialstatementschedule formksummary signature exhibitindex cautionary note forwardlooke statement thisannualreportonformkandjohnsonjohnsonsotherpubliclyavailabledocumentscontainforwardlooke statementswithinthemeaningofthesafeharborprovisionsoftheusprivatesecuritieslitigationreformactof managementandrepresentativesofjohnsonjohnsonanditssubsidiariesthecompanyalsomayfromtimeto timemakeforwardlookingstatementsforwardlookingstatementsdonotrelatestrictlytohistoricalorcurrentfactsand reflectmanagementsassumptionsviewsplansobjectivesandprojectionsaboutthefutureforwardlookingstatement maybeidentifiedbytheuseofwordssuchasplansexpectswillanticipatesestimatesandotherwordsof similarmeaninginconjunctionwithamongotherthingsdiscussionsoffutureoperationsexpectedoperatingresultsand financialperformanceimpactofplannedacquisitionsanddispositionsthecompanysstrategyforgrowthproduct developmentregulatoryapprovalsmarketpositionandexpenditure becauseforwardlookingstatementsarebasedoncurrentbeliefsexpectationsandassumptionsregardingfutureevent theyaresubjecttouncertaintiesrisksandchangesthataredifficulttopredictandmanyofwhichareoutsideofthe companyscontrolinvestorsshouldrealizethatifunderlyingassumptionsproveinaccurateorknownorunknownrisksor uncertaintiesmaterializethecompanysactualresultsandfinancialconditioncouldvarymateriallyfromexpectationsand projectionsexpressedorimpliedinitsforwardlookingstatementsinvestorsarethereforecautionednottorelyonthese forwardlookingstatementsrisksanduncertaintiesincludebutarenotlimitedto risksrelatedtoproductdevelopmentmarketsuccessandcompetition challengesanduncertaintiesinherentininnovationanddevelopmentofnewandimprovedproductsandtechnologie onwhichthecompanyscontinuedgrowthandsuccessdependincludinguncertaintyofclinicaloutcomesadditional analysisofexistingclinicaldataobtainingregulatoryapprovalshealthplancoverageandcustomeraccessandinitial andcontinuedcommercialsuccess challengestothecompanysabilitytoobtainandprotectadequatepatentandotherintellectualpropertyrightsfornew andexistingproductsandtechnologiesintheunitedstatesandotherimportantmarket theimpactofpatentexpirationstypicallyfollowedbytheintroductionofcompetingbiosimilarsandgenericsand resultingrevenueandmarketsharelosse increasinglyaggressiveandfrequentchallengestothecompanyspatentsbycompetitorsandothersseekingtolaunch competinggenericbiosimilarorotherproductsandincreasedreceptivityofcourtstheunitedstatespatentand trademarkofficeandotherdecisionmakerstosuchchallengespotentiallyresultinginlossofmarketexclusivityand rapiddeclineinsalesfortherelevantproductsoonerthanexpecte competitioninresearchanddevelopmentofnewandimprovedproductsprocessesandtechnologieswhichcanresult inproductandprocessobsolescence competitiontoreachagreementwiththirdpartiesforcollaborationlicensingdevelopmentandmarketingagreement forproductsandtechnologie competitionbasedoncosteffectivenessproductperformancetechnologicaladvancesandpatentsattainedby competitorsand allegationsthatthecompanysproductsinfringethepatentsandotherintellectualpropertyrightsofthirdpartieswhich couldadverselyaffectthecompanysabilitytoselltheproductsinquestionandrequirethepaymentofmoneydamage andfutureroyaltie risksrelatedtoproductliabilitylitigationandregulatoryactivity productefficacyorsafetyconcernswhetherornotbasedonscientificevidencepotentiallyresultinginproduct withdrawalsrecallsregulatoryactiononthepartoftheunitedstatesfoodanddrugadministrationorinternational counterpartsdecliningsalesreputationaldamageincreasedlitigationexpenseandsharepriceimpact impactincludingdecliningsalesandreputationaldamageofsignificantlitigationorgovernmentactionadversetothe companyincludingproductliabilityclaimsandallegationsrelatedtopharmaceuticalmarketingpracticesand contractingstrategie impactofanadversejudgmentorsettlementandtheadequacyofreservesrelatedtolegalproceedingsinclude patentlitigationproductliabilitypersonalinjuryclaimssecuritiesclassactionsgovernmentinvestigationsemployment andotherlegalproceeding increasedscrutinyofthehealthcareindustrybygovernmentagenciesandstateattorneysgeneralresultingin investigationsandprosecutionswhichcarrytheriskofsignificantcivilandcriminalpenaltiesincludingbutnotlimite todebarmentfromgovernmentbusiness johnsonjohnsonannualreport failuretomeetcomplianceobligationsinthemcneilppcincconsentdecreeoranyothercomplianceagreement withgovernmentsorgovernmentagencieswhichcouldresultinsignificantsanction potentialchangestoapplicablelawsandregulationsaffectingunitedstatesandinternationaloperationsinclude relatingtoapprovalofnewproductslicensingandpatentrightssalesandpromotionofhealthcareproductsaccess toandreimbursementandpricingforhealthcareproductsandservicesenvironmentalprotectionandsourcingofraw material compliancewithlocalregulationsandlawsthatmayrestrictthecompanysabilitytomanufactureorsellitsproductsin relevantmarketsincludingrequirementstocomplywithmedicaldevicereportingregulationsandotherrequirement suchastheeuropeanunionsmedicaldevicesregulation changesindomesticandinternationaltaxlawsandregulationsincludingchangesrelatedtothetaxcutsandjob actintheunitedstatesthefederalactontaxreformandahvfinancinginswitzerlandincreasingauditscrutinyby taxauthoritiesaroundtheworldandexposurestoadditionaltaxliabilitiespotentiallyinexcessofexistingreservesand issuanceofneworrevisedaccountingstandardsbythefinancialaccountingstandardsboardandregulationsbythe securitiesandexchangecommission risksrelatedtothecompanysstrategicinitiativesandhealthcaremarkettrend pricingpressuresresultingfromtrendstowardhealthcarecostcontainmentincludingthecontinuedconsolidation amonghealthcareprovidersandothermarketparticipantstrendstowardmanagedcaretheshifttowardgovernment increasinglybecomingtheprimarypayersofhealthcareexpensessignificantnewentrantstothehealthcaremarket seekingtoreducecostsandgovernmentpressureoncompaniestovoluntarilyreducecostsandpriceincrease restrictedspendingpatternsofindividualinstitutionalandgovernmentalpurchasersofhealthcareproductsand servicesduetoeconomichardshipandbudgetaryconstraint challengestothecompanysabilitytorealizeitsstrategyforgrowthincludingthroughexternallysourcedinnovation suchasdevelopmentcollaborationsstrategicacquisitionslicensingandmarketingagreementsandthepotential heightenedcostsofanysuchexternalarrangementsduetocompetitivepressure thepotentialthattheexpectedstrategicbenefitsandopportunitiesfromanyplannedorcompletedacquisitionor divestiturebythecompanymaynotberealizedormaytakelongertorealizethanexpectedand thepotentialthattheexpectedbenefitsandopportunitiesrelatedtopastandongoingrestructuringactionsmaynotbe realizedormaytakelongertorealizethanexpecte risksrelatedtoeconomicconditionsfinancialmarketsandoperatinginternationally marketconditionsandthepossibilitythatthecompanyssharerepurchaseprogrammaybedelayedsuspendedor discontinue impactofinflationandfluctuationsininterestratesandcurrencyexchangeratesandthepotentialeffectofsuch fluctuationsonrevenuesexpensesandresultingmargin potentialchangesinexportimportandtradelawsregulationsandpoliciesoftheunitedstatesandothercountrie includinganyincreasedtraderestrictionsortariffsandpotentialdrugreimportationlegislation theimpactoninternationaloperationsfromfinancialinstabilityininternationaleconomiessovereignriskpossible impositionofgovernmentalcontrolsandrestrictiveeconomicpoliciesandunstableinternationalgovernmentsandlegal system changestoglobalclimateextremeweatherandnaturaldisastersthatcouldaffectdemandforthecompanysproduct andservicescausedisruptionsinmanufacturinganddistributionnetworksaltertheavailabilityofgoodsandservice withinthesupplychainandaffecttheoveralldesignandintegrityofthecompanysproductsandoperationsand theimpactofarmedconflictsandterroristattacksintheunitedstatesandotherpartsoftheworldincludingsocialand economicdisruptionsandinstabilityoffinancialandothermarket risksrelatedtosupplychainandoperation difficultiesanddelaysinmanufacturinginternallythroughthirdpartyprovidersorotherwisewithinthesupplychainthat mayleadtovoluntaryorinvoluntarybusinessinterruptionsorshutdownsproductshortageswithdrawalsor suspensionsofproductsfromthemarketandpotentialregulatoryaction interruptionsandbreachesofthecompanysinformationtechnologysystemsorthoseofthecompanysvendor whichcouldresultinreputationalcompetitiveoperationalorotherbusinessharmaswellasfinancialcostsand regulatoryaction relianceonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexandsubjecttoincreasing regulatoryrequirementsthatmayadverselyaffectsupplysourcingandpricingofmaterialsusedinthecompany productsand johnsonjohnsonannualreport thepotentialthattheexpectedbenefitsandopportunitiesrelatedtorestructuringactionscontemplatedfortheglobal supplychainmaynotberealizedormaytakelongertorealizethanexpectedincludingduetoanyrequiredapproval fromapplicableregulatoryauthoritiesdisruptionsassociatedwiththeannouncedglobalsupplychainactionsmay adverselyaffectsupplyandsourcingofmaterialsusedinthecompanysproduct investorsalsoshouldcarefullyreadtheriskfactorsdescribedinitemaofthisannualreportonformkfora descriptionofcertainrisksthatcouldamongotherthingscausethecompanysactualresultstodiffermateriallyfrom thoseexpressedinitsforwardlookingstatementsinvestorsshouldunderstandthatitisnotpossibletopredictoridentify allsuchfactorsandshouldnotconsidertherisksdescribedaboveandinitematobeacompletestatementofall potentialrisksanduncertaintiesthecompanydoesnotundertaketopubliclyupdateanyforwardlookingstatementthat maybemadefromtimetotimewhetherasaresultofnewinformationorfutureeventsordevelopment johnsonjohnsonannualreport item business general johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldjohnsonjohnson isaholdingcompanywhichhasmorethanoperatingcompaniesconductingbusinessinvirtuallyallcountriesofthe worldthecompanysprimaryfocusisproductsrelatedtohumanhealthandwellbeingjohnsonjohnsonwas incorporatedinthestateofnewjerseyin theexecutivecommitteeofjohnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategic operationsandallocationoftheresourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesofthe companysthreebusinesssegmentsconsumerpharmaceuticalandmedicaldeviceswithinthestrategicparameter providedbythecommitteeseniormanagementgroupsatusandinternationaloperatingcompaniesareeach responsiblefortheirownstrategicplansandthedaytodayoperationsofthosecompanieseachsubsidiarywithinthe businesssegmentsiswithlimitedexceptionsmanagedbyresidentsofthecountrywherelocated segment business thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicesadditional informationrequiredbythisitemisincorporatedhereinbyreferencetothenarrativeandtabulardescriptionsofsegments andoperatingresultsunderitemmanagementsdiscussionandanalysisofresultsofoperationsandfinancial conditionofthisreportandnotesegmentsofbusinessandgeographicareasofthenotestoconsolidate financialstatementsincludedinitemofthisreport consumer theconsumersegmentincludesabroadrangeofproductsusedinthebabycareoralcarebeautyoverthecounter pharmaceuticalwomenshealthandwoundcaremarketsbabycareincludesthejohnsonslineofproductsoral careincludesthelisterineproductlinemajorbrandsinbeautyincludetheaveenocleanclear dabaojohnsonsadultlepetitemarseillaisneutrogenaandogxproductlines overthecountermedicinesincludethebroadfamilyoftylenolacetaminophenproductssudafedcoldfluand allergyproductsbenadrylandzyrtecallergyproductsmotrinibibuprofenproductsandthepepcidline ofacidrefluxproductsmajorbrandsinwomenshealthoutsideofnorthamericaarestayfreeandcarefree sanitarypadsandobtamponbrandswoundcarebrandsincludethebandaidbrandadhesivebandagesand neosporinfirstaidproductlinestheseproductsaremarketedtothegeneralpublicandsoldbothtoretailoutlets anddistributorsthroughouttheworld pharmaceutical thepharmaceuticalsegmentisfocusedonsixtherapeuticareasimmunologyegrheumatoidarthritisinflammatory boweldiseaseandpsoriasisinfectiousdiseasesandvaccineseghivaidsneuroscienceegmooddisorder neurodegenerativedisordersandschizophreniaoncologyegprostatecancerandhematologicmalignancie cardiovascularandmetabolismegthrombosisanddiabetesandpulmonaryhypertensionegpulmonaryarterial hypertensionmedicinesinthissegmentaredistributeddirectlytoretailerswholesalershospitalsandhealthcare professionalsforprescriptionusekeyproductsinthepharmaceuticalsegmentincluderemicadeinfliximaba treatmentforanumberofimmunemediatedinflammatorydiseasessimponigolimumabasubcutaneoustreatment foradultswithmoderatetosevererheumatoidarthritisactivepsoriaticarthritisactiveankylosingspondylitisand moderatelyactivetoseverelyactiveulcerativecolitissimponiariagolimumabanintravenoustreatmentforadult withmoderatetosevererheumatoidarthritisactivepsoriaticarthritisandactiveankylosingspondylitisstelara ustekinumabatreatmentforadultsandchildrenwithmoderatetosevereplaquepsoriasisforadultswithactivepsoriatic arthritisandforadultswithmoderatelytoseverelyactivecrohnsdiseasetremfyaguselkumabatreatmentfor adultswithmoderatetosevereplaquepsoriasisedurantrilpivirineintelenceetravirineprezista johnsonjohnsonannualreport darunavirandprezcobixrezolstadarunavircobicistatantiretroviralmedicinesforthetreatmentofhuman immunodeficiencyvirushivincombinationwithotherantiretroviralproductsandsymtuzadarunavircobicistat emtricitabinetenofoviralafenamideaoncedailysingletabletregimenforthetreatmentofhivconcerta methylphenidatehclextendedreleasetabletsciiatreatmentforattentiondeficithyperactivitydisorderinvega sustennaxeplionpaliperidonepalmitateforthetreatmentofschizophreniaandschizoaffectivedisorderin adultsinvegatrinzatrevictapaliperidonepalmitateforthetreatmentofschizophreniainpatientsafterthey havebeenadequatelytreatedwithinvegasustennaforatleastfourmonthsrisperdalconstarisperidone longactinginjectionforthetreatmentofschizophreniaandthemaintenancetreatmentofbipolardisorderinadults zytigaabirateroneacetateatreatmentformetastaticcastrationresistantprostatecancercrpcandmetastatic highriskcastrationsensitiveprostatecancerimbruvicaibrutinibatreatmentforcertainbcellmalignanciesor bloodcancerschronicgraftversushostdiseaseandwaldenstrmsmacroglobulinemiadarzalexdaratumumaba treatmentforrelapsedrefractorymultiplemyelomavelcadebortezomibatreatmentformultiplemyelomamantlecell lymphomaprocriteprexepoetinalfaatreatmentforchemotherapyinducedanemiaandpatientswithchronic kidneydiseasexareltorivaroxabananoralanticoagulantforthepreventionofdeepveinthrombosisdvtwhich mayleadtopulmonaryembolismpeinpatientsundergoinghiporkneereplacementsurgerytoreducetheriskofstroke andsystemicembolisminpatientswithnonvalvularatrialfibrillationandforthetreatmentandreductionofriskof recurrenceofdvtandpeinvokanacanagliflozinforthetreatmentofadultswithtypediabetesinvokamet vokanametcanagliflozinmetforminhclacombinationtherapyoffixeddosesofcanagliflozinandmetformin hydrochlorideforthetreatmentofadultswithtypediabetesandinvokametxrcanagliflozinmetformin hydrochlorideextendedreleaseaoncedailyfixeddosecombinationtherapyofcanagliflozinandmetformin hydrochlorideextendedreleaseforthetreatmentofadultswithtypediabetesopsumitmacitentanas monotherapyorincombinationindicatedforthelongtermtreatmentofpulmonaryarterialhypertensionpahuptravi selexipagtheonlyapprovedoralselectiveipreceptoragonisttargetingaprostacyclinpathwayinpahmanyofthese medicinesweredevelopedincollaborationwithstrategicpartnersorarelicensedfromothercompaniesandmaintain activelifecycledevelopmentprograms medicaldevices themedicaldevicessegmentincludesabroadrangeofproductsusedintheorthopaedicsurgeryinterventional solutionscardiovascularandneurovasculardiabetescaredivestedinthefiscalfourthquarterofandeyehealth fieldstheseproductsaredistributedtowholesalershospitalsandretailersandusedprincipallyintheprofessionalfield byphysiciansnurseshospitalseyecareprofessionalsandclinicstheyincludeorthopaedicproductsgeneralsurgery biosurgicalendomechanicalandenergyproductselectrophysiologyproductstotreatcardiovasculardiseasesterilization anddisinfectionproductstoreducesurgicalinfectionandvisionproductssuchasdisposablecontactlensesand ophthalmicproductsrelatedtocataractandlaserrefractivesurgery geographic area thebusinessofjohnsonjohnsonisconductedbymorethanoperatingcompanieslocatedinmorethan countriesincludingtheuswhichsellproductsinvirtuallyallcountriesthroughouttheworldtheproductsmadeand soldintheinternationalbusinessincludemanyofthosedescribedaboveundersegmentsofbusinessconsumer pharmaceuticalandmedicaldeviceshowevertheprincipalmarketsproductsandmethodsofdistributionin theinternationalbusinessvarywiththecountryandtheculturetheproductssoldininternationalbusinessincludethose developedintheusandbysubsidiariesabroad investmentsandactivitiesinsomecountriesoutsidetheusaresubjecttohigherrisksthancomparableusactivitie becausetheinvestmentandcommercialclimatemaybeinfluencedbyfinancialinstabilityininternationaleconomie restrictiveeconomicpoliciesandpoliticalandlegalsystemuncertaintie raw material rawmaterialsessentialtothecompanysbusinessaregenerallyreadilyavailablefrommultiplesourceswherethereare exceptionsthetemporaryunavailabilityofthoserawmaterialswouldnotlikelyhaveamaterialadverseeffectonthe financialresultsofthecompany patent thecompanyssubsidiarieshavemadeapracticeofobtainingpatentprotectionontheirproductsandprocesseswhere possibletheyownorarelicensedunderasignificantnumberofpatentsintheusandothercountriesrelatingtotheir johnsonjohnsonannualreportproductsproductusesformulationsandmanufacturingprocesseswhichintheaggregatearebelievedtobeofmaterial importancetothecompanyintheoperationofitsbusinessesthecompanyssubsidiariesfacepatentchallengesfrom thirdpartiesincludingchallengesseekingtomanufactureandmarketgenericandbiosimilarversionsofthecompanys keypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductssignificantlegal proceedingsandclaimsinvolvingthecompanyspatentandotherintellectualpropertyaredescribedinnotelegal proceedingsintellectualpropertyofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport salesofthecompanysndlargestproductstelaraustekinumabaccountedforapproximatelyofthe companystotalrevenuesforfiscalaccordinglythepatentsrelatedtothisproductarebelievedtobematerialto thecompany thereisonesetofgrantedpatentsrelatedspecificallytostelarathissetofpatentsisownedbyjanssenbiotech incawhollyownedsubsidiaryofjohnsonjohnsonthesepatentsareinforceintheusandmanycountriesoutside theunitedstatesintheusthelatestprojectedexpirationdateforpatentsinthissetisduetoapatentterm extensionineuropethelatestprojectedexpirationdateforpatentsinthissetisduetoasupplementalpatent certificatepatenttermextensioninmostothercountriesthelatestprojectedexpirationdateis inadditiontocompetingintheimmunologymarketwithstelarathecompanyiscurrentlymarketingsimponi golimumabandsimponiariagolimumabnextgenerationimmunologyproductswithremainingpatentlivesofupto sixyearsthecompanyalsomarketsremicadeinfliximabintheimmunologymarketwhichisthecompanyslargest productpatentsonthisproducthaveexpiredandthefoodanddrugadministrationapprovedthefirstinfliximabbiosimilar forsaleintheusinandanumberofsuchproductshavebeenlaunchedsincethenforamoreextensive descriptionoflegalmattersregardingthepatentsrelatedtoremicadeseenotelegalproceedingsintellectual propertypharmaceuticalremicaderelatedcasesofthenotestoconsolidatedfinancialstatementsinclude initemofthisreport trademark thecompanyssubsidiarieshavemadeapracticeofsellingtheirproductsundertrademarksandofobtainingprotection forthesetrademarksbyallavailablemeansthesetrademarksareprotectedbyregistrationintheusandothercountrie wheresuchproductsaremarketedthecompanyconsidersthesetrademarksintheaggregatetobeofmaterial importanceintheoperationofitsbusinesse seasonality worldwidesalesdonotreflectanysignificantdegreeofseasonalityhoweverspendinghasbeenheavierinthefourth quarterofeachyearthaninotherquartersthisreflectsincreasedspendingdecisionsprincipallyforadvertisingand researchanddevelopmentactivity competition inalloftheirproductlinesthecompanyssubsidiariescompetewithcompaniesbothlocallyandgloballycompetition existsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolvedcompetitionin researchbothinternallyandexternallysourcedinvolvingthedevelopmentandtheimprovementofnewandexiste productsandprocessesisparticularlysignificantthedevelopmentofnewandinnovativeproductsaswellasprotecting theunderlyingintellectualpropertyofthecompanysproductportfolioisimportanttothecompanyssuccessinallarea ofitsbusinessthecompetitiveenvironmentrequiressubstantialinvestmentsincontinuingresearchinadditionthe developmentandmaintenanceofcustomerdemandforthecompanysconsumerproductsinvolvesignificant expendituresforadvertisingandpromotion environment thecompanyissubjecttoavarietyofusandinternationalenvironmentalprotectionmeasuresthecompanybelieve thatitsoperationscomplyinallmaterialrespectswithapplicableenvironmentallawsandregulationsthecompanys compliancewiththeserequirementsdidnotchangeduringthepastyearandisnotexpectedtohaveamaterialeffect uponitscapitalexpenditurescashflowsearningsorcompetitiveposition regulation thecompanysbusinessesaresubjecttovaryingdegreesofgovernmentalregulationinthecountriesinwhichoperation areconductedandthegeneraltrendistowardincreasinglystringentregulationintheusthedrugdeviceandcosmetic johnsonjohnsonannualreport industrieshavelongbeensubjecttoregulationbyvariousfederalandstateagenciesprimarilyastoproductsafety efficacymanufacturingadvertisinglabelingandsafetyreportingtheexerciseofbroadregulatorypowersbytheus foodanddrugadministrationthefdacontinuestoresultinincreasesintheamountsoftestinganddocumentation requiredforfdaapprovalofnewdrugsanddevicesandacorrespondingincreaseintheexpenseofproductintroduction similartrendsarealsoevidentinmajormarketsoutsideoftheusthenewmedicaldeviceregulatoryframeworkandthe newprivacyregulationsineuropeareexamplesofsuchincreasedregulation thecostsofhumanhealthcarehavebeenandcontinuetobeasubjectofstudyinvestigationandregulationby governmentalagenciesandlegislativebodiesaroundtheworldintheusattentionhasbeenfocusedondrugprice andprofitsandprogramsthatencouragedoctorstowriteprescriptionsforparticulardrugsortorecommenduseor purchaseparticularmedicaldevicespayershavebecomeamorepotentforceinthemarketplaceandincreasedattention isbeingpaidtodrugandmedicaldevicepricingappropriatedrugandmedicaldeviceutilizationandthequalityandcost ofhealthcaregenerally usgovernmentagenciescontinuetoimplementtheextensiverequirementsofthepatientprotectionandaffordablecare acttheacathesehavebothpositiveandnegativeimpactsontheushealthcareindustrywithmuchremaine uncertainastohowvariousprovisionsoftheacaandpotentialmodificationorrepealofacaprovisionswillultimately affecttheindustry theregulatoryagenciesunderwhosepurviewthecompanyoperateshaveadministrativepowersthatmaysubjectitto actionssuchasproductwithdrawalsrecallsseizureofproductsandothercivilandcriminalsanctionsinsomecasesthe companyssubsidiariesmaydeemitadvisabletoinitiateproductrecall inadditionbusinesspracticesinthehealthcareindustryhavecomeunderincreasedscrutinyparticularlyintheusby governmentagenciesandstateattorneysgeneralandresultinginvestigationsandprosecutionscarrytheriskofsignificant civilandcriminalpenaltie furtherthecompanyreliesonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexare subjecttoincreasingregulatoryrequirementsandmaybefacedwithunexpectedchangessuchasthoseresultingfrom brexitthatmayaffectsourcingsupplyandpricingofmaterialsusedinthecompanysproductstheseprocessesalso aresubjecttolengthyregulatoryapproval available information thecompanysmaincorporatewebsiteaddressiswwwjnjcomallofthecompanyssecfilingsarealsoavailableonthe companyswebsiteatwwwinvestorjnjcomseccfmassoonasreasonablypracticableafterhavingbeenelectronically filedorfurnishedtothesecallsecfilingsarealsoavailableatthesecswebsiteatwwwsecgovinadditionthe writtenchartersoftheauditcommitteethecompensationbenefitscommitteethenominatingcorporate governancecommitteetheregulatorycompliancecommitteeandthesciencetechnologysustainabilitycommittee oftheboardofdirectorsandthecompanysprinciplesofcorporategovernancecodeofbusinessconductfor employeescodeofbusinessconductethicsformembersoftheboardofdirectorsandexecutiveofficersandother corporategovernancematerialsareavailableatwwwinvestorjnjcomgovcfmonthecompanyswebsiteandwillbe providedwithoutchargetoanyshareholdersubmittingawrittenrequestasprovidedabovetheinformationonthe companyswebsiteisnotandwillnotbedeemedapartofthisreportorincorporatedintoanyotherfilingsthecompany makeswiththesec item risk factor thecompanyfacesanumberofuncertaintiesandrisksthataredifficulttopredictandmanyofwhichareoutsideofthe companyscontrolinadditiontotheotherinformationinthisreportandthecompanysotherfilingswiththesec investorsshouldconsidercarefullythefactorssetforthbelowinvestorsshouldbeawarethatitisnotpossibletopredict oridentifyallsuchfactorsandthatthefollowingisnotmeanttobeacompletediscussionofallpotentialrisksor uncertaintiesifknownorunknownrisksoruncertaintiesmaterializethecompanysbusinessresultsofoperationsor financialconditioncouldbeadverselyaffectedpotentiallyinamaterialway globalsalesinthecompanyspharmaceuticalandmedicaldevicessegmentsmaybenegativelyimpacte byhealthcarereformsandincreasingpricingpressure salesofthecompanyspharmaceuticalandmedicaldeviceproductsaresignificantlyaffectedbyreimbursementsby thirdpartypayerssuchasgovernmenthealthcareprogramsprivateinsuranceplansandmanagedcareorganizationsas johnsonjohnsonannualreportpartofvariouseffortstocontainhealthcarecoststhesepayersareputtingdownwardpressureonpricesatwhich productswillbereimbursedintheusincreasedpurchasingpowerofentitiesthatnegotiateonbehalfofmedicare medicaidandprivatesectorbeneficiariesinpartduetocontinuedconsolidationamonghealthcareproviderscould resultinfurtherpricingpressuresinadditionincreasedpoliticalscrutinycouldresultinadditionalpricingpressures outsidetheusnumerousmajormarketsincludingtheeuandjapanhavepervasivegovernmentinvolvementinfunding healthcareandinthatregarddirectlyorindirectlyimposepricecontrolslimitaccesstoorreimbursementforthe companysproductsorreducethevalueofitsintellectualpropertyprotection thecompanyissubjecttosignificantlegalproceedingsthatcanresultinsignificantexpensesfinesand reputationaldamage intheordinarycourseofbusinessjohnsonjohnsonanditssubsidiariesaresubjecttonumerousclaimsandlawsuit involvingvariousissuessuchaspatentdisputesproductliabilityandclaimsthattheirproductsalesmarketingandprice practicesviolatevariousantitrustunfairtradepracticesandorconsumerprotectionlawsthemostsignificantofthese proceedingsaredescribedinnotelegalproceedingsundernotestotheconsolidatedfinancialstatement includedinitemofthisreportwhilethecompanybelievesithassubstantialdefensesinthesemattersitisnot feasibletopredicttheultimateoutcomeoflitigationthecompanycouldinthefutureberequiredtopaysignificant amountsasaresultofsettlementsorjudgmentsinthesematterspotentiallyinexcessofaccrualsincludingmatterswhere thecompanycouldbeheldjointlyandseverallyliableamongotherdefendantstheresolutionoforincreaseinaccrual foroneormoreofthesemattersinanyreportingperiodcouldhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiodfurthermoreasaresultofcostandavailabilityfactorseffectivenovember thecompanyceasedpurchasingthirdpartyproductliabilityinsurance productreliabilitysafetyandeffectivenessconcernscanhavesignificantnegativeimpactsonsalesand resultsofoperationsleadtolitigationandcausereputationaldamage concernsaboutproductsafetywhetherraisedinternallyorbylitigantsregulatorsorconsumeradvocatesandwhetheror notbasedonscientificevidencecanresultinsafetyalertsproductrecallsgovernmentalinvestigationsregulatoryaction onthepartofthefdaoritscounterpartinothercountriesprivateclaimsandlawsuitspaymentoffinesandsettlement decliningsalesandreputationaldamagethesecircumstancescanalsoresultindamagetobrandimagebrandequity andconsumertrustinthecompanysproductsproductrecallshaveinthepastandcouldinthefutureprompt governmentinvestigationsandinspectionstheshutdownofmanufacturingfacilitiescontinuedproductshortagesand relatedsalesdeclinessignificantremediationcostsreputationaldamagepossiblecivilpenaltiesandcriminalprosecution changesintaxlawsorexposurestoadditionaltaxliabilitiescouldnegativelyimpactthecompany operatingresult changesintaxlawsorregulationsaroundtheworldcouldnegativelyimpactthecompanyseffectivetaxrateandresult ofoperationsachangeinstatutorytaxrateinanycountrywouldresultintherevaluationofthecompanysdeferredtax assetsandliabilitiesrelatedtothatparticularjurisdictionintheperiodinwhichthenewtaxlawisenactedthischange wouldresultinanexpenseorbenefitrecordedtothecompanysconsolidatedstatementofearningsthecompany closelymonitorstheseproposalsastheyariseinthecountrieswhereitoperateschangestothestatutorytaxratemay occuratanytimeandanyrelatedexpenseorbenefitrecordedmaybematerialtothefiscalquarterandyearinwhichthe lawchangeisenacte ondecembertheusenactedthetaxcutsandjobsactthetcjawhichintroducedsignificantchangesto uscorporateincometaxlawthatwillhaveameaningfulimpactonthecompanysprovisionforincometaxesaccounte fortheincometaxeffectsofthetcjarequiressignificantjudgmentstobemadeininterpretingitsprovisionsanticipate guidancefromtheustreasuryaboutimplementingthetcjawhichshouldbefinalbyjunemonthsafter enactmentmayresultinadjustmentsthatcouldmateriallyaffectthecompanysfinancialpositionandresultsof operationsaswellastheeffectivetaxrateintheperiodinwhichtheadjustmentsaremade onseptembertheswissparliamentapprovedthefederalactontaxreformandahvfinancingswisstax reformhoweverareferendumhasbeencalledandasaresultapublicvoteontheswisstaxreformwilltakeplaceon maythiftheswisstaxreformpassesthenthemeasuresareexpectedtocomeintoforceineitherjanuary orjanuarypriortoapprovalinthereferendumanditssubsequentcantonalimplementationthepropose swisstaxreformisnotenactedandthereforethecompanyhasnotreflectedanyofthepotentialimpactsinitsfiscal resultsthecompanyiscurrentlyassessingtheimpactoftheproposedswisstaxreformandwhenenactedthelaw mayhaveamaterialimpactonthecompanysoperatingresult thecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandisaddressingtaxauditsanddispute withmanytaxauthoritiesinconnectionwiththeorganizationforeconomiccooperationanddevelopmentbaseerosion johnsonjohnsonannualreport andprofitshiftingbepsprojectcompaniesarerequiredtodisclosemoreinformationtotaxauthoritiesonoperation aroundtheworldwhichmayleadtogreaterauditscrutinyofprofitsearnedinothercountriesthecompanyregularly assessesthelikelyoutcomesofitstaxauditsanddisputestodeterminetheappropriatenessofitstaxreserveshowever anytaxauthoritycouldtakeapositionontaxtreatmentthatiscontrarytothecompanysexpectationswhichcouldresult intaxliabilitiesinexcessofreserve thecompanymaynotbeabletosuccessfullysecureanddefendintellectualpropertyrightsessentialto thecompanysbusinesse thecompanyownsorlicensesasignificantnumberofpatentsandotherproprietaryrightsdeterminedbypatentoffice courtsandlawmakersinvariouscountriesrelatingtoitsproductsandmanufacturingprocessestheserightsareessential tothecompanysbusinessesandmateriallyimportanttothecompanysresultsofoperationspublicpolicybothwithin andoutsidetheushasbecomeincreasinglyunfavorabletowardintellectualpropertyrightsthecompanycannotbe certainthatitwillobtainadequatepatentprotectionfornewproductsandtechnologiesintheusandotherimportant marketsorthatsuchprotectionsoncegrantedwilllastaslongasoriginallyanticipate competitorsroutinelychallengethevalidityorextentofthecompanysownedorlicensedpatentsandproprietaryright throughlitigationinterferencesoppositionsandotherproceedingstheseproceedingsabsorbresourcesandcanbe protractedaswellasunpredictableinadditionchallengesthatthecompanysproductsinfringethepatentsofthird partiescouldresultintheneedtopaypastdamagesandfutureroyaltiesandadverselyaffectthecompetitivepositionand salesoftheproductsinquestion thecompanyhasfacedincreasingpatentchallengesfromthirdpartiesseekingtomanufactureandmarketgenericand biosimilarversionsofthecompanyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscovering thoseproductsintheusmanufacturersofgenericversionsofinnovativehumanpharmaceuticalproductsmay challengethevalidityorclaimnoninfringementofinnovatorproductsthroughtheabbreviatednewdrugapplicationor andaprocesswiththefdathebiologicspricecompetitionandinnovationactbpciaenactedinwhich createdanewregulatorypathwayfortheapprovalbythefdaofbiosimilaralternativestoinnovatordevelopedbiological productsalsocreatedmechanismsforbiosimilarapplicantstochallengethepatentsontheinnovatorbiologicstheinter partesreviewiprprocesswiththeusptocreatedundertheamericainventsactisalsobeingusedby competitorstochallengepatentsheldbythecompanyssubsidiarie intheeventthecompanyisnotsuccessfulindefendingitspatentsagainstsuchchallengesorupontheatrisklaunch despitependingpatentinfringementlitigationbythegenericorbiosimilarfirmofitsproductthecompanycanlosea majorportionofrevenuesforthereferencedproductinaveryshortperiodoftimecurrentlegalproceedingsinvolvingthe companyspatentsandotherintellectualpropertyrightsaredescribedinnotelegalproceedingsintellectual propertyofthenotestotheconsolidatedfinancialstatementsincludedinitemofthisreport thecompanysbusinessesoperateinhighlycompetitiveproductmarketsandcompetitivepressurescould adverselyaffectthecompanysearning thecompanyfacessubstantialcompetitioninallthreeoperatingsegmentsandinallgeographicmarketsthecompanys businessescompetewithcompaniesofallsizesonthebasisofcosteffectivenesstechnologicalinnovationsintellectual propertyrightsproductperformancerealorperceivedproductadvantagespricingandavailabilityandrateof reimbursementthecompanyalsocompeteswithothermarketparticipantsinsecuringrightstoacquisition collaborationsandlicensingagreementswiththirdpartiescompetitionforrightstoproductcandidatesandtechnologie mayresultinsignificantinvestmentandacquisitioncostsandonerousagreementtermsforthecompanycompetitor developmentofmoreeffectiveorlesscostlyproductsandortheirabilitytosecurepatentandotherintellectualproperty rightsandsuccessfullymarketproductsaheadofthecompanycouldnegativelyimpactsalesofthecompanysexisting productsaswellasitsabilitytobringnewproductstomarketdespitesignificantpriorinvestmentintherelatedproduct development forthecompanyspharmaceuticalbusinesseslossofpatentexclusivityforaproductoftenisfollowedbyasubstantial reductioninsalesascompetitorsgainregulatoryapprovalforgenericandothercompetingproductsandenterthemarket similarcompetitioncanbetriggeredbythelossofexclusivityforabiologicalproductforthecompanysmedicaldevice businessestechnologicalinnovationproductqualityreputationandcustomerserviceareespeciallyimportantto competitivenessdevelopmentbyothercompaniesofneworimprovedproductsprocessesandtechnologiescould threatentomakethecompanysproductsortechnologieslessdesirablelesseconomicalorobsoletethecompany consumerbusinessesfaceintensecompetitionfromotherbrandedproductsandretailersprivatelabelbrandsifthe companyfailstosufficientlydifferentiateandmarketitsbrandnameconsumerproductsthiscouldadverselyaffect revenuesandprofitabilityofthoseproduct johnsonjohnsonannualreportsignificantchallengesordelaysinthecompanysinnovationanddevelopmentofnewproduct technologiesandindicationscouldhaveanadverseimpactonthecompanyslongtermsuccess thecompanyscontinuedgrowthandsuccessdependsonitsabilitytoinnovateanddevelopnewanddifferentiate productsandservicesthataddresstheevolvinghealthcareneedsofpatientsprovidersandconsumersdevelopmentof successfulproductsandtechnologiesisalsonecessarytooffsetrevenuelosseswhenthecompanysexistingproduct losemarketshareduetovariousfactorssuchascompetitionandlossofpatentexclusivitynewproductsintroduce withinthepastfiveyearsaccountedforapproximatelyofsalesthecompanycannotbecertainwhenor whetheritwillbeabletodeveloplicenseorotherwiseacquirecompaniesproductsandtechnologieswhetherparticular productcandidateswillbegrantedregulatoryapprovalandifapprovedwhethertheproductswillbecommercially successful thecompanypursuesproductdevelopmentthroughinternalresearchanddevelopmentaswellasthroughcollaboration acquisitionsjointventuresandlicensingorotherarrangementswiththirdpartiesinallofthesecontextsdevelopingnew productsparticularlypharmaceuticalandbiotechnologyproductsandmedicaldevicesrequiressignificantinvestmentof resourcesovermanyyearsonlyaveryfewbiopharmaceuticalresearchanddevelopmentprogramsresultincommercially viableproductstheprocessdependsonmanyfactorsincludingtheabilitytodiscernpatientsandhealthcareproviders futureneedsdeveloppromisingnewcompoundsstrategiesandtechnologiesachievesuccessfulclinicaltrialresults secureeffectiveintellectualpropertyprotectionobtainregulatoryapprovalsonatimelybasisandifandwhentheyreach themarketsuccessfullydifferentiatethecompanysproductsfromcompetingproductsandapproachestotreatment newproductsorenhancementstoexistingproductsmaynotbeacceptedquicklyorsignificantlyinthemarketplacedue toproductandpricecompetitionchangesincustomerpreferencesorhealthcarepurchasingpatternsresistanceby healthcareprovidersoruncertaintyoverthirdpartyreimbursementevenfollowinginitialregulatoryapprovalthesuccess ofaproductcanbeadverselyimpactedbysafetyandefficacyfindingsinlargerrealworldpatientpopulationsaswellas marketentryofcompetitiveproduct thecompanyfacesincreasingregulatoryscrutinywhichimposessignificantcompliancecostsandexpose thecompanytogovernmentinvestigationslegalactionsandpenaltie likeothercompaniesinthehealthcareindustrythecompanyissubjecttoextensiveregulationinvestigationsandlegal actionbynationalstateandlocalgovernmentagenciesintheusandothercountriesinwhichtheyoperateregulatory issuesregardingcompliancewithgoodmanufacturingpracticescgmpandcomparablequalityregulationsinforeign countriesbymanufacturersofdrugsdevicesandconsumerproductscanleadtofinesandpenaltiesproductrecall productshortagesinterruptionsinproductiondelaysinnewproductapprovalsandlitigationinadditionthemarkete pricingandsaleofthecompanysproductsaresubjecttoregulationinvestigationsandlegalactionsincludingunderthe federalfooddrugandcosmeticactthemedicaidrebateprogramfederalandstatefalseclaimsactsstateunfair tradepracticesactsandconsumerprotectionlawsincreasedscrutinyofhealthcareindustrybusinesspracticesinrecent yearsbygovernmentagenciesandstateattorneysgeneralintheusandanyresultinginvestigationsandprosecution carryriskofsignificantcivilandcriminalpenaltiesincludingbutnotlimitedtodebarmentfromparticipationingovernment healthcareprogramsanysuchdebarmentcouldhaveamaterialadverseeffectonthecompanysbusinessandresultsof operationsthemostsignificantcurrentinvestigationsandlitigationbroughtbygovernmentagenciesaredescribedin notelegalproceedingsgovernmentproceedingsundernotestotheconsolidatedfinancialstatementsinclude initemofthisreport thecompanyfacesavarietyofrisksassociatedwithconductingbusinessinternationally thecompanysextensiveoperationsandbusinessactivityoutsidetheusareaccompaniedbycertainfinancial economicandpoliticalrisksincludingthoselistedbelow foreigncurrencyexchangeinfiscalapproximatelyofthecompanyssalesoccurredoutsideoftheuswith approximatelyineuropeinthewesternhemisphereexcludingtheusandintheasiapacificandafrica regionchangesinnonuscurrenciesrelativetotheusdollarimpactthecompanysrevenuesandexpenseswhile thecompanyusesfinancialinstrumentstomitigatetheimpactoffluctuationsincurrencyexchangeratesonitscashflow unhedgedexposurescontinuetobesubjecttocurrencyfluctuationsinadditiontheweakeningorstrengtheningofthe usdollarmayresultinsignificantfavorableorunfavorabletranslationeffectswhentheoperatingresultsofthe companysnonusbusinessactivityaretranslatedintousdollar inflationandcurrencydevaluationrisksthecompanyfaceschallengesinmaintainingprofitabilityofoperationsin economiesexperiencinghighinflationratesthecompanyhasaccountedforoperationsinargentinabeginninginthe fiscalthirdquarterofandvenezuelaashighlyinflationaryasthepriorthreeyearcumulativeinflationratesurpassed whilethecompanystrivestomaintainprofitmarginsintheseareasthroughcostreductionprogramsproductivity johnsonjohnsonannualreport improvementsandperiodicpriceincreasesitmightexperienceoperatinglossesasaresultofcontinuedinflationin additiontheimpactofcurrencydevaluationsincountriesexperiencinghighinflationratesorsignificantcurrencyexchange fluctuationscouldnegativelyimpactthecompanysoperatingresult illegalimportationofpharmaceuticalproductstheillegalimportationofpharmaceuticalproductsfromcountrieswhere governmentpricecontrolsorothermarketdynamicsresultinlowerpricesmayadverselyaffectthecompanyssalesand profitabilityintheusandothercountriesinwhichthecompanyoperateswiththeexceptionoflimitedquantitiesof prescriptiondrugsforpersonaluseforeignimportsofpharmaceuticalproductsareillegalundercurrentuslaw howeverthevolumeofillegalimportscontinuestoriseastheabilityofpatientsandothercustomerstoobtainthelower pricedimportshasgrownsignificantly antibriberyandotherregulationsthecompanyissubjecttovariousfederalandforeignlawsthatgovernitsinternational businesspracticeswithrespecttopaymentstogovernmentofficialsthoselawsincludetheusforeigncorrupt practicesactfcpawhichprohibitsuspubliclytradedcompaniesfrompromisingofferingorgivinganythingofvalue toforeignofficialswiththecorruptintentofinfluencingtheforeignofficialforthepurposeofhelpingthecompanyobtain orretainbusinessorgainanyimproperadvantagethecompanysbusinessisheavilyregulatedandthereforeinvolve significantinteractionwithforeignofficialsalsoinmanycountriesoutsidetheusthehealthcareproviderswho prescribehumanpharmaceuticalsareemployedbythegovernmentandthepurchasersofhumanpharmaceuticalsare governmententitiesthereforethecompanysinteractionswiththeseprescribersandpurchasersaresubjecttoregulation underthefcpainadditiontotheusapplicationandenforcementofthefcpavariousjurisdictionsinwhichthe companyoperateshavelawsandregulationsincludingtheukbriberyactaimedatpreventingandpenalize corruptandanticompetitivebehaviorenforcementactivitiesundertheselawscouldsubjectthecompanytoadditional administrativeandlegalproceedingsandactionswhichcouldincludeclaimsforcivilpenaltiescriminalsanctionsand administrativeremediesincludingexclusionfromhealthcareprograms otherlegalsocialandpoliticalrisksotherrisksinherentinconductingbusinessgloballyinclude protectiveeconomicpoliciestakenbygovernmentssuchastradeprotectionmeasuresandimportexportlicensing requirement compliancewithlocalregulationsandlawsincludinginsomecountriesregulatoryrequirementsrestrictingthe companysabilitytomanufactureorsellitsproductsintherelevantmarket diminishedprotectionofintellectualpropertyandcontractualrightsincertainjurisdiction potentialnationalizationorexpropriationofthecompanysforeignassetsand disruptionstomarketsduetowararmedconflictterrorismsocialupheavalsorpandemic interruptionsanddelaysinmanufacturingoperationscouldadverselyaffectthecompanysbusinesssale andreputation thecompanysmanufactureofproductsrequiresthetimelydeliveryofsufficientamountsofcomplexhighquality componentsandmaterialsthecompanyssubsidiariesoperatemanufacturingfacilitiesaswellassourcingfrom hundredsofsuppliersaroundtheworldthecompanyhasinthepastandmayinthefuturefaceunanticipated interruptionsanddelaysinmanufacturingthroughitsinternalorexternalsupplychainmanufacturingdisruptionscanoccur formanyreasonsincludingregulatoryactionproductionqualitydeviationsorsafetyissueslabordisputessitespecific incidentssuchasfiresnaturaldisasterssuchashurricanesandothersevereweathereventsrawmaterialshortage politicalunrestandterroristattackssuchdelaysanddifficultiesinmanufacturingcanresultinproductshortagesdecline insalesandreputationalimpactaswellassignificantremediationandrelatedcostsassociatedwithaddressingthe shortage thecompanyreliesonthirdpartiestomanufacturecertainofourproductsanyfailurebyorlossofathird partymanufacturercouldresultindelaysandincreasedcostswhichmayadverselyaffectourbusiness thecompanyreliesonthirdpartiestomanufacturecertainofourproductswedependonthesethirdparty manufacturerstoallocatetousaportionoftheirmanufacturingcapacitysufficienttomeetourneedstoproduceproduct ofacceptablequalityandatacceptablemanufacturingyieldsandtodeliverthoseproductstousonatimelybasisandat acceptablepriceshoweverwecannotguaranteethatthesethirdpartymanufacturerswillbeabletomeetournearterm orlongtermmanufacturingrequirementswhichcouldresultinlostsalesandhaveanadverseeffectonourbusiness otherrisksassociatedwithourrelianceonthirdpartiestomanufacturetheseproductsincluderelianceonthethirdparty forregulatorycomplianceandqualityassurancemisappropriationofthecompanysintellectualpropertylimitedabilityto manageourinventorypossiblebreachofthemanufacturingagreementbythethirdpartyandthepossibleterminationor nonrenewalofthemanufacturingagreementbythethirdpartyatatimethatiscostlyorinconvenientforusmoreoverif johnsonjohnsonannualreportanyofourthirdpartymanufacturerssufferanydamagetofacilitieslosebenefitsundermaterialagreementsexperience poweroutagesencounterfinancialdifficultiesareunabletosecurenecessaryrawmaterialsfromtheirsuppliersorsuffer anyotherreductioninefficiencythecompanymayexperiencesignificantbusinessdisruptionintheeventofanysuch disruptionthecompanywouldneedtoseekandsourceotherqualifiedthirdpartymanufacturerslikelyresultinginfurther delaysandincreasedcostswhichcouldaffectourbusinessadversely aninformationsecurityincidentincludingacybersecuritybreachcouldhaveanegativeimpacttothe companysbusinessorreputation tomeetbusinessobjectivesthecompanyreliesonbothinternalinformationtechnologyitsystemsandnetworksand thoseofthirdpartiesandtheirvendorstoprocessandstoresensitivedataincludingconfidentialresearchbusiness plansfinancialinformationintellectualpropertyandpersonaldatathatmaybesubjecttolegalprotectiontheextensive informationsecurityandcybersecuritythreatswhichaffectcompaniesgloballyposearisktothesecurityandavailability oftheseitsystemsandnetworksandtheconfidentialityintegrityandavailabilityofthecompanyssensitivedatathe companycontinuallyassessesthesethreatsandmakesinvestmentstoincreaseinternalprotectiondetectionand responsecapabilitiesaswellasensurethecompanysthirdpartyprovidershaverequiredcapabilitiesandcontrolsto addressthisrisktodatethecompanyhasnotexperiencedanymaterialimpacttothebusinessoroperationsresulte frominformationorcybersecurityattackshoweverbecauseofthefrequentlychangingattacktechniquesalongwiththe increasedvolumeandsophisticationoftheattacksthereisthepotentialforthecompanytobeadverselyimpactedthis impactcouldresultinreputationalcompetitiveoperationalorotherbusinessharmaswellasfinancialcostsand regulatoryactionthecompanymaintainscybersecurityinsuranceintheeventofaninformationsecurityorcyberincident howeverthecoveragemaynotbesufficienttocoverallfinanciallosses item b unresolved staff comment notapplicable item property thecompanyssubsidiariesoperatemanufacturingfacilitiesoccupyingapproximatelymillionsquarefeetoffloor spacethemanufacturingfacilitiesareusedbytheindustrysegmentsofthecompanysbusinessapproximatelyas follow squarefeet segment inthousand consumer pharmaceutical medicaldevice worldwidetotal withintheusfivefacilitiesareusedbytheconsumersegmentfivebythepharmaceuticalsegmentandbythe medicaldevicessegmentoutsideoftheusfacilitiesareusedbytheconsumersegmentbythepharmaceutical segmentandbythemedicaldevicessegment thelocationsofthemanufacturingfacilitiesbymajorgeographicareasoftheworldareasfollow squarefeet geographicarea numberoffacilitie inthousand unitedstate europe westernhemisphereexcludingus africaasiaandpacific worldwidetotal inadditiontothemanufacturingfacilitiesdiscussedabovethecompanymaintainsnumerousofficeandwarehouse facilitiesthroughouttheworldresearchfacilitiesarealsodiscussedinitemmanagementsdiscussionandanalysisof resultsofoperationsandfinancialconditionofthisreport johnsonjohnsonannualreport thecompanyssubsidiariesgenerallyseektoownratherthanleasetheirmanufacturingfacilitiesalthoughsome principallyinnonuslocationsareleasedofficeandwarehousefacilitiesareoftenleasedthecompanyalsoengage contractmanufacturers thecompanyiscommittedtomaintainingallofitspropertiesingoodoperatingcondition mcneilppcincnowjohnsonjohnsonconsumerincmcneilppccontinuestooperateunderaconsentdecree signedinwiththefdawhichgovernscertainmcneilconsumerhealthcaremanufacturingoperationsandrequire mcneilppctoremediatethefacilitiesitoperatesinlancasterpennsylvaniafortwashingtonpennsylvaniaandlas piedraspuertoricotheconsentdecreefollowingfdainspectionsinmcneilppcreceivednotification fromthefdathatallthreemanufacturingfacilitiesareinconformitywithapplicablelawsandregulationsandcommercial productionhasrestarte undertheconsentdecreeafterreceivingnoticefromthefdaofbeingincompliancewithapplicablelawsand regulationseachofthethreefacilitiesissubjecttoafiveyearauditperiodbyathirdpartycgmpexpertthusathird partyexpertwillcontinuetoreassessthesitesatvarioustimesuntilatleast forinformationregardingleaseobligationsseenoterentalexpenseandleasecommitmentsofthenotesto consolidatedfinancialstatementsincludedinitemofthisreportsegmentinformationonadditionstopropertyplant andequipmentiscontainedinnotesegmentsofbusinessandgeographicareasofthenotestoconsolidate financialstatementsincludedinitemofthisreport item legal proceeding theinformationcalledforbythisitemisincorporatedhereinbyreferencetotheinformationsetforthinnotelegal proceedingsofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport inadditionjohnsonjohnsonanditssubsidiariesarealsopartiestoanumberofproceedingsbroughtunderthe comprehensiveenvironmentalresponsecompensationandliabilityactcommonlyknownassuperfundand comparablestatelocalorforeignlawsinwhichtheprimaryreliefsoughtisthecostofpastandorfutureremediation item safety disclosure notapplicable johnsonjohnsonannualreportexecutive officer registrant listedbelowaretheexecutiveofficersofthecompanytherearenofamilyrelationshipsbetweenanyoftheexecutive officersandthereisnoarrangementorunderstandingbetweenanyexecutiveofficerandanyotherpersonpursuantto whichtheexecutiveofficerwasselectedattheannualmeetingoftheboardofdirectorstheexecutiveofficersare electedbytheboardtoholdofficeforoneyearanduntiltheirrespectivesuccessorsareelectedandqualifiedoruntil earlierresignationorremoval informationwithregardtothedirectorsofthecompanyincludinginformationforalexgorskywhoisalsoanexecutive officerisincorporatedhereinbyreferencetothematerialcaptioneditemelectionofdirectorsintheproxystatement age position joaquinduato vicechairmanexecutivecommitteea memberexecutivecommitteeexecutivevicepresidentchiefhuman petermfasolo resourcesofficerb chairmanboardofdirectorschairmanexecutivecommitteechiefexecutive alexgorsky officer memberexecutivecommitteeexecutivevicepresidentworldwidechairman ashleymcevoy medicaldevicesc memberexecutivecommitteeexecutivevicepresidentworldwidechairman jorgemesquita consumerd appointeememberexecutivecommitteeexecutivevicepresidentworldwide thibautmongon chairmanconsumere memberexecutivecommitteeexecutivevicepresidentglobalcorporate michaelesneed affairsandchiefcommunicationofficerf paulusstoffel vicechairmanexecutivecommitteechiefscientificofficerg memberexecutivecommitteeexecutivevicepresidentworldwidechairman jenniferltaubert pharmaceuticalsh michaelhullmann memberexecutivecommitteeexecutivevicepresidentgeneralcounseli memberexecutivecommitteeexecutivevicepresidentchiefglobalsupply kathrynewengel chainofficerj memberexecutivecommitteeexecutivevicepresidentchieffinancial josephjwolk officerk mrjduatojoinedthecompanyinwithjanssenfarmaceuticasaspainasubsidiaryofthecompanyandheldexecutive positionsofincreasingresponsibilityinthepharmaceuticalsectorinhewasnamedcompanygroupchairman pharmaceuticalsandinhewasnamedworldwidechairmanpharmaceuticalsinmrduatobecameamemberofthe executivecommitteeandwasnamedexecutivevicepresidentworldwidechairmanpharmaceuticalsinjulymrduatowa promotedtovicechairmanoftheexecutivecommitteewithresponsibilityforthecompanyspharmaceuticalandconsumersector supplychaininformationtechnologyglobalservicesandthehealthwellnessgroup b drpmfasolojoinedthecompanyinasvicepresidentworldwidehumanresourcesforcordiscorporationasubsidiary ofthecompanyandwassubsequentlynamedvicepresidentglobaltalentmanagementforthecompanyheleft johnsonjohnsonintojoinkohlbergkravisrobertscoaschieftalentofficerdrfasoloreturnedtothecompanyin asthevicepresidentglobalhumanresourcesandinhebecameamemberoftheexecutivecommitteeinapril hewasnamedexecutivevicepresidentchiefhumanresourcesofficerdrfasolohasresponsibilityforglobaltalent recruitingdiversitycompensationbenefitsemployeerelationsandallaspectsofthehumanresourcesagendaforthecompany c msamcevoyjoinedthecompanyinasassistantbrandmanagerofmcneilconsumerhealthasubsidiaryofthecompany advancingthroughpositionsofincreasingresponsibilitiesuntilshewasappointedcompanygroupchairmanvisioncarein followedbycompanygroupchairmanconsumermedicaldevicesininjulymsmcevoywaspromotedtoexecutive vicepresidentworldwidechairmanmedicaldevicesandbecameamemberoftheexecutivecommitteeshehasresponsibilityfor thesurgeryorthopaedicsinterventionalsolutionsandeyehealthbusinessesacrossethicondepuysynthesbiosensewebsterand johnsonjohnsonvision mrjmesquitajoinedthecompanyinasworldwidechairmanconsumerpriortojoiningthecompanyheservedinvarious marketingandleadershipcapacitiesacrosslatinamericaincludingrolesinoralcareandbeautyattheproctergamble johnsonjohnsonannualreport companyfromtoinaprilmrmesquitabecameamemberoftheexecutivecommitteeandwaspromotedto executivevicepresidentworldwidechairmanconsumermrmesquitaplanstoretirefromthecompanyinmarch e mrtmongonjoinedthecompanyinasdirectorofmarketingforthevisioncaregroupinfranceandsubsequentlyheld generalmanagementpositionsascountrymanagerfrancebelgiumandnorthafricamanagingdirectorlatinamericaand presidentasiapacificmrmongontransitionedtothepharmaceuticalsectorinastheglobalcommercialstrategyleaderfor theneurosciencetherapeuticareabeforejoiningtheconsumersectorascompanygroupchairmanasiapacificthecompanyhas announcedthatmrmongonwillbenamedexecutivevicepresidentandworldwidechairmanconsumerandamemberofthe executivecommitteeupontheretirementofhispredecessormrmesquitaeffectivemarchinadditiontoleadingthe consumerbusinessmrmongonwillhaveresponsibilityforjohnsonjohnsonsoutheastasia f mrmesneedjoinedthecompanyinasproductdirectorforpersonalproductsasubsidiaryofthecompanyandgaine increasedresponsibilitiesinexecutivepositionsacrosstheglobalenterpriseinmrsneedwasappointedcompanygroup chairmanconsumernorthamericafollowedbycompanygroupchairmanvisioncarefranchiseininhebecame thevicepresidentglobalcorporateaffairsandchiefcommunicationsofficermrsneedwasappointedexecutivevicepresident globalcorporateaffairsandchiefcommunicationsofficerinjanuaryandbecameamemberoftheexecutivecommitteein julyleadingthecorporationsglobalmarketingcommunicationdesignandphilanthropyfunction g drpstoffelsjoinedthecompanyinwiththeacquisitionoftibotecvirconvwherehewaschiefexecutiveofficerofvirco nvandchairmanoftibotecnvinhewasappointedcompanygroupchairmanglobalvirologyinheassumedthe roleofcompanygroupchairmanpharmaceuticalsdrstoffelswasappointedglobalheadresearchdevelopment pharmaceuticalsinandinbecameworldwidechairmanpharmaceuticalsindrstoffelswasappointedchief scientificofficerandbecameamemberoftheexecutivecommitteeindrstoffelswasnamedexecutivevicepresident chiefscientificofficerindrstoffelswaspromotedtovicechairmanoftheexecutivecommitteechiefscientificofficerhe isresponsibleforthecompanysinnovationagendaacrossthepharmaceuticalmedicaldevicesandconsumersectorsproduct safetystrategyandthecompanysglobalpublichealthstrategy h msjltaubertjoinedthecompanyinasworldwidevicepresidentatjohnsonjohnsonpharmaceuticalservicesa subsidiaryofthecompanysheheldseveralexecutivepositionsinthepharmaceuticalsectoruntilwhenshewasappointed companygroupchairmannorthamericapharmaceuticalsandinbecamecompanygroupchairmantheamericas pharmaceuticalsinjulymstaubertwaspromotedtoexecutivevicepresidentworldwidechairmanpharmaceuticalsand becameamemberoftheexecutivecommittee mrmhullmannjoinedthecompanyinasacorporateattorneyinthelawdepartmenthewasappointedcorporate secretaryinandservedinthatroleuntilduringthattimehealsoheldvariousmanagementpositionsinthelaw departmentinhewasnamedgeneralcounselmedicaldevicesanddiagnosticsandwasappointedvicepresidentgeneral counselandbecameamemberoftheexecutivecommitteeininaprilmrullmannwasnamedexecutivevice presidentgeneralcounselmrullmannhasworldwideresponsibilityforlegalgovernmentaffairspolicyglobalsecurityaviation andhealthcarecomplianceprivacy j mskewengeljoinedthecompanyinasprojectengineerandengineeringsupervisoratjanssenasubsidiaryofthe companyduringhertenurewiththecompanyshehasheldavarietyofstrategicleadershipandexecutivepositionsacrossthe globalenterpriseinroleswithinoperationsqualityengineeringnewproductsinformationtechnologyandothertechnicaland businessfunctionsinmswengelbecamethefirstchiefqualityofficerofthecompanyinshewaspromotedtovice presidentjohnsonjohnsonsupplychaininjulyshewaspromotedtoexecutivevicepresidentchiefglobalsupplychain officerandbecameamemberoftheexecutivecommittee k mrjjwolkjoinedthecompanyinasfinancemanagerbusinessdevelopmentfororthomcneilasubsidiaryofthe companyandthroughtheyearsheldavarietyofseniorleadershiprolesinseveralsegmentsandfunctionsacrossthecompany subsidiariesinpharmaceuticalsmedicaldevicesandsupplychainfromtoheservedasvicepresidentfinanceand chieffinancialofficerofthejanssenpharmaceuticalcompaniesofjohnsonjohnsoninmrwolkbecamethevice presidentinvestorrelationsinjulyhewasappointedexecutivevicepresidentchieffinancialofficerandbecameamember oftheexecutivecommitteemrwolkisresponsibleforleadingthedevelopmentandexecutionofthecompanysgloballongterm financialstrategy johnsonjohnsonannualreportpart ii item market registrant common equity relate stockholder matter issuer purchase equity security asoffebruarytherewererecordholdersofcommonstockofthecompanyadditionalinformation calledforbythisitemisincorporatedhereinbyreferencetothefollowingsectionsofthisreportnotecommon stockstockoptionplansandstockcompensationagreementsofthenotestoconsolidatedfinancialstatement includedinitemanditemsecurityownershipofcertainbeneficialownersandmanagementandrelate stockholdermattersequitycompensationplaninformation issuer purchase equity security ondecemberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyscommonstocksharerepurchasestakeplace fromtimetotimeontheopenmarketorthroughprivatelynegotiatedtransactionstherepurchaseprogramhasnotime limitandmaybesuspendedforperiodsordiscontinuedatanytime thefollowingtableprovidesinformationwithrespecttocommonstockpurchasesbythecompanyduringthefiscalfourth quarterofcommonstockpurchasesontheopenmarketaremadeaspartofasystematicplantomeettheneed ofthecompanyscompensationprogramstherepurchasesbelowalsoincludethestockforstockoptionexercisesthat settledinthefiscalfourthquarter totalnumberof maximumnumberor sharesorunit approximatedollar purchasedaspart valueofsharesorunit totalnumber ofpublicly thatmayyetbe ofshare avgprice announcedplans purchasedunderthe period purchase paidpershare orprogram plansorprogram octoberthroughoctober octoberthroughnovember novemberthrough december total duringthefiscalfourthquarterofthecompanyrepurchasedanaggregateofsharesofjohnsonjohnson commonstockinopenmarkettransactionsofwhichshareswerepurchasedpursuanttotherepurchaseprogramthat waspubliclyannouncedondecemberandofwhichshareswerepurchasedinopenmarkettransactionsas partofasystematicplantomeettheneedsofthecompanyscompensationprograms asofdecemberanaggregateofshareswerepurchasedforatotalofbillionsincetheinceptionofthe repurchaseprogramannouncedondecember asofdecemberthemaximumnumberofsharesthatmayyetbepurchasedundertheplanisbasedonthe closingpriceofjohnsonjohnsoncommonstockonthenewyorkstockexchangeondecemberofpershare johnsonjohnsonannualreport item select financial datum summary operation statistical datum dollarsinmillionsexcept pershareamount salestocustomersus salestocustomer international totalsale costofproductssold sellingmarketingand administrativeexpense researchanddevelopment expense inprocessresearchand development interestincome interestexpensenetof portioncapitalize otherincomeexpense net restructure earningsbeforeprovision fortaxesonincome provisionfortaxeson income netearning addnetlossattributable tononcontrollinginterest netearning attributableto johnsonjohnson percentofsalesto customer dilutednetearningsper shareofcommonstock percentreturnonaverage shareholdersequity percentincrease decreaseover previousyear salestocustomer dilutednetearningsper share nm supplementarybalance sheetdata propertyplantand equipmentnet additionstopropertyplant andequipment totalasset longtermdebt operatingcashflow commonstock information dividendspaidpershare shareholdersequityper share marketpricepershare yearendclose averagesharesoutstande millions basic diluted employeesthousand attributabletojohnsonjohnson pertheadoptionofasuprioryearamountsontheconsolidatedstatementofearningshavebeenreclassifiedtoretroactivelyapply classificationoftheservicecostcomponentandtheothercomponentsofnetperiodicbenefitcost nmnotmeaningful johnsonjohnsonannualreportitem management discussion analysis result operation financial condition organization business segment descriptionofthecompanyandbusinesssegment johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldthecompany conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand wellbee thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicesthe consumersegmentincludesabroadrangeofproductsusedinthebabycareoralcarebeautyoverthecounter pharmaceuticalwomenshealthandwoundcaremarketstheseproductsaremarketedtothegeneralpublicandsold bothtoretailoutletsanddistributorsthroughouttheworldthepharmaceuticalsegmentisfocusedonsixtherapeutic areasincludingimmunologyinfectiousdiseasesneuroscienceoncologypulmonaryhypertensionandcardiovascular andmetabolicdiseasesproductsinthissegmentaredistributeddirectlytoretailerswholesalershospitalsandhealth careprofessionalsforprescriptionusethemedicaldevicessegmentincludesabroadrangeofproductsusedinthe orthopaedicsurgeryinterventionalsolutionscardiovascularandneurovasculardiabetescaredivestedinthefiscal fourthquarterofandvisionfieldswhicharedistributedtowholesalershospitalsandretailersandusedprincipally intheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsandclinic theexecutivecommitteeofjohnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategic operationsandallocationoftheresourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesofthe consumerpharmaceuticalandmedicaldevicesbusinesssegment inallofitsproductlinesthecompanycompeteswithcompaniesbothlocallyandgloballythroughouttheworld competitionexistsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolve competitioninresearchinvolvingthedevelopmentandtheimprovementofnewandexistingproductsandprocessesis particularlysignificantthedevelopmentofnewandinnovativeproductsaswellasprotectingtheunderlyingintellectual propertyofthecompanysproductportfolioisimportanttothecompanyssuccessinallareasofitsbusinessthe competitiveenvironmentrequiressubstantialinvestmentsincontinuingresearchinadditionthedevelopmentand maintenanceofcustomerdemandforthecompanysconsumerproductsinvolvessignificantexpendituresforadvertising andpromotion johnsonjohnsonannualreport managementsobjective withourcredoasthefoundationthecompanyspurposeistoblendheartscienceandingenuitytoprofoundly changethetrajectoryofhealthforhumanitythecompanyiscommittedtobringingitsfullbreadthanddepthtoensure healthforpeopletodayandforfuturegenerationsunitedaroundthiscommonambitionthecompanyispoisedtofulfillits purposeandsuccessfullymeetthedemandsoftherapidlyevolvingmarketsinwhichitcompete thecompanyisbroadlybasedinhumanhealthcareandiscommittedtocreatingvaluebydevelopingaccessiblehigh qualityinnovativeproductsandservicesnewproductsintroducedwithinthepastfiveyearsaccountedforapproximately ofsalesinbillionwasinvestedinresearchanddevelopmentandbillionspenton acquisitionsreflectingmanagementscommitmenttocreatelifeenhancinginnovationsandtocreatevaluethrough partnershipsthatwillprofoundlychangethetrajectoryofhealthforhumanity acriticaldriverofthecompanyssuccessisthediverseemployeesthatworkacrossmorethanoperate companieswhicharelocatedinmorethancountriesemployeesareempoweredandinspiredtoleadwiththe companysourcredoandpurposeasguidesthisallowseveryemployeetousethecompanysreachandsizeto advancethecompanyspurposeandtoalsoleadwithagilityandurgencyleveragingtheextensiveresourcesacrossthe enterpriseenablesthecompanytoinnovateandexecutewithexcellencethisensuresthecompanycanremainfocused onaddressingtheunmetneedsofsocietyeverydayandinvestforanenduringimpactultimatelydeliveringvaluetoit patientsconsumersandhealthcareprofessionalsemployeescommunitiesandshareholder snoillib ni snoillib ni srallod ni research acquisicidon net cash dividend pay development acquire share result operation analysisofconsolidatedsale inworldwidesalesincreasedtobillioncomparedtoanincreasesofandinand respectivelythesesaleschangesconsistedofthefollowe salesincreasedecreasedueto volume price currency total inthenetimpactofacquisitionsanddivestituresontheworldwidesalesgrowthwasapositiveimpactofin acquisitionsanddivestitureshadapositiveimpactofontheworldwidesalesgrowthinacquisition anddivestitureshadanegativeimpactofontheworldwidesalesgrowthandcompetitiveproductstothe companyshepatitiscproductsolysiosovriadsimeprevirandincivotelaprevirhadanegativeimpactof ontheworldwidesalesgrowthoperationsinvenezuelanegativelyimpactedtheworldwidesalesgrowth salesbyuscompanieswerebillioninbillioninandbillioninthisrepresent increasesofininandinsalesbyinternationalcompanieswerebillionin billioninandbillioninthisrepresentsanincreaseofininanda decreaseofin johnsonjohnsonannualreportthefiveyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectivelythetenyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectively insalesbycompaniesineuropeachievedgrowthofascomparedtotheprioryearincludingoperational growthofandapositivecurrencyimpactofsalesbycompaniesinthewesternhemisphereexcludingthe usachievedgrowthofascomparedtotheprioryearincludingoperationalgrowthofandanegative currencyimpactofsalesbycompaniesintheasiapacificafricaregionachievedgrowthofascomparedto theprioryearincludingoperationalgrowthofandapositivecurrencyimpactof inthecompanyhadthreewholesalersdistributingproductsforallthreesegmentsthatrepresentedapproximately andofthetotalconsolidatedrevenuesinthecompanyhadtwowholesalersdistribute productsforallthreesegmentsthatrepresentedapproximatelyandofthetotalconsolidatedrevenuesin thecompanyhadtwowholesalersdistributingproductsforallthreesegmentsthatrepresentedapproximately andofthetotalconsolidatedrevenue sale geographic region billion sale segment billions europe western hemisphere consumer pharmaceutical asiapacific africa medical device analysis sale business segment consumersegment consumersegmentsalesinwerebillionanincreaseoffromwhichincludedoperational growthandanegativecurrencyimpactofusconsumersegmentsaleswerebillionanincreaseof internationalsaleswerebillionanincreaseofwhichincludedoperationalgrowthandanegative currencyimpactofinacquisitionsanddivestitureshadanetnegativeimpactofontheoperational salesgrowthoftheworldwideconsumersegment majorconsumerfranchisesale change dollarsinmillion vs vs beauty otc babycare oralcare womenshealth woundcareother totalconsumersale johnsonjohnsonannualreport thebeautyfranchisesalesofbillionincreasedascomparedtotheprioryeargrowthwasprimarilydrivenby neutrogenaogxandaveenoproductsaswellasstrengthofdrcilaboanddabaoproductsoutside theusgrowthwaspartiallyoffsetbythedivestitureofnizoral theoverthecounterotcfranchisesalesofbillionincreasedascomparedtotheprioryeargrowthwa primarilydrivenbyshareconsumptionandmarketgrowthacrossmultiplebrandsincludingzyrtectylenoland childrensmotrinaswellasdigestivehealthproductsandantismokingaidsadditionallysalesfromtherecentus acquisitionofzarbeesinccontributedapproximatelytogrowth thebabycarefranchisesaleswerebillioninadecreaseofcomparedtotheprioryearprimarilydueto johnsonssharedeclineandincreasedtradepromotionsduetothejohnsonsbabyrelaunchandthenegative impactofcurrencythiswaspartiallyoffsetbystronggrowthofaveenobabydrivenbygeographicexpansion theoralcarefranchisesalesofbillionincreasedascomparedtotheprioryearprimarilydrivenbystrong marketingcampaignsandnewproductlaunche thewomenshealthfranchisesaleswerebillioninadecreaseofascomparedtotheprioryeargrowth inlatinamericawasoffsetbythenegativeimpactofcurrency thewoundcareotherfranchisesaleswerebillioninadecreaseofascomparedtotheprioryear primarilyduetothedivestitureofcompeed consumersegmentsalesinwerebillionanincreaseoffromwhichincludedoperational growthandapositivecurrencyimpactofusconsumersegmentsaleswerebillionanincreaseof internationalsaleswerebillionanincreaseofwhichincludedoperationalgrowthandapositivecurrency impactofinacquisitionsanddivestitureshadanetpositiveimpactofontheoperationalsalesgrowth oftheworldwideconsumersegment johnsonjohnsonannualreportpharmaceutical segment pharmaceuticalsegmentsalesinwerebillionanincreaseoffromwhichincludedoperational growthofandapositivecurrencyimpactofussaleswerebillionanincreaseofinternational saleswerebillionanincreaseofwhichincludedoperationalgrowthandapositivecurrencyimpact ofinacquisitionsanddivestitureshadanetpositiveimpactofontheoperationalsalesgrowthofthe worldwidepharmaceuticalsegment majorpharmaceutical therapeuticareasale change dollarsinmillion vs vs totalimmunology remicade simponisimponiaria stelara tremfya otherimmunology totalinfectiousdisease edurantrilpivirine prezistaprezcobixrezolstasymtuza otherinfectiousdisease totalneuroscience concertamethylphenidate invegasustennaxeplioninvegatrinza trevicta risperdalconsta otherneuroscience totaloncology darzalex imbruvica velcade zytigaabirateroneacetate otheroncology pulmonaryhypertension opsumit tracleer uptravi cardiovascularmetabolismother xarelto invokanainvokamet procriteprex totalpharmaceuticalsale prioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation percentagegreaterthanornotmeaningful productsacquiredfromacteliononjune johnsonjohnsonannualreport immunologyproductssaleswerebillioninrepresentinganincreaseofascomparedtotheprioryear growthwasdrivenbystronguptakeofstelaraustekinumabincrohnsdiseasestronglaunchuptakeoftremfya guselkumabexpandedindicationsofsimponisimponiariagolimumabandtheusimmunologymarket growthimmunologywasnegativelyimpactedbylowersalesofremicadeinfliximabduetoincreaseddiscount rebatesandbiosimilarcompetition thepatentsforremicadeinfliximabincertaincountriesineuropeexpiredinfebruarybiosimilarversionsof remicadehavebeenintroducedincertainmarketsoutsidetheusresultinginareductioninsalesofremicadein thosemarketsadditionalbiosimilarcompetitionwilllikelyresultinafurtherreductioninremicadesalesinmarket outsidetheunitedstatesintheusabiosimilarversionofremicadewasintroducedinandadditional competitorscontinuetoenterthemarketcontinuedinfliximabbiosimilarcompetitionintheusmarketwillresultina furtherreductioninussalesofremicadeseenotetotheconsolidatedfinancialstatementsforadescriptionof legalmattersregardingtheremicadepatents infectiousdiseaseproductssaleswerebillioninrepresentinganincreaseofascomparedtotheprior yearsalesgrowthofprezcobixrezolstadarunavircobicistatedurantrilpivirineandthelaunchof symtuzaandjulucadolutegravirrilpivirinewaspartiallyoffsetbylowersalesofprezistadarunavir neuroscienceproductssaleswerebillionrepresentinganincreaseofascomparedtotheprioryearstrong salesoflongactinginjectablesinvegatrinzatrevictapaliperidonepalmitateandinvegasustenna xeplionwerepartiallyoffsetbycannibalizationofrisperdalconstarisperidoneandgenericcompetitionfor concertamethylphenidate oncologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yearcontributorstothegrowthwerestrongsalesofdarzalexdaratumumabwithcontinuedmarketgrowthand sharegainimbruvicaibrutinibduetoincreasedpatientuptakegloballyandsalesofzytigaabirateroneacetate drivenbylatitudedataandmarketgrowthadditionallysalesfromthelaunchoferleadaapalutamidecontribute tothegrowthanumberofcompaniesmarketinggenericpharmaceuticalshavefiledabbreviatednewdrugapplication andaswiththefdaorundertakensimilarregulatoryprocessesoutsideoftheusseekingtomarketgenericformsof zytigapriortoexpirationofitsapplicablepatentstheseandasincludeallegationsofnoninfringementandinvalidity oftheapplicablepatentsinoctoberthecourtissuedarulinginvalidatingallassertedclaimsoftheapplicable patentjanssenhasappealedthecourtsdecisioninnovembertheuscourtofappealsforthefederalcircuit deniedjanssensrequestforaninjunctionpendingappealasaresultseveralgenericversionsofzytigahaveentere themarketresultinginadeclineinsalesofzytigaintheunitedstatesinthecompanyreportedussalesof billionforzytigaseenotetotheconsolidatedfinancialstatementsforadescriptionoflegalmatter regardingzytiga thepulmonaryhypertensiontherapeuticareawasestablishedwiththeacquisitionofactelionltdonjune salesinrepresentedafullyearascomparedtohalfayearinsalesofopsumitmacitentanand uptraviselexipagwerepositivelyimpactedbymarketgrowthandsharegainswhilesalesoftracleerbosetan werenegativelyimpactedbyincreaseduseofopsumitandgenerics cardiovascularmetabolismotherproductssaleswerebillionadeclineofascomparedtotheprioryear lowersalesofinvokanainvokametcanagliflozinintheuswasprimarilyduetoanincreaseinpricediscount higherrebatesandmarketsharedeclinedrivenbycompetitivepressurelowersalesofxareltorivaroxabanwere drivenbyanincreaseindiscountsandrebatespartiallyoffsetbyanincreaseinmarketshare johnsonjohnsonannualreportduringthecompanyadvanceditspipelinewithseveralregulatorysubmissionsandapprovalsfornewdrugsand additionalindicationsforexistingdrugsasfollow productnamechemical eu eu indication approval approval filing filing darzalexdaratumumab frontlinemultiplemyelomatransplantineligiblepatientsin combinationwithbortezomibmelphalanandprednisone erdafitinib treatmentoflocallyadvancedormetastaticurothelialcancer erleadaapalutamide treatmentofnonmetastaticcastrationresistantprostate cancer esketamine antidepressantfortreatmentresistantdepressioninadult imbruvicaibrutinib treatmentofwaldenstromsmacroglobulinemiausedin combinationwithrituximab treatmentforpreviouslyuntreatedchroniclymphocytic leukemiaincombinationwithobinutuzumab invokanacanagliflozin reducetheriskofdeathintypediabeteswithestablishe orriskforcardiovasculardiseasecanvascanvasr julucarilpivirineand singletabletoncedailytwodrugregimenforthetreatment dolutegravir ofhivinfection opsumitmacitentan treatmentofadultswithinoperablechronicthromboembolic pulmonaryhypertensiontoimproveexercisecapacityand pulmonaryvascularresistance stelaraustekinumab treatmentofadultswithmoderatelytoseverelyactive ulcerativecolitis symtuzadarunavir cobicistatemtricitabinetenofovir acompletedarunavirbasedsingletabletregimenforthe alafenamide treatmentofhivinfection tremfyaguselkumab patientcontrolledinjectorforthetreatmentofadultslivingwith moderatetosevereplaquepsoriasis xareltorivaroxaban treatmenttoreducetheriskofmajorcardiovasculareventsin peoplewithchroniccoronaryorperipheralarterydisease forthepreventionofvenousthromboembolismformedicallyill patient zytigaabirateroneacetate treatmentofhormonenavemetastaticprostatecancer pharmaceuticalsegmentsalesinwerebillionanincreaseoffromwhichincludedoperational growthofandapositivecurrencyimpactofussaleswerebillionanincreaseofinternational saleswerebillionanincreaseofwhichincludedoperationalgrowthandapositivecurrencyimpact ofinacquisitionsanddivestitureshadanetpositiveimpactofontheoperationalsalesgrowthofthe worldwidepharmaceuticalsegmentadjustmentstopreviousreserveestimatesascomparedtotheprioryearnegatively impactedthereportedpharmaceuticalsegmentoperationalgrowthbyapproximatelyprimarilyintheimmunology andcardiovascularmetabolismothertherapeuticarea medicaldevicessegment themedicaldevicessegmentsalesinwerebillionanincreaseoffromwhichincludedan operationalincreaseofandapositivecurrencyimpactofussaleswerebillionanincreaseof ascomparedtotheprioryearinternationalsaleswerebillionanincreaseofascomparedtotheprioryear withanoperationalincreaseofandapositivecurrencyimpactofinacquisitionsanddivestitureshada netnegativeimpactofontheworldwideoperationalsalesgrowthofthemedicaldevicessegmentascomparedto johnsonjohnsonannualreport majormedicaldevicesfranchisesale change dollarsinmillion vs vs surgery advanced general specialty orthopaedic hip knee trauma spineother vision contactlensesother surgical interventionalsolution diabetescare diagnostic totalmedicaldevicessale previouslyreferredtoascardiovascular onjunethecompanydivestedtheorthoclinicaldiagnosticsbusinessthediagnosticsfranchiseandamount representtransitionalserviceagreementthatconcludedin prioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation productsacquiredfromabbottmedicalopticsamoonfebruary percentagegreaterthanornotmeaningful thesurgeryfranchisesaleswerebillioninanincreaseoffromgrowthinadvancedsurgerywa primarilydrivenbyendocutterbiosurgeryandenergyproductsgrowthingeneralsurgerywasprimarilydrivenbywound careproductsgrowthinspecialtysurgerywasprimarilydrivenbyadvancedsterilizationproduct theorthopaedicsfranchisesaleswerebillioninadecreaseoffromthedeclineinspineother wasprimarilyduetothecodmanneurosurgerydivestitureandsharelossinspinepartiallyoffsetbynewproduct launchesthedeclineinkneeswasprimarilyduetocompetitivepressureintheuspartiallyoffsetbygrowthinasia pacificgrowthinhipsandtraumawasduetocontinueduptakeofnewproduct thevisionfranchiseachievedsalesofbillioninanincreaseoffromgrowthwasprimarilydriven bystrengthoftheastigmatismanddailydisposablelensesintheoasyscontactlensescategorysurgicalgrowthwa drivenbycataractperformanceprimarilyoutsidetheus theinterventionalsolutionsfranchiseincludesthecerenovusbusinesspreviouslyincludedinspineandotherin orthopaedicssaleswerebillionanincreaseoffromstronggrowthintheelectrophysiologybusiness wasdrivenbyatrialfibrillationproceduregrowthandcontinueduptakeofthethermocoolsmarttouchcontact forcesensingcatheter thediabetescarefranchisesaleswerebillionadecreaseoffromthedeclinewasprimarilydueto divestitureofitslifescanbusinessinthefiscalfourthquarterofandthecompanysdecisiontoexittheanima insulinpumpbusinessinthefiscalfourthquarterof themedicaldevicessegmentsalesinwerebillionanincreaseoffromwhichincludedan operationalincreaseofandapositivecurrencyimpactofussaleswerebillionanincreaseof ascomparedtotheprioryearinternationalsaleswerebillionanincreaseofascomparedtotheprioryear withanoperationalincreaseofandapositivecurrencyimpactofinacquisitionsanddivestitureshada netpositiveimpactofontheworldwideoperationalsalesgrowthofthemedicaldevicessegmentascomparedto johnsonjohnsonannualreportanalysis consolidated earning provision taxis income consolidatedearningsbeforeprovisionfortaxesonincomewasbillionbillionandbillionforthefiscal yearsendedandrespectivelyasapercenttosalesconsolidatedearningsbeforeprovisionfortaxe onincomewasandinandrespectively earning provision taxis period end income tax snoillib percent sale costofproductssoldandsellingmarketingandadministrativeexpensescostofproductssoldandselling marketingandadministrativeexpensesasapercenttosaleswereasfollow ofsale costofproductssold percentpointincreasedecreaseovertheprioryear sellingmarketingandadministrativeexpense percentpointincreasedecreaseovertheprioryear prioryearsamountswerereclassifiedtoconformtocurrentyearpresentationadoptionofasu incostofproductssoldasapercenttosalesdecreasedtofromascomparedtothesameperioda yearagoprimarilyduetolowerinventorystepupcostsrelatedtotheactelionacquisitionandfavorableproductand segmentmixdrivenbyahigherpercentageofsalesfromthepharmaceuticalsegmentthiswasmostlyoffsetbyhigher amortizationexpenseprimarilyrelatedtotheactelionacquisitiononjuneintangibleassetamortizationexpense ofbillionwasincludedincostofproductssoldforascomparedtobillionintherewasadecrease inthepercenttosalesofsellingmarketingandadministrativeexpensesinascomparedtotheprioryearprimarily duetolowercostsrelativetosalesgrowthinthepharmaceuticalbusinessandfavorablesegmentmix incostofproductssoldasapercenttosalesincreasedtofromascomparedtothesameperioda yearagotheunfavorableincreasewasprimarilydrivenbybillionofhigheramortizationexpenseandchargesfor inventorystepuprelatedtotherecentacquisitionsprimarilyactelionintangibleassetamortizationexpenseofbillion wasincludedincostofproductssoldforascomparedtobillionintherewasanincreaseinthepercent tosalesofsellingmarketingandadministrativeexpensesinascomparedtotheprioryearprimarilydueto investmentsinnewproductlaunchespartiallyoffsetbyfavorablemix johnsonjohnsonannualreport researchanddevelopmentexpenseresearchanddevelopmentexpensebysegmentofbusinesswasasfollow dollarsinmillion ofsale ofsale ofsale consumer pharmaceutical medicaldevice totalresearchanddevelopmentexpense percentincreasedecreaseovertheprior year prioryearsamountswerereclassifiedtoconformtocurrentyearpresentationadoptionofasu asapercenttosegmentsale researchanddevelopmentactivitiesrepresentasignificantpartofthecompanysbusinesstheseexpendituresrelateto theprocessesofdiscoveringtestinganddevelopingnewproductsupfrontpaymentsandmilestonesimprovingexisting productsaswellasensuringproductefficacyandregulatorycompliancepriortolaunchthecompanyremain committedtoinvestinginresearchanddevelopmentwiththeaimofdeliveringhighqualityandinnovativeproductsin worldwidecostsofresearchanddevelopmentactivitiesincreasedbycomparedtobutdecreasedasa percentofsalesthedecreaseasapercentofsalesinthepharmaceuticalsegmentwasattributabletolowercost relativetosalesgrowththeincreaseddollarspendinthemedicaldevicesandpharmaceuticalsegmentswasfor investmentspendingtoadvancethepipelineinworldwidecostsofresearchanddevelopmentactivitiesincrease bycomparedtotheincreaseasapercentofsaleswasprimarilyinthepharmaceuticalsegmentdueto generalportfolioprogressionaswellascollaborativeagreementsenteredintowithidorsialtdandlegendbiotech researchfacilitiesarelocatedintheusbelgiumbrazilchinafrancegermanyindiaisraelthenetherlandspoland singaporeswedenswitzerlandandtheunitedkingdomwithadditionalrdsupportinoverothercountrie inprocessresearchanddevelopmentiprdinthecompanyrecordedaniprdchargeofbillion ofthebillionapartialimpairmentchargeofbillionrelatedtothedevelopmentprogramofalan investigationaldrugforthetreatmentofrespiratorysyncytialvirusrsvandhumanmetapneumovirushmpvacquire withtheacquisitionofaliosbiopharmainctheimpairmentchargewascalculatedbasedonupdatedcashflow projectionsdiscountedfortheinherentriskintheassetdevelopmentandreflectstheimpactofthephasebclinicaltrial suspensionadecreaseintheprobabilityofsuccessfactorsandtheongoinganalysisofassetdevelopmentactivitiesthe companycontinuestoevaluateinformationwithrespecttothedevelopmentprogramandwillmonitortheremaining billionintangibleassetforfurtherimpairmentinadditionanimpairmentchargeofbillionwasrecordedforthe discontinuationofthedevelopmentprojectforanantithrombinantibodyassociatedwiththeacquisitionofxo limited inthecompanyrecordedaniprdchargeofbillionprimarilyforthediscontinuationofcertaindevelopment projectsrelatedtonovirawhichwasacquiredintheproductdevelopmentwascanceledduetosafetyconcernsin thecompanyrecordedaniprdchargeofmillionforthediscontinuationofadevelopmentprogramrelatedto crucell otherincomeexpensenetotherincomeexpensenetistheaccountwherethecompanyrecordsgainsand lossesrelatedtothesaleandwritedownofcertaininvestmentsinequitysecuritiesheldbyjohnsonjohnson innovationjjdcincjjdcunrealizedgainsandlossesoninvestmentsgainsandlossesondivestiturescertain transactionalcurrencygainsandlossesacquisitionrelatedcostslitigationaccrualsandsettlementsaswellasroyalty income thechangeinotherincomeexpensenetforthefiscalyearwasanunfavorablechangeofbillionprimarilydue tolitigationexpenseofbillioninascomparedtobillioninadditionallyincludedunrealize lossesonsecuritiesofbillionandlowerrealizedgainsofbillionrelatedtoinvestmentsinequitysecuritiesas comparedtotheprioryearthiswaspartiallyoffsetbyareversalofacontingentliabilityofbillionandlowercostsof billionrelatedtotheactelionandamoacquisitionsinascomparedtothefiscalyearofinclude againofbillionrelatedtomonetizationoffutureroyaltyreceivablesoffsetbyanassetimpairmentchargeof billionprimarilyrelatedtotheinsulinpumpbusinessdivestituregainswereapproximatelybillioninand includedthelifescanbusinessnizoralrocandcertainnonstrategicpharmaceuticalproductsdivestituregains wereapproximatelybillioninandprimarilyincludedthecodmanneurosurgeryandcompeeddivestiture additionallyrestructuringrelatedexpenseinwasbillionascomparedtobillion johnsonjohnsonannualreportthechangeinotherincomeexpensenetforthefiscalyearwasafavorablechangeofbillionduetohigher gainsofbilliononthesaleofassetsbusinessesprimarilythecodmanneurosurgeryandcompeeddivestituresa gainofbillionrelatedtomonetizationoffutureroyaltyreceivablesandahighergainofbillionrelatedtothesale ofcertaininvestmentsinequitysecuritiesascomparedtotheprioryearthiswaspartiallyoffsetbyhigherlitigation expenseofbillionbillionofacquisitioncostsrelatedtoactelionandamoanassetimpairmentchargeof billionprimarilyrelatedtotheinsulinpumpbusinessandahigherrestructuringrelatedchargeofbilliona comparedtothefiscalyear interestincomeexpenseinterestincomewashigherinascomparedtoduetoahigheraverageinter rateandabenefitfromnetinvestmenthedgingpartiallyoffsetbyaloweraveragecashcashequivalentsandmarketable securitiesbalanceduringtheperiodcashcashequivalentsandmarketablesecuritiestotaledbillionattheendof andaveragedbillionascomparedtothecashcashequivalentsandmarketablesecuritiestotalof billionandbillionaveragecashbalanceinthedecreaseintheaveragebalanceofcashcash equivalentsandmarketablesecuritieswasduetotheuseofcashforgeneralcorporatepurposesprimarilytheactelion acquisitionforbillionnetofcashacquiredlateinthefiscalsecondquarterof interestexpenseinwashigherascomparedtoduetoahigheraveragedebtbalancetheaveragedebt balancewasbillioninversusbillioninthetotaldebtbalanceattheendofwa billionascomparedtobillionattheendof interestincomeinincreasedslightlyascomparedtoduetohigheraverageinterestratespartiallyoffsetby lowercashcashequivalentsandmarketablesecuritiesbalancesduringtheperiodcashcashequivalentsand marketablesecuritiestotaledbillionattheendofandaveragedbillionascomparedtothe billionaveragecashbalanceinthedecreaseinthebalanceofcashcashequivalentsandmarketable securitieswasduetotheuseofcashforgeneralcorporatepurposesincludingacquisitionsprimarilytheactelion acquisitionforbillionnetofcashacquire interestexpenseinwashigherascomparedtotheaveragedebtbalancewasbillioninversus billioninthetotaldebtbalanceattheendofwasbillionascomparedtobillionattheend ofthehigherdebtbalanceofapproximatelybillionwasprimarilyduetoincreasedborrowingsthecompany increasedborrowingsinfebruaryandnovemberofcapitalizingonfavorabletermsinthecapitalmarketsthe proceedsoftheborrowingswereusedforgeneralcorporatepurposesincludingthecompletionofthestockrepurchase program incomebeforetaxbysegment incomebeforetaxbysegmentofbusinesswereasfollow percentof incomebeforetax segmentsale segmentsale dollarsinmillion consumer pharmaceutical medicaldevice total lessexpensesnotallocatedtosegment earningsbeforeprovisionfortaxesonincome seenotetotheconsolidatedfinancialstatementsformoredetail amountsnotallocatedtosegmentsincludeinterestincomeexpenseandgeneralcorporateincomeexpense consumersegmentintheconsumersegmentincomebeforetaxasapercenttosaleswasversus inthedecreaseintheincomebeforetaxasapercentofsalesinascomparedtowasprimarily attributabletohigherlitigationexpenseofbillioninpartiallyoffsetbyslowerincreasesinexpensesrelativeto theincreaseinsalesdivestituregainsforthefiscalyearofwhichincludedthedivestituresofnizoralandroc werecomparabletofiscalyearofagainofbillionwasrecognizedfromthedivestitureofnizoral intheconsumersegmentincomebeforetaxasapercenttosaleswasversusintheincrease intheincomebeforetaxasapercentofsalesinascomparedtowasattributabletohighergainson johnsonjohnsonannualreport divestituresprimarilythedivestitureofcompeedinthiswaspartiallyoffsetbyhighersellingmarketingand administrativeexpensesascomparedtotheprioryearduetoincreasedadvertisingandpromotionalspendingandslightly higheramortizationexpenseinrelatedtoacquisitionsadditionallythefiscalyearwasnegativelyimpactedby operationsinvenezuela pharmaceuticalsegmentinthepharmaceuticalsegmentincomebeforetaxasapercenttosaleswa versusintheincreaseintheincomebeforetaxasapercentofsaleswasprimarilyduetolowerinventory stepupcostsrelatedtoactelionofbillionfavorableproductmixandslowerincreasesinexpensesrelativetothe increaseinsalesacontingentliabilityreversalofbillionandhigherdivestituregainsofbillionfromdivestituresof certainnonstrategicpharmaceuticalproductsthiswaspartiallyoffsetbyhigheramortizationexpenseofbillion primarilyrelatedtotheactelionacquisitionahigheriprdchargeofbillionandanunrealizedlossonsecuritiesof billionascomparedtotheprioryearadditionallyincludedagainofbillionrelatedtomonetizationof futureroyaltyreceivablesandahighergainofbillionrelatedtothesaleofcertaininvestmentsinequitysecurities inthepharmaceuticalsegmentincomebeforetaxasapercenttosaleswasversusinthe decreaseintheincomebeforetaxasapercentofsaleswasprimarilyduetobillionofhigheramortizationexpense andothercostsrelatedtotheactelionacquisitionhigherresearchanddevelopmentexpenseahigheriprdchargeof billionrelatedtonoviraandlowergainsondivestituresascomparedtotheprioryearadditionallythefiscalyear includedapositiveadjustmentofbilliontopreviousreserveestimatesthiswaspartiallyoffsetbyagainof billionrelatedtomonetizationoffutureroyaltyreceivablesahighergainofbillionrelatedtothesaleofcertain investmentsinequitysecuritiesandfavorableproductmixin medicaldevicessegmentinthemedicaldevicessegmentincomebeforetaxasapercenttosaleswa versusinthedecreaseintheincomebeforetaxasapercenttosaleswasprimarilyduehigherlitigation expenseofbillioninascomparedtobillioninandhigherinvestmentsinthebusinessin additionallyhadlowerdivestituregainsofapproximatelybillionascomparedtodivestituregainsinin thecompanyrecordedagainofbillionrelatedtothelifescandivestiturethiswaspartiallyoffsetbylower restructuringexpenseofbillioninascomparedtoadditionallyincludedanassetimpairment chargeofbillionprimarilyrelatedtotheinsulinpumpbusiness inthemedicaldevicessegmentincomebeforetaxasapercenttosaleswasversusinthe decreaseintheincomebeforetaxasapercenttosaleswasprimarilyduetobillionofhigheramortizationexpense andotheracquisitioncostsrelatedtoamobillionofhigherlitigationanassetimpairmentchargeofbillion primarilyrelatedtotheinsulinpumpbusinessbillionofhigherrestructuringandinvestmentsinnewproductlaunche ascomparedtothefiscalyearthiswaspartiallyoffsetbybillionhighergainsinrelatedtodivestiture primarilythedivestitureofcodmanneurosurgery restructuringinthefirstquarterofthecompanyannouncedrestructuringactionsinitsmedicaldevice segmentthecompanyhasachievedapproximatelybillionofannualizedpretaxcostsavinginandisontrack toachievetheannualizedpretaxcostsavingsofbilliontobillionasoutlinedintherestructuringactionsthe savingswillprovidethecompanywithaddedflexibilityandresourcestofundinvestmentinnewgrowthopportunitiesand innovativesolutionsforcustomersandpatientsinthecompanyrecordedapretaxchargeofmillionof whichmillionisincludedincostofproductssoldandmillionisincludedinotherincomeexpensetotal projectcostsofapproximatelybillionhavebeenrecordedsincetherestructuringwasannouncedthisrestructuring programwascompletedinthefiscalfourthquarterof inthesecondquarterofthecompanyannouncedplanstoimplementactionsacrossitsglobalsupplychainthatare intendedtoenablethecompanytofocusresourcesandincreaseinvestmentsincriticalcapabilitiestechnologiesand solutionsnecessarytomanufactureandsupplyitsproductportfolioofthefutureenhanceagilityanddrivegrowththe companyexpectsthesesupplychainactionswillincludeexpandingitsuseofstrategiccollaborationsandbolsteringit initiativestoreducecomplexityimprovingcostcompetitivenessenhancingcapabilitiesandoptimizingit networkdiscussionsregardingspecificfutureactionsareongoingandaresubjecttoallrelevantconsultation requirementsbeforetheyarefinalizedintotalthecompanyexpectstheseactionstogenerateapproximatelyto billioninannualpretaxcostsavingsthatwillbesubstantiallydeliveredbythecompanyexpectstorecord pretaxrestructuringchargesofapproximatelytobillionthecompanyestimatesthatapproximatelyofthe cumulativepretaxcostswillresultincashoutlaysinthecompanyrecordedapretaxchargeofmillionof whichmillionisincludedincostofproductssoldandmillionisincludedinotherincomeexpense seenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtotherestructuringprogram johnsonjohnsonannualreportprovisionfortaxesonincometheworldwideeffectiveincometaxratewasininand intheeffectivetaxratedecreasedbyascomparedtotheeffectivetaxratewas primarilydrivenbyaprovisionaltaxchargeofapproximatelybillionasaresultofthetaxcutsandjobsacttcja recordedinthefourthquarterofandtheimpactofabelgianstatutorytaxratechangewhichincreasedthe effectiveratebythecompanyalsoreceivedabenefitinfromalowerusstatutorytaxratevsaswell asfavorableadjustmentstotheprovisionaltcjataxchargepartiallyoffsetbyunfavorableincometaxmixandthe ustaxonglobalintangiblelowtaxedincomegilti theeffectivetaxrateincreasedbyascomparedtoprimarilydrivenbytheenactmentofthetaxcut andjobsacttcjaintheunitedstatesindecembertheenactmentofthetcjaresultedinaprovisionaltax chargeinthefourthquarterofofapproximatelybillionorapproximatelypercentagepointincreasetothe effectivetaxrateseenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtothetcja theremainderoftheincreaseinthetaxrateforwasrelatedtotheremeasurementofthecompanysdeferredtax assetsinbelgiumasaresultofchangesinthebelgianstatutorycorporatetaxrateenactedindecemberoffsetby ataxbenefitfortheclosureofthecompanysanimasinsulinpumpbusiness thegovernmentinswitzerlandiscurrentlyconsideringtaxreformlegislationwhichcouldhaveamaterialimpactonthe companyseffectivetaxrateifenactedintolaw seenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtothetcjaandincometaxe liquidity capital resource liquiditycashflow cashandcashequivalentswerebillionattheendofascomparedtobillionattheendofthe primarysourcesandusesofcashthatcontributedtothebillionincreasewereapproximatelybillionofcash generatedfromoperatingactivitiesthiswaspartiallyoffsetbybillionnetcashusedbyinvestingactivitie billionnetcashusedbyfinancingactivitiesandbillionduetotheeffectonexchangeratechangesoncash andcashequivalentsinadditionthecompanyhadbillioninmarketablesecuritiesattheendofand billionattheendofseenotetotheconsolidatedfinancialstatementsforadditionaldetailsoncashcash equivalentsandmarketablesecuritie cashflowfromoperationsofbillionwastheresultofbillionofnetearningsandbillionofnoncash expensesandotheradjustmentsfordepreciationandamortizationstockbasedcompensationandassetswritedown offsetbybillionfromnetgainsonsaleofassetsbusinessesdeferredtaxprovisionandaccountsreceivable allowancesbillionrelatedtoanincreaseinaccountsreceivableinventoriesandothercurrentandnoncurrentasset andadecreaseinothercurrentandnoncurrentliabilitiesadditionalsourcesofoperatingcashflowofbillion resultedfromanincreaseinaccountspayableandaccruedliabilitiesthedecreaseincurrentandnoncurrentliabilitiesis primarilyduetothetaxpaymentrelatedtotcja investingactivitiesuseofbillionwasforadditionstopropertyplantandequipmentofbillionthenetpurchase ofinvestmentsprimarilymarketablesecuritiesofbillionacquisitionsnetofcashacquiredofbillionprimarilythe acquisitionsofzarbeesandotherusesofbillionthiswaspartiallyoffsetbybillionofproceedsfromthe disposalofassetsbusinessesprimarilythedivestitureoflifescan financingactivitiesuseofbillionwasprimarilyfordividendstoshareholdersofbillionbillionforthe repurchaseofcommonstockbillionforthenetretirementofshortandlongtermdebtandbillionofother financingfinancingactivitiesalsoincludedsourcesofbillionofproceedsfromstockoptionsexercisedemployee withholdingtaxonstockawardsnet ondecemberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyssharesofcommonstocktherepurchase programhasnotimelimitandmaybesuspendedforperiodsordiscontinuedatanytimeanysharesacquiredwillbe availableforgeneralcorporatepurposesthecompanyintendstofinancethesharerepurchaseprogramthroughavailable cashasofdecemberbillionhasbeenrepurchasedundertheprogram asofdecemberthecompanysnotespayableandlongtermdebtwasinexcessofcashcashequivalentsand marketablesecuritiesasofdecemberthenetdebtpositionwasbillionascomparedtotheprioryearof billiontherewasadecreaseinthenetdebtpositionduetoretirementofdebtthedebtbalanceattheendof johnsonjohnsonannualreport wasbillionascomparedtobillioninadditionallytherewasahighercashcashequivalentsand marketablesecuritiesbalanceattheendofinthecompanycontinuedtohaveaccesstoliquiditythroughthe commercialpapermarketadditionallyasaresultofthetcjathecompanyhasaccesstoitscashoutsidetheusata significantlyreducedcostthecompanyanticipatesthatoperatingcashflowstheabilitytoraisefundsfromexternal sourcesborrowingcapacityfromexistingcommittedcreditfacilitiesandaccesstothecommercialpapermarketswill continuetoprovidesufficientresourcestofundoperatingneedsforthenexttwelvemonthsthecompanymonitorsthe globalcapitalmarketsonanongoingbasisandfromtimetotimemayraisecapitalwhenmarketconditionsarefavorable thecompanyfiledanewshelfregistrationonfebruarywhichwillenableittoissuedebtsecuritiesonatimely basisforadditionaldetailsonborrowingsseenotetotheconsolidatedfinancialstatement financingandmarketrisk thecompanyusesfinancialinstrumentstomanagetheimpactofforeignexchangeratechangesoncashflow accordinglythecompanyentersintoforwardforeignexchangecontractstoprotectthevalueofcertainforeigncurrency assetsandliabilitiesandtohedgefutureforeigncurrencytransactionsprimarilyrelatedtoproductcostsgainsorlosse onthesecontractsareoffsetbythegainsorlossesontheunderlyingtransactionsaappreciationoftheusdollar fromthedecembermarketrateswouldincreasetheunrealizedvalueofthecompanysforwardcontractsby millionconverselyadepreciationoftheusdollarfromthedecembermarketrateswoulddecrease theunrealizedvalueofthecompanysforwardcontractsbymillionineitherscenariothegainorlossontheforward contractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhavenoimpactonfuture anticipatedearningsandcashflow thecompanyhedgestheexposuretofluctuationsincurrencyexchangeratesandtheeffectoncertainassetsand liabilitiesinforeigncurrencybyenteringintocurrencyswapcontractsachangeinthespreadbetweenusand foreigninterestratesonthecompanysinterestratesensitivefinancialinstrumentswouldeitherincreaseordecreasethe unrealizedvalueofthecompanysswapcontractsbyapproximatelymillionineitherscenarioatmaturitythegainor lossontheswapcontractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhaveno impactonfutureanticipatedcashflow thecompanydoesnotenterintofinancialinstrumentsfortradingorspeculativepurposesfurtherthecompanyhasa policyofonlyenteringintocontractswithpartiesthathaveatleastaninvestmentgradecreditratingthecounterpartie tothesecontractsaremajorfinancialinstitutionsandthereisnosignificantconcentrationofexposurewithanyone counterpartymanagementbelievestheriskoflossisremoteduringthefiscalsecondquarterofthecompany enteredintocreditsupportagreementscsawithcertainderivativecounterpartiesestablishingcollateralthreshold basedonrespectivecreditratingsandnettingagreement thecompanyinvestsinbothfixedrateandfloatingrateinterestearningsecuritieswhichcarryadegreeofinterestrate riskthefairmarketvalueoffixedratesecuritiesmaybeadverselyimpactedduetoariseininterestrateswhilefloate ratesecuritiesmayproducelessincomethanpredictedifinterestratesfallabasispointschangeinspreadon thecompanysinterestratesensitiveinvestmentswouldeitherincreaseordecreasetheunrealizedvalueofcash equivalentsandcurrentmarketablesecuritiesbyapproximatelymillion thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementisbasedoneitherbids providedbybankstheprimerateorlondoninterbankofferedratesliborplusapplicablemarginscommitmentfee undertheagreementarenotmaterial totalborrowingsattheendofandwerebillionandbillionrespectivelythedecreasein borrowingswasduetotheretirementofdebtininnetdebtcashandcurrentmarketablesecuritiesnetof debtwasbillioncomparedtonetdebtofbillionintotaldebtrepresentedoftotalcapital shareholdersequityandtotaldebtinandoftotalcapitalinshareholdersequitypershareattheend ofwascomparedtoatyearend asummaryofborrowingscanbefoundinnotetotheconsolidatedfinancialstatement contractualobligationsandcommitment thecompanyscontractualobligationsareprimarilyfortherecentlyenactedtaxlegislationleasesdebtandunfunde retirementplanstherearenoothersignificantobligationstosatisfytheseobligationsthecompanywillusecashfrom johnsonjohnsonannualreportoperationsthefollowingtablesummarizesthecompanyscontractualobligationsandtheiraggregatematuritiesasof decemberseenotesandtotheconsolidatedfinancialstatementsforfurtherdetail tax intereston unfunded legislation debt debt retirement operating dollarsinmillion tcja obligation obligation plan lease total total fortaxmattersseenotetotheconsolidatedfinancialstatementsforotherretirementplanandpostemployment medicalbenefitinformationseenotetotheconsolidatedfinancialstatementsthetabledoesnotincludeactivity relatedtobusinesscombination dividend thecompanyincreaseditsdividendinforthethconsecutiveyearcashdividendspaidwerepersharein comparedwithdividendsofpershareinandpersharein information criticalaccountingpoliciesandestimate managementsdiscussionandanalysisofresultsofoperationsandfinancialconditionarebasedonthecompany consolidatedfinancialstatementsthathavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedin theusgaapthepreparationofthesefinancialstatementsrequiresthatmanagementmakeestimatesand assumptionsthataffecttheamountsreportedforrevenuesexpensesassetsliabilitiesandotherrelateddisclosure actualresultsmayormaynotdifferfromtheseestimatesthecompanybelievesthattheunderstandingofcertainkey accountingpoliciesandestimatesareessentialinachievingmoreinsightintothecompanysoperatingresultsand financialconditionthesekeyaccountingpoliciesincluderevenuerecognitionincometaxeslegalandselfinsurance contingenciesvaluationoflonglivedassetsassumptionsusedtodeterminetheamountsrecordedforpensionsandother employeebenefitplansandaccountingforstockbasedawards revenuerecognitionthecompanyrecognizesrevenuefromproductsaleswhenobligationsunderthetermsofa contractwiththecustomeraresatisfiedgenerallythisoccurswiththetransferofcontrolofthegoodstocustomersthe companysglobalpaymenttermsaretypicallybetweentodaysprovisionsforcertainrebatessalesincentives tradepromotionscouponsproductreturnsanddiscountstocustomersareaccountedforasvariableconsiderationand recordedasareductioninsalesseenotetotheconsolidatedfinancialstatementsfortheaccountingstandard updaterelatedtorevenuewhichwasadoptedin productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingconsiderationofcompetitorpricingrebatesareestimatedbasedoncontractual termshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsinthevariousmarket servedthecompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarilythroughtheanalysisof wholesalerandotherthirdpartysellthroughandmarketresearchdataaswellasinternallygeneratedinformation salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibitunusual salesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas partoftheaccountingforsalesreturnaccrual salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthesalesreturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarket asapercenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescredit johnsonjohnsonannualreport tocustomersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewiththe usgaapguidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerandpharmaceuticalsegmentsarealmostexclusivelynotresalablesalesreturnsfor certainfranchisesinthemedicaldevicessegmentaretypicallyresalablebutarenotmaterialthecompanyinfrequently exchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyhasbeen approximatelyofannualnettradesalesduringthefiscalreportingyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe sameperiodasrelatedsalescontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentive programstheredemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue volumebasedincentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedas productsaresoldthesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedas areductionofrevenuethecompanyalsoearnsprofitsharepaymentsthroughcollaborativearrangementsofcertain productswhichareincludedinsalestocustomersforallyearspresentedprofitsharepaymentswerelessthanof thetotalrevenuesandareincludedinsalestocustomer inadditionthecompanyentersintocollaborationarrangementsthatcontainmultiplerevenuegeneratingactivitie amountsduefromcollaborativepartnersforthesearrangementsarerecognizedaseachactivityisperformedordelivere basedontherelativesellingpriceupfrontfeesreceivedaspartofthesearrangementsaredeferredandrecognizedover theperformanceperiodseenotetotheconsolidatedfinancialstatementsforadditionaldisclosuresoncollaboration reasonablylikelychangestoassumptionsusedtocalculatetheaccrualsforrebatesreturnsandpromotionsarenot anticipatedtohaveamaterialeffectonthefinancialstatementsthecompanycurrentlydisclosestheimpactofchange toassumptionsinthequarterlyorannualfilinginwhichthereisamaterialfinancialstatementimpact belowaretablesthatshowtheprogressionofaccruedrebatesreturnspromotionsreservefordoubtfulaccountsand reserveforcashdiscountsbysegmentofbusinessforthefiscalyearsendeddecemberanddecember consumersegment balanceat balanceat beginning payment endof dollarsinmillion ofperiod accrual credit period accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatdecemberandmillionatdecemberrecordedasa contraasset johnsonjohnsonannualreportpharmaceutical segment balanceat balanceat beginning payment endof dollarsinmillion ofperiod accrual credit period accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatdecemberandmillionatdecemberrecordedasa contraasset includesadjustment medicaldevicessegment balanceat balanceat beginning payment endof dollarsinmillion ofperiod accrual credit period accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatdecemberandmillionatdecemberrecordedasa contraasset johnsonjohnsonannualreport incometaxesincometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludethe resultsofanydifferencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilitie thecompanyestimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesin taxlawsandratesmayaffectrecordeddeferredtaxassetsandliabilitie thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition thecompanyhasrecordeddeferredtaxliabilitiesonallundistributedearningspriortodecemberfromit internationalsubsidiariesthecompanyhasnotprovideddeferredtaxesontheundistributedearningssubsequentto januaryfromcertaininternationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvestedthe companyintendstocontinuetoreinvesttheseearningsinthoseinternationaloperationsifthecompanydecidesata laterdatetorepatriatetheseearningstotheusthecompanywouldberequiredtoprovideforthenettaxeffectson theseamountsthecompanyestimatesthatthetotaltaxeffectofthisrepatriationwouldbeapproximatelybillion undercurrentenactedtaxlawsandregulationsandatcurrentcurrencyexchangerate seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxe legalandselfinsurancecontingenciesthecompanyrecordsaccrualsforvariouscontingenciesincludinglegal proceedingsandproductliabilityclaimsastheseariseinthenormalcourseofbusinesstheaccrualsarebasedon managementsjudgmentastotheprobabilityoflossesandwhereapplicableactuariallydeterminedestimatesthe companyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyinadditiontoaccrualsintheself insuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe reasonablyestimate thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorde whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrue seenotesandtotheconsolidatedfinancialstatementsforfurtherinformationregardingproductliabilityandlegal proceeding longlivedandintangibleassetsthecompanyassesseschangesineconomicconditionsandmakesassumption regardingestimatedfuturecashflowsinevaluatingthevalueofthecompanyspropertyplantandequipmentgoodwill andintangibleassetsastheseassumptionsandestimatesmaychangeovertimeitmayormaynotbenecessaryforthe companytorecordimpairmentcharges employeebenefitplansthecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefit definedcontributionandterminationindemnityplanswhichcovermostemployeesworldwidetheseplansarebasedon assumptionsforthediscountrateexpectedreturnonplanassetsmortalityratesexpectedsalaryincreaseshealthcare costtrendratesandattritionratesseenotetotheconsolidatedfinancialstatementsforfurtherdetailsontheserate andtheeffectaratechangetothehealthcarecosttrendwouldhaveonthecompanysresultsofoperation stockbasedcompensationthecompanyrecognizescompensationexpenseassociatedwiththeissuanceofequity instrumentstoemployeesfortheirservicesbasedonthetypeofequityinstrumentthefairvalueisestimatedonthedate ofgrantusingeithertheblackscholesoptionvaluationmodeloracombinationofboththeblackscholesoption valuationmodelandmontecarlovaluationmodelandisexpensedinthefinancialstatementsovertheserviceperiodthe inputassumptionsusedindeterminingfairvaluearetheexpectedlifeexpectedvolatilityriskfreerateandexpected dividendyieldforperformanceshareunitsthefairmarketvalueiscalculatedforeachofthethreecomponentgoalsatthe dateofgrantthefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedon thedateofgrantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividendswhicharenot paidontheperformanceshareunitsduringthevestingperiodthefairvaluefortherelativetotalshareholderreturngoalof eachperformanceshareunitwasestimatedonthedateofgrantusingthemontecarlovaluationmodelseenoteto theconsolidatedfinancialstatementsforadditionalinformation newaccountingpronouncement refertonotetotheconsolidatedfinancialstatementsforrecentlyadoptedaccountingpronouncementsandrecently issuedaccountingpronouncementsnotyetadoptedasofdecember johnsonjohnsonannualreporteconomicandmarketfactors thecompanyisawarethatitsproductsareusedinanenvironmentwhereformorethanadecadepolicymaker consumersandbusinesseshaveexpressedconcernsabouttherisingcostofhealthcareinresponsetotheseconcern thecompanyhasalongstandingpolicyofpricingproductsresponsiblyfortheperiodintheusthe weightedaveragecompoundannualgrowthrateofthecompanysnetpriceincreasesforhealthcareproduct prescriptionandoverthecounterdrugshospitalandprofessionalproductswasbelowtheusconsumerpriceindex cpi thecompanyoperatesincertaincountrieswheretheeconomicconditionscontinuetopresentsignificantchallengesthe companycontinuestomonitorthesesituationsandtakeappropriateactionsinflationratescontinuetohaveaneffecton worldwideeconomiesandconsequentlyonthewaycompaniesoperatethecompanyhasaccountedforoperationsin argentinabeginninginthefiscalthirdquarterofandvenezuelaashighlyinflationaryasthepriorthreeyear cumulativeinflationratesurpassedthisdidnothaveamaterialimpacttothecompanysresultsintheperiodin thefaceofincreasingcoststhecompanystrivestomaintainitsprofitmarginsthroughcostreductionprogram productivityimprovementsandperiodicpriceincrease injunetheunitedkingdomukheldareferenduminwhichvotersapprovedanexitfromtheeuropeanunion eucommonlyreferredtoasbrexitandinmarchtheukformallystartedtheprocessfortheuktoleavethe eugiventhelackofcomparableprecedentitisunclearwhatfinancialtraderegulatoryandlegalimplicationsthe withdrawaloftheukfromtheeuwillhavebrexitcreatesglobalpoliticalandeconomicuncertaintywhichmaycause amongotherconsequencesvolatilityinexchangeratesandinterestratesadditionalcostcontainmentbythirdparty payorsandchangesinregulationshoweverthecompanycurrentlydoesnotbelievethattheseandotherrelatedeffect willhaveamaterialimpactonthecompanysconsolidatedfinancialpositionoroperatingresultsasofdecember thebusinessofthecompanysuksubsidiariesrepresentedlessthanofboththecompanysconsolidate assetsandfiscaltwelvemonthsrevenuesrespectively thecompanyisexposedtofluctuationsincurrencyexchangeratesachangeinthevalueoftheusdollara comparedtoallforeigncurrenciesinwhichthecompanyhadsalesincomeorexpenseinwouldhaveincreasedor decreasedthetranslationofforeignsalesbyapproximatelymillionandnetincomebyapproximatelymillion governmentsaroundtheworldconsidervariousproposalstomakechangestotaxlawswhichmayincludeincreasingor decreasingexistingstatutorytaxratesachangeinstatutorytaxrateinanycountrywouldresultintherevaluationofthe companysdeferredtaxassetsandliabilitiesrelatedtothatparticularjurisdictionintheperiodinwhichthenewtaxlawis enactedthischangewouldresultinanexpenseorbenefitrecordedtothecompanysconsolidatedstatementof earningsthecompanycloselymonitorstheseproposalsastheyariseinthecountrieswhereitoperateschangestothe statutorytaxratemayoccuratanytimeandanyrelatedexpenseorbenefitrecordedmaybematerialtothefiscalquarter andyearinwhichthelawchangeisenactedonseptembertheswissparliamentapprovedthefederalacton taxreformandahvfinancingswisstaxreformhoweverareferendumhasbeencalledandasaresultapublicvote ontheswisstaxreformwilltakeplaceonmaythiftheswisstaxreformpassesthenthemeasuresare expectedtocomeintoforceineitherjanuaryorjanuarypriortoapprovalinthereferendumandit subsequentcantonalimplementationtheproposedswisstaxreformisnotenactedandthereforethecompanyhasnot reflectedanyofthepotentialimpactsinitsfiscalresultsthecompanyiscurrentlyassessingtheimpactofthepropose swisstaxreformandwhenenactedthelawmayhaveamaterialimpactonthecompanysoperatingresult thecompanyfacesvariousworldwidehealthcarechangesthatmaycontinuetoresultinpricingpressuresthatinclude healthcarecostcontainmentandgovernmentlegislationrelatingtosalespromotionsandreimbursementofhealthcare product changesinthebehaviorandspendingpatternsofpurchasersofhealthcareproductsandservicesincludingdelaye medicalproceduresrationingprescriptionmedicationsreducingthefrequencyofphysicianvisitsandforegoinghealth careinsurancecoverageasaresultofthecurrentglobaleconomicdownturnmaycontinuetoimpactthecompany business thecompanyalsooperatesinanenvironmentincreasinglyhostiletointellectualpropertyrightsfirmshavefile abbreviatednewdrugapplicationsorbiosimilarbiologicalproductapplicationswiththefdaorotherwisechallenge thecoverageandorvalidityofthecompanyspatentsseekingtomarketgenericorbiosimilarformsofmanyofthe companyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductsintheevent thecompanyisnotsuccessfulindefendingthepatentclaimschallengedintheresultinglawsuitsgenericorbiosimilar versionsoftheproductsatissuewillbeintroducedtothemarketresultinginthepotentialforsubstantialmarketshareand johnsonjohnsonannualreport revenuelossesforthoseproductsandwhichmayresultinanoncashimpairmentchargeinanyassociatedintangible assetthereisalsoariskthatoneormorecompetitorscouldlaunchagenericorbiosimilarversionoftheproductatissue followingregulatoryapprovaleventhoughoneormorevalidpatentsareinplaceforfurtherinformationseethe discussiononremicaderelatedcasesandlitigationagainstfilersofabbreviatednewdrugapplicationsin notetotheconsolidatedfinancialstatement legalproceeding johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialandothermattersgovernmentalinvestigationsandotherlegalproceedingsthatarise fromtimetotimeintheordinarycourseofbusiness thecompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimatedthecompanyhasaccruedforcertain litigationmattersandcontinuestomonitoreachrelatedlegalissueandadjustaccrualsfornewinformationandfurther developmentsinaccordancewithaccountingstandardscodificationascfortheseandotherlitigation andregulatorymatterscurrentlydisclosedforwhichalossisprobableorreasonablypossiblethecompanyisunableto estimatethepossiblelossorrangeoflossbeyondtheamountsalreadyaccruedamountsaccruedforlegalcontingencies oftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyonestimatesand assumptionstheabilitytomakesuchestimatesandjudgmentscanbeaffectedbyvariousfactorsincludingwhether damagessoughtintheproceedingsareunsubstantiatedorindeterminatescientificandlegaldiscoveryhasnot commencedorisnotcompleteproceedingsareinearlystagesmatterspresentlegaluncertaintiestherearesignificant factsindisputeortherearenumerouspartiesinvolve inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutionoforincreaseinaccrualsfor oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardinglegalproceeding commonstock thecompanyscommonstockislistedonthenewyorkstockexchangeunderthesymboljnjasoffebruary therewererecordholdersofcommonstockofthecompany johnsonjohnsonannualreportitem quantitative qualitative disclosure market risk theinformationcalledforbythisitemisincorporatedhereinbyreferencetoitemmanagementsdiscussionand analysisofresultsofoperationsandfinancialconditionliquidityandcapitalresourcesfinancingandmarketrisk ofthisreportandnotesummaryofsignificantaccountingpoliciesfinancialinstrumentsofthenotesto consolidatedfinancialstatementsincludedinitemofthisreport item financial statement supplementary data indextoauditedconsolidatedfinancialstatement consolidatedbalancesheet consolidatedstatementsofearning consolidatedstatementsofcomprehensiveincome consolidatedstatementsofequity consolidatedstatementsofcashflow notestoconsolidatedfinancialstatement reportofindependentregisteredpublicaccountingfirm managementsreportoninternalcontroloverfinancialreporte johnsonjohnsonannualreport johnson johnson subsidiaries consolidate balance sheet atdecemberanddecember dollarsinmillionsexceptshareandpershareamountsnote asset currentasset cashandcashequivalentsnotesand marketablesecuritiesnotesand accountsreceivabletradelessallowancesfordoubtfulaccount inventoriesnotesand prepaidexpensesandotherreceivable assetsheldforsalenote totalcurrentassets propertyplantandequipmentnetnotesand intangibleassetsnetnotesand goodwillnotesand deferredtaxesonincomenote otherasset totalasset liabilitiesandshareholdersequity currentliabilitie loansandnotespayablenote accountspayable accruedliabilitie accruedrebatesreturnsandpromotion accruedcompensationandemployeerelatedobligation accruedtaxesonincomenote totalcurrentliabilities longtermdebtnote deferredtaxesonincomenote employeerelatedobligationsnotesand longtermtaxespayablenote otherliabilitie totalliabilitie shareholdersequity preferredstockwithoutparvalueauthorizedandunissuedshare commonstockparvaluepersharenoteauthorizedsharesissue share accumulatedothercomprehensiveincomelossnote retainedearning lesscommonstockheldintreasuryatcostnotesharesandshare totalshareholdersequity totalliabilitiesandshareholdersequity seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreportjohnson johnson subsidiaries consolidate statement earning dollarsandsharesinmillionsexceptpershareamountsnote salestocustomer costofproductssold grossprofit sellingmarketingandadministrativeexpense researchanddevelopmentexpense inprocessresearchanddevelopment interestincome interestexpensenetofportioncapitalizednote otherincomeexpensenet restructuringnote earningsbeforeprovisionfortaxesonincome provisionfortaxesonincomenote netearning netearningspersharenotesand basic diluted averagesharesoutstandingnotesand basic diluted prioryearsamountswerereclassifiedtoconformtocurrentyearpresentationadoptionofasu seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreport johnson johnson subsidiaries consolidate statement comprehensive income dollarsinmillionsnote netearning othercomprehensiveincomelossnetoftax foreigncurrencytranslation security unrealizedholdinggainlossarisingduringperiod reclassificationstoearning netchange employeebenefitplans priorservicecreditcostnetofamortization gainlossnetofamortization effectofexchangerate netchange derivativeshedge unrealizedgainlossarisingduringperiod reclassificationstoearning netchange othercomprehensiveincomeloss comprehensiveincome includestheimpactfromadoptionofasuforfurtherdetailsseenotetotheconsolidatedfinancialstatement thetaxeffectsinothercomprehensiveincomeforthefiscalyearsendedandrespectivelyforeign currencytranslationmillioninduetotheenactmentoftheustaxcutsandjobsactsecuritiesmillion millionandmillionemployeebenefitplansmillionmillionandmillionderivativeshedge millionmillionandmillion seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreportjohnson johnson subsidiaries consolidate statement equity dollarsinmillionsnote accumulate common stock treasury retain comprehensive issue stock total earning income balancejanuary netearning cashdividendspaidpershare employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancejanuary netearning cashdividendspaidpershare employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancedecember cumulativeadjustment netearning cashdividendspaidpershare employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancedecember seenotetoconsolidatedfinancialstatementsforadditionaldetailsontheeffectofcumulativeadjustmentstoretainedearnings seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreport johnson johnson subsidiaries consolidate statement cash flow dollarsinmillionsnote cashflowsfromoperatingactivitie netearning adjustmentstoreconcilenetearningstocashflowsfromoperatingactivitie depreciationandamortizationofpropertyandintangible stockbasedcompensation assetwritedown gainonsaleofassetsbusinesse deferredtaxprovision accountsreceivableallowance changesinassetsandliabilitiesnetofeffectsfromacquisitionsanddivestiture increaseinaccountsreceivable increasedecreaseininventorie increaseinaccountspayableandaccruedliabilitie increaseinothercurrentandnoncurrentasset decreaseincreaseinothercurrentandnoncurrentliabilitie netcashflowsfromoperatingactivitie cashflowsfrominvestingactivities additionstopropertyplantandequipment proceedsfromthedisposalofassetsbusinessesnet acquisitionsnetofcashacquirednote purchasesofinvestment salesofinvestment otherprimarilyintangible netcashusedbyinvestingactivitie cashflowsfromfinancingactivitie dividendstoshareholder repurchaseofcommonstock proceedsfromshorttermdebt retirementofshorttermdebt proceedsfromlongtermdebtnetofissuancecosts retirementoflongtermdebt proceedsfromtheexerciseofstockoptionsemployeewithholdingtaxonstockawardsnet netcashusedbyfinancingactivitie effectofexchangeratechangesoncashandcashequivalent increasedecreaseincashandcashequivalent cashandcashequivalentsbeginningofyearnote cashandcashequivalentsendofyearnote supplementalcashflowdata cashpaidduringtheyearfor interest interestnetofamountcapitalize incometaxe supplementalscheduleofnoncashinvestingandfinancingactivitie treasurystockissuedforemployeecompensationandstockoptionplansnetofcashproceedsemployee withholdingtaxonstockaward conversionofdebt acquisition fairvalueofassetsacquire fairvalueofliabilitiesassumedandnoncontrollinginterest netcashpaidforacquisition seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreportnote consolidated financial statement summary significant accounting policy principlesofconsolidation theconsolidatedfinancialstatementsincludetheaccountsofjohnsonjohnsonanditssubsidiariesthecompany intercompanyaccountsandtransactionsareeliminate descriptionofthecompanyandbusinesssegment thecompanyhasapproximatelyemployeesworldwideengagedintheresearchanddevelopmentmanufacture andsaleofabroadrangeofproductsinthehealthcarefieldthecompanyconductsbusinessinvirtuallyallcountriesof theworldanditsprimaryfocusisonproductsrelatedtohumanhealthandwellbee thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicesthe consumersegmentincludesabroadrangeofproductsusedinthebabycareoralcarebeautyoverthecounter pharmaceuticalwomenshealthandwoundcaremarketstheseproductsaremarketedtothegeneralpublicandsold bothtoretailoutletsanddistributorsthroughouttheworldthepharmaceuticalsegmentisfocusedonsixtherapeutic areasincludingimmunologyinfectiousdiseasesneuroscienceoncologypulmonaryhypertensionandcardiovascular andmetabolicdiseasesproductsinthissegmentaredistributeddirectlytoretailerswholesalershospitalsandhealth careprofessionalsforprescriptionusethemedicaldevicessegmentincludesabroadrangeofproductsusedinthe orthopaedicsurgeryinterventionalsolutionscardiovascularandneurovasculardiabetescaredivestedinthefiscal fourthquarterofandvisionfieldswhicharedistributedtowholesalershospitalsandretailersandusedprincipally intheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsandclinic newaccountingstandard recentlyadoptedaccountingstandard asurevenuefromcontractswithcustomer onjanuarythecompanyadoptedthenewaccountingstandardascrevenuefromcontractswith customersandalltherelatedamendmentsnewrevenuestandardtoallcontractsusingthemodifiedretrospective methodthecumulativeeffectofinitiallyapplyingthenewrevenuestandardwasrecognizedasanadjustmenttothe openingbalanceofretainedearningsthecomparativeinformationhasnotbeenrestatedandcontinuestobereporte undertheaccountingstandardsineffectforthoseperiodstheadoptionofthenewrevenuestandardhasnothada materialimpacttoeitherreportedsalestocustomersornetearningsadditionallythecompanywillcontinueto recognizerevenuefromproductsalesasgoodsareshippedordeliveredtothecustomerascontrolofgoodstransfersat thesametime inaccordancewiththenewrevenuestandardrequirementsthedisclosureoftheimpactofadoptiononthecompany consolidatedstatementofearningsandbalancesheetwasasfollow statementofearningsforthefiscalyearendeddecember balancewithoutadoption dollarsinmillion asreporte effectofchange ofasc salestocustomer netearning balancesheetasofdecember balancewithoutadoption asreporte effectofchange ofasc assets liabilities equity thecompanymadeacumulativeeffectadjustmenttotheopeningbalanceofretainedearningsuponadoptionof asuwhichdecreasedbeginningretainedearningsbymillion johnsonjohnsonannualreport aspartoftheadoptionofascseenotetotheconsolidatedfinancialstatementsforfurtherdisaggregationof revenue asufinancialinstrumentsrecognitionandmeasurementoffinancialassetsandfinancialliabilitie thecompanyadoptedthisstandardasofthebeginningofthefiscalyearonamodifiedretrospectivebasisthe amendmentsinthisupdatesupersedetheguidancetoclassifyequitysecuritieswithreadilydeterminablefairvaluesinto differentcategoriesthatistradingoravailableforsaleandrequireequitysecuritiestobemeasuredatfairvaluewith changesinthefairvaluerecognizedthroughnetearningsthestandardamendsfinancialreportingbyprovidingrelevant informationaboutanentitysequityinvestmentsandreducingthenumberofitemsthatarerecognizedinother comprehensiveincome thecompanymadeacumulativeeffectadjustmenttotheopeningbalanceofretainedearningsuponadoptionofasu thatincreasedretainedearningsbymillionnetoftaxanddecreasedaccumulatedothercomprehensive incomeforpreviouslyunrealizedgainsfromequityinvestmentsforadditionaldetailsseenotetotheconsolidate financialstatement asuincometaxesintraentitytransfersofassetsotherthaninventory thecompanyadoptedthisstandardasofthebeginningofthefiscalyearthisupdateremovesthecurrent exceptioninusgaapprohibitingentitiesfromrecognizingcurrentanddeferredincometaxexpensesorbenefitsrelate totransferofassetsotherthaninventorywithintheconsolidatedentitythecurrentexceptiontodefertherecognitionof anytaximpactonthetransferofinventorywithintheconsolidatedentityuntilitissoldtoathirdpartyremainsunaffecte asdiscussedfurtherinnotetotheconsolidatedfinancialstatementsinthefourthfiscalquarterofthecompany electedanaccountingpolicytotreatthetaxonglobalintangiblelowtaxedincomegiltiunderthedeferredtax accountingmodelasaresultthecompanyisrequiredtorecordanadditionaldeferredtaxliabilityrelatedtothebasis differenceoftheseintraentityassettransfersthecompanyrecordednetadjustmentsincludinganincreasetodeferre taxassetsofapproximatelybillionanincreasetodeferredtaxliabilitiesofapproximatelybillionrelatedtothe giltiaccountingpolicyelectioninthefourthfiscalquarterofadecreasetootherassetsofapproximately billionandadecreasetoretainedearningsofapproximatelybilliontheadoptionofthisstandarddidnothavea materialimpactonthecompanysconsolidatedfinancialstatement asuclarifyingthedefinitionofabusiness thecompanyadoptedthisstandardasofthebeginningofthefiscalyearthisupdatenarrowsthedefinitionofa businessbyprovidingascreentodeterminewhenanintegratedsetofassetsandactivitiesisnotabusinessthescreen specifiesthatanintegratedsetofassetsandactivitiesisnotabusinessifsubstantiallyallofthefairvalueofthegross assetsacquiredordisposedofisconcentratedinasingleoragroupofsimilaridentifiableassetsthisupdatewasapplie prospectivelytheadoptionofthisstandarddidnothaveamaterialimpactonthecompanysconsolidatedfinancial statement asuimprovingthepresentationofnetperiodicpensioncostandnetperiodicpostretirementbenefitcost thecompanyadoptedthisstandardasofthebeginningofthefiscalyearthisupdaterequiresthatanemployer disaggregatetheservicecostcomponentfromtheothercomponentsofnetperiodicbenefitcostnpbcinadditiononly theservicecostcomponentwillbeeligibleforcapitalizationtheamendmentsinthisupdatearerequiredtobeapplie retrospectivelyforthepresentationoftheservicecostcomponentandtheothercomponentsofnpbcinthe consolidatedstatementofearningsandprospectivelyonandaftertheadoptiondateforthecapitalizationoftheservice costcomponentofnpbcinassetsasrequiredbythetransitionprovisionsofthisupdatethefollowingtableshowsthe impactoftheadoptionontherespectivelineitemsintheconsolidatedstatementofearningsforandthe reclassificationstotheandfiscalyearconsolidatedstatementofearningstoretroactivelyapplyclassification oftheservicecostcomponentandtheothercomponentsofnpbc increasedecrease tonetexpense dollarsinmillion costofproductssold sellingmarketingandadministrativeexpense researchanddevelopmentexpense otherincomeexpensenet earningsbeforeprovisionfortaxesonincome johnsonjohnsonannualreportthefollowingtablesummarizesthecumulativeeffectadjustmentsmadetotheopeningbalanceofretainedearning uponadoptionofthenewaccountingstandardsmentionedabove cumulativeeffect adjustmentincrease decreaseto dollarsinmillion retainedearning asurevenuefromcontractswithcustomer asufinancialinstrument asuincometaxesintraentitytransfer total asutargetedimprovementstoaccountingforhedgingactivitie thecompanyelectedtoearlyadoptthisstandardasofthebeginningofthefiscalsecondquarterofthisupdate makesmorefinancialandnonfinancialhedgingstrategieseligibleforhedgeaccountingitalsoamendsthepresentation anddisclosurerequirementsandchangeshowcompaniesassesseffectivenesstheadoptionofthisstandarddidnot haveamaterialimpactonthecompanysconsolidatedfinancialstatementsforadditionalrequireddisclosuresseenote totheconsolidatedfinancialstatement recentlyissuedaccountingstandard notadoptedasofdecember asucollaborativearrangement thisupdateclarifiestheinteractionbetweenasccollaborativearrangementsandascrevenuefrom contractswithcustomerstheupdateclarifiesthatcertaintransactionsbetweenparticipantsinacollaborative arrangementshouldbeaccountedforunderascwhenthecounterpartyisacustomerinadditiontheupdate precludesanentityfrompresentingconsiderationfromatransactioninacollaborativearrangementasrevenueifthe counterpartyisnotacustomerforthattransactionthisupdatewillbeeffectiveforthecompanyforfiscalyearsbeginne afterdecemberandinterimperiodswithinthosefiscalyearsasushouldbeappliedretrospectivelyto thedateofinitialapplicationofascandearlyadoptionispermittedthecompanyiscurrentlyassessingtheimpact ofthisupdateonthecompanysconsolidatedfinancialstatementsandrelateddisclosure asuderivativesandhedgingtopicasc thisupdateaddstheovernightindexswapoisratebasedonthesecuredovernightfinancingratesofrasan eligiblebenchmarkinterestratepermittedintheapplicationofhedgeaccountingthisupdatewillbeeffectiveforthe companyforfiscalyearsbeginningafterdecemberandinterimperiodswithinthosefiscalyearsearlyadoption ispermittedifanentityhasadoptedasuthecompanyiscurrentlyassessingtheimpactofthisupdateonthe companysconsolidatedfinancialstatementsandrelateddisclosure asureclassificationofcertaintaxeffectsfromaccumulatedothercomprehensiveincome thisupdateallowsareclassificationfromaccumulatedothercomprehensiveincometoretainedearningsforstrandedtax effectsresultingfromthetaxcutsandjobactenactedindecemberthisupdatewillbeeffectiveforthecompany forfiscalyearsbeginningafterdecemberandinterimperiodswithinthosefiscalyearsthecompanydoesnot expectthisstandardtohaveamaterialimpactonthecompanysconsolidatedfinancialstatement asufinancialinstrumentscreditlosse thisupdateintroducesthecurrentexpectedcreditlossceclmodelwhichwillrequireanentitytomeasurecredit lossesforcertainfinancialinstrumentsandfinancialassetsincludingtradereceivablesunderthisupdateoninitial recognitionandateachreportingperiodanentitywillberequiredtorecognizeanallowancethatreflectstheentitys currentestimateofcreditlossesexpectedtobeincurredoverthelifeofthefinancialinstrumentthisupdatewillbe effectiveforthecompanyforfiscalyearsbeginningafterdecemberandinterimperiodswithinthosefiscalyear earlyadoptionispermittedthecompanyiscurrentlyassessingtheimpactofthisupdateonthecompanysconsolidate financialstatementsandrelateddisclosure asulease thisupdaterequirestherecognitionofleaseassetsandleaseliabilitiesonthebalancesheetforallleaseobligationsand disclosingkeyinformationaboutleasingarrangementsthisupdaterequirestherecognitionofleaseassetsandlease liabilitiesbylesseesforthoseleasesclassifiedasoperatingleasesundercurrentgenerallyacceptedaccounte johnsonjohnsonannualreport principlesthisupdatewillbeeffectiveforthecompanyforallannualperiodsbeginningafterdecember includinginterimperiodswithinthosefiscalyearsthecompanywillapplythenewstandardatitsadoptiondaterather thanattheearliestcomparativeperiodpresentedinthefinancialstatementsthecompanysoperatingleaseswillresultin therecognitionofadditionalassetsandthecorrespondingliabilitiesonitsconsolidatedbalancesheetstheadoptionof thisstandardwillnothaveamaterialimpactonthecompanysconsolidatedfinancialstatement cashequivalent thecompanyclassifiesallhighlyliquidinvestmentswithstatedmaturitiesofthreemonthsorlessfromdateofpurchase ascashequivalentsandallhighlyliquidinvestmentswithstatedmaturitiesofgreaterthanthreemonthsfromthedateof purchaseascurrentmarketablesecuritiesthecompanyhasapolicyofmakinginvestmentsonlywithcommercial institutionsthathaveatleastaninvestmentgradecreditratingthecompanyinvestsitscashprimarilyingovernment securitiesandobligationscorporatedebtsecuritiesmoneymarketfundsandreverserepurchaseagreementsrra rrasarecollateralizedbydepositsintheformofgovernmentsecuritiesandobligationsforanamountnotlessthan oftheirvaluethecompanydoesnotrecordanassetorliabilityasthecompanyisnotpermittedtosellor repledgetheassociatedcollateralthecompanyhasapolicythatthecollateralhasatleastanaorequivalentcredit ratingthecompanyutilizesathirdpartycustodiantomanagetheexchangeoffundsandensurethatcollateralreceivedis maintainedatofthevalueoftherrasonadailybasisrraswithstatedmaturitiesofgreaterthanthreemonth fromthedateofpurchaseareclassifiedasmarketablesecuritie investment investmentsclassifiedasheldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesare reportedinearningsinvestmentsclassifiedasavailableforsalearecarriedatestimatedfairvaluewithunrealizedgain andlossesrecordedasacomponentofaccumulatedothercomprehensiveincomeavailableforsalesecuritiesavailable forcurrentoperationsareclassifiedascurrentassetsotherwisetheyareclassifiedaslongtermmanagementdetermine theappropriateclassificationofitsinvestmentindebtandequitysecuritiesatthetimeofpurchaseandreevaluatessuch determinationateachbalancesheetdatethecompanyreviewsitsinvestmentsinequitysecuritiesforimpairmentand adjuststheseinvestmentstofairvaluethroughearningsasrequire propertyplantandequipmentanddepreciation propertyplantandequipmentarestatedatcostthecompanyutilizesthestraightlinemethodofdepreciationoverthe estimatedusefullivesoftheasset buildingandbuildingequipment year landandleaseholdimprovement year machineryandequipment year thecompanycapitalizescertaincomputersoftwareanddevelopmentcostsincludedinmachineryandequipmentwhen incurredinconnectionwithdevelopingorobtainingcomputersoftwareforinternalusecapitalizedsoftwarecostsare amortizedovertheestimatedusefullivesofthesoftwarewhichgenerallyrangefromtoyears thecompanyreviewslonglivedassetstoassessrecoverabilityusingundiscountedcashflowswhencertaineventsor changesinoperatingoreconomicconditionsoccuranimpairmentassessmentmaybeperformedontherecoverabilityof thecarryingvalueoftheseassetsiftheassetisdeterminedtobeimpairedthelossismeasuredbasedonthedifference betweentheassetsfairvalueanditscarryingvalueifquotedmarketpricesarenotavailablethecompanywillestimate fairvalueusingadiscountedvalueofestimatedfuturecashflow revenue recognition thecompanyrecognizesrevenuefromproductsaleswhenobligationsunderthetermsofacontractwiththecustomer aresatisfiedgenerallythisoccurswiththetransferofcontrolofthegoodstocustomersthecompanysglobalpayment termsaretypicallybetweentodaysprovisionsforcertainrebatessalesincentivestradepromotionscoupon productreturnsanddiscountstocustomersareaccountedforasvariableconsiderationandrecordedasareductionin sale productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingconsiderationofcompetitorpricingrebatesareestimatedbasedoncontractual johnsonjohnsonannualreporttermshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsinthevariousmarket servedthecompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarilythroughtheanalysisof wholesalerandotherthirdpartysellthroughandmarketresearchdataaswellasinternallygeneratedinformation salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibitunusual salesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas partoftheaccountingforsalesreturnaccrual salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthesalesreturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarket asapercenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescredit tocustomersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewiththe usgaapguidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerandpharmaceuticalsegmentsarealmostexclusivelynotresalablesalesreturnsfor certainfranchisesinthemedicaldevicessegmentaretypicallyresalablebutarenotmaterialthecompanyinfrequently exchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyhasbeen approximatelyofannualnettradesalesduringthefiscalreportingyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe sameperiodasrelatedsalescontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentive programstheredemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue volumebasedincentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedas productsaresoldthesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedas areductionofrevenuethecompanyalsoearnsprofitsharepaymentsthroughcollaborativearrangementsforcertain productswhichareincludedinsalestocustomersforallyearspresentedprofitsharepaymentswerelessthanof thetotalrevenuesandareincludedinsalestocustomer shippingandhandle shippingandhandlingcostsincurredweremillionmillionandmillioninand respectivelyandareincludedinsellingmarketingandadministrativeexpensetheamountofrevenuereceivedfor shippingandhandlingislessthanofsalestocustomersforallperiodspresente inventory inventoriesarestatedatthelowerofcostornetrealizablevaluedeterminedbythefirstinfirstoutmethod intangibleassetsandgoodwill theauthoritativeliteratureonusgaaprequiresthatgoodwillandintangibleassetswithindefinitelivesbeassesse annuallyforimpairmentthecompanycompletedtheannualimpairmenttestforinthefiscalfourthquarterfuture impairmenttestswillbeperformedannuallyinthefiscalfourthquarterorsoonerifwarrantedpurchasedinprocess researchanddevelopmentisaccountedforasanindefinitelivedintangibleassetuntiltheunderlyingprojectiscomplete atwhichpointtheintangibleassetwillbeaccountedforasadefinitelivedintangibleassetorabandonedatwhichpoint theintangibleassetwillbewrittenofforpartiallyimpaire intangibleassetsthathavefiniteusefullivescontinuetobeamortizedovertheirusefullivesandarereviewedfor impairmentwhenwarrantedbyeconomicconditionsseenoteforfurtherdetailsonintangibleassetsandgoodwill financialinstrument asrequiredbyusgaapallderivativeinstrumentsarerecordedonthebalancesheetatfairvaluefairvalueistheexit pricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbasedmeasurement determinedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitytheauthoritativeliterature establishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluewithlevelhavingthehighest priorityandlevelhavingthelowestchangesinthefairvalueofderivativesarerecordedeachperiodincurrentearning orothercomprehensiveincomedependingonwhetherthederivativeisdesignatedaspartofahedgetransactionandif sothetypeofhedgetransaction johnsonjohnsonannualreport thecompanydocumentsallrelationshipsbetweenhedgeditemsandderivativestheoverallriskmanagementstrategy includesreasonsforundertakinghedgetransactionsandenteringintoderivativestheobjectivesofthisstrategyare minimizeforeigncurrencyexposuresimpactonthecompanysfinancialperformanceprotectthecompanyscash flowfromadversemovementsinforeignexchangeratesensuretheappropriatenessoffinancialinstrumentsand managetheenterpriseriskassociatedwithfinancialinstitutionsseenoteforadditionalinformationonfinancial instrument productliability accrualsforproductliabilityclaimsarerecordedonanundiscountedbasiswhenitisprobablethataliabilityhasbeen incurredandtheamountoftheliabilitycanbereasonablyestimatedbasedonexistinginformationandactuarially determinedestimateswhereapplicabletheaccrualsareadjustedperiodicallyasadditionalinformationbecome availablethecompanyaccruesanestimateofthelegaldefensecostsneededtodefendeachmatterwhenthosecost areprobableandcanbereasonablyestimatedtotheextentadverseverdictshavebeenrenderedagainstthecompany thecompanydoesnotrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimate asaresultofcostandavailabilityfactorseffectivenovemberthecompanyceasedpurchasingthirdparty productliabilityinsurancethecompanyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyin additiontoaccrualsintheselfinsuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesare probableandamountscanbereasonablyestimate researchanddevelopment researchanddevelopmentexpensesareexpensedasincurredinaccordancewithascresearchand developmentupfrontandmilestonepaymentsmadetothirdpartiesinconnectionwithresearchanddevelopment collaborationsareexpensedasincurreduptothepointofregulatoryapprovalpaymentsmadetothirdpartiessubsequent toregulatoryapprovalarecapitalizedandamortizedovertheremainingusefullifeoftherelatedproductamount capitalizedforsuchpaymentsareincludedinotherintangiblesnetofaccumulatedamortization thecompanyentersintocollaborativearrangementstypicallywithotherpharmaceuticalorbiotechnologycompaniesto developandcommercializedrugcandidatesorintellectualpropertythesearrangementstypicallyinvolvetwoormore partieswhoareactiveparticipantsinthecollaborationandareexposedtosignificantrisksandrewardsdependentonthe commercialsuccessoftheactivitiesthesecollaborationsusuallyinvolvevariousactivitiesbyoneormorepartie includingresearchanddevelopmentmarketingandsellinganddistributionoftenthesecollaborationsrequireupfront milestoneandroyaltyorprofitsharepaymentscontingentupontheoccurrenceofcertainfutureeventslinkedtothe successoftheassetindevelopmentamountsduefromcollaborativepartnersrelatedtodevelopmentactivitiesare generallyreflectedasareductionofresearchanddevelopmentexpensebecausetheperformanceofcontract developmentservicesisnotcentraltothecompanysoperationsingeneraltheincomestatementpresentationforthese collaborationsisasfollow naturetypeofcollaboration statementofearningspresentation thirdpartysaleofproductprofitsharepaymentsreceive salestocustomer royaltiesmilestonespaidtocollaborativepartnerpost costofproductssold regulatoryapproval royaltiesreceivedfromcollaborativepartner otherincomeexpensenet upfrontpaymentsmilestonespaidtocollaborativepartner researchanddevelopmentexpense preregulatoryapproval researchanddevelopmentpaymentstocollaborative researchanddevelopmentexpense partner researchanddevelopmentpaymentsreceivedfrom reductionofresearchanddevelopmentexpense collaborativepartner milestonesarecapitalizedasintangibleassetsandamortizedtocostofproductssoldovertheusefullife forallyearspresentedtherewasnoindividualprojectthatrepresentedgreaterthanofthetotalannualconsolidate researchanddevelopmentexpense johnsonjohnsonannualreportthecompanyhasanumberofproductsandcompoundsdevelopedincollaborationwithstrategicpartnersincluding xareltocodevelopedwithbayerhealthcareagandimbruvicadevelopedincollaborationandcomarkete withpharmacyclicsllcanabbviecompany thecompanyhasanumberoflicensingarrangementsforproductsandcompoundsincludingdarzalexlicense fromgenmabas advertising costsassociatedwithadvertisingareexpensedintheyearincurredandareincludedinsellingmarketingand administrativeexpensesadvertisingexpensesworldwidewhichcomprisedtelevisionradioprintmediaandinternet advertisingwerebillionbillionandbillioninandrespectively incometaxe incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludetheresultsofany differencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilitiesthecompany estimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesintaxlawsand ratesmayaffectrecordeddeferredtaxassetsandliabilitiesinthefuture thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition inthefourthfiscalquarterofthecompanyhaselectedtoaccountforthegiltitaxunderthedeferredmethodthe deferredtaxamountsrecordedarebasedontheevaluationoftemporarydifferencesthatareexpectedtoreverseasgilti isincurred thecompanyhasrecordeddeferredtaxliabilitiesonallundistributedearningspriortodecemberfromit internationalsubsidiariesthecompanyhasnotprovideddeferredtaxesontheundistributedearningssubsequentto januaryfromcertaininternationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvestedthe companyintendstocontinuetoreinvesttheseearningsinthoseinternationaloperationsifthecompanydecidesata laterdatetorepatriatetheseearningstotheusthecompanywouldberequiredtoprovideforthenettaxeffectson theseamountsthecompanyestimatesthatthetotaltaxeffectofthisrepatriationwouldbeapproximatelybillion undercurrentenactedtaxlawsandregulationsandatcurrentcurrencyexchangerate seenoteforfurtherinformationregardingincometaxe netearningspershare basicearningspershareiscomputedbydividingnetearningsavailabletocommonshareholdersbytheweightedaverage numberofcommonsharesoutstandingfortheperioddilutedearningspersharereflectsthepotentialdilutionthatcould occurifsecuritieswereexercisedorconvertedintocommonstockusingthetreasurystockmethod useofestimate thepreparationofconsolidatedfinancialstatementsinconformitywithaccountingprinciplesgenerallyacceptedinthe usrequiresmanagementtomakeestimatesandassumptionsthataffecttheamountsreportedestimatesareusedwhen accountingforsalesdiscountsrebatesallowancesandincentivesproductliabilitiesincometaxeswithholdingtaxes depreciationamortizationemployeebenefitscontingenciesandintangibleassetandliabilityvaluationsactualresults mayormaynotdifferfromthoseestimate thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorde whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrue annualclosingdate thecompanyfollowstheconceptofafiscalyearwhichendsonthesundaynearesttotheendofthemonthof decembernormallyeachfiscalyearconsistsofweeksbuteveryfiveorsixyearsthefiscalyearconsistsofweeks andthereforeincludesadditionalshippingdaysaswasthecaseinandwillbethecaseagainin reclassification certainpriorperiodamountshavebeenreclassifiedtoconformtocurrentyearpresentation johnsonjohnsonannualreport cash cash equivalent current marketable security attheendofandcashcashequivalentsandcurrentmarketablesecuritieswerecomprisedof cash current carry estimate cash marketable dollarsinmillion fairvalue equivalent security cash usreverserepurchaseagreement otherreverserepurchaseagreement moneymarketfund timedeposit subtotal govtsecuritie corporatedebtsecurities subtotalavailableforsale totalcashcashequivalentsandcurrentmarketablesecurities inthecarryingamountwasthesameastheestimatedfairvalue inthecarryingamountwasthesameastheestimatedfairvalue estimate cash current carry fair cash marketable dollarsinmillion value equivalent security cash othersovereignsecuritie usreverserepurchaseagreement corporatedebtsecuritie moneymarketfund timedeposit subtotal govtsecuritie othersovereignsecuritie corporatedebtsecuritie subtotalavailableforsale totalcashcashequivalentsandcurrentmarketablesecuritie heldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesarereportedinearning availableforsaledebtsecuritiesarereportedatfairvaluewithunrealizedgainsandlossesreportednetoftaxesinother comprehensiveincome fairvalueofgovernmentsecuritiesandobligationsandcorporatedebtsecuritieswereestimatedusingquotedbroker pricesandsignificantotherobservableinput johnsonjohnsonannualreportthecontractualmaturitiesoftheavailableforsaledebtsecuritiesatdecemberareasfollow cost fair dollarsinmillion basis value duewithinoneyear dueafteroneyearthroughfiveyear dueafterfiveyearsthroughtenyear totaldebtsecuritie thecompanyinvestsitsexcesscashinbothdepositswithmajorbanksthroughouttheworldandotherhighquality moneymarketinstrumentsthecompanyhasapolicyofmakinginvestmentsonlywithcommercialinstitutionsthathaveat leastaninvestmentgradecreditrate inventory attheendofandinventorieswerecomprisedof dollarsinmillion rawmaterialsandsupplie goodsinprocess finishedgood totalinventorie netofassetsheldforsaleontheconsolidatedbalancesheetforapproximatelybillionrelatedtothedivestitureofthe advancedsterilizationproductsbusinessandbillionrelatedtothestrategiccollaborationwithjabilincbothofwhichwere pendingasofdecember property plant equipment attheendofandpropertyplantandequipmentatcostandaccumulateddepreciationwere dollarsinmillion landandlandimprovement buildingsandbuildingequipment machineryandequipment constructioninprogress totalpropertyplantandequipmentgross lessaccumulateddepreciation totalpropertyplantandequipmentnet netofassetsheldforsaleontheconsolidatedbalancesheetforapproximatelybillionrelatedtothedivestitureofthe advancedsterilizationproductsbusinessandbillionrelatedtothestrategiccollaborationwithjabilincbothofwhichwere pendingasofdecember thecompanycapitalizesinterestexpenseaspartofthecostofconstructionoffacilitiesandequipmentinterestexpense capitalizedinandwasmillionmillionandmillionrespectively depreciationexpenseincludingtheamortizationofcapitalizedinterestinandwasbillion billionandbillionrespectively uponretirementorotherdisposalofpropertyplantandequipmentthecostsandrelatedamountsofaccumulate depreciationoramortizationareeliminatedfromtheassetandaccumulateddepreciationaccountsrespectivelythe differenceifanybetweenthenetassetvalueandtheproceedsarerecordedinearning johnsonjohnsonannualreport intangible asset goodwill attheendofandthegrossandnetamountsofintangibleassetswere dollarsinmillion intangibleassetswithdefinitelive patentsandtrademarksgross lessaccumulatedamortization patentsandtrademarksnet customerrelationshipsandotherintangiblesgross lessaccumulatedamortization customerrelationshipsandotherintangiblesnet intangibleassetswithindefinitelive trademark purchasedinprocessresearchanddevelopment totalintangibleassetswithindefinitelive totalintangibleassetsnet thedecreasewasprimarilyattributabletothewritedownofbillionrelatedtotheassetsacquiredintheacquisitionsofalios biopharmaincaliosandxolimitedxoofthebillionthecompanyrecordedapartialimpairmentchargeofbillion relatedtothedevelopmentprogramofalaninvestigationaldrugforthetreatmentofrespiratorysyncytialvirusrsvand humanmetapneumovirushmpvacquiredwiththeacquisitionofaliostheimpairmentchargewascalculatedbasedon updatedcashflowprojectionsdiscountedfortheinherentriskintheassetdevelopmentandreflectstheimpactofthephaseb clinicaltrialsuspensionadecreaseintheprobabilityofsuccessfactorsandtheongoinganalysisofassetdevelopmentactivitiesin additionanimpairmentchargeofbillionwasrecordedforthediscontinuationofthedevelopmentprojectforanantithrombin antibodyassociatedwiththeacquisitionofxoadditionallybillionofiprdrelatedtoerleadawasreclassifiedto definitelivedintangibleassetsuponcommercialization goodwillasofdecemberanddecemberasallocatedbysegmentofbusinesswasasfollow dollarsinmillion consumer pharmaceutical medicaldevice total goodwillatjanuary goodwillrelatedtoacquisition goodwillrelatedtodivestiture currencytranslationother goodwillatdecember goodwillrelatedtoacquisition goodwillrelatedtodivestitures currencytranslationother goodwillatdecember goodwillofbillionrelatedtotheactelionacquisitionacquiredinthefiscalsecondquarterofwithinthepharmaceutical segmentandbillionrelatedtotheamoacquisitionacquiredinthefiscalfirstquarterofwithinthemedicaldevice segment goodwillofbillionisrelatedtothedivestitureofthelifescanbusinessgoodwillofbillionisrelatedtothedivestitureof theadvancedsterilizationproductsbusinesswhichwaspendingandclassifiedasassetsheldforsaleontheconsolidatedbalance sheetasofdecember theweightedaverageamortizationperiodsforpatentsandtrademarksandcustomerrelationshipsandotherintangible assetsareyearsandyearsrespectivelytheamortizationexpenseofamortizableassetsincludedincostof productssoldwasbillionbillionandbillionbeforetaxforthefiscalyearsendeddecember decemberandjanuaryrespectivelytheestimatedamortizationexpenseforthefivesucceedingyear approximatesbillionbeforetaxperyearintangibleassetwritedownsareincludedinotherincomeexpensenet seenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtoacquisitionsanddivestitures johnsonjohnsonannualreport fair value measurement thecompanyusesforwardforeignexchangecontractstomanageitsexposuretothevariabilityofcashflowsprimarily relatedtotheforeignexchangeratechangesoffutureintercompanyproductsandthirdpartypurchasesofmaterial denominatedinaforeigncurrencythecompanyusescrosscurrencyinterestrateswapstomanagecurrencyrisk primarilyrelatedtoborrowingsbothtypesofderivativesaredesignatedascashflowhedge additionallythecompanyusesinterestrateswapsasaninstrumenttomanageinterestrateriskrelatedtofixedrate borrowingsthesederivativesaredesignatedasfairvaluehedgesthecompanyusescrosscurrencyinterestrateswap andforwardforeignexchangecontractsdesignatedasnetinvestmenthedgesadditionallythecompanyusesforward foreignexchangecontractstooffsetitsexposuretocertainforeigncurrencyassetsandliabilitiestheseforwardforeign exchangecontractsarenotdesignatedashedgesandthereforechangesinthefairvaluesofthesederivativesare recognizedinearningstherebyoffsettingthecurrentearningseffectoftherelatedforeigncurrencyassetsandliabilitie thecompanyearlyadoptedasutargetedimprovementstoaccountingforhedgeactivitieseffectiveasofthe beginningoffiscalsecondquarterof thecompanydoesnotenterintoderivativefinancialinstrumentsfortradingorspeculativepurposesorthatcontaincredit riskrelatedcontingentfeaturesduringthefiscalsecondquarterofthecompanyenteredintocreditsupport agreementscsawithcertainderivativecounterpartiesestablishingcollateralthresholdsbasedonrespectivecredit ratingsandnettingagreementsasofdecemberthetotalamountofcollateralpaidunderthecreditsupport agreementscsaamountedtomillionnetonanongoingbasisthecompanymonitorscounterpartycredit ratingsthecompanyconsiderscreditnonperformancerisktobelowbecausethecompanyprimarilyentersinto agreementswithcommercialinstitutionsthathaveatleastaninvestmentgradecreditratingrefertothetableon significantfinancialassetsandliabilitiesmeasuredatfairvaluecontainedinthisfootnoteforreceivablesandpayableswith thesecommercialinstitutionsasofdecemberthecompanyhadnotionalamountsoutstandingforforward foreignexchangecontractscrosscurrencyinterestrateswapsandinterestrateswapsofbillionbillionand billionrespectivelyasofdecemberthecompanyhadnotionalamountsoutstandingforforwardforeign exchangecontractscrosscurrencyinterestrateswapsandinterestrateswapsofbillionbillionand billionrespectively allderivativeinstrumentsarerecordedonthebalancesheetatfairvaluechangesinthefairvalueofderivativesare recordedeachperiodincurrentearningsorothercomprehensiveincomedependingonwhetherthederivativeis designatedaspartofahedgetransactionandifsothetypeofhedgetransaction thedesignationasacashflowhedgeismadeattheentrancedateofthederivativecontractatinceptionallderivative areexpectedtobehighlyeffectiveforeignexchangecontractsdesignatedascashflowhedgesareaccountedforunder theforwardmethodandallgainslossesassociatedwiththesecontractswillberecognizedintheincomestatementwhen thehedgeditemimpactsearningschangesinthefairvalueofthesederivativesarerecordedinaccumulatedother comprehensiveincomeuntiltheunderlyingtransactionaffectsearningsandarethenreclassifiedtoearningsinthesame accountasthehedgedtransaction gainsandlossesassociatedwithinterestrateswapsandchangesinfairvalueofhedgeddebtattributabletochangesin interestratesarerecordedtointerestexpenseintheperiodinwhichtheyoccurgainsandlossesonnetinvestment hedgeareaccountedthroughthecurrencytranslationaccountwithinaccumulatedothercomprehensiveincomethe portionexcludedfromeffectivenesstestingisrecordedthroughinterestincomeexpenseusingthespotmethodonan ongoingbasisthecompanyassesseswhethereachderivativecontinuestobehighlyeffectiveinoffsettingchangesof hedgeditemsifandwhenaderivativeisnolongerexpectedtobehighlyeffectivehedgeaccountingisdiscontinue duringthefiscalsecondquarterofthecompanydesignateditseurodenominatednotesissuedinmaywith duedatesrangingfromtoasanetinvestmenthedgeofthecompanysinvestmentsincertainofit internationalsubsidiariesthatusetheeuroastheirfunctionalcurrencyinordertoreducethevolatilitycausedbychange inexchangerate asofdecemberthebalanceofdeferrednetlossonderivativesincludedinaccumulatedothercomprehensive incomewasmillionaftertaxforadditionalinformationseetheconsolidatedstatementsofcomprehensiveincome andnotethecompanyexpectsthatsubstantiallyalloftheamountsrelatedtoforwardforeignexchangecontractswill bereclassifiedintoearningsoverthenextmonthsasaresultoftransactionsthatareexpectedtooccuroverthat periodthemaximumlengthoftimeoverwhichthecompanyishedgingtransactionexposureismonthsexclude interestratecontractsnetinvestmenthedgesandequitycollarcontractstheamountultimatelyrealizedinearningsmay differasforeignexchangerateschangerealizedgainsandlossesareultimatelydeterminedbyactualexchangeratesat maturityofthederivative johnsonjohnsonannualreport thefollowingtableisasummaryoftheactivityrelatedtoderivativesandhedgesforthefiscalyearsendeddecember anddecember december december costof interest costof interest product rd income income product rd income income dollarsinmillion sale sell expense expense expense sale sell expense expense expense theeffectsoffairvaluenetinvestment andcashflowhedge gainlossonfairvaluehedge relationship interestrateswapscontract hedgeditem derivativesdesignatedashedge instrument gainlossonnetinvestment hedgingrelationship crosscurrencyinterestrateswap contract amountofgainorlossrecognizedin incomeonderivativeamount excludedfromeffectivenessteste amountofgainorlossrecognizedin aoci gainlossoncashflowhedge relationship forwardforeignexchange contract amountofgainorlossreclassifie fromaociintoincome amountofgainorlossrecognizedin aoci crosscurrencyinterestrateswap contract amountofgainorlossreclassifie fromaociintoincome amountofgainorlossrecognizedin aoci includesequitycollarcontractstheequitycollarcontractsexpiredindecemberof forthefiscalyearsendeddecemberanddecemberthefollowingamountswererecordedonthe consolidatedbalancesheet cumulativeamountoffairvalue lineitemintheconsolidatedbalance hedgingadjustment sheetinwhichthehedgeditemis includedinthecarrying include carryingamountofthehedgedliability amountofthehedgedliability dollarsinmillion december december december december currentportionoflongtermdebt longtermdebt thefollowingtableistheeffectofderivativesnotdesignatedashedginginstrumentforthefiscalyearsende decemberanddecember locationofgainloss gainloss recognizedinincomeon recognizedin dollarsinmillion derivative incomeonderivative derivativesnotdesignatedashedginginstrument december december foreignexchangecontract otherincomeexpense johnsonjohnsonannualreportthefollowingtableistheeffectofnetinvestmenthedgesforthefiscalyearsendeddecemberand december gainloss gainloss locationofgainorlossreclassifie reclassifiedfrom recognizedin fromaccumulatedothercomprehensive accumulatedoci accumulatedoci incomeintoincome intoincome dollarsinmillion debt otherincomeexpense crosscurrencyinterestrateswap otherincomeexpense thecompanyadoptedasufinancialinstrumentsrecognitionandmeasurementoffinancialassetsand financialliabilitiesasofthebeginningofthefiscalyearthisasuamendspriorguidancetoclassifyequity investmentswithreadilydeterminablemarketvaluesintodifferentcategoriesthatistradingoravailableforsaleand requireequityinvestmentstobemeasuredatfairvaluewithchangesinfairvaluerecognizedthroughnetearningsthe companymadeacumulativeeffectadjustmenttotheopeningbalanceofretainedearningsuponadoptionofasu whichincreasedretainedearningsbymillionnetoftaxanddecreasedaccumulatedothercomprehensive incomeforpreviouslynetunrealizedgainsfromequityinvestment thecompanyholdsequityinvestmentswithreadilydeterminablefairvaluesandequityinvestmentswithoutreadily determinablefairvaluesthecompanyhaselectedtomeasureequityinvestmentsthatdonothavereadilydeterminable fairvaluesatcostminusimpairmentifanyplusorminuschangesresultingfromobservablepricechangesinorderly transactionsfortheidenticalorasimilarinvestmentofthesameissu thefollowingtableisasummaryoftheactivityrelatedtoequityinvestmentsasofdecember changesinfairvalue december december reflectedinnet sale noncurrentother dollarsinmillion carryingvalue income purchasesother carryingvalue asset equityinvestmentswithreadily determinablevalue equityinvestmentswithoutreadily determinablevalue recordedinotherincomeexpense otherincludesimpactofcurrency forequityinvestmentswithoutreadilydeterminablemarketvaluesmillionofthechangesinfairvaluereflectedinnet incomeweretheresultofimpairmentsthereweremillionofchangesinfairvaluereflectedinnetincomedueto changesinobservableprice forthefiscalyearsendeddecemberchangesinfairvaluereflectedwithinothercomprehensiveincomedueto previouslyunrealizedgainsonequityinvestmentswithreadilydeterminablefairvaluesnetoftaxwasanetgainof million fairvalueistheexitpricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbase measurementdeterminedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitythe authoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevel withinthehierarchyaredescribedbelowwithlevelhavingthehighestpriorityandlevelhavingthelow thefairvalueofaderivativefinancialinstrumentieforwardforeignexchangecontractsinterestratecontractsisthe aggregationbycurrencyofallfuturecashflowsdiscountedtoitspresentvalueattheprevailingmarketinterestratesand subsequentlyconvertedtotheusdollaratthecurrentspotforeignexchangeratethecompanydoesnotbelievethat fairvaluesofthesederivativeinstrumentsmateriallydifferfromtheamountsthatcouldberealizeduponsettlementor maturityorthatthechangesinfairvaluewillhaveamaterialeffectonthecompanysresultsofoperationscashflowsor financialpositionthecompanyalsoholdsequityinvestmentswhichareclassifiedaslevelanddebtsecuritieswhich areclassifiedaslevelthecompanydidnothaveanyothersignificantfinancialassetsorliabilitieswhichwouldrequire revisedvaluationsunderthisstandardthatarerecognizedatfairvalue johnsonjohnsonannualreport thefollowingthreelevelsofinputsareusedtomeasurefairvalue levelquotedpricesinactivemarketsforidenticalassetsandliabilitie levelsignificantotherobservableinput levelsignificantunobservableinput thecompanyssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofdecemberand decemberwereasfollow dollarsinmillion level level level total total derivativesdesignatedashedginginstrument asset forwardforeignexchangecontract interestratecontract total liability forwardforeignexchangecontract interestratecontract total derivativesnotdesignatedashedginginstrument asset forwardforeignexchangecontract liability forwardforeignexchangecontract availableforsaleotherinvestment equityinvestment debtsecuritie grosstonetderivativereconciliation dollarsinmillion totalgrossasset creditsupportagreementcsa totalnetasset totalgrossliabilitie creditsupportagreementcsa totalnetliabilitie assetsandliabilitiesareallclassifiedaslevelwiththeexceptionofequityinvestmentsofmillionwhichareclassifiedas level includesmillionandmillionofnoncurrentassetsforthefiscalyearsendingdecemberanddecember respectively includesmillionandmillionofnoncurrentliabilitiesforthefiscalyearsendingdecemberanddecember respectively includescrosscurrencyinterestrateswapsandinterestrateswaps classifiedasnoncurrentotherassetsthecarryingamountoftheequityinvestmentsweremillionandmillionasof decemberanddecemberrespectively classifiedascashequivalentsandcurrentmarketablesecuritie seenotesandforfinancialassetsandliabilitiesheldatcarryingamountontheconsolidatedbalancesheet johnsonjohnsonannualreport borrowing thecomponentsoflongtermdebtareasfollow effective effective dollarsinmillion rate rate debenturesdue notesdue notesduebeurobeuro notesdue notesdue notesdue zerocouponconvertiblesubordinateddebenturesdue debenturesdue notesdue notesdue notesdue notesdue notesduebeurobeuro notesdue debenturesdue notesdue notesdue notesduemmeurommeuro notesduemmgbpmmgbp notesdue notesdue notesdue notesduemmeurommeuro notesdue notesdue debenturesdue notesdue notesduebeurobeuro notesdue notesdue notesdue debenturesdue notesdue debenturesdue notesdue notesdue notesdue notesdue notesdue subtotal lesscurrentportion totallongtermdebt johnsonjohnsonannualreport weightedaverageeffectiverate translationrateatdecember translationrateatdecember theexcessofthefairvalueoverthecarryingvalueofdebtwasbillioninandbillionin fairvalueofthelongtermdebtwasestimatedusingmarketpriceswhichwerecorroboratedbyquotedbrokerpricesand significantotherobservableinputslevel thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementsisbasedoneitherbid providedbybankstheprimerateorlondoninterbankofferedratesliborplusapplicablemarginscommitmentfee undertheagreementsarenotmaterial throughoutthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarketshortterm borrowingsandthecurrentportionoflongtermdebtamountedtoapproximatelybillionattheendofofwhich billionisthecurrentportionofthelongtermdebtandtheremainderprincipallyrepresentslocalborrowingby internationalsubsidiarie throughoutthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarketshortterm borrowingsandthecurrentportionoflongtermdebtamountedtoapproximatelybillionattheendofofwhich billionwasborrowedunderthecommercialpaperprogrambillionisthecurrentportionofthelongtermdebt andtheremainderprincipallyrepresentslocalborrowingbyinternationalsubsidiarie aggregatematuritiesoflongtermobligationscommencinginare dollarsinmillion income taxis theprovisionfortaxesonincomeconsistsof dollarsinmillion currentlypayable ustaxe ustaxesoninternationaloperation internationaltaxe totalcurrentlypayable defer ustaxe ustaxesoninternationaloperation internationaltaxe totaldeferre provisionfortaxesonincome johnsonjohnsonannualreportacomparisonofincometaxexpenseattheusstatutoryrateofinandinandtothe companyseffectivetaxrateisasfollow dollarsinmillion international earningsbeforetaxesonincome taxrate usstatutoryrate internationaloperation researchandorphandrugtaxcredit usstateandlocal usmanufacturingdeduction ustaxoninternationalincome taxbenefitsonsharebasedcompensation ustaxbenefitonassetbusinessdisposal allother tcjaandrelatedimpact effectiverate forallperiodspresentedthecompanyhassubsidiariesoperatinginpuertoricoundervarioustaxincentivesinternational operationsreflectstheimpactsofoperationsinjurisdictionswithstatutorytaxratesdifferentthantheusparticularlyireland switzerlandandpuertoricowhichisafavorableimpactontheeffectivetaxrateascomparedwiththeusstatutoryratethe amountalsoincludestaxcostrelatedtotherevaluationofdeferredtaxbalancesrelatedtothechangeinthebelgianstatutorytaxrate increasingthetaxprovisionbyapproximately includestheimpactofthegiltitaxtheforeignderivedintangibleincomedeductionandotherforeignincomethatistaxableunder theustaxcode representsimpactofadjustmentstothetcjaprovisionaltaxchargethisalsoincludesanettaxbenefitfromthereductionof adeferredtaxliabilityrelatedtoforeignwithholdingtaxesoriginallyaccruedaspartoftheprovisionalchargethisbenefitreducedthe companyseffectivetaxratebyapproximatelyfurtherdescriptionisincludedbelow includesusstateandlocaltaxesprovisionallyrecordedasparttcjaprovisionalchargewhichwasapproximatelyofthetotal effectivetaxrate ondecembertheunitedstatesenactedintolawnewustaxlegislationthetaxcutsandjobsacttcja thislawincludedprovisionsforacomprehensiveoverhaulofthecorporateincometaxcodeincludingareductionofthe statutorycorporatetaxratefromtoeffectiveonjanuarythislegislationalsoeliminatedorreduced certaincorporateincometaxdeductionsaswellasintroducednewprovisionsthattaxedcertainforeignincomenot previouslytaxedbytheunitedstatesthetcjaalsoincludedaprovisionforataxonallpreviouslyundistributedearning ofuscompanieslocatedinforeignjurisdictionsundistributedearningsintheformofcashandcashequivalentswere taxedatarateofandallotherearningsaretaxedatarateofthistaxispayableoveryearsandwillnot accrueinterestandthesepaymentsbeganinandwillcontinuethroughtheremainingbalanceattheendof thefiscalyearwasapproximatelybillion indecemberthesecprovidedregulatoryguidanceforaccountingoftheimpactsofthetcjareferredtoassab undertheguidanceinsabtheincometaxeffectswhichtheaccountingunderascisincompleteare reportedasaprovisionalamountbasedonareasonableestimatethereasonableestimateissubjecttoadjustmentdure ameasurementperiodnottoexceedoneyearuntiltheaccountingiscompletetheestimateisalsosubjecttothe finalizationofmanagementsanalysisrelatedtocertainmatterssuchasdevelopinginterpretationsoftheprovisionofthe tcjachangestocertainestimatesandamountsrelatedtotheearningsandprofitsofcertainsubsidiariesandthefilingof taxreturn inthefourthquarterofthecompanyrecordedaprovisionaltaxcostofapproximatelybillionwhichconsiste primarilyofthefollowingcomponent abillionchargeonpreviouslyundistributedforeignearningsasofdecember johnsonjohnsonannualreport abilliondeferredtaxliabilityforforeignlocalandwithholdingtaxesoffsetbyabilliondeferredtaxassetfor usforeigntaxcreditsforrepatriationofsubstantiallyallthoseearning abilliontaxbenefitrelatingtotheremeasurementofusdeferredtaxassetsandliabilitiesandtheimpactofthe tcjaonunrecognizedtaxbenefit abillionchargeforusstateandlocaltaxesontherepatriationoftheseforeignearning duringthefourthquarterofthecompanycompleteditsfullassessmentandfinalizedtheaccountingfortheimpact oftcjathecompanyrecordednetadjustmentstotheabovecomponentsoftheprovisionalchargeofapproximately billiontheserevisionswerebasedonupdatedestimatesandadditionalanalysisbymanagementaswellasapplye interpretativeguidanceissuedbytheusdepartmentoftreasurytothefactsandcircumstancesthatexistedasofthe tcjaenactmentdatethischargewasprimarilyrelatedtoadditionaldeferredtaxliabilitiesforforeignlocaland withholdingtaxesfortheremainingbalanceofundistributedforeignearningsasofdecemberthatwerenot providedforintheprovisionalchargeinthefourthquarterof thetcjaalsoincludesprovisionsforataxonglobalintangiblelowtaxedincomegiltigiltiisdescribedasthe excessofausshareholderstotalnetforeignincomeoveradeemedreturnontangibleassetsasprovidedbythetcja injanuarythefasbissuedguidancethatallowscompaniestoelectasanaccountingpolicywhethertorecordthe taxeffectsofgiltiintheperiodthetaxliabilityisgeneratedieperiodcostorprovidefordeferredtaxassetsand liabilitiesrelatedtobasisdifferencesthatexistandareexpectedtoeffecttheamountofgiltiinclusioninfutureyear uponreversaliedeferredmethodthroughthethirdfiscalquarterofthecompanyhadprovisionallyelectedto treatgiltiasaperiodexpenseuponfurtheranalysisofthisnewtaxprovisionthecompanyhaselectedtoaccountfor giltiunderthedeferredmethodthedeferredtaxamountsrecordedarebasedontheevaluationoftemporary differencesthatareexpectedtoreverseasgiltiisincurredasaresultofthiselectionthecompanyrecordedadeferre taxcostrelatedtogiltiofapproximatelybillioninthefourthfiscalquarterofrelatedtofactsand circumstancesthatexistedonthedateoftcjaenactment asaresultofthegiltideferredtaxchargeandtheotheradjustmentstotheprovisionalamountthecompanyrecordeda totalofbillionofadjustmentstotheprovisionalchargeincreasingthecompanysannualeffectivetaxrateby approximately duringthecompanyreorganizedtheownershipstructureofcertainforeignsubsidiarieswhichresultedina reductionofcertainforeignwithholdingtaxesthatithadrecognizedaspartoftheprovisionaltcjataxchargeinthefourth quarteroffollowingthecompletionofthisrestructuringinthefourthquarterandasaresultofclarificationby swisstaxauthoritiesregardingtheapplicabilityofwithholdingtaxtorepatriationofcertainearningsthecompany reversedadeferredtaxliabilityofbillionandarelateddeferredtaxassetofbillionforusforeigntaxcreditsfor anetdeferredtaxbenefitofbillionasthisrestructuringoccurredafterthetcjaenactmentdatethebenefitisnot consideredanadjustmenttotheprovisionalamountrecordedinundersabthisbenefitwiththesab adjustmentshasbeenreflectedastcjaandrelatedimpactsonthecompanyseffectivetaxratereconciliation asdescribedinnotetotheconsolidatedfinancialstatementsinthecompanyadoptedasuincome taxesintraentitytransfersofassetsotherthaninventorythisstandardrequiresentitiestorecognizedeferredtaxasset andliabilitiesrelatedtotransferofassetsotherthaninventorywithintheconsolidatedentityatthebeginningoffiscal thecompanyrecordedanetadjustmenttodeferredtaxassetsofapproximatelybillioninthefourthquarterof asaresultoftheelectiontorecordgiltionthedeferredmethodthecompanyrecordedagiltideferredtax liabilityofbillionrelatedtotheadoptionprovisionsofasuasanadjustmenttoretainedearning theeffectivetaxratedecreasedbycomparedtotheeffectivetaxratewasprimarilydrivenbythe approximatelybillionprovisionaltaxchargerecordedinthefourthquarterofandtheimpactofabelgianstatutory taxratechangewhichincreasedtheeffectiveratebyadditionaldriversoftheannualeffectivetaxwere thereductionoftheusstatutorycorporatetaxrateincludingtheeffectsoftaxelectionswhichresultedinthe accelerationofcertaindeductionsintothetaxreturntheimpactoftheseaccelerateddeductionsdecreasedthe annualeffectivetaxratebyapproximately theimpactoftheadjustmentstotheprovisionaltcjachargeincludingbothsabadjustmentsandthe internalrestructuringdecreasedtheeffectivetaxratebyapproximately giltitaxwhichincreasedtheannualeffectivetaxratebyapproximatelywhichexcludestheimpactofthesab adjustmentfortheadoptionofthedeferredmethodforgilti taxbenefitsreceivedfromstockbasedcompensationduringfiscalandreducedtheeffectivetaxrateby andrespectively johnsonjohnsonannualreport inthefourthquarterofthecompanycompletedthedivestitureofitslifescanbusinessnotewhich increasedthecompanyannualeffectivetaxratebyapproximately moreincomeinhighertaxjurisdictionsrelativetolowertaxjurisdictionsascomparedto theeffectivetaxrateincreasedbyascomparedtoprimarilydrivenbytheenactmentofthetcjain theusindecembertheenactmentofthetcjaresultedinaprovisionaltaxchargeinthefourthquarterof ofapproximatelybillionorapproximatelypercentagepointincreasetotheeffectivetaxrate theremainderoftheincreaseinthetaxrateforwasrelatedtotheremeasurementofthecompanysdeferredtax assetsinbelgiumasaresultofchangesinthebelgianstatutorycorporatetaxrateenactedindecemberoffsetby ataxbenefitfortheclosureofthecompanysanimasinsulinpumpbusiness temporarydifferencesandcarryforwardsforandwereasfollow deferredtax deferredtax dollarsinmillion asset liability asset liability employeerelatedobligation stockbasedcompensation depreciationamortization nondeductibleintangible internationalrdcapitalizedfortax reservesliabilitie incomereportedfortaxpurpose netoperatinglosscarryforwardinternational undistributedforeignearning globalintangiblelowtaxedincome miscellaneousinternational miscellaneousus totaldeferredincometaxe thecompanyhaswhollyownedinternationalsubsidiariesthathavecumulativenetlossesthecompanybelievesthatitis morelikelythannotthatthesesubsidiarieswillgeneratefuturetaxableincomesufficienttoutilizethesedeferredtaxasset thefollowingtablesummarizestheactivityrelatedtounrecognizedtaxbenefit dollarsinmillion beginningofyear increasesrelatedtocurrentyeartaxposition increasesrelatedtopriorperiodtaxposition decreasesrelatedtopriorperiodtaxposition settlement lapseofstatuteoflimitation endofyear inmillionofthisdecreaseisrelatedtothetcja theunrecognizedtaxbenefitsofbillionatdecemberifrecognizedwouldaffectthecompanysannual effectivetaxratethecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxaudit inprogresswithanumberoftaxauthoritiestheirshascompleteditsauditforthetaxyearsthroughandis currentlyauditingthetaxyearsthecompanycurrentlyexpectscompletionofthisauditduringfinal conclusionofthetaxauditmayresultinanoutcomethatisdifferentthanthecompanysestimatesandmayresultina materialimpactonthecompanyscurrentandfutureoperatingresultsorcashflowsintheperiodthattheauditis concludedinothermajorjurisdictionswherethecompanyconductsbusinesstheyearsthatremainopentotaxauditgo johnsonjohnsonannualreport backtotheyearthecompanybelievesitispossiblethatauditsmaybecompletedbytaxauthoritiesinsome jurisdictionsoverthenexttwelvemonthshoweverthecompanyisnotabletoprovideareasonablyreliableestimateof thetimingofanyotherfuturetaxpaymentsrelatingtouncertaintaxposition thecompanyclassifiesliabilitiesforunrecognizedtaxbenefitsandrelatedinterestandpenaltiesaslongtermliabilitie interestexpenseandpenaltiesrelatedtounrecognizedtaxbenefitsareclassifiedasincometaxexpensethecompany recognizedaftertaxinterestexpenseofmillionmillionandmillioninandrespectivelythe totalamountofaccruedinterestwasmillionandmillioninandrespectively employee relate obligation attheendofandemployeerelatedobligationsrecordedontheconsolidatedbalancesheetswere dollarsinmillion pensionbenefit postretirementbenefit postemploymentbenefit deferredcompensation totalemployeeobligation lesscurrentbenefitspayable employeerelatedobligationsnoncurrent prepaidemployeerelatedobligationsofmillionandmillionforandrespectivelyareincludedin otherassetsontheconsolidatedbalancesheet pension benefit plan thecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefitdefinedcontributionand terminationindemnityplanswhichcovermostemployeesworldwidethecompanyalsoprovidespostretirement benefitsprimarilyhealthcaretoalleligibleusretiredemployeesandtheirdependent manyinternationalemployeesarecoveredbygovernmentsponsoredprogramsandthecosttothecompanyisnot significant retirementplanbenefitsforemployeeshiredbeforejanuaryareprimarilybasedontheemployeescompensation duringthelastthreetofiveyearsbeforeretirementandthenumberofyearsofserviceinthecompanyannounce thattheusdefinedbenefitplanwasamendedtoadoptanewbenefitformulaeffectiveforemployeeshiredonorafter januarythebenefitsarecalculatedusinganewformulabasedonemployeecompensationovertotalyearsof service internationalsubsidiarieshaveplansunderwhichfundsaredepositedwithtrusteesannuitiesarepurchasedundergroup contractsorreservesareprovide thecompanydoesnottypicallyfundretireehealthcarebenefitsinadvancebutmaydosoatitsdiscretionthecompany alsohastherighttomodifytheseplansinthefuture inandthecompanyuseddecemberanddecemberrespectivelyasthemeasurement dateforallusandinternationalretirementandotherbenefitplans johnsonjohnsonannualreportnetperiodicbenefitcostsforthecompanysdefinedbenefitretirementplansandotherbenefitplansforand includethefollowingcomponent retirementplan otherbenefitplan dollarsinmillion servicecost interestcost expectedreturnonplanasset amortizationofpriorservicecostcredit recognizedactuariallosse curtailmentsandsettlement netperiodicbenefitcost inaspertheadoptionofasutheservicecostcomponentofnetperiodicbenefitcostwaspresentedin thesamelineitemsontheconsolidatedstatementofearningswhereotheremployeecompensationcostsarereporte allothercomponentsofnetperiodicbenefitcostarepresentedaspartofotherincomeexpensenetonthe consolidatedstatementofearning amountsexpectedtoberecognizedinnetperiodicbenefitcostinthecomingyearforthecompanysdefinedbenefit retirementplansandotherpostretirementplans dollarsinmillion amortizationofnettransitionobligation amortizationofnetactuariallosse amortizationofpriorservicecredit unrecognizedgainsandlossesfortheuspensionplansareamortizedovertheaverageremainingfutureserviceforeach planforplanswithnoactiveemployeestheyareamortizedovertheaveragelifeexpectancytheamortizationofgain andlossesfortheotherusbenefitplansisdeterminedbyusingacorridorofthegreaterofthemarketvalueof assetsortheaccumulatedpostretirementbenefitobligationtotalunamortizedgainsandlossesinexcessofthecorridor areamortizedovertheaverageremainingfutureservice priorservicecostsbenefitsfortheuspensionplansareamortizedovertheaverageremainingfutureserviceofplan participantsatthetimeoftheplanamendmentpriorservicecostbenefitfortheotherusbenefitplansisamortizedover theaverageremainingservicetofulleligibilityageofplanparticipantsatthetimeoftheplanamendment thefollowingtablerepresentstheweightedaverageactuarialassumption retirementplan otherbenefitplan worldwidebenefitplan netperiodicbenefitcost servicecostdiscountrate interestcostdiscountrate rateofincreaseincompensationlevel expectedlongtermrateofreturnonplanasset benefitobligation discountrate rateofincreaseincompensationlevel thecompanysdiscountratesaredeterminedbyconsideringcurrentyieldcurvesrepresentinghighqualitylongterm fixedincomeinstrumentstheresultingdiscountratesareconsistentwiththedurationofplanliabilitiesinthefiscalyear thecompanychangeditsmethodologyindeterminingserviceandinterestcostfromthesingleweightedaverage discountrateapproachtodurationspecificspotratesalongthatyieldcurvetotheplansliabilitycashflowswhich managementhasconcludedisamorepreciseestimatepriortothischangeinmethodologythecompanymeasure johnsonjohnsonannualreport serviceandinterestcostsutilizingasingleweightedaveragediscountratederivedfromtheyieldcurveusedtomeasure theplanobligationsthecompanyhasaccountedforthischangeasachangeinaccountingestimateandaccordingly hasaccountedforitonaprospectivebasisthischangedoesnotimpactthebenefitobligationanddidnothavea materialimpacttothefullyearresult theexpectedratesofreturnonplanassetassumptionsrepresentthecompanysassessmentoflongtermreturnson diversifiedinvestmentportfoliosgloballytheassessmentisdeterminedusingprojectionsfromexternalfinancialsource longtermhistoricalaveragesactualreturnsbyassetclassandthevariousassetclassallocationsbymarket thefollowingtabledisplaystheassumedhealthcarecosttrendratesforallindividual healthcareplan healthcarecosttrendrateassumedfornextyear ratetowhichthecosttrendrateisassumedtodeclineultimatetrend yeartheratereachestheultimatetrendrate aonepercentagepointchangeinassumedhealthcarecosttrendrateswouldhavethefollowingeffect onepercentage onepercentage dollarsinmillion pointincrease pointdecrease healthcareplan totalinterestandservicecost postretirementbenefitobligation johnsonjohnsonannualreportthefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatyearend andforthecompanysdefinedbenefitretirementplansandotherpostretirementplan otherbenefit retirementplan plan dollarsinmillion changeinbenefitobligation projectedbenefitobligationbeginningofyear servicecost interestcost planparticipantcontribution amendment actuarialgainslosse divestituresacquisition curtailmentssettlementsrestructure benefitspaidfromplan effectofexchangerate projectedbenefitobligationendofyear changeinplanasset planassetsatfairvaluebeginningofyear actualreturnonplanasset companycontribution planparticipantcontribution settlement divestituresacquisition benefitspaidfromplanasset effectofexchangerate planassetsatfairvalueendofyear fundedstatusendofyear amountsrecognizedinthecompanysbalancesheetconsistofthefollowe noncurrentasset currentliabilitie noncurrentliabilitie totalrecognizedintheconsolidatedbalancesheetendofyear amountsrecognizedinaccumulatedothercomprehensiveincomeconsistof thefollowe netactuarialloss priorservicecostcredit unrecognizednettransitionobligation totalbeforetaxeffect accumulatedbenefitobligationsendofyear johnsonjohnsonannualreport otherbenefit retirementplan plan dollarsinmillion amountsrecognizedinnetperiodicbenefitcostandothercomprehensive income netperiodicbenefitcost netactuarialgainloss amortizationofnetactuarialloss priorservicecostcredit amortizationofpriorservicecostcredit effectofexchangerate totallossincomerecognizedinothercomprehensiveincomebeforetax totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome thecompanyplanstocontinuetofunditsusqualifiedplanstocomplywiththepensionprotectionactof internationalplansarefundedinaccordancewithlocalregulationsadditionaldiscretionarycontributionsaremadewhen deemedappropriatetomeetthelongtermobligationsoftheplansforcertainplansfundingisnotacommonpracticea fundingprovidesnoeconomicbenefitconsequentlythecompanyhasseveralpensionplansthatarenotfunde inthecompanycontributedmillionandmilliontoitsusandinternationalpensionplansrespectively thefollowingtabledisplaysthefundedstatusofthecompanysusqualifiednonqualifiedpensionplansand internationalfundedandunfundedpensionplansatdecemberanddecemberrespectively usplans internationalplans qualifiedplan nonqualifiedplans fundedplan unfundedplan dollarsinmillion planasset projectedbenefitobligation accumulatedbenefitobligation overunderfundedstatus projectedbenefitobligation accumulatedbenefitobligation planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligationprojected benefitobligationandplanassetsofbillionbillionandbillionrespectivelyattheendofand billionbillionandbillionrespectivelyattheendof thefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromthecompanysretirementandotherbenefitplan dollarsinmillion projectedfuturebenefitpayment retirementplan otherbenefitplan thefollowingtabledisplaystheprojectedfutureminimumcontributionstotheunfundedretirementplanstheseamount donotincludeanydiscretionarycontributionsthatthecompanymayelecttomakeinthefuture dollarsinmillion projectedfuturecontribution eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationand investmentofthepensionplansindetermininginvestmentpoliciesstrategiesandgoalseachcommitteeorboard johnsonjohnsonannualreportconsidersfactorsincludinglocalpensionrulesandregulationslocaltaxregulationsavailabilityofinvestmentvehicles separateaccountscommingledaccountsinsurancefundsetcfundedstatusoftheplansratioofactivestoretiree durationofliabilitiesandotherrelevantfactorsincludingdiversificationliquidityoflocalmarketsandliquidityofbase currencyamajorityofthecompanyspensionfundsareopentonewentrantsandareexpectedtobeongoingplan permittedinvestmentsareprimarilyliquidandorlistedwithlittlerelianceonilliquidandnontraditionalinvestmentssuch ashedgefund thecompanysretirementplanassetallocationattheendofandandtargetallocationsforareas follow percentof target planasset allocation worldwideretirementplan equitysecuritie debtsecuritie totalplanasset determinationoffairvalueofplanasset theplanhasanestablishedandwelldocumentedprocessfordeterminingfairvaluesfairvalueisbaseduponquote marketpriceswhereavailableiflistedpricesorquotesarenotavailablefairvalueisbaseduponmodelsthatprimarily useasinputsmarketbasedorindependentlysourcedmarketparametersincludingyieldcurvesinterestratesvolatilitie equityordebtpricesforeignexchangeratesandcreditcurve whiletheplanbelievesitsvaluationmethodsareappropriateandconsistentwithothermarketparticipantstheuseof differentmethodologiesorassumptionstodeterminethefairvalueofcertainfinancialinstrumentscouldresultinadifferent estimateoffairvalueatthereportingdate valuationhierarchy theauthoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevel withinthehierarchyaredescribedinthetablebelowwithlevelhavingthehighestpriorityandlevelhavingthelowest afinancialinstrumentscategorizationwithinthevaluationhierarchyisbaseduponthelowestlevelofinputthatis significanttothefairvaluemeasurement followingisadescriptionofthevaluationmethodologiesusedfortheinvestmentsmeasuredatfairvalue shortterminvestmentfundscashandquotedshortterminstrumentsarevaluedattheclosingpriceortheamount heldondepositbythecustodianbankotherinvestmentsarethroughinvestmentvehiclesvaluedusingthenetasset valuenavprovidedbytheadministratorofthefundthenavisbasedonthevalueoftheunderlyingassetsowne bythefundminusitsliabilitiesandthendividedbythenumberofsharesoutstandingthenavisaquotedpriceina marketthatisnotactiveandclassifiedaslevel governmentandagencysecuritiesalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedon themajormarketonwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarket theinvestmentsareclassifiedwithinlevelofthevaluationhierarchyifquotedmarketpricesarenotavailableforthe specificsecuritythenfairvaluesareestimatedbyusingpricingmodelsquotedpricesofsecuritieswithsimilar characteristicsordiscountedcashflowswhenquotedmarketpricesforasecurityarenotavailableinanactivemarket theyareclassifiedaslevel debtinstrumentsalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedonthemajormarket onwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarkettheinvestmentsare classifiedaslevelifquotedmarketpricesarenotavailableforthespecificsecuritythenfairvaluesareestimatedby usingpricingmodelsquotedpricesofsecuritieswithsimilarcharacteristicsordiscountedcashflowsandareclassifie aslevelleveldebtinstrumentsarepricedbasedonunobservableinput equitysecuritiesequitysecuritiesarevaluedattheclosingpricereportedonthemajormarketonwhichtheindividual securitiesaretradedsubstantiallyallcommonstockisclassifiedwithinlevelofthevaluationhierarchy johnsonjohnsonannualreport commingledfundstheseinvestmentvehiclesarevaluedusingthenavprovidedbythefundadministratorthenav isbasedonthevalueoftheunderlyingassetsownedbythefundminusitsliabilitiesandthendividedbythenumberof sharesoutstandingassetsinthelevelcategoryhaveaquotedmarketprice insurancecontractstheinstrumentsareissuedbyinsurancecompaniesthefairvalueisbasedonnegotiatedvalue andtheunderlyinginvestmentsheldinseparateaccountportfoliosaswellasconsideringthecreditworthinessofthe issuertheunderlyinginvestmentsaregovernmentassetbackedandfixedincomesecuritiesingeneralinsurance contractsareclassifiedaslevelastherearenoquotedpricesnorotherobservableinputsforprice otherassetsotherassetsarerepresentedprimarilybylimitedpartnershipsandrealestateinvestmentsaswellas commercialloansandcommercialmortgagesthatarenotclassifiedascorporatedebtotherassetsthatareexchange listedandactivelytradedareclassifiedaslevelwhileinactivelytradedassetsareclassifiedaslevel thefollowingtablesetsforththeretirementplansinvestmentsmeasuredatfairvalueasofdecemberand december quotedprice significant inactive significant investment marketsfor observable unobservable measuredat identicalasset input inputsa netasset level level level value totalasset dollarsinmillion shortterminvestmentfund governmentandagencysecuritie debtinstrument equitysecuritie commingledfund insurancecontract otherasset investmentsatfairvalue theactivityforthelevelassetsisnotsignificantforallyearspresente thecompanysotherbenefitplansareunfundedexceptforuscommingledfundslevelofmillionand millionandusshortterminvestmentfundslevelofmillionandmillionatdecemberand decemberrespectively thefairvalueofjohnsonjohnsoncommonstockdirectlyheldinplanassetswasmillionoftotalplan assetsatdecemberandmillionoftotalplanassetsatdecember saving plan thecompanyhasvoluntaryksavingsplansdesignedtoenhancetheexistingretirementprogramscoveringeligible employeesthecompanymatchesapercentageofeachemployeescontributionsconsistentwiththeprovisionsofthe planforwhichhesheiseligibletotalcompanymatchingcontributionstotheplansweremillionmillionand millioninandrespectively johnsonjohnsonannualreport capital treasury stock changesintreasurystockwere treasurystock amountsinmillionsexcepttreasurystocksharesinthousand share balanceatjanuary employeecompensationandstockoptionplans repurchaseofcommonstock balanceatjanuary employeecompensationandstockoptionplans repurchaseofcommonstock balanceatdecember employeecompensationandstockoptionplans repurchaseofcommonstock balanceatdecember aggregatesharesofcommonstockissuedwereapproximatelysharesattheendofand cashdividendspaidwerepershareincomparedwithdividendsofpershareinandper sharein ondecemberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyssharesofcommonstocktherepurchase programhasnotimelimitandmaybesuspendedforperiodsordiscontinuedatanytimeanysharesacquiredwillbe availableforgeneralcorporatepurposesthecompanyintendstofinancethesharerepurchaseprogramthroughavailable cashasofdecemberbillionhasbeenrepurchasedundertheprogram onoctoberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyssharesofcommonstockthisshare repurchaseprogramwascompletedasofjuly accumulate comprehensive income loss componentsofothercomprehensiveincomelossconsistofthefollowe total gainloss accumulate foreign gainloss employee currency benefit derivative comprehensive dollarsinmillion translation security plan hedge incomeloss january netchange january netchange december cumulativeadjustmenttoretainedearning netchange december seenotetoconsolidatedfinancialstatementsforadditionaldetailsontheadoptionofasu amountsinaccumulatedothercomprehensiveincomearepresentednetoftherelatedtaximpactforeigncurrency translationisnotadjustedforincometaxeswhereitrelatestopermanentinvestmentsininternationalsubsidiariesfor additionaldetailsoncomprehensiveincomeseetheconsolidatedstatementsofcomprehensiveincome johnsonjohnsonannualreport detailsonreclassificationsoutofaccumulatedothercomprehensiveincome gainlossonsecuritiesreclassificationsreleasedtootherincomeexpensenet employeebenefitplansreclassificationsareincludedinnetperiodicbenefitcostseenoteforadditional detail gainlossonderivativeshedgesreclassificationstoearningsarerecordedinthesameaccountasthe hedgedtransactionseenoteforadditionaldetail international currency translation fortranslationofitssubsidiariesoperatinginnonusdollarcurrenciesthecompanyhasdeterminedthatthelocal currenciesofitsinternationalsubsidiariesarethefunctionalcurrenciesexceptthoseinhighlyinflationaryeconomieswhich aredefinedasthosewhichhavehadcompoundcumulativeratesofinflationoformoreduringthepastthreeyear orwhereasubstantialportionofitscashflowsarenotinthelocalcurrencybeginninginthefiscalthirdquarterof thecompanyaccountedforoperationsinargentinaashighlyinflationaryforthemajorityofthecompanyssubsidiaries thelocalcurrencyisthefunctionalcurrency inconsolidatinginternationalsubsidiariesbalancesheetcurrencyeffectsarerecordedasacomponentofaccumulate othercomprehensiveincomethisequityaccountincludestheresultsoftranslatingcertainbalancesheetassetsand liabilitiesatcurrentexchangeratesandsomeaccountsathistoricalratesexceptforthoselocatedinhighlyinflationary economiesthetranslationofbalancesheetaccountsforhighlyinflationaryeconomiesarereflectedintheoperate result arollforwardofthechangesduringandforforeigncurrencytranslationadjustmentsisincludedin note netcurrencytransactiongainsandlossesincludedinotherincomeexpensewerelossesofmillionmillion andmillioninandrespectively earning share thefollowingisareconciliationofbasicnetearningspersharetodilutednetearningspershareforthefiscalyearsende decemberdecemberandjanuary inmillionsexceptpershareamount basicnetearningspershare averagesharesoutstandingbasic potentialsharesexercisableunderstockoptionplan lesssharesrepurchasedundertreasurystockmethod convertibledebtshare adjustedaveragesharesoutstandingdilute dilutednetearningspershare thedilutednetearningspersharecalculationincludedthedilutiveeffectofconvertibledebtthatisoffsetbytherelate reductionininterestexpenseofmillionaftertaxforandandmillionfor thedilutednetearningspersharecalculationforandincludedallsharesrelatedtostockoptionsas theexercisepriceofalloptionswaslessthantheaveragemarketvalueofthecompanysstock rental expense lease commitment rentalsofspacevehiclesmanufacturingequipmentandofficeanddataprocessingequipmentunderoperatinglease wereapproximatelymillionmillionandmillioninandrespectively johnsonjohnsonannualreporttheapproximateminimumrentalpaymentsrequiredunderoperatingleasesthathaveinitialorremainingnoncancelable leasetermsinexcessofoneyearatdecemberare dollarsinmillion total commitmentsundercapitalleasesarenotsignificant common stock stock option plan stock compensation agreement atdecemberthecompanyhadstockbasedcompensationplansthesharesoutstandingareforcontract underthecompanyslongtermincentiveplanandthelongtermincentiveplanthelongterm incentiveplanexpiredaprilalloptionsandrestrictedsharesgrantedsubsequenttothatdatewereunderthe longtermincentiveplanunderthelongtermincentiveplanthecompanymayissueuptomillion sharesofcommonstockplusanysharescanceledexpiredforfeitedornotissuedfromthelongtermincentive plansubsequenttoaprilsharesavailableforfuturegrantsunderthelongtermincentiveplanwere millionattheendof thecompensationcostthathasbeenchargedagainstincomefortheseplanswasmillionmillionand millionforandrespectivelythetotalincometaxbenefitrecognizedintheincomestatementfor sharebasedcompensationcostswasmillionmillionandmillionforand respectivelyanadditionaltaxbenefitofmillionwasrecognizedinduetotheadoptionofanewaccounte standardforthereportingofadditionaltaxbenefitsonsharebasedcompensationthetotalunrecognizedcompensation costwasmillionmillionandmillionforandrespectivelytheweightedaverage periodforthiscosttoberecognizedwasyearsyearsandyearsforandrespectively sharebasedcompensationcostscapitalizedaspartofinventorywereinsignificantinallperiod thecompanysettlesemployeebenefitequityissuanceswithtreasurysharestreasurysharesarereplenishedthroughout theyearforthenumberofsharesusedtosettleemployeebenefitequityissuance stockoption stockoptionsexpireyearsfromthedateofgrantandvestoverserviceperiodsthatrangefrommonthstoyearsall optionsaregrantedattheaverageofthehighandlowpricesofthecompanyscommonstockonthenewyorkstock exchangeonthedateofgrant thefairvalueofeachoptionawardwasestimatedonthedateofgrantusingtheblackscholesoptionvaluationmodel thatusestheassumptionsnotedinthefollowingtableforandgrantsexpectedvolatilityrepresentsa blendedrateofyearweeklyhistoricaloverallvolatilityrateandaweekaverageimpliedvolatilityratebasedon atthemoneytradedjohnsonjohnsonoptionswithalifeofyearsforallgrantshistoricaldataisusedtodetermine theexpectedlifeoftheoptiontheriskfreeratewasbasedontheustreasuryyieldcurveineffectatthetimeofgrant theaveragefairvalueofoptionsgrantedwasandinandrespectivelythe fairvaluewasestimatedbasedontheweightedaverageassumptionsof riskfreerate expectedvolatility expectedlifeinyear expecteddividendyield johnsonjohnsonannualreport asummaryofoptionactivityundertheplanasofdecemberdecemberandjanuaryand changesduringtheyearsendingonthosedatesispresentedbelow aggregate intrinsic weight value outstanding average dollarsin sharesinthousand share exerciseprice millions sharesatjanuary optionsgrante optionsexercised optionscanceledforfeite sharesatjanuary optionsgrante optionsexercised optionscanceledforfeite sharesatdecember optionsgrante optionsexercised optionscanceledforfeite sharesatdecember thetotalintrinsicvalueofoptionsexercisedwasmillionmillionandmillioninand respectively thefollowingtablesummarizesstockoptionsoutstandingandexercisableatdecember sharesinthousand outstanding exercisable average average average exercise exercise exercisepricerange option life price option price averagecontractualliferemaininginyear stockoptionsoutstandingatdecemberandjanuarywereandanaveragelifeofyearsand andanaveragelifeofyearsrespectivelystockoptionsexercisableatdecemberandjanuary wereatanaveragepriceofandatanaveragepriceofrespectively restrictedshareunitsandperformance shareunit thecompanygrantsrestrictedshareunitswhichvestoverserviceperiodsthatrangefrommonthstoyearsthe companyalsograntsperformanceshareunitswhicharepaidinsharesofjohnsonjohnsoncommonstockafterthe endofathreeyearperformanceperiodwhetheranyperformanceshareunitsvestandtheamountthatdoesvestistied tothecompletionofserviceperiodsthatrangefrommonthstoyearsandtheachievementoverathreeyearperiod ofthreeequallyweightedgoalsthatdirectlyalignwithorhelpdrivelongtermtotalshareholderreturnoperationalsales adjustedoperationalearningspershareandrelativetotalshareholderreturnthenumberofsharesactuallyearnedatthe endofthethreeyearperiodwillvarybasedonlyonactualperformancefromtoofthetargetnumberof performanceshareunitsgrantedinthefourthquarterofthecompanymodifiedtherestrictedshareunitsthatare scheduledtovestbetweenjanuaryandmarchthismodificationguaranteedaminimumaggregate johnsonjohnsonannualreportvaluebelowthemarketvalueofthetotalexpectedpayoutamountforallawardsexpectedtovestduringthisperiodthe amountthatwascommittedwasnotmaterialtothecompanysoverallfinancialposition asummaryoftherestrictedshareunitsandperformanceshareunitsactivityundertheplansasofdecemberis presentedbelow outstanding outstanding restricted performance sharesinthousand shareunit shareunit sharesatdecember grant issue canceledforfeitedadjuste sharesatdecember theaveragefairvalueoftherestrictedshareunitsgrantedwasandinand respectivelyusingthefairmarketvalueatthedateofgrantthefairvalueofrestrictedshareunitswasdiscountedfor dividendswhicharenotpaidontherestrictedshareunitsduringthevestingperiodthefairvalueofrestrictedshareunit issuedwasmillionmillionandmillioninandrespectively theweightedaveragefairvalueoftheperformanceshareunitsgrantedwasandin andcalculatedusingtheweightedaveragefairmarketvalueforeachofthethreecomponentgoalsatthe dateofgrant thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedonthedateof grantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividendswhicharenotpaidonthe performanceshareunitsduringthevestingperiodthefairvaluefortherelativetotalshareholderreturngoalofeach performanceshareunitwasestimatedonthedateofgrantusingthemontecarlovaluationmodelthefairvalueof performanceshareunitsissuedwasmillionmillionandmillioninand respectively johnsonjohnsonannualreport segment business geographic area salestocustomer change dollarsinmillion vs vs consumer babycare international worldwide beauty international worldwide oralcare international worldwide otc international worldwide womenshealth international worldwide woundcareother international worldwide totalconsumer international worldwide pharmaceutical immunology international worldwide remicade usexport international worldwide simponisimponiaria international johnsonjohnsonannualreportsalestocustomer change dollarsinmillion vs vs worldwide stelara international worldwide tremfaya international worldwide otherimmunology international worldwide infectiousdisease international worldwide edurantrilpivirine international worldwide prezistaprezcobixrezolstasymtuza international worldwide otherinfectiousdisease international worldwide neuroscience international worldwide concertamethylphenidate international worldwide invegasustennaxeplioninvegatrinza trevicta international worldwide johnsonjohnsonannualreport salestocustomer change dollarsinmillion vs vs risperdalconsta international worldwide otherneuroscience international worldwide oncology international worldwide darzalex international worldwide imbruvica international worldwide velcade international worldwide zytigaabirateroneacetate international worldwide otheroncology international worldwide pulmonaryhypertension international worldwide opsumit international worldwide tracleer international johnsonjohnsonannualreportsalestocustomer change dollarsinmillion vs vs worldwide uptravi international worldwide international worldwide cardiovascularmetabolismother international worldwide xarelto international worldwide invokanainvokamet international worldwide procriteprex international worldwide international worldwide totalpharmaceutical international worldwide medicaldevice diabetescare international worldwide diagnostic international worldwide johnsonjohnsonannualreport salestocustomer change dollarsinmillion vs vs interventionalsolution international worldwide orthopaedic international worldwide hip international worldwide knee international worldwide trauma international worldwide spineother international worldwide surgery international worldwide advance international worldwide general international worldwide specialty international worldwide johnsonjohnsonannualreportsalestocustomer change dollarsinmillion vs vs vision international worldwide contactlensesother international worldwide surgical international worldwide totalmedicaldevice international worldwide worldwide international worldwide percentagegreaterthanornotmeaningful incomebeforetax identifiableasset dollarsinmillion consumer pharmaceutical medicaldevice total lessexpensenotallocatedtosegment generalcorporate worldwidetotal additionstoproperty depreciationand plantequipment amortization dollarsinmillion consumer pharmaceutical medicaldevice segmentstotal generalcorporate worldwidetotal johnsonjohnsonannualreport salestocustomer longlivedasset dollarsinmillion unitedstate europe westernhemisphereexcludingus asiapacificafrica segmentstotal generalcorporate othernonlonglivedasset worldwidetotal seenoteforadescriptionofthesegmentsinwhichthecompanyoperate exportsalesarenotsignificantinthecompanyhadthreewholesalersdistributingproductsforallthreesegment thatrepresentedapproximatelyandofthetotalconsolidatedrevenuesinthecompanyhad twowholesalersdistributingproductsforallthreesegmentsthatrepresentedapproximatelyandofthetotal consolidatedrevenuesinthecompanyhadtwowholesalersdistributingproductsforallthreesegmentsthat representedapproximatelyandofthetotalconsolidatedrevenue amountsnotallocatedtosegmentsincludeinterestincomeexpenseandgeneralcorporateincomeexpense generalcorporateincludescashcashequivalentsandmarketablesecuritie theconsumersegmentincludesagainofbillionfromthedivestitureofnizoralandlitigationexpenseofbillionthe pharmaceuticalsegmentincludesaninprocessresearchanddevelopmentchargeofbillionrelatedtothealiosandxo assetsandthecorrespondingxocontingentliabilityreversalofbillionactelionacquisitionrelatedcostsofbillion unrealizedlossonsecuritiesofbillionandagainofbillionfromthedivestitureofcertainnonstrategicpharmaceutical productsthemedicaldevicessegmentincludesnetlitigationexpenseofbillionarestructuringrelatedchargeofbillion amoacquisitionrelatedcostsofbillionandagainofbillionfromthedivestitureofthelifescanbusinessinthefiscal fourthquarter thepharmaceuticalsegmentincludesbillionforactelionacquisitionrelatedcostsaninprocessresearchanddevelopment expenseofbillionandlitigationexpenseofbillionthemedicaldevicessegmentincludeslitigationexpenseofbillion arestructuringrelatedchargeofbillionanassetimpairmentofbillionprimarilyrelatedtotheinsulinpumpbusinessand billionforamoacquisitionrelatedcoststhemedicaldevicessegmentincludesagainofbillionfromthedivestitureof codmanneurosurgerytheconsumersegmentincludesagainofbillionfromthedivestitureofcompeed includesnetlitigationexpenseofbillionandarestructuringrelatedchargeofbillioninthemedicaldevicessegmentthe pharmaceuticalsegmentincludesapositiveadjustmentofbilliontopreviousreserveestimatesandgainsfromthedivestitures ofthecontrolledsubstancerawmaterialandactivepharmaceuticalingredientapibusinessandcertainanestheticproductsin europe longlivedassetsincludepropertyplantandequipmentnetforandofandrespectivelyand intangibleassetsandgoodwillnetforandofandrespectively johnsonjohnsonannualreport select quarterly financial datum unaudite selectedunauditedquarterlyfinancialdatafortheyearsandaresummarizedbelow dollarsinmillionsexceptpershare second fourth second fourth datum quarter quarter quarter quarter quarter quarter quarter quarter segmentsalestocustomer consumer pharmaceutical medicaldevice totalsale grossprofit earningsbeforeprovisionfortaxeson income netearningsloss basicnetearningslosspershare dilutednetearningslosspershare thefirstquarterofincludesanactelionacquisitionrelatedcostofmillionaftertaxmillionbeforetaxanda restructuringrelatedchargeofmillionaftertaxmillionbeforetax thesecondquarterofincludesalitigationexpenseofmillionaftertaxmillionbeforetaxandarestructure relatedchargeofmillionaftertaxmillionbeforetax thethirdquarterofincludesaninprocessresearchanddevelopmentexpenseofmillionaftertaxmillion beforetaxrelatedtothealiosandxoassetsandthecorrespondingxocontingentliabilityreversalofmillionafterand beforetaxarestructuringrelatedchargeofmillionaftertaxmillionbeforetaxandamillionbenefitaftertaxfrom theimpactoftaxlegislation thefourthquarterofincludesalitigationexpenseofmillionaftertaxmillionbeforetaxarestructuringrelate chargeofmillionaftertaxmillionbeforetaxandamillionbenefitaftertaxfromtheimpactoftaxlegislation thefirstquarterofincludesarestructuringchargeofmillionaftertaxmillionbeforetaxandanamoacquisition relatedcostofmillionaftertaxmillionbeforetax thesecondquarterofincludesalitigationexpenseofmillionaftertaxmillionbeforetaxactelionacquisition relatedcostsofmillionaftertaxmillionbeforetaxarestructuringchargeofmillionaftertaxmillion beforetaxandanassetimpairmentchargeofmillionaftertaxmillionbeforetax thethirdquarterofincludesalitigationexpenseofmillionaftertaxmillionbeforetaxactelionacquisitionrelate costsofmillionaftertaxmillionbeforetaxandarestructuringchargeofmillionaftertaxmillionbeforetax thefourthquarterofincludesalitigationexpenseofmillionaftertaxmillionbeforetaxactelionacquisitionrelate costsofmillionaftertaxmillionbeforetaxarestructuringchargeofmillionaftertaxmillionbeforetaxan inprocessresearchanddevelopmentexpenseofmillionaftertaxmillionbeforetaxandanaftertaxbenefitof millionrelatedtotheinsulinpumpbusinessadditionallythefourthquarterofincludesaprovisionalchargeof billionforrecentlyenactedtaxlegislation johnsonjohnsonannualreport business combination divestiture certainbusinesseswereacquiredforbillionincashandbillionofliabilitiesassumedduringthese acquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeeninclude inthefinancialstatementsfromtheirrespectivedatesofacquisition theacquisitionsprimarilyincludedzarbeesincaprivatelyheldcompanythatisaleaderinnaturallybase consumerhealthcareproductsmedicalenterprisesdistributionllcaprivatelyheldhealthcaretechnologyfirmfocused onsurgicalprocedureinnovationbenevirbiopharmincbeneviraprivatelyheldbiopharmaceuticalcompany specializinginthedevelopmentofoncolyticimmunotherapiesandorthotaxyaprivatelyhelddeveloperofsoftware enabledsurgerytechnologiesincludingadifferentiatedroboticassistedsurgerysolution theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtobillionandha beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwill onoctoberthecompanyenteredintoanagreementtoacquirecizholdingscoltdajapanesecompany focusedonthemarketingdevelopmentanddistributionofabroadrangeofdermocosmeticcosmeticandskincare productsforatotalpurchasepriceofapproximatelybillionwhichequatestoapproximatelybillionusingthe exchangerateofjapaneseyentoeachusdollaronjanuarytheacquisitionwascompletedon januarythroughaseriesoftransactionsthatincludedanallcashtenderoffertoacquirethepubliclyheldshare notalreadyheldbythecompanyforpershareuponcompletionofthetenderofferandtherelatedtransaction thecompanyacquiredoftheoutstandingsharesthecompanyplanstoacquiretheremainingsharesthatwerenot tenderedinthetenderofferthroughashareconsolidationunderjapaneselawduringthefirsthalfofandtake appropriateactionstodelistfromthetokyostockexchangetheacquisitionwillincludetherangeofbrandscomprise drcilabolabolaboandgenomerlineofskincareproductsthecompanyexpectstotreatthistransactionasa businesscombinationandwillincludeitintheconsumersegment onfebruarythecompanyenteredintoadefinitiveagreementtoacquireaurishealthincforapproximately billionincashadditionalcontingentpaymentsofuptobillionintheaggregatemaybepayableupon reachingcertainpredeterminedmilestonesaurishealthisaprivatelyhelddeveloperofrobotictechnologiesinitially focusedinlungcancerwithanfdaclearedplatformcurrentlyusedinbronchoscopicdiagnosticandtherapeutic procedurestheclosingissubjecttoantitrustclearanceandothercustomaryclosingconditionsthetransactioni expectedtoclosebytheendofthesecondquarterofthecompanyexpectstotreatthistransactionasabusiness combinationandwillincludeitinthemedicaldevicessegment duringcertainbusinesseswereacquiredforbillionincashandbillionofliabilitiesassumedthese acquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeeninclude inthefinancialstatementsfromtheirrespectivedatesofacquisition theacquisitionsprimarilyincludedactelionltdanestablishedleadingfranchiseofdifferentiatedinnovative productsforpulmonaryarterialhypertensionpahabbottmedicalopticsamoawhollyownedsubsidiaryofabbott laboratorieswhichincludedophthalmicproductsrelatedtocataractsurgerylaserrefractivesurgeryandconsumereye healthneuravilimitedaprivatelyheldmedicaldevicecompanythatdevelopsandmarketsmedicaldevicesfor neurointerventionaltherapytearscienceincamanufacturerofproductsdedicatedtotreatingmeibomiangland dysfunctionsightboxincaprivatelyheldcompanythatdevelopedasubscriptionvisioncareservicethatconnect consumerswitheyecareprofessionalsandasupplyofcontactlensestoraxmedicalincaprivatelyheldmedicaldevice companythatmanufacturesandmarketsthelinxrefluxmanagementsystemforthesurgicaltreatmentof gastroesophagealrefluxdiseaseandmegadynemedicalproductsincaprivatelyheldmedicaldevicecompanythat developsmanufacturesandmarketselectrosurgicaltool theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtobillionandha beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwillofthisamountapproximately billionhasbeenidentifiedasthevalueofiprdprimarilyassociatedwiththeacquisitionofactelionltdthevalue oftheiprdwascalculatedusingcashflowprojectionsdiscountedfortheinherentriskintheproject duringthecompanycompletedtheacquisitionofactelionltdthroughanallcashtenderofferinswitzerlandfor pershareamountingtobillionnetofcashacquiredaspartofthetransactionimmediatelypriortothe completionoftheacquisitionactelionspunoutitsdrugdiscoveryoperationsandearlystageclinicaldevelopmentasset intoanewlycreatedswissbiopharmaceuticalcompanyidorsialtdthesharesofidorsiaarelistedonthesixswiss exchangesixinthecompanyheldofthesharesofidorsiaandhadrightstoanadditionalofidorsia equitythroughaconvertibleloanwithaprincipalamountofapproximatelybillionasaresultofidorsiaraise johnsonjohnsonannualreportadditionalcapitalinjulythecompanycurrentlyholdsofthesharesofidorsiaandhasrightstoanadditional ofidorsiaequitythroughaconvertibleloanwithaprincipalamountofapproximatelybilliontheconvertible loanmaybeconvertedintoidorsiasharesasfollowsiuptoanaggregateshareholdingofofidorsiasharesasa resultofcertainshareholdersholdingmorethanoftheissuedidorsiasharesandiiuptothebalanceofthe remainingamountwithinbusinessdaysofthematuritydateoftheconvertibleloanwhichhasayeartermorif idorsiaundergoesachangeofcontroltransactiontheinvestmentinidorsiawasrecordedasacostmethodinvestmentin otherassetsinthecompanysconsolidatedbalancesheetthecompanyalsoexercisedtheoptionacquiredon actaproductwithinidorsiabeingdevelopedforresistanthypertensioncurrentlyinphaseofclinical developmentthecompanyhasalsoenteredintoanagreementtoprovideidorsiawithaswissfrancdenominatedcredit facilityofapproximatelymillionasofdecemberidorsiahasnotmadeanydrawdownsunderthecredit facilityactelionhasenteredintoatransitionalservicesagreementwithidorsiaactelionhasestablishedaleading franchiseofdifferentiatedinnovativeproductsforpulmonaryarterialhypertensionpahthatarehighlycomplementaryto theexistingportfolioofthecompanytheadditionofactelionsspecialtyinmarketmedicinesandlatestageproductsis consistentwiththecompanyseffortstogrowinattractiveandcomplementarytherapeuticareasandservepatientswith seriousillnessesandsignificantunmetmedicalnee duringthefiscalsecondquarterofthecompanyfinalizedthepurchasepriceallocationtotheindividualasset acquiredandliabilitiesassumedusingtheacquisitionmethodthefollowingtablepresentstheamountsrecognizedfor assetsacquiredandliabilitiesassumedasoftheacquisitiondatewithadjustmentsmadethroughthesecondquarterof dollarsinmillion cashcashequivalent inventory accountsreceivable othercurrentasset propertyplantandequipment goodwill intangibleasset deferredtaxe othernoncurrentasset totalassetsacquired currentliabilitie deferredtaxe othernoncurrentliabilitie totalliabilitiesassume netassetsacquired includesadjustmentofmilliontowriteuptheacquiredinventorytoitsestimatedfairvalue theadjustmentsmadesincethedateofacquisitionwerebilliontothedeferredtaxesandbilliontothecurrent liabilitieswiththeoffsettogoodwilltheassetsacquiredarerecordedinthepharmaceuticalsegmenttheacquisitionof actelionresultedinapproximatelybillionofgoodwillthegoodwillisprimarilyattributabletosynergiesexpectedto arisefromtheacquisitionthegoodwillisnotexpectedtobedeductiblefortaxpurpose johnsonjohnsonannualreport thepurchasepriceallocationtotheidentifiableintangibleassetsisasfollow dollarsinmillion intangibleassetswithdefinitelive patentsandtrademark totalamortizableintangible inprocessresearchanddevelopment totalintangibleasset includesbillionrelatedtovalchloroneoftheacquiredproductswhichwasdivestedinthefiscalsecondquarterof thepatentsandtrademarksacquiredarecomprisedofdevelopedtechnologywithaweightedaveragelifeofyearsand wasprimarilybasedonthepatentlifeofthemarketedproductstheintangibleassetswithdefiniteliveswereassigned assetlivesrangingfromtoyearstheinprocessresearchanddevelopmentintangibleassetswerevaluedfor technologyprogramsforunapprovedproduct thevalueoftheiprdwascalculatedusingprobabilityadjustedcashflowprojectionsdiscountedfortheriskinherentin suchprojectsthediscountrateappliedwa theacquisitionwasaccountedforusingtheacquisitionmethodandaccordinglytheresultsofoperationsofactelion werereportedinthecompanysfinancialstatementsbeginningonjunethedateofacquisitionfortheyear endeddecembertotalsalesandanetlossforactelionfromthedateofacquisitionwerebillionand billionrespectively thefollowingtableprovidesproformaresultsofoperationsforthefiscalyearendeddecemberandjanuary asifactelionhadbeenacquiredasofjanuarytheproformaresultsincludetheeffectofcertainpurchase accountingadjustmentssuchastheestimatedchangesindepreciationandamortizationexpenseontheacquiredtangible andintangibleassetshoweverproformaresultsdonotincludeanyanticipatedcostsavingsorothereffectsofthe plannedintegrationofactelionaccordinglysuchamountsarenotnecessarilyindicativeoftheresultsiftheacquisition hadoccurredonthedatesindicatedorwhichmayoccurinthefuture unauditedproformaconsolidatedresult dollarsinmillionsexceptpersharedata netsale netearning dilutednetearningspercommonshare thecompanyrecordedactelionacquisitionrelatedcostsbeforetaxofapproximatelybillionandbillionin andrespectivelywhichwasrecordedinotherincomeexpenseandcostofproductssold duringthecompanyacquiredabbottmedicalopticsamoawhollyownedsubsidiaryofabbottlaboratoriesfor billionnetofcashacquiredtheacquisitionincludedophthalmicproductsrelatedtocataractsurgerylaser refractivesurgeryandconsumereyehealththenetpurchasepricewasprimarilyrecordedasamortizableintangible assetsforbillionandgoodwillforbilliontheweightedaveragelifeoftotalamortizableintangiblesthemajority beingcustomerrelationshipsisapproximatelyyearsthegoodwillisprimarilyattributabletosynergiesexpectedto arisefromthebusinessacquisitionandisnotdeductiblefortaxpurposestheintangibleassetsandgoodwillamountsare basedonthefinalpurchasepriceallocationtheassetsacquiredwererecordedinthemedicaldevicessegment certainbusinesseswereacquiredforbillionincashandbillionofliabilitiesassumedduringthese acquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeeninclude inthefinancialstatementsfromtheirrespectivedatesofacquisition theacquisitionsprimarilyincludedvogueinternationalllcaprivatelyheldcompanyfocusedonthemarkete developmentanddistributionofsaloninfluencedandnatureinspiredhaircareandotherpersonalproductsneuwave medicalincaprivatelyheldmedicaldevicecompanythatmanufacturesandmarketsminimallyinvasivesofttissue microwaveablationsystemsneostratacompanyincagloballeaderindermocosmeticsandtheglobalrightsforthe commercializationofrhinocortallergysprayoutsidetheunitedstates johnsonjohnsonannualreporttheexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtobillionandhas beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwill thenetpurchasepriceforvogueinternationalllcofbillionwasprimarilyrecordedasamortizableintangibleasset forbillionandgoodwillforbilliontheweightedaveragelifeforthebillionoftotalamortizableintangiblesis approximatelyyearsthetrademarkassetvaluesweredeterminedtohavedefinitelivesrangingfromtoyear withthemajoritybeingyearsthegoodwillisprimarilyattributabletosynergiesexpectedtoarisefromthebusiness acquisitionandisexpectedtobedeductiblefortaxpurposestheassetsacquiredwererecordedintheconsumer segment inthecompanycompletedtheacquisitionofsynthesincforapurchasepriceofbillionincashandstock inconnectionwiththeacquisitionofsynthesincthecompanyenteredintotwoacceleratedsharerepurchaseasr agreementsinthecompanysettledtheremainingliabilitiesundertheasragreementswhilethecompany believesthatthetransactionsundereachasragreementandaseriesofrelatedinternaltransactionswereconsummate inataxefficientmannerinaccordancewithapplicablelawitispossiblethattheinternalrevenueservicecouldassert oneormorecontrarypositionstochallengethetransactionsfromataxperspectiveifchallengedanamountuptothe totalpurchasepriceforthesynthessharescouldbetreatedassubjecttoapplicableustaxatapproximatelythe statutoryratetothecompanyplusinterest withtheexceptionoftheactelionltdacquisitionsupplementalproformainformationforandin accordancewithusgaapstandardsrelatedtobusinesscombinationsandgoodwillandotherintangibleassetsisnot providedastheimpactoftheaforementionedacquisitionsdidnothaveamaterialeffectonthecompanysresultsof operationscashflowsorfinancialposition duringthecompanydivestedthelifescanincbusinessforapproximatelybillionandretainedcertainnet liabilitiesotherdivestituresinincludednizoralrocandcertainnonstrategicpharmaceuticalproductsin thepretaxgainsonthedivestitureswereapproximatelybillionadditionallyinthecompanyaccepte thebindingofferfromfortivecorporationtoacquireitsadvancedsterilizationproductsaspbusinessforapproximately billionsubjecttocustomaryadjustmentsthetransactionisexpectedtocloseinasofdecember theassetsheldforsaleontheconsolidatedbalancesheetwerebillionofinventorybillionofpropertyplant andequipmentandbillionofgoodwillthecompanywillretaincertainnetreceivablesofapproximatelybillion associatedwiththeaspbusiness inthecompanyacceptedabindingoffertoformastrategiccollaborationwithjabilinconeoftheworldsleade manufacturingservicesprovidersforhealthcareproductsandtechnologyproductsthecompanyisexpandingayear relationshipwithjabiltoproducearangeofproductswithintheethiconendosurgeryanddepuysynthesbusinesse thistransactionincludesthetransferofemployeesandmanufacturingsitesasofdecembertheassetsheldfor saleontheconsolidatedbalancesheetwerebillionofinventoryandbillionofpropertyplantandequipment netforadditionaldetailsontheglobalsupplychainrestructuringseenotetotheconsolidatedfinancialstatement duringthecompanydivestituresprimarilyincludedthecodmanneurosurgerybusinesstointegralifescience holdingscorporationandthedivestitureofcompeedtohrapharmainthepretaxgainsonthedivestiture wereapproximatelybillion duringthecompanydivestituresincludedthecontrolledsubstancerawmaterialandactivepharmaceutical ingredientapibusinesscertainanestheticproductsineuropeandcertainnonstrategicconsumerbrandsinthe pretaxgainsonthedivestitureswereapproximatelybillion legal proceeding johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialsupplierindemnificationandothermattersgovernmentalinvestigationsandotherlegal proceedingsthatarisefromtimetotimeintheordinarycourseoftheirbusiness thecompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimatedasofdecemberthecompany hasdeterminedthattheliabilitiesassociatedwithcertainlitigationmattersareprobableandcanbereasonablyestimate thecompanyhasaccruedforthesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsas mightbewarrantedbasedonnewinformationandfurtherdevelopmentsinaccordancewithascforthese andotherlitigationandregulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossiblethe companyisunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsalreadyaccruedamountsaccrue johnsonjohnsonannualreport forlegalcontingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrely heavilyonestimatesandassumptionstheabilitytomakesuchestimatesandjudgmentscanbeaffectedbyvarious factorsincludingwhetherdamagessoughtintheproceedingsareunsubstantiatedorindeterminatescientificandlegal discoveryhasnotcommencedorisnotcompleteproceedingsareinearlystagesmatterspresentlegaluncertaintie therearesignificantfactsindisputeortherearenumerouspartiesinvolve inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutionoforincreaseinaccrualsfor oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod productliability johnsonjohnsonandcertainofitssubsidiariesareinvolvedinnumerousproductliabilityclaimsandlawsuitsinvolving multipleproductsclaimantsinthesecasesseeksubstantialcompensatoryandwhereavailablepunitivedamageswhile thecompanybelievesithassubstantialdefensesitisnotfeasibletopredicttheultimateoutcomeoflitigationthe companyhasestablishedaccrualsforproductliabilityclaimsandlawsuitsincompliancewithascbasedon currentlyavailableinformationwhichinsomecasesmaybelimitedthecompanyaccruesanestimateofthelegal defensecostsneededtodefendeachmatterwhenthosecostsareprobableandcanbereasonablyestimatedforcertain ofthesemattersthecompanyhasaccruedadditionalamountssuchasestimatedcostsassociatedwithsettlement damagesandotherlossestotheextentadverseverdictshavebeenrenderedagainstthecompanythecompanydoe notrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimatedproductliabilityaccrual canrepresentprojectedproductliabilityforthousandsofclaimsaroundtheworldeachindifferentlitigationenvironment andwithdifferentfactpatternschangestotheaccrualsmayberequiredinthefutureasadditionalinformationbecomes available themostsignificantofthesecasesincludethedepuyasrxlacetabularsystemanddepuyasrhipresurfacing systemthepinnacleacetabularcupsystempelvicmeshesrisperdalxareltobodypowderscontaine talcprimarilyjohnsonsbabypowderinvokanaandethiconphysiomeshflexiblecompositemeshasof decemberintheunitedstatestherewereapproximatelyplaintiffswithdirectclaimsinpendinglawsuit regardinginjuriesallegedlyduetothedepuyasrxlacetabularsystemanddepuyasrhipresurfacingsystem withrespecttothepinnacleacetabularcupsystemwithrespecttopelvicmesheswith respecttorisperdalwithrespecttoxareltowithrespecttobodypowderscontainingtalc withrespecttoinvokanaandwithrespecttoethiconphysiomeshflexiblecompositemesh inaugustdepuyorthopaedicsincdepuyannouncedaworldwidevoluntaryrecallofitsasrxlacetabular systemanddepuyasrhipresurfacingsystemusedinhipreplacementsurgeryclaimsforpersonalinjuryhavebeen madeagainstdepuyandjohnsonjohnsonthenumberofpendinglawsuitsisexpectedtofluctuateascertainlawsuit aresettledordismissedandadditionallawsuitsarefiledcasesfiledinfederalcourtsintheunitedstateshavebeen organizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthenortherndistrictofohiolitigationha alsobeenfiledincountriesoutsideoftheunitedstatesprimarilyintheunitedkingdomcanadaaustraliaireland germanyanditalyinnovemberdepuyreachedanagreementwithacourtappointedcommitteeoflawyer representingasrhipsystemplaintiffstoestablishaprogramtosettleclaimswitheligibleasrhippatientsintheunite stateswhohadsurgerytoreplacetheirasrhipsknownasrevisionsurgeryasofaugustdepuyreached additionalagreementsinfebruaryandmarchwhichfurtherextendedthesettlementprogramtoincludeasr hippatientswhohadrevisionsurgeriesafteraugustandpriortofebruarythissettlementprogram hasresolvedmorethanclaimsthereforebringingtoresolutionsignificantasrhiplitigationactivityintheunited stateshoweverlawsuitsintheunitedstatesremainandthesettlementprogramdoesnotaddresslitigationoutsideof theunitedstatesinaustraliaaclassactionsettlementwasreachedthatresolvedtheclaimsofthemajorityofasrhip patientsinthatcountryincanadathecompanyhasreachedagreementstosettletwopendingclassactionswhichhave beenapprovedbythequbecsuperiorcourtandthesupremecourtofbritishcolumbiathebritishcolumbiaorderis currentlythesubjectofanappealthecompanycontinuestoreceiveinformationwithrespecttopotentialadditionalcost associatedwiththisrecallonaworldwidebasisthecompanyhasestablishedaccrualsforthecostsassociatedwiththe unitedstatessettlementprogramanddepuyasrhiprelatedproductliabilitylitigation claimsforpersonalinjuryhavealsobeenmadeagainstdepuyorthopaedicsincandjohnsonjohnsoncollectively depuyrelatingtothepinnacleacetabularcupsystemusedinhipreplacementsurgerythenumberofpende productliabilitylawsuitscontinuestoincreaseandthecompanycontinuestoreceiveinformationwithrespecttopotential johnsonjohnsonannualreportcostsandtheanticipatednumberofcasescasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasa multidistrictlitigationintheunitedstatesdistrictcourtforthenortherndistrictoftexaslitigationhasalsobeenfiledin somestatecourtsandincountriesoutsideoftheunitedstatesseveraladverseverdictshavebeenrenderedagainst depuyoneofwhichwasreversedonappealandremandedforretrialthesecondremainsunderappealandthethirdis pendingdecisiononposttrialmotionsinthedistrictcourtthecompanyhasestablishedanaccrualforproductliability litigationassociatedwiththepinnacleacetabularcupsystemthecompanyisnegotiatingsettlementsofthese casesandtherelatedcostsarereflectedinthecompanysaccrual claimsforpersonalinjuryhavebeenmadeagainstethiconincethiconandjohnsonjohnsonarisingoutofethicon pelvicmeshdevicesusedtotreatstressurinaryincontinenceandpelvicorganprolapsethecompanycontinuesto receiveinformationwithrespecttopotentialcostsandadditionalcasescasesfiledinfederalcourtsintheunitedstate havebeenorganizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthesoutherndistrictofwest virginiathecompanyhassettledorotherwiseresolvedamajorityoftheunitedstatescasesandthecostsassociate withthesesettlementsarereflectedinthecompanysaccrualsinadditionclassactionsandindividualpersonalinjury casesorclaimshavebeencommencedinvariouscountriesoutsideoftheunitedstatesincludingclaimsandcasesinthe unitedkingdomthenetherlandsandbelgiumandclassactionsinisraelaustraliaandcanadaseekingdamagesfor allegedinjuryresultingfromethiconspelvicmeshdevicesinaustraliaatrialofclassactionissueshasbeencomplete andthepartiesareawaitingadecisionthecompanyhasestablishedaccrualswithrespecttoproductliabilitylitigation associatedwithethiconspelvicmeshproduct followingajuneworldwidemarketwithdrawalofethiconphysiomeshflexiblecompositemeshclaimsfor personalinjuryhavebeenmadeagainstethiconincandjohnsonjohnsonallegingpersonalinjuryarisingoutoftheuse ofthisherniameshdevicecasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamultidistrict litigationmdlintheunitedstatesdistrictcourtforthenortherndistrictofgeorgiaamulticountylitigationmclhas alsobeenformedinnewjerseystatecourtandassignedtoatlanticcountyforcasespendinginnewjerseyproduct liabilitylawsuitscontinuetobefiledandthecompanycontinuestoreceiveinformationwithrespecttopotentialcostsand theanticipatednumberofcasesthecompanyhasestablishedaccrualswithrespecttoproductliabilitylitigation associatedwithethiconphysiomeshflexiblecompositemesh claimsforpersonalinjuryhavebeenmadeagainstjanssenpharmaceuticalsincandjohnsonjohnsonarisingoutofthe useofrisperdalindicatedforthetreatmentofschizophreniaacutemanicormixedepisodesassociatedwithbipolari disorderandirritabilityassociatedwithautismandrelatedcompoundslawsuitshavebeenprimarilyfiledinstatecourtsin pennsylvaniacaliforniaandmissouriotheractionsarependinginvariouscourtsintheunitedstatesandcanada productliabilitylawsuitscontinuetobefiledandthecompanycontinuestoreceiveinformationwithrespecttopotential costsandtheanticipatednumberofcasesthecompanyhassettledorotherwiseresolvedmanyoftheunitedstate casesandthecostsassociatedwiththesesettlementsarereflectedinthecompanysaccrual claimsforpersonalinjuryarisingoutoftheuseofxareltoanoralanticoagulanthavebeenmadeagainstjanssen pharmaceuticalsincjpijohnsonjohnsonandjpiscollaborationpartnerforxareltobayeragandcertainofit affiliatesthenumberofpendingproductliabilitylawsuitscontinuestoincreaseandthecompanycontinuestoreceive informationwithrespecttopotentialcostsandtheanticipatednumberofcasescasesfiledinfederalcourtsintheunite stateshavebeenorganizedasamultidistrictlitigationintheunitedstatesdistrictcourtfortheeasterndistrictof louisianainadditioncaseshavebeenfiledinstatecourtsacrosstheunitedstatesmanyofthesecaseshavebeen consolidatedintoastatemasstortlitigationinphiladelphiapennsylvaniaandtherearecoordinatedproceedingsin delawarecaliforniaandmissouriclassactionlawsuitsalsohavebeenfiledincanadathecompanyhasestablishedan accrualfordefensecostsonlyinconnectionwithproductliabilitylitigationassociatedwithxarelto personalinjuryclaimsallegingthattalccausescancerhavebeenmadeagainstjohnsonjohnsonconsumerincand johnsonjohnsonarisingoutoftheuseofbodypowderscontainingtalcprimarilyjohnsonsbabypowderthe numberofpendingproductliabilitylawsuitscontinuestoincreaseandthecompanycontinuestoreceiveinformationwith respecttopotentialcostsandtheanticipatednumberofcaseslawsuitshavebeenprimarilyfiledinstatecourtsin missourinewjerseyandcaliforniacasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamulti districtlitigationintheunitedstatesdistrictcourtforthedistrictofnewjerseythecompanyhassuccessfullydefende anumberofthesecasesbuttherehavebeenverdictsagainstthecompanyincludingaverdictinjulyof billionthecompanybelievesthatithasstronggroundsonappealtooverturntheseverdictsthecompanyha establishedanaccrualfordefensecostsonlyinconnectionwithproductliabilitylitigationassociatedwithbodypowders containingtalc infebruaryasecuritiesclassactionlawsuitwasfiledagainstjohnsonjohnsonandcertainnamedofficersinthe unitedstatesdistrictcourtforthedistrictofnewjerseyallegingthatjohnsonjohnsonviolatedthefederalsecurities johnsonjohnsonannualreport lawsbyfailingtoadequatelydisclosetheallegedasbestoscontaminationinbodypowderscontainingtalcprimarily johnsonsbabypowderandthatpurchasersofjohnsonjohnsonssharessufferedlossesasaresultplaintiffsare seekingdamagesinoctoberashareholderderivativelawsuitwasfiledagainstjohnsonjohnsonasthenominal defendantanditscurrentdirectorsasdefendantsintheunitedstatesdistrictcourtforthedistrictofnewjerseyallege abreachoffiduciarydutiesrelatedtotheallegedasbestoscontaminationinbodypowderscontainingtalcprimarily johnsonsbabypowderandthatjohnsonjohnsonhassuffereddamagesasaresultofthoseallege breachesplaintiffisseekingdamagesandanorderforthecompanytoreformitsinternalpoliciesandproceduresin januarytwoerisaclassactionlawsuitswerefiledbyparticipantsinthejohnsonjohnsonsavingsplanagainst johnsonjohnsonitspensionandbenefitscommitteeandcertainnamedofficersintheunitedstatesdistrictcourtfor thedistrictofnewjerseyallegingthatthedefendantsbreachedtheirfiduciarydutiesbyofferingjohnsonjohnson stockasajohnsonjohnsonsavingsplaninvestmentoptionwhenitwasimprudenttodosobecauseoffailuresto discloseallegedasbestoscontaminationinbodypowderscontainingtalcprimarilyjohnsonsbabypowderplaintiff areseekingdamagesandinjunctivereliefeachofthesematterswillbeadjudicatedinconjunctionwiththemultidistrict litigationreferencedinthepriorparagraphinadditionthecompanyhasreceivedpreliminaryinquiriesandsubpoenasto producedocumentsregardingthesemattersfromsenatormurrayamemberofthesenatecommitteeonhealth educationlaborandpensionsthedepartmentofjusticeandthesecuritiesandexchangecommissionthecompanyis cooperatingwiththesegovernmentinquiriesandwillbeproducingdocumentsinresponse claimsforpersonalinjuryhavebeenmadeagainstanumberofjohnsonjohnsoncompaniesincludingjanssen pharmaceuticalsincandjohnsonjohnsonarisingoutoftheuseofinvokanaaprescriptionmedicationindicate toimproveglycemiccontrolinadultswithtypediabeteslawsuitsfiledinfederalcourtsintheunitedstateshavebeen organizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthedistrictofnewjerseycaseshavealso beenfiledinstatecourtsinpennsylvaniacaliforniaandnewjerseyclassactionlawsuitshavebeenfiledincanada productliabilitylawsuitscontinuetobefiledandthecompanycontinuestoreceiveinformationwithrespecttopotential costsandtheanticipatednumberofcasesthecompanyhassettledorotherwiseresolvedmanyofthecasesandclaim intheunitedstatesandthecostsassociatedwiththesesettlementsarereflectedinthecompanysaccrual intellectualproperty certainsubsidiariesofjohnsonjohnsonaresubjectfromtimetotimetolegalproceedingsandclaimsrelatedto patenttrademarkandotherintellectualpropertymattersarisingoutoftheirbusinessesmanyofthesemattersinvolve challengestothecoverageandorvalidityofthepatentsonvariousproductsandallegationsthatcertainofthecompanys productsinfringethepatentsofthirdpartiesalthoughthesesubsidiariesbelievethattheyhavesubstantialdefensesto thesechallengesandallegationswithrespecttoallsignificantpatentstherecanbenoassuranceastotheoutcomeof thesemattersalossinanyofthesecasescouldadverselyaffecttheabilityofthesesubsidiariestoselltheirproduct resultinlossofsalesduetolossofmarketexclusivityrequirethepaymentofpastdamagesandfutureroyaltiesandmay resultinanoncashimpairmentchargeforanyassociatedintangibleassetthemostsignificantofthesemattersare describedbelow medicaldevice injunerembrandtvisiontechnologieslprembrandtfiledapatentinfringementlawsuitagainstjohnson johnsonvisioncareincjjvciintheunitedstatesdistrictcourtfortheeasterndistrictoftexasallegingthatjjvcis manufactureandsaleofitsacuvueadvanceandacuvueoasyshydrogelcontactlensesinfringe rembrandtsunitedstatespatentnoandseekingmonetaryreliefthecasewastransferredtotheunite statesdistrictcourtforthemiddledistrictoffloridawhereatrialinmayresultedinaverdictofnoninfringement thatwassubsequentlyupheldonappealinjulyrembrandtsoughtanewtrialbasedonallegednewevidence whichthedistrictcourtdeniedinaprilthecourtofappealsoverturnedthatrulingandremandedthecasetothe districtcourtforanewtrialanewtrialwasheldinaugustandthejuryreturnedaverdictofnoninfringementin favorofjjvcirembrandthasappealedtheverdicttotheunitedstatescourtofappealsforthefederalcircuitcafc infebruarythecafcaffirmedthejudgmentinfavorofjjvci inmarchmedinolltdmedinolfiledapatentinfringementlawsuitagainstcordiscorporationcordisand johnsonjohnsonintheunitedstatesdistrictcourtforthesoutherndistrictofnewyorkallegingthatcordisssalesof thecypherandcypherselectstentsmadeintheunitedstatessincewillfullyinfringedfourofmedinol patentsdirectedtothegeometryofarticulatedstentsmedinolisseekingdamagesandattorneysfeesalthough johnsonjohnsonhassincesoldcordisithasretainedliabilityforthiscaseaftertrialinjanuarythedistrictcourt dismissedthecasefindingmedinolunreasonablydelayedbringingitsclaimsthelachesdefenseinseptember johnsonjohnsonannualreportthedistrictcourtdeniedamotionbymedinoltovacatethejudgmentandgrantitanewtrialmedinolappealedthe decisiontotheunitedstatescourtofappealsforthefederalcircuitinmarchtheunitedstatessupremecourt heldthatthelachesdefenseisnotavailableinpatentcasesinapriltheunitedstatescourtofappealsforthe federalcircuitremandedthecasebacktothedistrictcourttoreconsidermedinolsmotionforanewtrialandbriefingin thedistrictcourtwascompletedinjune innovembermedideallcmedideafiledapatentinfringementlawsuitagainstdepuyorthopaedicsincinthe unitedstatesdistrictcourtforthenortherndistrictofillinoisalleginginfringementbytheattunekneesystemin aprilmedideafiledanamendedcomplaintaddingdepuysynthesproductsincanddepuysynthessalesincas nameddefendantsmedideaallegesinfringementofunitedstatespatentnos andrelatingtoposteriorstabilizedkneesystemsspecificallymedideaallegesthatthe sofcamtmcontactfeatureoftheattuneposteriorstabilizedkneeproductsinfringesthepatentsinsuitmedideais seekingmonetarydamagesandinjunctivereliefinjunethecasewastransferredtotheunitedstatesdistrictcourtfor thedistrictofmassachusettsaclaimconstructionhearingwasheldinoctoberandaclaimconstructionorderwa issuedinnovemberindecembermedideastipulatedtononinfringementoftheandpatent basedonthedistrictcourtsclaimconstructionandreservingitsrighttoappealthatconstructionleavingonlythepatent atissuebeforethedistrictcourtinjanuarythedistrictcourtstayedthecasependingadecisionintheinterparte reviewproceedingonthepatentseebelowindecemberdepuysynthesproductsincfiledapetitionforinter partesreviewwiththeunitedstatespatentandtrademarkofficeusptoseekingtoinvalidatethetwoclaimsofthe patentassertedinthedistrictcourtlitigationandinjunetheusptoinstitutedreviewofthoseclaimsahearing trialisscheduledformarchandadecisionintheproceedingisduebyjune indecemberethiconendosurgeryincandethiconendosurgeryllcnowknownasethiconllcsued covidienincintheunitedstatesdistrictcourtforthedistrictofmassachusettsseekingadeclarationthatunitedstate patentnosthepatentandthepatentareeither invalidornotinfringedbyethiconsensealxlargejawtissuesealerproductinaprilcovidienlpcovidien salesllcandcovidienagcollectivelycovidienansweredandcounterclaimeddenyingtheallegationsasserte willfulinfringementofthepatentthepatentandunitedstatespatentnosthepatent thepatentandandseekingdamagesandaninjunctioncovidienfiledamotion forpreliminaryinjunctionwhichwasdeniedinoctoberthepartieshaveenteredjointstipulationssuchthatonlythe patentthepatentandthepatentremainindisputetrialisscheduledtobegininseptember innovemberboardofregentstheuniversityoftexassystemandtissuegeninccollectivelyutfiledalawsuit intheunitedstatesdistrictcourtforthewesterndistrictoftexasagainstethiconincandethiconusllcallegingthe manufactureandsaleofvicrylplusantibacterialsuturesmonocrylplusantibacterialsuturespdsplus antibacterialsuturesstratafixposantibacterialsuturesandstratafixmonocrylplusantibacterial suturesinfringeplaintiffsunitedstatespatentnosanddirectedtoimplantablepolymerdrug releasingbiodegradablefiberscontainingatherapeuticagentutisseekingdamagesandaninjunctionindecember ethiconfiledpetitionswiththeusptoseekinginterpartesreviewiprofbothassertedpatentsthosepetition havebeenstayedbytheusptopendingadecisionbytheuscourtofappealsforthefederalcircuitinanunrelate case pharmaceutical inaprilmorphosysagagermanbiotechcompanyfiledapatentinfringementlawsuitagainstjanssenbiotech incjbigenmabusincandgenmabascollectivelygenmabintheunitedstatesdistrictcourtforthedistrictof delawaremorphosysallegedthatjbismanufactureandsaleofdarzalexdaratumumabwillfullyinfringe morphosysunitedstatespatentnosandmorphosyssoughtmoneydamagesjbi licensespatentsandthecommercialrightstodarzalexfromgenmabinjanuarythedistrictcourtgrante summaryjudgmentinjbiandgenmabsfavorinvalidatingtheassertedclaimsofthepatentsinsuitandthepartiesfileda jointstipulationofdismissaloftheaction inaugustsandozltdandhexalagcollectivelysandozfiledalawsuitintheenglishhighcourtagainstgd searlellcapfizercompanysearleandjanssensciencesirelanducjsiallegingthatsearlessupplementary protectioncertificatespcgbspcwhichisexclusivelylicensedtojsiisinvalidandshouldberevoke janssencilaglimitedsellsprezistadarunavirintheunitedkingdompursuanttothislicenseinoctober searleandjsicounterclaimedagainstsandozforthreatenedinfringementofthespcbasedonstatementsofitsplansto launchgenericdarunavirintheunitedkingdomsandozadmittedthatitsgenericdarunavirproductwouldinfringethe johnsonjohnsonannualreport spcifitisfoundvalidsearleandjsiareseekinganorderenjoiningsandozfrommarketingitsgenericdarunavirbefore theexpirationofthespcfollowingatrialinaprilthecourtenteredadecisionholdingthatthespcisvalidand grantingafinalinjunctionsandozhasappealedthecourtsdecisionandtheinjunctionisstayedpendingtheappealin januarythecourtreferredtheissueonappealtothecourtofjusticefortheeuropeanunioncjeuandstayedthe proceedingspendingthecjeusrulingontheissue inaprilacertapharmabvastrazenecaukltdandastrazenecapharmaceuticalslpfiledapatentinfringement lawsuitintheunitedstatesdistrictcourtforthedistrictofdelawareagainstpharmacylicsllcandabbvieinc collectivelyabbvieallegingthatthemanufactureandsaleofimbruvicainfringesuspatentno janssenbiotechincwhichcommercializesimbruvicajointlywithabbvieintervenedintheactioninnovember atrialisscheduledtobegininjanuary remicaderelatedcase inaugustcelltrionhealthcarecoltdandcelltrioninccollectivelycelltrionfiledanapplicationwiththeunite statesfoodanddrugadministrationfdaforapprovaltomakeandsellitsowninfliximabbiosimilarinmarch janssenbiotechincjbifiledalawsuitintheunitedstatesdistrictcourtforthedistrictofmassachusettsagainst celltrionandhospirahealthcarecorporationhospirawhichhasexclusivemarketingrightsforcelltrionsinfliximab biosimilarintheunitedstatesseekingamongotherthingsadeclaratoryjudgmentthattheirbiosimilarproductinfringesor potentiallyinfringesseveraljbipatentsincludingunitedstatespatentnorelatingtoremicadeinfliximab thepatentandunitedstatespatentnothepatentdirectedtothecellculturemediausedtomake celltrionsbiosimilarinaugustthedistrictcourtgrantedbothcelltrionsandhospirasmotionsforsummary judgmentofinvalidityofthepatentjbiappealedthosedecisionstotheunitedstatescourtofappealsforthefederal circuitinjanuarythefederalcircuitdismissedtheappealasmootbasedonitsaffirmanceofadecisionbythe usptospatenttrialandappealboardaffirminginvalidityofthepatent injunejbifiledtwoadditionalpatentinfringementlawsuitsassertingthepatentoneagainstcelltrionand hospiraintheunitedstatesdistrictcourtforthedistrictofmassachusettsandtheotheragainsthyclonelaboratorie incthemanufacturerofthecellculturemediathatcelltrionusestomakeitsbiosimilarproductintheunitedstate districtcourtforthedistrictofutahonjulythedistrictcourtgrantedcelltrionsmotionforsummaryjudgment ofnoninfringementandenteredanorderdismissingthelawsuitagainstcelltrionandhospirajbiappealedtothe unitedstatescourtofappealsforthefederalcircuitthelitigationagainsthycloneinutahisstayedpendingthe outcomeofthemassachusettsaction thefdaapprovedthefirstinfliximabbiosimilarforsaleintheunitedstatesinandanumberofsuchproductshave beenlaunche litigationagainstfilersofabbreviatednewdrugapplicationsandas thefollowingsummarizeslawsuitspendingagainstgenericcompaniesthathavefiledabbreviatednewdrugapplications andaswiththefdaorundertakensimilarregulatoryprocessesoutsideoftheunitedstatesseekingtomarketgeneric formsofproductssoldbyvarioussubsidiariesofjohnsonjohnsonpriortoexpirationoftheapplicablepatentscovering thoseproductstheseandastypicallyincludeallegationsofnoninfringementandinvalidityoftheapplicablepatentsin theeventthesubsidiariesarenotsuccessfulinanactionortheautomaticstatutorystayoftheandasexpiresbeforethe unitedstatesdistrictcourtrulingsareobtainedthethirdpartycompaniesinvolvedwouldhavetheabilityuponapproval ofthefdatointroducegenericversionsoftheirproductstothemarketresultinginthepotentialforsubstantialmarket shareandrevenuelossesfortheapplicableproductsandwhichmayresultinanoncashimpairmentchargeinany associatedintangibleassetinadditionfromtimetotimesubsidiariesmaysettlethesetypesofactionsandsuch settlementscaninvolvetheintroductionofgenericversionsoftheproductsatissuetothemarketpriortotheexpirationof therelevantpatentstheinterpartesreviewiprprocesswiththeunitedstatespatentandtrademarkofficeuspto createdundertheamericainventsactisalsobeingusedattimesbygenericcompaniesinconjunctionwithandas andlawsuitstochallengetheapplicablepatent zytiga injulyjanssenbiotechincjanssenoncologyincandjanssenresearchdevelopmentllccollectively janssenandbtginternationalltdbtginitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthe districtofnewjerseyagainstanumberofgenericcompaniesandcertainoftheiraffiliatesandorsupplierswhofile andasseekingapprovaltomarketagenericversionofzytigamgbeforetheexpirationofunitedstatespatent nothepatentthegenericcompaniesincludeamnealpharmaceuticalsllcand johnsonjohnsonannualreportamnealpharmaceuticalsofnewyorkllccollectivelyamnealapotexincandapotexcorpcollectivelyapotex citronpharmallccitrondrreddyslaboratoriesltdanddrreddyslaboratoriesinccollectivelydrreddys mylanpharmaceuticalsincandmylaninccollectivelymylanparpharmaceuticalsincandparpharmaceutical companiesinccollectivelyparsunpharmaceuticalindustriesltdandsunpharmaceuticalsindustriesinc collectivelysuntevapharmaceuticalsusainctevawockhardtbioagwockhardtusallcandwockhardt ltdcollectivelywockhardtwestwardpharmaceuticalcorpwestwardandhikmapharmaceuticalsllchikma janssenandbtgalsoinitiatedpatentinfringementlawsuitsintheunitedstatesdistrictcourtforthedistrictofnew jerseyagainstamerigenpharmaceuticalslimitedamerigeninmayandglenmarkpharmaceuticalsincglenmarkin juneeachofwhomfiledanandaseekingapprovaltomarketitsgenericversionofzytigabeforetheexpirationof thepatenttheselawsuitshavebeenconsolidatedwiththelawsuitfiledinjuly inaugustjanssenandbtgfiledanadditionaljurisdictionalprotectivelawsuitagainstthemylandefendantsinthe unitedstatesdistrictcourtforthenortherndistrictofwestvirginiawhichhasbeenstayed inaugustjanssenandbtginitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrict ofnewjerseyagainsttevawhofiledanandaseekingapprovaltomarketagenericversionofzytigamgbefore theexpirationofthepatentthislawsuithasbeenconsolidatedwiththelawsuitfiledinjuly infebruaryjanssenandbtgfiledapatentinfringementlawsuitagainstmsnpharmaceuticalsincandmsn laboratoriesprivatelimitedcollectivelymsninunitedstatesdistrictcourtforthedistrictofnewjerseybasedonit andaseekingapprovalforagenericversionofzytigapriortotheexpirationofthepatent innovemberjanssenandbtginitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthe districtofnewjerseyagainstqilupharmaceuticalcoltdandqilupharmainccollectivelyqiluwhofiledananda seekingapprovaltomarketagenericversionofzytigabeforetheexpirationofthepatent indecemberjanssenandbtgenteredintoasettlementagreementwithglenmarkinjanuaryjanssen dismisseditslawsuitagainstsunafteritwithdrewitsandainapriljanssenandbtgenteredintoasettlement agreementwithapotex inoctobertheunitedstatesdistrictcourtforthedistrictofnewjerseyissuedarulinginvalidatingallasserte claimsofthepatentthecourtheldthatthepatentclaimswouldbeinfringedifthepatentwerevalidjanssen appealedthecourtsdecision innovembertheunitedstatescourtofappealsforthefederalcircuitdeniedjanssensrequestforaninjunction pendingappealasaresultseveralgenericversionsofzytigahaveenteredthemarketjanssenhasappealedthe decisionoftheunitedstatesdistrictcourtforthedistrictofnewjerseyandtheoralargumentontheappealis scheduledformarch thelawsuitsagainstmsnandqiluremainpendinginthedistrictcourtsineachoftheselawsuitsjanssenisseekingan orderenjoiningthedefendantsfrommarketingtheirgenericversionsofzytigabeforetheexpirationofthepatent severalgenericcompaniesincludingamerigenargentumpharmaceuticalsllcargentummylanwockhardtactavis amnealdrreddyssuntevawestwardandhikmafiledpetitionsforinterpartesreviewiprwiththeuspto seekingtoinvalidatethepatentinjanuarytheusptoissueddecisionsfindingthepatentclaim unpatentableandjanssenrequestedrehearingindecembertheusptodeniedjanssensrequestforrehearingof theiprdecisionsjanssenfiledanappealwhichwasconsolidatedwiththeabovementionedappealofthedecisionof theunitedstatesdistrictcourtforthedistrictofnewjersey inoctoberjanssenincandjanssenoncologyinccollectivelyjansseninitiatedtwonoticesofapplication undersectionofthepatentedmedicinesnoticeofcomplianceregulationsagainsttevacanadalimitedtevaand theministerofhealthincanadainresponsetotevasfilingabbreviatednewdrugsubmissionsandsandseeke approvaltomarketgenericversionsofzytigamgandzytigamgbeforetheexpirationofcanadianpatent noinjunethepartiesenteredintoasettlementagreement innovemberjansseninitiatedanoticeofapplicationundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstapotexincapotexandtheministerofhealthincanadainresponsetoapotexsfile ofanabbreviatednewdrugsubmissionandsseekingapprovaltomarketagenericversionofzytigabeforethe expirationofcanadianpatentnothefederalcourtofcanadascheduledthefinalhearingforapril janssenisseekinganorderprohibitingtheministerofhealthfromissuinganoticeofcompliancewithrespectto apotexsandsbeforetheexpirationofjanssenspatent johnsonjohnsonannualreport injanuaryjansseninitiatedanoticeofapplicationundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstapotexandtheministerofhealthincanadainresponsetoapotexsfilingofan abbreviatednewdrugsubmissionandsseekingapprovaltomarketafilmcoatedgenericversionofzytigabefore theexpirationofcanadianpatentnojanssenisseekinganorderprohibitingtheministerofhealthfrom issuinganoticeofcompliancewithrespecttoapotexsandsbeforetheexpirationofjanssenspatent xarelto beginninginoctoberjanssenpharmaceuticalsincjpiandbayerpharmaagandbayerintellectualproperty gmbhcollectivelybayerfiledpatentinfringementlawsuitsintheunitedstatesdistrictcourtforthedistrictofdelaware againstanumberofgenericcompanieswhofiledandasseekingapprovaltomarketgenericversionsofxarelto beforeexpirationofbayersunitedstatespatentnosandrelatingtoxareltojpiis theexclusivesublicenseeoftheassertedpatentsthefollowinggenericcompaniesarenameddefendantsaurobindo pharmalimitedandaurobindopharmausainccollectivelyaurobindobreckenridgepharmaceuticalinc breckenridgeinvagenpharmaceuticalsincinvagenmicrolabsusaincandmicrolabsltdcollectivelymicro mylanpharmaceuticalsincmylanprinstonpharmaceuticalsincsigmapharmlaboratoriesllcsigmapharmtorrent pharmaceuticalslimitedandtorrentpharmainccollectivelytorrenttrialconcludedinaprilinjulythe districtcourtenteredjudgmentagainstmylanandsigmapharmholdingthattheassertedcompoundpatentisvalidand infringedinseptemberthedistrictcourtenteredjudgmentagainsttheremainingdefendantsnoneofthe defendantsappealedthejudgment beginninginapriljpiandbayerintellectualpropertygmbhandbayeragcollectivelybayeragfiledpatent infringementlawsuitsintheunitedstatesdistrictcourtforthedistrictofdelawareagainstanumberofgeneric companieswhofiledandasseekingapprovaltomarketgenericversionsofxareltobeforeexpirationofbayerag unitedstatespatentnorelatingtoxareltojpiistheexclusivesublicenseeoftheassertedpatent thefollowinggenericcompaniesarenameddefendantsalembicpharmaceuticalslimitedalembicglobalholdingsa andalembicpharmaceuticalsincalembicaurobindobreckenridgeinvagenlupinlimitedandlupin pharmaceuticalsinccollectivelylupinmicromylansigmapharmtaropharmaceuticalindustriesltdandtaro pharmaceuticalsusainccollectivelytaroandtorrentlupincounterclaimedfordeclaratoryjudgmentof noninfringementandinvalidityofunitedstatespatentnobutlupindismisseditscounterclaimsafteritwa providedacovenantnottosueonthatpatentaurobindotarotorrentmicrobreckenridgeinvagensigmapharm lupinandalembichaveagreedtohavetheircasesstayedandtobeboundbytheoutcomeofanyfinaljudgment renderedagainstanyoftheotherdefendantsthecaseshavebeenconsolidatedfordiscoveryandtrialandare currentlysetfortrialinapril indecemberjpiandbayeragfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrict ofdelawareagainsttevapharmaceuticalsusaincandtevapharmaceuticalindustriesltdcollectivelytevawhofile anandaseekingapprovaltomarketagenericversionofxareltobeforeexpirationofbayeragspatent ineachoftheselawsuitsjpiisseekinganorderenjoiningthedefendantsfrommarketingtheirgenericversionsof xareltobeforetheexpirationoftherelevantpatent inmaymylanfiledapetitionforinterpartesreviewwiththeusptoseekingtoinvalidatethepatentin decembertheusptoissuedadecisiondenyinginstitutionofmylanspetitionforinterpartesreview prezista inmayjanssenproductslpandjanssensciencesirelanduccollectivelyjansseninitiatedapatent infringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainstdrreddyslaboratoriesinc drreddyslaboratoriesltdlauruslabsltdandpharmaqinccollectivelydrlwhofiledanandaseekingapproval tomarketgenericversionsofprezistabeforetheexpirationofunitedstatespatentnosand trialisscheduledtobegininmay indecemberjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictof newjerseyagainstamnealpharmaceuticalsllcamnealpharmaceuticalscompanygmbhamnealpharmaceuticalsof newyorkllcamnealpharmaceuticalspvtltdandrakspharmapvtltdcollectivelyamnealwhofiledananda seekingapprovaltomarketgenericversionsofprezistabeforetheexpirationofunitedstatespatentnos ineachoftheselawsuitsjanssenisseekinganorderenjoiningthedefendantsfrommarketingitsgenericversionsof prezistabeforetheexpirationoftherelevantpatent johnsonjohnsonannualreportinvokanainvokamet beginninginjulyjanssenpharmaceuticalsincjanssenresearchdevelopmentllccilaggmbhinternational andjanssenpharmaceuticanvcollectivelyjanssenandmitsubishitanabepharmacorporationmtpcfiledpatent infringementlawsuitsintheunitedstatesdistrictcourtforthedistrictofnewjerseytheunitedstatesdistrictcourtfor thedistrictofcoloradoandtheunitedstatesdistrictcourtforthedistrictofdelawareagainstanumberofgeneric companieswhofiledandasseekingapprovaltomarketgenericversionsofinvokanaandorinvokametbefore expirationofmtpcsunitedstatespatentnosandorrelatingtoinvokanaandinvokamet janssenistheexclusivelicenseeoftheassertedpatentsthefollowinggenericcompaniesarenameddefendantsapotex incandapotexcorpapotexaurobindopharmausaincaurobindomacleodspharmaceuticalsltdandmacleods pharmausaincinvagenpharmaceuticalsincinvagenprinstonpharmaceuticalsincdrreddyslaboratoriesinc anddrreddyslaboratoriesltdheterousaincheterolabslimitedunitvandheterolabslimitedmsn laboratoriesprivateltdandmsnpharmaceuticalsinclauruslabsltdindocoremediesltdzyduspharmaceuticals usainczydussandozincsandoztevapharmaceuticalsusaincandlupinltdandlupinpharmaceuticals inc beginninginjulyjanssenandmtpcfiledpatentinfringementlawsuitsintheunitedstatesdistrictcourtforthe districtofnewjerseyandtheunitedstatesdistrictcourtforthedistrictofcoloradoagainstsandozandinvagenwho filedandasseekingapprovaltomarketgenericversionsofinvokanaandorinvokametbeforeexpirationof mtpcsunitedstatespatentnothepatentrelatingtoinvokanaandinvokametandagainst zyduswhofiledandasseekingapprovaltomarketgenericversionsofinvokanaandinvokametbeforeexpiration ofthepatentmtpcsunitedstatespatentnorelatingtoinvokanaandinvokametandmtpc unitedstatespatentnorelatingtoinvokametandagainstaurobindowhofiledanandaseeke approvaltomarketagenericversionofinvokanabeforeexpirationofthepatentandthepatentrelatingto invokana janssenistheexclusivelicenseeoftheassertedpatentsinoctoberthecoloradolawsuitsagainstsandozwere dismissedindecemberthedelawarelawsuitsagainstapotexandtevaweredismisse inapriljanssenandmtpcfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictof newjerseyagainstprinstonwhofiledanandaseekingapprovaltomarketagenericversionofinvokanabefore expirationofthepatentrelatingtoinvokana ineachoftheselawsuitsjanssenandmtpcareseekinganorderenjoiningthedefendantsfrommarketingtheirgeneric versionsofinvokanaandorinvokametbeforetheexpirationoftherelevantpatent opsumit injanuaryactelionpharmaceuticalsltdactelioninitiatedapatentinfringementlawsuitintheunitedstate districtcourtforthedistrictofnewjerseyagainstzyduspharmaceuticalsusainczydusandamneal pharmaceuticalsllcamnealeachofwhomfiledanandaseekingapprovaltomarketagenericversionofopsumit beforetheexpirationofunitedstatespatentnointhelawsuitactelionisseekinganorderenjoiningzydus andamnealfrommarketinggenericversionsofopsumitbeforetheexpirationofthepatentindecemberthe districtcourtenteredanorderwhereinoneofthedefendantsamnealstipulatedtoinfringementtrialisscheduledto commenceinoctober invegasustenna injanuaryjanssenpharmaceuticanvandjanssenpharmaceuticalsinccollectivelyjansseninitiatedapatent infringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainsttevapharmaceuticalsusa inctevawhofiledanandaseekingapprovaltomarketagenericversionofinvegasustennabeforethe expirationofunitedstatespatentnointhelawsuitjanssenisseekinganorderenjoiningtevafrom marketingagenericversionofinvegasustennabeforetheexpirationofthepatent infebruaryjanssenincandjanssenpharmaceuticanvcollectivelyjansseninitiatedanoticesofapplication undersectionofthepatentedmedicinesnoticeofcomplianceregulationsagainsttevacanadalimitedtevaand theministerofhealthinresponsetotevasfilingofanabbreviatednewdrugsubmissionandsseekingapprovalto marketagenericversionofinvegasustennabeforetheexpirationofcanadianpatentnosand janssenisseekinganorderprohibitingtheministerofhealthfromissuinganoticeofcompliancewith respecttotevasandsbeforetheexpirationofthesepatentsthefinalhearingisscheduledtobegininseptember johnsonjohnsonannualreport imbruvica beginninginjanuarypharmacyclicsllcpharmacyclicsandjanssenbiotechincjbifiledpatentinfringement lawsuitsintheunitedstatesdistrictcourtforthedistrictofdelawareagainstanumberofgenericcompanieswhofile andasseekingapprovaltomarketgenericversionsofimbruvicabeforeexpirationofpharmacyclicsunitedstate patentnos andorrelatingtoimbruvicajbiistheexclusivelicenseeoftheassertedpatentsthefollowe genericcompaniesarenameddefendantsciplalimitedandciplausaincciplafreseniuskabiusallcfresenius kabiusaincandfreseniuskabioncologylimitedfreseniuskabisandozincandlekpharmaceuticalsdd sandozshilpamedicarelimitedshilpasunpharmaglobalfzeandsunpharmaceuticalindustrieslimitedsun tevapharmaceuticalsusainctevaandzydusworldwidedmccandcadilahealthcarelimitedzydustrialis scheduledtobegininoctober inoctoberpharmacyclicsandjbifiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthe districtofdelawareagainstsunassertingnewlyissuedunitedstatespatentno ineachofthelawsuitspharmacyclicsandjbiareseekinganorderenjoiningthedefendantsfrommarketinggeneric versionsofimbruvicabeforetheexpirationoftherelevantpatents injanuarypharmacyclicsandjbiamendedtheircomplaintsagainstfreseniuskabizydustevaandsandozto furtherallegeinfringementofuspatentnosand injanuarypharmacyclicsandjbifiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthe districtofdelawareagainstzyduswhofiledanandaseekingapprovaltomarketagenericversionofimbruvica mgbeforetheexpirationofuspatentnos governmentproceedings likeothercompaniesinthepharmaceuticalandmedicaldevicesindustriesjohnsonjohnsonandcertainofits subsidiariesaresubjecttoextensiveregulationbynationalstateandlocalgovernmentagenciesintheunitedstatesand othercountriesinwhichtheyoperateasaresultinteractionwithgovernmentagenciesisongoingthemostsignificant litigationbroughtbyandinvestigationsconductedbygovernmentagenciesarelistedbelowitispossiblethatcriminal chargesandsubstantialfinesandorcivilpenaltiesordamagescouldresultfromgovernmentinvestigationsorlitigation averagewholesalepriceawplitigation johnsonjohnsonandseveralofitspharmaceuticalsubsidiariesthejjawpdefendantsalongwithnumerousother pharmaceuticalcompanieswerenamedasdefendantsinaseriesoflawsuitsinstateandfederalcourtsinvolve allegationsthatthepricingandmarketingofcertainpharmaceuticalproductsamountedtofraudulentandotherwise actionableconductbecauseamongotherthingsthecompaniesallegedlyreportedaninflatedaveragewholesaleprice awpforthedrugsatissuepayorsallegedthattheyusedthoseawpsincalculatingproviderreimbursementlevelsthe plaintiffsinthesecasesincludedthreeclassesofprivatepersonsorentitiesthatpaidforanyportionofthepurchaseof thedrugsatissuebasedonawpandstategovernmententitiesthatmademedicaidpaymentsforthedrugsatissue basedonawpmanyofthesecasesbothfederalactionsandstateactionsremovedtofederalcourtwereconsolidate forpretrialpurposesinamultidistrictlitigationintheunitedstatesdistrictcourtforthedistrictofmassachusettswhere allclaimsagainstthejjawpdefendantswereultimatelydismissedthejjawpdefendantsalsoprevailedinacase broughtbythecommonwealthofpennsylvaniaotherawpcaseshavebeenresolvedthroughcourtorderorsettlement twocasesremainpendinginacasebroughtbyillinoistrialhasbeenscheduledformarchinnewjerseya putativeclassactionbaseduponawpallegationsispendingagainstcentocorincandorthobiotechincbothnow janssenbiotechincjohnsonjohnsonandalzacorporation opioidslitigation beginninginandcontinuingtothepresentjohnsonjohnsonandjanssenpharmaceuticalsincjpialongwith otherpharmaceuticalcompanieshavebeennamedinmorethanlawsuitsbroughtbycertainstateandlocal governmentsrelatedtothemarketingofopioidsincludingduragesicnucyntaandnucyntaertodate complaintsagainstpharmaceuticalcompaniesincludingjohnsonjohnsonandjpihavebeenfiledinstatecourtbythe johnsonjohnsonannualreportstateattorneysgeneralinarkansasfloridakentuckylouisianamississippimissourinewhampshirenewjerseynew mexicoohiooklahomaandsouthdakotacomplaintsagainstthemanufacturersalsohavebeenfiledinstateorfederalcourt bycitycountyandlocalgovernmentagenciesinthefollowingstatesalabamaarkansascaliforniaconnecticutflorida georgiaillinoiskentuckylouisianamainemarylandmassachusettsmississippimissourinevadanewhampshirenew jerseynewmexiconewyorknorthcarolinaohiooklahomaoregonpennsylvaniarhodeislandsouthcarolinasouth dakotatennesseetexasutahvirginiawashingtonwestvirginiaandwisconsinthegovernmentofpuertoricofiledsuit insuperiorcourtofsanjuaninadditiontheprovinceofbritishcolumbiafiledsuitincanadatheseactionsallegeavariety ofclaimsrelatedtoopioidsmarketingpracticesincludingfalseadvertisingunfaircompetitionpublicnuisanceconsumerfraud violationsdeceptiveactsandpracticesfalseclaimsandunjustenrichmentthesuitsgenerallyseekpenaltiesandorinjunctive andmonetaryreliefandinsomeofthesuitstheplaintiffsareseekingjointandseveralliabilityamongthedefendantsthese casesareinearlystagesoflitigationinoctoberjohnsonjohnsonandjpiwerebothservedwithamotionto consolidatependingmattersintoafederalmultidistrictlitigationmdlinthesoutherndistrictofohioin decemberthemdlwasapprovedinthenortherndistrictofohioandthereareovercasesthathavebeen transferredtothemdl johnsonjohnsonjpiandotherpharmaceuticalcompanieshavealsoreceivedsubpoenasorrequestsforinformation relatedtoopioidsmarketingpracticesfromthefollowingstateattorneysgeneralalaskaindianamontananew hampshiresouthcarolinatennesseetexasandwashingtoninseptemberjohnsonjohnsonandjpiwere contactedbythetexasandcoloradoattorneygeneralsofficesonbehalfofapproximatelystatesregardingamulti stateattorneygeneralinvestigationthemultistatecoalitionservedjohnsonjohnsonandjpiwithsubpoenasaspartof theinvestigationjohnsonjohnsonandjpihavealsoreceivedrequestsforinformationfromtherankingminoritymember oftheunitedstatessenatecommitteeonhomelandsecurityandgovernmentalaffairsregardingthesalesmarketing andeducationalstrategiesrelatedtothepromotionofopioidsuse inaugustdepuyorthopaedicsincdepuyincnowknownasdepuysynthesincandjohnsonjohnson servicesinccollectivelydepuyreceivedaninformalrequestfromtheunitedstatesattorneysofficeforthedistrictof massachusettsandthecivildivisionoftheunitedstatesdepartmentofjusticetheunitedstatesfortheproductionof materialsrelatingtothedepuyasrxlhipdeviceinjulytheunitedstatesnotifiedtheunitedstatesdistrict courtforthedistrictofmassachusettsthatithaddeclinedtointerveneinaquitamcasefiledpursuanttothefalse claimsactagainstthecompaniesinfebruarythedistrictcourtgrantedthecompaniesmotiontodismisswith prejudiceunsealedthequitamcomplaintanddeniedthequitamrelatorsrequestforleavetofileafurtheramende complaintthequitamrelatorsappealedthecasetotheunitedstatescourtofappealsforthefirstcircuitinjuly thefirstcircuitaffirmedthedistrictcourtsdismissalinpartreversedinpartandaffirmedthedecisiontodenythe relatorsrequesttofileathirdamendedcomplainttherelatorsremainingclaimsarenowpendingbeforethedistrictcourt andfactdiscoveryiscurrentlyscheduledtocloseinseptemberadditionallydepuyfiledapetitionforcertiorariwith theunitedstatessupremecourtseekingreviewofthefirstcircuitsdecisionthesupremecourtdeniedthepetitionin april sinceoctoberagroupofstateattorneysgeneralhaveissuedcivilinvestigativedemandsrelatingtothe developmentsalesandmarketingofseveralofdepuyorthopaedicsincshipproductsinjulytheoregon departmentofjusticewhichwasinvestigatingthesemattersindependentlyoftheotherstatesannouncedasettlementof itsasrxlhipdeviceinvestigationwiththestateoforegonindecemberthecompanytheremainingstate andthedistrictofcolumbiaagreedtosettlealloftheinvestigationsandonjanuarythestatesandthe companyfiledconsentjudgmentsresolvingthematter inoctoberjohnsonjohnsonwascontactedbythecaliforniaattorneygeneralsofficeregardingamultistate attorneygeneralinvestigationofthemarketingofsurgicalmeshproductsforherniaandurogynecologicalpurposesby johnsonjohnsonssubsidiaryethiconincethiconjohnsonjohnsonandethiconhavesinceenteredintoaserie oftollingagreementswiththestatesandthedistrictofcolumbiaparticipatinginthemultistateinvestigationandhave respondedtocivilinvestigativedemandsservedbycertainoftheparticipatingstatesthestatesareseekingmonetary andinjunctivereliefinmaycaliforniaandwashingtonfiledcivilcomplaintsagainstjohnsonjohnsonethiconand ethiconusllcallegingviolationsoftheirconsumerprotectionstatutessimilarcomplaintswerefiledagainstthe companiesbykentuckyinaugustandbymississippiinoctoberjohnsonjohnsonandethiconhave enteredintoanewtollingagreementwiththeremainingstatesandthedistrictofcolumbia indecembertherakosinctherakosformerlyasubsidiaryofjohnsonjohnsonandpartoftheorthoclinical diagnosticsincocdfranchisereceivedaletterfromthecivildivisionoftheunitedstatesattorneysofficeforthe johnsonjohnsonannualreport easterndistrictofpennsylvaniainformingtherakosthattheunitedstatesattorneysofficewasinvestigatingthesales andmarketingofuvadexmethoxsalenandtheuvarxtsandcellexsystemsduringtheperiodtothepresent theunitedstatesattorneysofficerequestedthatocdandjohnsonjohnsonpreservedocumentsthatcouldrelateto theinvestigationtherakoswassubsequentlyacquiredbyanaffiliateofgorescapitalpartnersiiilpinjanuary andocdwasdivestedinjunefollowingthedivestitureofocdjohnsonjohnsonretainsocdsportionofany liabilitythatmayresultfromtheinvestigationforactivitythatoccurredpriortothesaleoftherakosinmarchand marchtheunitedstatesattorneysofficerequestedthatjohnsonjohnsonproducecertaindocumentsand johnsonjohnsoniscooperatingwiththoserequest injunethemississippiattorneygeneralfiledacomplaintinchancerycourtofthefirstjudicialdistrictofhind countymississippiagainstjohnsonjohnsonandjohnsonjohnsonconsumercompaniesincnowknownas johnsonjohnsonconsumerincjjcithecomplaintallegesthatdefendantsfailedtodiscloseallegedhealthrisk associatedwithfemaleconsumersuseoftalccontainedinjohnsonsbabypowderandjohnsonsshowerto showeraproductdivestedinandseeksinjunctiveandmonetaryrelieftrialisstayedpendinginterlocutoryappeal ofadenialofjjcismotionforsummaryjudgment inmarchjanssenpharmaceuticalsincjpireceivedacivilinvestigativedemandfromtheunitedstate attorneysofficeforthesoutherndistrictofnewyorkrelatedtojpiscontractualrelationshipswithpharmacybenefit managersovertheperiodfromjanuarytothepresentwithregardtocertainofjpispharmaceuticalproductsthe demandwasissuedinconnectionwithaninvestigationunderthefalseclaimsact injanuaryjanssenpharmaceuticalsincjpireceivedacivilinvestigativedemandfromtheunitedstate departmentofjusticerelatingtoallegationsconcerningthesalesandmarketingpracticesofolysioindecember johnsonjohnsonandjpiwereservedwithawhistleblowerlawsuitfiledintheunitedstatesdistrictcourtforthe centraldistrictofcaliforniaallegingtheofflabelpromotionofolysioandadditionalproductsincludingnucynta xareltolevaquinandremicadeatthistimethefederalandstategovernmentshavedeclinedtointervene andthelawsuitwhichisrelatedtothecivilinvestigativedemandisbeingprosecutedbyaformercompanyemployee theunitedstatesdistrictcourtforthecentraldistrictofcaliforniadismissedtheclaiminaprilinmaythe relatorfiledanoticeofappealtotheunitedstatescourtofappealsfortheninthcircuit innovemberasecondwhistleblowerlawsuitwasunsealedintheunitedstatesdistrictcourtforthecentral districtofcaliforniathelawsuitissubstantiallysimilartothelawsuitunderappealbutisbroughtinthenameofthe originalrelatorthefederalandstategovernmentshavedeclinedtointerveneinthesecondsuitatthistime infebruaryjohnsonjohnsonreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsseekingtheproductionofrecordspertainingtopaymentstoanyccharitableorganizationthat providesfinancialassistancetomedicarepatientsmultiplepharmaceuticalcompanieshavepubliclyreportedreceiptof subpoenasandongoinginquiriessimilartothisoneandtheonedescribedbelowthegovernmenthasrepresentedthatit willnotbepursuingactionagainstthecompanyinthismatter actelionpharmaceuticalsusincactelionusreceivedasubpoenainmaywithfollowuprequestsfor documentsfromtheunitedstatesattorneysofficeforthedistrictofmassachusettsthesubpoenaseekstheproduction ofrecordspertainingtoactelionuspaymentstoccharitableorganizationsthatprovidefinancialassistanceto medicarepatientsindecemberthecompanyandtheunitedstatesdepartmentofjusticeagreedtoasettlement inthismatter inmarchjanssenbiotechincreceivedacivilinvestigativedemandfromtheunitedstatesdepartmentofjustice regardingafalseclaimsactinvestigationconcerningmanagementandadvisoryservicesprovidedtorheumatologyand gastroenterologypracticesthatpurchasedremicadeorsimponiaria inaprilandseptemberjohnsonjohnsonreceivedsubpoenasfromtheunitedstatesattorneyforthedistrictof massachusettsseekingdocumentsbroadlyrelatingtopharmaceuticalcopaymentsupportprogramsfordarzalex olysioremicadesimponistelaraandzytigathesubpoenasalsoseekdocumentsrelatingtoaverage manufacturerpriceandbestpricereportingtothecenterformedicareandmedicaidservicesrelatedtothoseproduct aswellasrebatepaymentstostatemedicaidagencie injunejohnsonjohnsonreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsseekinginformationregardingpracticespertainingtothesterilizationofdepuysynthesincspinal implantsatthreehospitalsinbostonaswellasinteractionsofemployeesofcompanysubsidiarieswithphysiciansat thesehospitalsjohnsonjohnsonanddepuysynthesinchaveproduceddocumentsinresponsetothesubpoenaand arefullycooperatingwiththegovernmentsinvestigation johnsonjohnsonannualreportinjulyadvancedsterilizationproductsaspreceivedacivilinvestigativedemandfromtheunitedstate departmentofjusticeregardingafalseclaimsactinvestigationconcerningthepricingqualitymarketingandpromotion ofevotechecrtyvekpeelpouchesorsterradcyclesurebiologicalindicator injulythepublicprosecutionserviceinriodejaneiroandrepresentativesfromthebrazilianantitrustauthority cadeinspectedtheofficesofmorethancompaniesincludingjohnsonjohnsondobrasilindstriaecomrciode produtosparasadeltdatheauthoritiesappeartobeinvestigatingallegationsofpossibleanticompetitivebehaviorand possibleimproperpaymentsinthemedicaldeviceindustrytheunitedstatesdepartmentofjusticeandtheunite statessecuritiesandexchangecommissionhavemadeadditionalpreliminaryinquiriesabouttheinspectioninbraziland johnsonjohnsondobrasilindstriaecomrciodeprodutosparasadeltdaiscooperatingwiththoserequest fromtimetotimethecompanyhasreceivedrequestsfromavarietyofunitedstatescongressionalcommitteesto produceinformationrelevanttoongoingcongressionalinquiriesitisthepolicyofjohnsonjohnsontocooperatewith theseinquiriesbyproducingtherequestedinformation generallitigation inaprilaputativeclassactionwasfiledagainstjohnsonjohnsonjohnsonjohnsonsalesandlogistic companyllcandmcneilppcincnowknownasjohnsonjohnsonconsumerincinnewjerseysuperiorcourt camdencountyonbehalfofpersonswhoresideinthestateofnewjerseywhopurchasedvariousmcneil overthecounterproductsfromdecemberthroughthepresentthecomplaintallegesviolationsofthenewjersey consumerfraudactfollowingthegrantofamotiontodismissandthefilingofanamendedcomplaintinmaythe courtdeniedamotiontodismisstheamendedcomplaintindecemberasettlementwasreachedandthematter hasbeendismisse inmaytwopurportedclassactionswerefiledinfederalcourtoneintheunitedstatesdistrictcourtforthecentral districtofcaliforniaandoneintheunitedstatesdistrictcourtforthesoutherndistrictofillinoisagainstjohnson johnsonandjohnsonjohnsonconsumercompaniesincnowknownasjohnsonjohnsonconsumerincjjci allegingviolationsofstateconsumerfraudstatutesbasedonnondisclosureofallegedhealthrisksassociatedwithtalc containedinjohnsonsbabypowderandjohnsonsshowertoshoweraproductnolongersoldbyjjciboth casesseekinjunctivereliefandmonetarydamagesneitherincludesaclaimforpersonalinjuriesinoctoberboth casesweretransferredtotheunitedstatesdistrictcourtforthedistrictcourtofnewjerseyaspartofanewlycreate federalmultidistrictlitigationinjulythedistrictcourtgrantedjohnsonjohnsonsandjjcismotiontodismiss oneofthecasesinseptembertheunitedstatescourtofappealsforthethirdcircuitaffirmedthisdismissalin septembertheplaintiffinthesecondcasevoluntarilydismissedtheircomplaintinmarchtheplaintiffinthe secondcaserefiledinillinoisstatecourt inaugustunitedstatescustomsandborderprotectionuscbpissuedapenaltynoticeagainstjanssenortho llcjanssenorthoassessingpenaltiesfortheallegedimproperclassificationofdarunavirethanolatetheactive pharmaceuticalingredientinprezistainconnectionwithitsimportationintotheunitedstatesinoctober janssenorthosubmittedapetitionforreliefinresponsetothepenaltynoticeinmayuscbpissuedan amendedpenaltynoticeassessingsubstantialpenaltiesandjanssenorthofiledapetitionforreliefinjuly inmarchandapriloverputativeclassactioncomplaintswerefiledbycontactlenspatientsinanumberofcourt aroundtheunitedstatesagainstjohnsonjohnsonvisioncareincjjvciandothercontactlensmanufacturer distributorsandretailersallegingverticalandhorizontalconspiraciestofixtheretailpricesofcontactlensesthe complaintsallegethatthemanufacturersreachedagreementswitheachotherandcertaindistributorsandretailer concerningthepricesatwhichsomecontactlensescouldbesoldtoconsumerstheplaintiffsareseekingdamagesand injunctivereliefalloftheclassactioncasesweretransferredtotheunitedstatesdistrictcourtforthemiddledistrictof floridainjunetheplaintiffsfiledaconsolidatedclassactioncomplaintinnovemberinjunethe districtcourtdeniedmotionstodismissfiledbyjjvciandotherdefendantsdiscoveryisongoinginmarchthe plaintiffsfiledamotionforclasscertificationthedistrictcourtheldahearingonthemotionforclasscertificationinaugust indecemberthedistrictcourtgrantedtheplaintiffsmotionforclasscertification inaugusttwothirdpartypayorsfiledapurportedclassactionintheunitedstatesdistrictcourtfortheeastern districtoflouisianaagainstjanssenresearchdevelopmentllcjanssenorthollcjanssenpharmaceuticalsinc orthomcneiljanssenpharmaceuticalsincandjohnsonjohnsonaswellascertainbayerentitiesallegingthatthe defendantsimproperlymarketedandpromotedxareltoassaferandmoreeffectivethanlessexpensivealternative medicationswhilefailingtofullydiscloseitsrisksthecomplaintseeksdamages johnsonjohnsonannualreport inmaylonzasalesaglonzafiledarequestforarbitrationwiththelondoncourtofinternationalarbitration againstjanssenresearchdevelopmentllcjanssenrdlonzaallegesthatjanssenrdbreacheda agreementbetweenthepartiesbysublicensingcertainlonzatechnologyusedinthemanufactureofdaratumumab withoutlonzasconsentlonzaseeksmonetarydamagesthearbitrationhearingwasheldinseptemberpost hearingbriefingiscompleteandthepartiesareawaitingadecision inmayapurportedclassactionwasfiledintheunitedstatesdistrictcourtforthewesterndistrictofwashingtonagainst lifescanincjohnsonjohnsonotherdiabetesteststripmanufacturersandcertainpharmacybenefitmanagerspbmsthe complaintallegesthatconsumerspaidinflatedpricesforglucosemonitorteststripsasaconsequenceofundisclosedrebatesand otherincentivespaidbymanufacturerstopbmsthecomplaintincludesricoerisaandstateconsumerprotectionclaimsthe complaintseeksequitablereliefanddamagesinnovemberthecasewasorderedtransferredtounitedstatesdistrict courtforthedistrictofnewjerseythelifescanbusinesswasdivestedinoctoberandjohnsonjohnsonretainedliability thatmayresultfromtheseclaimspriortotheclosingofthedivestiture inseptemberpfizerincpfizerfiledanantitrustcomplaintagainstjohnsonjohnsonandjanssenbiotechinc collectivelyjansseninunitedstatesdistrictcourtfortheeasterndistrictofpennsylvaniapfizerallegesthatjanssen hasviolatedfederalantitrustlawsthroughitscontractingstrategiesforremicadethecomplaintseeksdamagesand injunctiverelief beginninginseptembermultiplepurportedclassactionswerefiledagainstjohnsonjohnsonandjanssen biotechinccollectivelyjanssenallegingthatjanssensremicadecontractingstrategiesviolatedfederalandstate antitrustandconsumerlawsandseekingdamagesandinjunctivereliefinnovemberthecaseswereconsolidate forpretrialpurposesinunitedstatesdistrictcourtfortheeasterndistrictofpennsylvaniaasinreremicadeantitrust litigation injunewalgreencoandkrogercofiledanantitrustcomplaintagainstjohnsonjohnsonandjanssenbiotech inccollectivelyjanssenintheunitedstatesdistrictcourtfortheeasterndistrictofpennsylvaniathecomplaint allegesthatjanssenhasviolatedfederalantitrustlawsthroughitscontractingstrategiesforremicadethecomplaint seeksdamagesandinjunctiverelief inoctobercertainunitedstatesservicemembersandtheirfamiliesbroughtacomplaintagainstanumberof pharmaceuticalandmedicaldevicescompaniesincludingjohnsonjohnsonandcertainofitssubsidiariesallegingthat thedefendantsviolatedtheunitedstatesantiterrorismactthecomplaintallegesthatthedefendantsprovidedfunde forterroristorganizationsthroughtheirsalespracticespursuanttopharmaceuticalandmedicaldevicecontractswiththe iraqiministryofhealth andoverhealthcareincandoverfiledalanhamactcaseagainstjohnsonjohnsonconsumerincinaprilinthe unitedstatesdistrictcourtforthedistrictofmassachusettsandoverassertsthattheclaimnotmadewithnatural rubberlatexoncoachsportswrapbandaidbrandsecureflexwrapandbandaidbrandhurt freewrapisfalseandoverseeksactualdamagesandprejudgmentinterestthereondisgorgementofprofitstreble damagesattorneysfeesandinjunctivereliefindecemberthepartiesenteredintoasettlementagreement inoctobertwoseparateputativeclassactionswerefiledagainstactelionpharmaceuticalltdactelion pharmaceuticalsusincandactelionclinicalresearchinccollectivelyactelioninunitedstatesdistrictcourtforthe districtofmarylandandunitedstatesdistrictcourtforthedistrictofcolumbiathecomplaintsallegethatactelion violatedstateandfederalantitrustandunfaircompetitionlawsbyallegedlyrefusingtosupplygenericpharmaceutical manufacturerswithsamplesoftracleertracleerissubjecttoariskevaluationandmitigationstrategywhich imposesrestrictionsondistributionoftheproductinjanuarytheplaintiffsdismissedthedistrictofcolumbiacase andfiledaconsolidatedcomplaintinfederalcourtinmaryland indecemberjanssenbiotechincjanssenoncologyincjanssenresearchdevelopmentllcandjohnson johnsoncollectivelyjanssenwereservedwithaquitamcomplaintfiledonbehalfoftheunitedstatesstatesand thedistrictofcolumbiathecomplaintwhichwasfiledindecemberinunitedstatesdistrictcourtforthenorthern districtofcaliforniaallegesthatjanssenviolatedthefederalfalseclaimsactandstatelawwhenprovidingprice informationforzytigatothegovernmentinconnectionwithdirectgovernmentsalesandgovernmentfundeddrug reimbursementprogramsatthistimethefederalandstategovernmentshavedeclinedtointervene johnsonjohnsonoritssubsidiariesarealsopartiestoanumberofproceedingsbroughtunderthecomprehensive environmentalresponsecompensationandliabilityactcommonlyknownassuperfundandcomparablestatelocalor foreignlawsinwhichtheprimaryreliefsoughtisthecostofpastandorfutureremediation johnsonjohnsonannualreport restructuring inthefirstquarterofthecompanyannouncedrestructuringactionsinitsmedicaldevicessegmenttobetterserve theneedsofpatientsandcustomersintodaysevolvinghealthcaremarketplacethecompanyhasundertakenactionsto strengthenitsgotomarketmodelacceleratethepaceofinnovationfurtherprioritizekeyplatformsandgeographiesand streamlineoperationswhilemaintaininghighqualitystandard inthecompanyrecordedapretaxchargeofmillionofwhichmillionwasincludedincostofproduct soldandmillionwasincludedinotherincomeexpensetotalprojectcostsofbillionhavebeenrecorde sincetherestructuringhasbeenannouncedthisrestructuringprogramwascompletedinthefiscalfourthquarterof onaprilthecompanyannouncedplanstoimplementaseriesofactionsacrossitsglobalsupplychainthat areintendedtofocusresourcesandincreaseinvestmentsinthecriticalcapabilitiestechnologiesandsolutionsnecessary tomanufactureandsupplyitsproductportfolioenhanceagilityanddrivegrowththeglobalsupplychainactionswill includeexpandingtheuseofstrategiccollaborationsandbolsteringinitiativestoreducecomplexityimprovecost competitivenessenhancecapabilitiesandoptimizethesupplychainnetworkforadditionaldetailsontheglobalsupply chainrestructuringstrategiccollaborationsseenotetotheconsolidatedfinancialstatementsinthecompany recordedapretaxchargeofmillionofwhichmillionwasincludedincostofproductssoldandmillion wasincludedinotherincomeexpenseseethefollowingtableforadditionaldetailsontherestructuringprogram intotalthecompanyexpectstheglobalsupplychainactionstogenerateapproximatelybilliontobillionin annualpretaxcostsavingsthatwillbesubstantiallydeliveredbythecompanyexpectstorecordpretax restructuringchargesofapproximatelybilliontobillionoverthetoyearperiodofthisactivitythesecost areassociatedwithnetworkoptimizationsexitcostsandaccelerateddepreciationandamortization thefollowingtablesummarizestheseverancechargesandtheassociatedspendingundertheseinitiativesthroughthe fiscalyearended dollarsinmillion severance assetwriteoff total reservebalancejanuary activity reservebalancejanuary activity reservebalancedecember currentyearactivity charge cashpayment settlednoncash reservebalancedecember cashoutlaysforseveranceareexpectedtobesubstantiallypaidoutoverthenextyearsinaccordancewiththecompanysplan andlocallaw otherincludesprojectexpensesuchassalariesforemployeessupportingtheinitiativeandconsultingexpense althoughthemedicaldevicesrestructuringprogramwascompletedinthecompanyexpectsthatseverance chargeswillcontinuebeyondthatdatethecompanycontinuouslyreevaluatesitsseverancereservesrelatedto restructuringandthetimingofpaymentshasextendedduetotheplannedreleaseofassociatesregardingseverallonger termprojectsthecompanybelievesthattheexistingseverancereservesaresufficienttocovertheglobalsupplychain plansgiventheperiodoverwhichtheactionswilltakeplacethecompanywillcontinuetoassessandmakeadjustment asnecessaryifadditionalamountsbecomeprobableandestimableapproximatelyindividualsreceivedseparation paymentssincetheserestructuringannouncement johnsonjohnsonannualreport report independent register public accounting firm totheboardofdirectorsandshareholdersofjohnsonjohnson opinionsonthefinancialstatementsandinternalcontroloverfinancialreporte wehaveauditedtheaccompanyingconsolidatedbalancesheetsofjohnsonjohnsonanditssubsidiariesthe companyasofdecemberanddecemberandtherelatedconsolidatedstatementsofearningsof comprehensiveincomeofequityandofcashflowsforeachofthethreeyearsintheperiodendeddecember includingtherelatednotescollectivelyreferredtoastheconsolidatedfinancialstatementswealsohaveauditedthe companysinternalcontroloverfinancialreportingasofdecemberbasedoncriteriaestablishedininternal controlintegratedframeworkissuedbythecommitteeofsponsoringorganizationsofthetreadway commissioncoso inouropiniontheconsolidatedfinancialstatementsreferredtoabovepresentfairlyinallmaterialrespectsthefinancial positionofthecompanyasofdecemberanddecemberandtheresultsofitsoperationsanditscash flowsforeachofthethreeyearsintheperiodendeddecemberinconformitywithaccountingprinciple generallyacceptedintheunitedstatesofamericaalsoinouropinionthecompanymaintainedinallmaterialrespect effectiveinternalcontroloverfinancialreportingasofdecemberbasedoncriteriaestablishedininternal controlintegratedframeworkissuedbythecoso basisforopinion thecompanysmanagementisresponsiblefortheseconsolidatedfinancialstatementsformaintainingeffectiveinternal controloverfinancialreportingandforitsassessmentoftheeffectivenessofinternalcontroloverfinancialreporte includedintheaccompanyingmanagementsreportoninternalcontroloverfinancialreportingourresponsibilityisto expressopinionsonthecompanysconsolidatedfinancialstatementsandonthecompanysinternalcontroloverfinancial reportingbasedonourauditsweareapublicaccountingfirmregisteredwiththepubliccompanyaccountingoversight boardunitedstatespcaobandarerequiredtobeindependentwithrespecttothecompanyinaccordancewiththe usfederalsecuritieslawsandtheapplicablerulesandregulationsofthesecuritiesandexchangecommissionandthe pcaob weconductedourauditsinaccordancewiththestandardsofthepcaobthosestandardsrequirethatweplanand performtheauditstoobtainreasonableassuranceaboutwhethertheconsolidatedfinancialstatementsarefreeofmaterial misstatementwhetherduetoerrororfraudandwhethereffectiveinternalcontroloverfinancialreportingwasmaintaine inallmaterialrespect ourauditsoftheconsolidatedfinancialstatementsincludedperformingprocedurestoassesstherisksofmaterial misstatementoftheconsolidatedfinancialstatementswhetherduetoerrororfraudandperformingproceduresthat respondtothoseriskssuchproceduresincludedexaminingonatestbasisevidenceregardingtheamountsand disclosuresintheconsolidatedfinancialstatementsourauditsalsoincludedevaluatingtheaccountingprinciplesused andsignificantestimatesmadebymanagementaswellasevaluatingtheoverallpresentationoftheconsolidatedfinancial statementsourauditofinternalcontroloverfinancialreportingincludedobtaininganunderstandingofinternalcontrol overfinancialreportingassessingtheriskthatamaterialweaknessexistsandtestingandevaluatingthedesignand operatingeffectivenessofinternalcontrolbasedontheassessedriskourauditsalsoincludedperformingsuchother proceduresasweconsiderednecessaryinthecircumstanceswebelievethatourauditsprovideareasonablebasisfor ouropinion definitionandlimitationsofinternalcontroloverfinancialreporte acompanysinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe reliabilityoffinancialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewith generallyacceptedaccountingprinciplesacompanysinternalcontroloverfinancialreportingincludesthosepoliciesand proceduresthatipertaintothemaintenanceofrecordsthatinreasonabledetailaccuratelyandfairlyreflectthe transactionsanddispositionsoftheassetsofthecompanyiiprovidereasonableassurancethattransactionsare recordedasnecessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccounte johnsonjohnsonannualreportprinciplesandthatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsof managementanddirectorsofthecompanyandiiiprovidereasonableassuranceregardingpreventionortimelydetection ofunauthorizedacquisitionuseordispositionofthecompanysassetsthatcouldhaveamaterialeffectonthefinancial statement becauseofitsinherentlimitationsinternalcontroloverfinancialreportingmaynotpreventordetectmisstatementsalso projectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequate becauseofchangesinconditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate spricewaterhousecoopersllp florhamparknewjersey february wehaveservedasthecompanysauditorsinceatleastwehavenotbeenabletodeterminethespecificyearwe beganservingasauditorofthecompany johnsonjohnsonannualreport management report internal control financial reporting undersectionofthesarbanesoxleyactofmanagementisrequiredtoassesstheeffectivenessofthe companysinternalcontroloverfinancialreportingasoftheendofeachfiscalyearandreportbasedonthatassessment whetherthecompanysinternalcontroloverfinancialreportingiseffective managementofthecompanyisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancial reportingthecompanysinternalcontroloverfinancialreportingisdesignedtoprovidereasonableassuranceastothe reliabilityofthecompanysfinancialreportingandthepreparationofexternalfinancialstatementsinaccordancewith generallyacceptedaccountingprinciple internalcontrolsoverfinancialreportingnomatterhowwelldesignedhaveinherentlimitationsthereforeinternalcontrol overfinancialreportingdeterminedtobeeffectivecanprovideonlyreasonableassurancewithrespecttofinancial statementpreparationandmaynotpreventordetectallmisstatementsmoreoverprojectionsofanyevaluationof effectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequatebecauseofchangesin conditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate thecompanysmanagementhasassessedtheeffectivenessofthecompanysinternalcontroloverfinancialreportingas ofdecemberinmakingthisassessmentthecompanyusedthecriteriaestablishedbythecommitteeof sponsoringorganizationsofthetreadwaycommissioncosoininternalcontrolintegratedframework thesecriteriaareintheareasofcontrolenvironmentriskassessmentcontrolactivitiesinformationandcommunication andmonitoringthecompanysassessmentincludedextensivedocumentingevaluatingandtestingthedesignand operatingeffectivenessofitsinternalcontrolsoverfinancialreporting basedonthecompanysprocessesandassessmentasdescribedabovemanagementhasconcludedthatasof decemberthecompanysinternalcontroloverfinancialreportingwaseffective theeffectivenessofthecompanysinternalcontroloverfinancialreportingasofdecemberhasbeenauditedby pricewaterhousecoopersllpanindependentregisteredpublicaccountingfirmasstatedintheirreportwhichappear salexgorsky sjosephjwolk alexgorsky josephjwolk chairmanboardofdirector executivevicepresident chiefexecutiveofficer chieffinancialofficer johnsonjohnsonannualreportshareholder return performance graph setforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnonthecompanyscommonstockfor periodsoffiveyearsandtenyearsendingdecemberagainstthecumulativetotalreturnofthestandard poorsstockindexthestandardpoorspharmaceuticalindexandthestandardpoorshealthcareequipment indexthegraphsandtablesassumethatwasinvestedondecemberanddecemberineachof thecompanyscommonstockthestandardpoorsstockindexthestandardpoorspharmaceuticalindexand thestandardpoorshealthcareequipmentindexandthatalldividendswerereinveste year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceucidcal index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceucidcal index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex johnsonjohnsonannualreport item change disagreement accountant account financial disclosure notapplicable item control procedure disclosurecontrolsandproceduresattheendoftheperiodcoveredbythisreportthecompanyevaluatedthe effectivenessofthedesignandoperationofitsdisclosurecontrolsandproceduresthecompanysdisclosurecontrols andproceduresaredesignedtoensurethatinformationrequiredtobedisclosedbythecompanyinthereportsthatit filesorsubmitsundertheexchangeactisrecordedprocessedsummarizedandreportedwithinthetimeperiods specifiedinthesecsrulesandformsdisclosurecontrolsandproceduresincludewithoutlimitationcontrolsand proceduresdesignedtoensurethatinformationrequiredtobedisclosedbythecompanyinthereportsthatitfilesor submitsundertheexchangeactisaccumulatedandcommunicatedtothecompanysmanagementincludingitsprincipal executiveandprincipalfinancialofficersorpersonsperformingsimilarfunctionsasappropriatetoallowtimelydecision regardingrequireddisclosurealexgorskychairmanandchiefexecutiveofficerandjosephjwolkexecutivevice presidentchieffinancialofficerreviewedandparticipatedinthisevaluationbasedonthisevaluationmessrsgorsky andwolkconcludedthatasoftheendoftheperiodcoveredbythisreportthecompanysdisclosurecontrolsand procedureswereeffective reportsoninternalcontroloverfinancialreportingtheinformationcalledforbythisitemisincorporatedhereinby referencetomanagementsreportoninternalcontroloverfinancialreportingandtheattestationregardinginternal controlsoverfinancialreportingincludedinthereportofindependentregisteredpublicaccountingfirmincludedin itemofthisreport changesininternalcontroloverfinancialreportingduringthefiscalquarterendeddecembertherewereno changesinthecompanysinternalcontroloverfinancialreportingidentifiedinconnectionwiththeevaluationrequire underrulesaanddundertheexchangeactthathavemateriallyaffectedorarereasonablylikelyto materiallyaffectthecompanysinternalcontroloverfinancialreporte thecompanyisimplementingamultiyearenterprisewideinitiativetointegratesimplifyandstandardizeprocessesand systemsforthehumanresourcesinformationtechnologyprocurementsupplychainandfinancefunctionstheseare enhancementstosupportthegrowthofthecompanysfinancialsharedservicecapabilitiesandstandardizefinancial systemsthisinitiativeisnotinresponsetoanyidentifieddeficiencyorweaknessinthecompanysinternalcontrolover financialreportinginresponsetothisinitiativethecompanyhasandwillcontinuetoalignandstreamlinethedesignand operationofitsfinancialcontrolenvironment item b information notapplicable johnsonjohnsonannualreportpart iii item director executive officer corporate governance theinformationcalledforbythisitemisincorporatedhereinbyreferencetothediscussionoftheauditcommitteeunder thecaptionitemelectionofdirectorsboardcommitteesandthematerialunderthecaptionsitemelectionof directorsandstockownershipandsectioncompliancesectionabeneficialownershipreporte complianceintheproxystatementandthematerialunderthecaptionexecutiveofficersoftheregistrantinpartiof thisreport thecompanyscodeofbusinessconductwhichcoversallemployeesincludingthechiefexecutiveofficerchief financialofficerandcontrollermeetstherequirementsofthesecrulespromulgatedundersectionofthe sarbanesoxleyactofthecodeofbusinessconductisavailableonthecompanyswebsiteatwwwjnjcom codeofbusinessconductandcopiesareavailabletoshareholderswithoutchargeuponwrittenrequesttothesecretary atthecompanysprincipalexecutiveofficesanysubstantiveamendmenttothecodeofbusinessconductoranywaiver ofthecodegrantedtothechiefexecutiveofficerthechieffinancialofficerorthecontrollerwillbepostedonthe companyswebsiteatwwwinvestorjnjcomgovcfmwithinfivebusinessdaysandretainedonthewebsiteforatleastone year inadditionthecompanyhasadoptedacodeofbusinessconductethicsformembersoftheboardofdirectorsand executiveofficersthecodeofbusinessconductethicsformembersoftheboardofdirectorsandexecutiveofficer isavailableonthecompanyswebsiteatwwwinvestorjnjcomgovboardconductcfmandcopiesareavailableto shareholderswithoutchargeuponwrittenrequesttothesecretaryatthecompanysprincipalexecutiveofficesany substantiveamendmenttothecodeoranywaiverofthecodegrantedtoanymemberoftheboardofdirectorsorany executiveofficerwillbepostedonthecompanyswebsiteatwwwinvestorjnjcomgovcfmwithinfivebusinessdaysand retainedonthewebsiteforatleastoneyear item executive compensation theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionsitem electionofdirectorsdirectorcompensationanditemcompensationcommitteereportcompensation discussionandanalysisandexecutivecompensationtablesintheproxystatement thematerialincorporatedhereinbyreferencetothematerialunderthecaptioncompensationcommitteereportinthe proxystatementshallbedeemedfurnishedandnotfiledinthisreportandshallnotbedeemedincorporatedby referenceintoanyfilingunderthesecuritiesactofasamendedorthesecuritiesexchangeactofas amendedasaresultofthisfurnishingexcepttotheextentthatthecompanyspecificallyincorporatesitbyreference item security ownership certain beneficial owner management relate stockholder matter theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionitemstock ownershipandsectioncomplianceintheproxystatementandnotecommonstockstockoptionplansand stockcompensationagreementsofthenotestoconsolidatedfinancialstatementsinitemofthisreport johnsonjohnsonannualreport equity compensation plan information thefollowingtableprovidescertaininformationasofdecemberconcerningthesharesofthecompany commonstockthatmaybeissuedunderexistingequitycompensationplan numberof securitiesto beissuedupon weightedaverage numberofsecuritie exerciseof exercisepriceof remainingavailablefor outstanding outstanding futureissuanceunderequity plancategory optionsandright optionsandright compensationplan equitycompensationplansapprovedbysecurity holder equitycompensationplansnotapprovedbysecurity holder total includedinthiscategoryarethefollowingequitycompensationplanswhichhavebeenapprovedbythecompanysshareholder longtermincentiveplanandlongtermincentiveplan thiscolumnexcludessharesreflectedunderthecolumnnumberofsecuritiestobeissueduponexerciseofoutstandingoption andright thelongtermincentiveplanexpiredaprilalloptionsandrestrictedsharesgrantedsubsequenttothatdatewere underthelongtermincentiveplan item certain relationship relate transaction director independence theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionsitem electionofdirectorsdirectorindependenceandrelatedpersontransactionsintheproxystatement item principal accountant fee service theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionitem ratificationofappointmentofindependentregisteredpublicaccountingfirmintheproxystatement johnsonjohnsonannualreportpart iv item exhibit financial statement schedule thefollowingdocumentsarefiledaspartofthisreport financialstatement consolidatedbalancesheetsatendoffiscalyearsand consolidatedstatementsofearningsforfiscalyearsand consolidatedstatementsofcomprehensiveincomeforfiscalyearsand consolidatedstatementsofequityforfiscalyearsand consolidatedstatementsofcashflowsforfiscalyearsand notestoconsolidatedfinancialstatement reportofindependentregisteredpublicaccountingfirm allschedulesareomittedbecausetheyarenotapplicableortherequiredinformationisincludedinthefinancial statementsornote exhibitsrequiredtobefiledbyitemlofregulationsk theinformationcalledforbythisitemisincorporatedhereinbyreferencetotheexhibitindexinthisreport item summary registrantsmayvoluntarilyincludeasummaryofinformationrequiredbyformkunderthisitemthecompanyha electednottoincludesuchsummaryinformation johnsonjohnsonannualreport signature pursuanttotherequirementsofsectionofthesecuritiesexchangeactoftheregistranthasdulycausedthis reporttobesignedonitsbehalfbytheundersignedthereuntodulyauthorize datefebruary johnsonjohnson registrant sagorsky agorskychairmanboardofdirector andchiefexecutiveofficer pursuanttotherequirementsofthesecuritiesexchangeactofthisreporthasbeensignedbelowbythefollowe personsonbehalfoftheregistrantandinthecapacitiesandonthedatesindicate signature title date sagorsky chairmanboardofdirector february agorsky chiefexecutiveofficer principalexecutiveofficer sjjwolk chieffinancialofficer february jjwolk principalfinancialofficer srakapusta controllerandchiefaccountingofficer february rakapusta principalaccountingofficer smcbeckerle director february mcbeckerle sdsdavis director february dsdavis sieldavis director february ieldavis sjadoudna director february jadoudna smbmcclellan director february mbmcclellan sammulcahy director february ammulcahy swdperez director february wdperez scprince director february cprince saewashington director february aewashington srawilliams director february rawilliams johnsonjohnsonannualreportexhibit index regsk exhibittable itemno descriptionofexhibit restatedcertificateofincorporationeffectivefebruaryincorporatedhereinbyreferencetoexhibitiofthe registrantsformkannualreportforthefiscalyearendedjanuary ii bylawsofthecompanyasamendedeffectivejanuaryincorporatedhereinbyreferencetoexhibitthe registrantsformkcurrentreportfiledjanuary upontherequestofthesecuritiesandexchangecommissiontheregistrantwillfurnishacopyofallinstrumentsdefiningthe rightsofholdersoflongtermdebtoftheregistrant longtermincentiveplanincorporatedhereinbyreferencetoexhibitoftheregistrantssregistrationstatement filedwiththecommissiononmayfileno b formofstockoptioncertificateunderthelongtermincentiveplanincorporatedhereinbyreferencetoexhibitof theregistrantsformkcurrentreportfiledjanuary c longtermincentiveplanincorporatedhereinbyreferencetoappendixaoftheregistrantsproxystatementfiledwith thecommissiononmarch formofstockoptioncertificaterestrictedshareunitcertificateandperformanceshareunitcertificateunderthe longtermincentiveplanincorporatedhereinbyreferencetoexhibitsandoftheregistrantsformq quarterlyreportfiledmay e globalnonqualifiedstockoptionawardagreementglobalrestrictedshareunitawardagreementandglobalperformance shareunitawardagreementunderthelongtermincentiveplanincorporatedhereinbyreferencetoexhibits andoftheregistrantsformqquarterlyreportfiledmay f johnsonjohnsonexecutiveincentiveplanasamendedincorporatedhereinbyreferencetoexhibitfoftheregistrants formkannualreportforthefiscalyearendeddecember g domesticdeferredcompensationcertificateofextracompensationplanincorporatedhereinbyreferencetoexhibitg oftheregistrantsformkannualreportfortheyearendeddecember h amendmentstothecertificateofextracompensationplaneffectiveasofjanuaryincorporatedhereinbyreferenceto exhibitjoftheregistrantsformkannualreportfortheyearendeddecember certificatesoflongtermperformanceplanincorporatedhereinbyreferencetoexhibitoftheregistrantsform qquarterlyreportforthequarterendedseptember j amendedandrestateddeferredfeeplanfordirectorsamendedasofjanuaryincorporatedhereinbyreference toexhibitkoftheregistrantsformkannualreportforthefiscalyearendedjanuary k thejohnsonjohnsonexecutiveincomedeferralplanamendedandrestatedeffectivejanuaryincorporated hereinbyreferencetoexhibitoftheregistrantsformqquarterlyreportforthequarterendedseptember l excesssavingsplaneffectiveasofjanuaryincorporatedhereinbyreferencetoexhibitjoftheregistrant formkannualreportforthefiscalyearendeddecember amendmentstothejohnsonjohnsonexcesssavingsplaneffectiveasofjanuaryincorporatedhereinbyreference toexhibitpoftheregistrantsformkannualreportforthefiscalyearendeddecember n excessbenefitplansupplementalretirementplanincorporatedhereinbyreferencetoexhibithoftheregistrantsform kannualreportforthefiscalyearendedjanuary amendmentstotheexcessbenefitplanofjohnsonjohnsonandaffiliatedcompanieseffectiveasofjanuary incorporatedhereinbyreferencetoexhibitroftheregistrantsformkannualreportforthefiscalyearende december p amendmenttotheexcessbenefitplanofjohnsonjohnsonandaffiliatedcompanieseffectiveasofjanuary incorporatedhereinbyreferencetoexhibitqoftheregistrantsformkannualreportforthefiscalyearende december q executivelifeplanagreementincorporatedhereinbyreferencetoexhibitioftheregistrantsformkannualreport forthefiscalyearendedjanuary r executivelifeplanagreementclosureletterincorporatedhereinbyreferencetoexhibitoftheregistrantsformq quarterlyreportforthequarterendedmarch employmentagreementfordrpaulusstoffelsincorporatedhereinbyreferencetoexhibitoftheregistrantsformq quarterlyreportforthequarterendedseptember summaryofemploymentarrangementsforsandraepetersonincorporatedhereinbyreferencetoexhibittofthe registrantsformkannualreportfortheyearendeddecember johnsonjohnsonannualreport u severancepayplanofjohnsonjohnsonandusaffiliatedcompaniesamendedandrestatedasofoctober incorporatedhereinbyreferencetoexhibitoftheregistrantsformqquarterlyreportforthequarterende september v firstamendmenttotheseverancepayplanofjohnsonjohnsonandusaffiliatedcompaniesasamendedandrestate effectiveoctoberincorporatedhereinbyreferencetoexhibitoftheregistrantsformqquarterlyreport forthequarterendedjune w secondamendmenttotheseverancepayplanofjohnsonjohnsonandusaffiliatedcompaniesasamendedandrestate effectiveoctoberincorporatedhereinbyreferencetoexhibitxoftheregistrantsformkannualreportfor thefiscalyearendedjanuary subsidiariesfiledwiththisdocument consentofindependentregisteredpublicaccountingfirmfiledwiththisdocument certificationofchiefexecutiveofficerpursuanttosectionofthesarbanesoxleyactfiledwiththisdocument certificationofchieffinancialofficerpursuanttosectionofthesarbanesoxleyactfiledwiththisdocument certificationofchiefexecutiveofficerpursuanttosectionofthesarbanesoxleyactfurnishedwiththisdocument certificationofchieffinancialofficerpursuanttosectionofthesarbanesoxleyactfurnishedwiththisdocument xbrlextensiblebusinessreportinglanguagethefollowingmaterialsfromthisreportforthefiscalyearendeddecember formattedinextensivebusinessreportinglanguagexbrliconsolidatedbalancesheetsiiconsolidate statementsofearningsiiiconsolidatedstatementsofcomprehensiveincomeivconsolidatedstatementsofequity vconsolidatedstatementsofcashflowsandvinotestotheconsolidatedfinancialstatement managementcontractorcompensatoryplan paperfile acopyofanyoftheexhibitslistedabovewillbeprovidedwithoutchargetoanyshareholdersubmittingawrittenrequ specifyingthedesiredexhibitstothesecretaryattheprincipalexecutiveofficesofthecompanypursuanttoitem biiiaofregulationskthecompanyhasnotfiledasexhibitstothisformkcertainlongtermdebt instrumentsincludingindenturesunderwhichthetotalamountofsecuritiesauthorizeddoesnotexceedofthetotal assetsofthecompanyanditssubsidiariesonaconsolidatedbasisthecompanyherebyagreestofurnishacopyofany suchinstrumenttothesecuponrequ thefollowingexhibitsindicatedasbeingfiledwiththisdocumentareomittedfromtheprintedversionofthis annualreport exhibit exhibit johnsonjohnsonannualreportexhibit certificationofchiefexecutiveofficer pursuanttosectionofthesarbanesoxleyact ialexgorskycertifythat ihavereviewedthisannualreportonformkforthefiscalyearendeddecemberthereportof johnsonjohnsonthecompany basedonmyknowledgethisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostatea materialfactnecessarytomakethestatementsmadeinlightofthecircumstancesunderwhichsuchstatementswere madenotmisleadingwithrespecttotheperiodcoveredbythisreport basedonmyknowledgethefinancialstatementsandotherfinancialinformationincludedinthisreportfairly presentinallmaterialrespectsthefinancialconditionresultsofoperationsandcashflowsofthecompanyasofand fortheperiodspresentedinthisreport thecompanysothercertifyingofficersandiareresponsibleforestablishingandmaintainingdisclosurecontrol andproceduresasdefinedinexchangeactrulesaeanddeandinternalcontroloverfinancial reportingasdefinedinexchangeactrulesafanddfforthecompanyandhave adesignedsuchdisclosurecontrolsandproceduresorcausedsuchdisclosurecontrolsandprocedure tobedesignedunderoursupervisiontoensurethatmaterialinformationrelatingtothecompanyincludingit consolidatedsubsidiariesismadeknowntousbyotherswithinthoseentitiesparticularlyduringtheperiodin whichthisreportisbeingprepare bdesignedsuchinternalcontroloverfinancialreportingorcausedsuchinternalcontroloverfinancial reportingtobedesignedunderoursupervisiontoprovidereasonableassuranceregardingthereliabilityof financialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerally acceptedaccountingprinciple cevaluatedtheeffectivenessofthecompanysdisclosurecontrolsandproceduresandpresentedinthis reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandproceduresasoftheendofthe periodcoveredbythisreportbasedonsuchevaluationand ddisclosedinthisreportanychangeinthecompanysinternalcontroloverfinancialreportingthat occurredduringthecompanysmostrecentfiscalquarterthecompanysfourthfiscalquarterinthecaseofan annualreportthathasmateriallyaffectedorisreasonablylikelytomateriallyaffectthecompanysinternalcontrol overfinancialreportingand thecompanysothercertifyingofficersandihavedisclosedbasedonourmostrecentevaluationofinternal controloverfinancialreportingtothecompanysauditorsandtheauditcommitteeofthecompanysboardof directorsorpersonsperformingtheequivalentfunction aallsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover financialreportingwhicharereasonablylikelytoadverselyaffectthecompanysabilitytorecordprocess summarizeandreportfinancialinformationand banyfraudwhetherornotmaterialthatinvolvesmanagementorotheremployeeswhohaveasignificant roleinthecompanysinternalcontroloverfinancialreporte salexgorsky alexgorsky chiefexecutiveofficer datefebruary johnsonjohnsonannualreportexhibit certificationofchieffinancialofficer pursuanttosectionofthesarbanesoxleyact ijosephjwolkcertifythat ihavereviewedthisannualreportonformkforthefiscalyearendeddecemberthereportof johnsonjohnsonthecompany basedonmyknowledgethisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostatea materialfactnecessarytomakethestatementsmadeinlightofthecircumstancesunderwhichsuchstatementswere madenotmisleadingwithrespecttotheperiodcoveredbythisreport basedonmyknowledgethefinancialstatementsandotherfinancialinformationincludedinthisreportfairly presentinallmaterialrespectsthefinancialconditionresultsofoperationsandcashflowsofthecompanyasofand fortheperiodspresentedinthisreport thecompanysothercertifyingofficersandiareresponsibleforestablishingandmaintainingdisclosurecontrol andproceduresasdefinedinexchangeactrulesaeanddeandinternalcontroloverfinancial reportingasdefinedinexchangeactrulesafanddfforthecompanyandhave adesignedsuchdisclosurecontrolsandproceduresorcausedsuchdisclosurecontrolsandprocedure tobedesignedunderoursupervisiontoensurethatmaterialinformationrelatingtothecompanyincludingit consolidatedsubsidiariesismadeknowntousbyotherswithinthoseentitiesparticularlyduringtheperiodin whichthisreportisbeingprepare bdesignedsuchinternalcontroloverfinancialreportingorcausedsuchinternalcontroloverfinancial reportingtobedesignedunderoursupervisiontoprovidereasonableassuranceregardingthereliabilityof financialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerally acceptedaccountingprinciple cevaluatedtheeffectivenessofthecompanysdisclosurecontrolsandproceduresandpresentedinthis reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandproceduresasoftheendofthe periodcoveredbythisreportbasedonsuchevaluationand ddisclosedinthisreportanychangeinthecompanysinternalcontroloverfinancialreportingthat occurredduringthecompanysmostrecentfiscalquarterthecompanysfourthfiscalquarterinthecaseofan annualreportthathasmateriallyaffectedorisreasonablylikelytomateriallyaffectthecompanysinternalcontrol overfinancialreportingand thecompanysothercertifyingofficersandihavedisclosedbasedonourmostrecentevaluationofinternal controloverfinancialreportingtothecompanysauditorsandtheauditcommitteeofthecompanysboardof directorsorpersonsperformingtheequivalentfunction aallsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover financialreportingwhicharereasonablylikelytoadverselyaffectthecompanysabilitytorecordprocess summarizeandreportfinancialinformationand banyfraudwhetherornotmaterialthatinvolvesmanagementorotheremployeeswhohaveasignificant roleinthecompanysinternalcontroloverfinancialreporte sjosephjwolk josephjwolk chieffinancialofficer datefebruary johnsonjohnsonannualreportexhibit certificationofchiefexecutiveofficer pursuanttosectionofthesarbanesoxleyact theundersignedalexgorskythechiefexecutiveofficerofjohnsonjohnsonanewjerseycorporationthe companypursuanttouscasadoptedpursuanttosectionofthesarbanesoxleyactof herebycertifiesthattothebestofmyknowledge thecompanysannualreportonformkforthefiscalyearendeddecemberthereportfully complieswiththerequirementsofsectionaofthesecuritiesexchangeactofand theinformationcontainedinthereportfairlypresentsinallmaterialrespectsthefinancialconditionand resultsofoperationsofthecompany salexgorsky alexgorsky chiefexecutiveofficer datedfebruary thiscertificationisbeingfurnishedtothesecwiththisreportonformkpursuanttosectionofthe sarbanesoxleyactofandshallnotexcepttotheextentrequiredbysuchactbedeemedfiledbythecompany forpurposesofsectionofthesecuritiesexchangeactofasamendedorotherwisesubjecttotheliabilityof thatsection johnsonjohnsonannualreportexhibit certificationofchieffinancialofficer pursuanttosectionofthesarbanesoxleyact theundersignedjosephjwolkthechieffinancialofficerofjohnsonjohnsonanewjerseycorporationthe companypursuanttouscasadoptedpursuanttosectionofthesarbanesoxleyactof herebycertifiesthattothebestofmyknowledge thecompanysannualreportonformkforthefiscalyearendeddecemberthereportfully complieswiththerequirementsofsectionaofthesecuritiesexchangeactofand theinformationcontainedinthereportfairlypresentsinallmaterialrespectsthefinancialconditionand resultsofoperationsofthecompany sjosephjwolk josephjwolk chieffinancialofficer datedfebruary thiscertificationisbeingfurnishedtothesecwiththisreportonformkpursuanttosectionofthe sarbanesoxleyactofandshallnotexcepttotheextentrequiredbysuchactbedeemedfiledbythecompany forpurposesofsectionofthesecuritiesexchangeactofasamendedorotherwisesubjecttotheliabilityof thatsection johnsonjohnsonannualreportthispageintentionallyleftblankthispageintentionallyleftblankthispageintentionallyleftblankreconciliationofnongaapfinancialmeasures twelvemonth incr dollarsinmillionsexceptpersharedata decr earningsbeforeprovisionfortaxesonincomeasreporte intangibleassetamortizationexpense litigationexpensenet actelionacquisitionrelatedcost restructuringother inprocessresearchanddevelopment diabetesassetimpairment amoacquisitionrelatedcost contingentliabilityreversal unrealizedlossonsecuritie impactoftaxlegislation earningsbeforeprovisionfortaxesonincomeasadjuste netearningsasreporte nm intangibleassetamortizationexpense litigationexpensenet actelionacquisitionrelatedcost restructuringother inprocessresearchanddevelopment diabetesassetimpairment amoacquisitionrelatedcost contingentliabilityreversal unrealizedlossonsecuritie impactoftaxlegislation netearningsasadjuste dilutednetearningspershareasreporte nm intangibleassetamortizationexpense litigationexpensenet actelionacquisitionrelatedcost restructuringother inprocessresearchanddevelopment amoacquisitionrelatedcost contingentliabilityreversal unrealizedlossonsecuritie impactoftaxlegislation dilutednetearningspershareasadjuste operationaldilutednetearningspershareasadjustedatforeigncurrencyexchange rate impactofcurrencyatforeigncurrencyexchangerate operationaldilutednetearningspershareasadjustedatforeigncurrencyexchange rate includesmillionrecordedincostofproductssoldandmillionrecordedinotherincomeexpenseinand millionrecordedincostofproductssoldandmillionrecordedinotherincomeexpensein includesforeigncurrencytranslation nmnotmeaningful johnsonjohnsonannualreportthecompanyprovidesearningsbeforeprovisionfortaxesonincomenetearningsandnetearningspersharedilutedon anadjustedbasisbecausemanagementbelievesthatthesemeasuresprovideusefulinformationtoinvestorsamongother thingsthesemeasuresmayassistinvestorsinevaluatingthecompanysresultsofoperationsperiodoverperiodin variousperiodsthesemeasuresmayexcludesuchitemsasintangibleassetamortizationexpensesignificantcost associatedwithacquisitionsrestructuringlitigationandchangesinapplicablelawsandregulationsincludingsignificant accountingortaxmattersthesespecialitemsmaybehighlyvariabledifficulttopredictandofasizethatsometimeshas substantialimpactonthecompanysreportedresultsofoperationsforaperiodmanagementusesthesemeasure internallyforplanningforecastingandevaluatingtheperformancesofthecompanysbusinessesincludingallocate resourcesandevaluatingresultsrelativetoemployeeperformancecompensationtargetsunlikeearningsbeforeprovision fortaxesonincomenetearningsandnetearningspersharedilutedpreparedinaccordancewithgaapadjuste earningsbeforeprovisionfortaxesonincomeadjustednetearningsandadjustednetearningspersharedilutedmaynot becomparablewiththecalculationofsimilarmeasuresforothercompaniesthelimitationsofusingthesenongaap financialmeasuresasperformancemeasuresarethattheyprovideaviewofthecompanysresultsofoperationswithout includingalleventsduringaperiodsuchasintangibleassetamortizationexpensetheeffectsofanacquisition restructuringlitigationandchangesinapplicablelawsandregulationsincludingsignificantaccountingortaxmattersand donotprovideacomparableviewofthecompanysperformancetoothercompaniesinthehealthcareindustryinvestor shouldconsidernongaapfinancialmeasuresinadditiontoandnotasreplacementsfororsuperiortomeasuresof financialperformancepreparedinaccordancewithgaap thetablesbelowareprovidedtoreconcilecertainnongaapfinancialdisclosuresinthechairmansletter dollarsinmillion netcashflowsfromoperatingactivitie additionstopropertyplantandequipment freecashflow operationalgrowth incr medicaldevice decr worldwideasreporte impactofacquisitionsdivestiture worldwideoperationalgrowthexcludingacquisitionsdivestitures operationalsalesgrowthexcludingthenetimpactofacquisitionsanddivestituresisanongaapfinancialmeasure investorsshouldconsidernongaapfinancialmeasuresinadditiontoandnotasreplacementsfororsuperiorto measuresoffinancialperformancepreparedinaccordancewithgaapduetothevariablenatureofacquisitionsand divestituresandtheimpacttheymayhaveontheanalysisofunderlyingbusinessperformanceandtrend managementbelievesthatprovidingthismeasureenhancesaninvestorsunderstandingofthecompany performanceandmayassistintheevaluationofongoingbusinessoperationsperiodoverperiodthisnongaap financialmeasureispresentedtopermitinvestorstomorefullyunderstandhowmanagementassessesthe performanceofthecompanyincludingforinternalevaluationoftheperformanceofthecompanysbusinessesand planningandforecastingforfutureperiodstheuseofthisnongaapfinancialmeasureasaperformancemeasureis limitedinthatitprovidesaviewofthecompanysresultsofoperationswithoutincludingalleventsduringaperiodand maynotprovideacomparableviewofthecompanysperformancetothatofothercompaniesinthehealthcare industry johnsonjohnsonannualreportboard director senior management alexgorsky alexgorsky chairmanboardofdirector chiefexecutiveofficer chairmanexecutivecommittee marycbeckerle chiefexecutiveofficerhuntsmancancerinstitute joaquinduato attheuniversityofutah vicechairmanexecutivecommittee distinguishedprofessorofbiology collegeofscienceuniversityofutah paulusstoffel vicechairmanexecutivecommitteechiefscientificofficer dscottdavis formerchairmanandchiefexecutiveofficer petermfasolo unitedparcelserviceinc executivevicepresidentchiefhumanresourcesofficer ianeldavis ronaldakapusta chairmanrollsroyceholdingsplc corporatecontrollerchiefaccountingofficer formerchairmanandworldwidemanagingdirector ashleymcevoy mckinseycompany executivevicepresidentworldwidechairman jenniferadoudna medicaldevice professorofchemistryprofessorofbiochemistry thibautmongon molecularbiology executivevicepresidentworldwidechairmanconsumer likashingchancellorsprofessorinbiomedical andhealthuniversityofcaliforniaberkeley michellerryan treasurer markbmcclellan directordukerobertjmargolismd michaelesneed centerforhealthpolicy executivevicepresidentglobalcorporateaffair chiefcommunicationsofficer annemmulcahy formerchairmanandchiefexecutiveofficer thomasjspellmaniii xeroxcorporation corporatesecretaryassistantgeneralcounsel williamdperez jennifertaubert retiredpresidentandchiefexecutiveofficer executivevicepresidentworldwidechairman wmwrigleyjrcompany pharmaceutical charlesprince michaelhullmann retiredchairmanandchiefexecutiveofficer executivevicepresidentgeneralcounsel citigroupinc kathrynewengel aeugenewashington executivevicepresidentchiefglobalsupplychainofficer dukeuniversityschancellorforhealthaffair presidentandchiefexecutiveofficer josephjwolk dukeuniversityhealthsystem executivevicepresidentchieffinancialofficer ronaldawilliams memberexecutivecommittee formerchairmanandchiefexecutiveofficer aetnainc johnsonjohnsonannualreportprincipaloffice stockliste johnsonjohnsononline onejohnsonjohnsonplaza johnsonjohnsoncommonstock ourwebsitewwwjnjcom newbrunswicknewjersey listedonnewyorkstockexchange stocksymboljnj httpwwwjnjcommediacenter annualmeetingofshareholder shareholderrelationscontact thursdayapril thomasjspellmaniii wwwfacebookcomjnj corporatesecretary ameasterndoorsopentomeetingat wwwtwittercomjnjnews wwwtwittercomjnjcare hyattregencynewbrunswick investorrelationscontact twoalbanystreet christopherdelorefice newbrunswicknewjersey wwwyoutubecomjnj vicepresidentinvestorrelation allshareholdersasoftherecorddateof februaryareinvitedtoattend httpwwwlinkedincomcompany johnsonjohnson aformalnoticeofannualmeete investorrelationswebsite proxystatementandproxyhavebeen wwwinvestorjnjcom thejohnsonjohnsonyearin madeavailabletoshareholders stocktransferagentandregistrar reviewisavailableonourwebsiteat annualreportonformkand questionsregardingstockholding httpswwwjnjcomyearinreview proxystatement certificatereplacementtransferdividend theinformationonthesewebsitesshould johnsonjohnsonsannualreportonformk andaddresschangesshouldbedirectedto notbedeemedtobepartofthisannual forthefiscalyearendeddecemberis ourstocktransferagentandregistrarat report includedinthisannualreportinitsentiretywith computersharetrustcompanyna theexceptionofcertainexhibitstheformk pobox completewithallofitsexhibitsisavailableonour louisvilleky websiteatwwwinvestorjnjcomseccfmandthe overnightmail secswebsiteatwwwsecgov computersharetrustcompanyna shareholdersmayalsoobtaincopiesofthe souththstreetsuite exhibitsourannualreporton louisvilleky formkandourproxystatement withoutchargeuponwrittenrequesttothe shareholderwebsite officeofthecorporatesecretaryatour wwwcomputersharecominvestor principalofficeaddressorbycalle dividendreinvestmentplan theplanallowsforfullorpartialdividend electronicdeliverynotification reinvestmentandadditionalweeklycash theproxystatementandourannual investmentsuptoperyearin reportareavailableonourwebsite johnsonjohnsoncommonstockwithout wwwinvestorjnjcomgov pershareorservicechargesonstock c annualmeetingmaterialscfmshareholderswho purchasesifyouareinterestedin receivepapercopiesofourproxystatementand participatingintheplanandneedan annualreportbymailcanelecttoreceiveinstead enrollmentformandormoreinformation anemailmessagewithalinktothosedocument pleasecalltheplanadministrator thejohnsonjohnsonannualreport ontheinternetregisteredshareholdersmay computersharetrustcompanynaat containsmanyofthevaluabletrademarks enrollinelectronicdeliveryat andtradenamesownedandusedbythe wwwcomputersharenacomgreenbeneficial outsidetheusoraccessonlineat johnsonjohnsonfamilyofcompaniesin shareholderswhoholdsharesofjohnson wwwcomputersharecominvestor theunitedstatesandinternationallyto johnsoncommonstockthroughabankbrokeror distinguishproductsandservicesof otherholderofrecordgenerallycanenrollfor hearingimpaired outstandingquality electronicdeliveryatenrollicsdeliverycomjnj shareholderswhohaveinquiriesregarde johnsonjohnson stockrelatedmatterscancommunicate directlywithcomputersharetrustcompany naviaatelecommunicationsdevicetdd thetelephonenumberforthisserviceis outsidetheuswe blend heart science ingenuity profoundly change trajectory health humanity